sentence,label,mention1,mention2
"Oral  DRUG1  has been reported to potentiate the anticoagulant effect of  DRUG2  and  DRUGOTHER , resulting in a prolongation of prothrombin time.",effect,metronidazole,coumarin
"Oral  DRUG1  has been reported to potentiate the anticoagulant effect of  DRUGOTHER  and  DRUG2 , resulting in a prolongation of prothrombin time.",effect,metronidazole,warfarin
"Oral  DRUGOTHER  has been reported to potentiate the anticoagulant effect of  DRUG1  and  DRUG2 , resulting in a prolongation of prothrombin time.",negative,coumarin,warfarin
"Drug interactions should be kept in mind when  DRUG1  ( DRUG2  gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical  DRUGOTHER  administration because of low absorption.",negative,METROGEL,metronidazole
"Drug interactions should be kept in mind when  DRUG1  ( DRUGOTHER  gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical  DRUG2  administration because of low absorption.",negative,METROGEL,metronidazole
"Drug interactions should be kept in mind when  DRUGOTHER  ( DRUG1  gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical  DRUG2  administration because of low absorption.",negative,metronidazole,metronidazole
"Because  DRUG1  have been shown to depress plasma prothrombin activity, patients who are on  DRUG2  therapy may require downward adjustment of their  DRUGOTHER  dosage.",advise,tetracyclines,anticoagulant
"Because  DRUG1  have been shown to depress plasma prothrombin activity, patients who are on  DRUGOTHER  therapy may require downward adjustment of their  DRUG2  dosage.",negative,tetracyclines,anticoagulant
"Because  DRUGOTHER  have been shown to depress plasma prothrombin activity, patients who are on  DRUG1  therapy may require downward adjustment of their  DRUG2  dosage.",negative,anticoagulant,anticoagulant
"Since bacteriostatic drugs may interfere with the bactericidal action of  DRUG1 , it is advisable to avoid giving  DRUG2  in conjunction with  DRUGOTHER .",negative,penicillin,tetracycline class drugs
"Since bacteriostatic drugs may interfere with the bactericidal action of  DRUG1 , it is advisable to avoid giving  DRUGOTHER  in conjunction with  DRUG2 .",negative,penicillin,penicillin
"Since bacteriostatic drugs may interfere with the bactericidal action of  DRUGOTHER , it is advisable to avoid giving  DRUG1  in conjunction with  DRUG2 .",advise,tetracycline class drugs,penicillin
"Absorption of  DRUG1  is impaired by  DRUG2  containing  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER , and  DRUGOTHER -containing preparations.",negative,tetracyclines,antacids
"Absorption of  DRUG1  is impaired by  DRUGOTHER  containing  DRUG2 ,  DRUGOTHER  or  DRUGOTHER , and  DRUGOTHER -containing preparations.",mechanism,tetracyclines,aluminum
"Absorption of  DRUG1  is impaired by  DRUGOTHER  containing  DRUGOTHER ,  DRUG2  or  DRUGOTHER , and  DRUGOTHER -containing preparations.",mechanism,tetracyclines,calcium
"Absorption of  DRUG1  is impaired by  DRUGOTHER  containing  DRUGOTHER ,  DRUGOTHER  or  DRUG2 , and  DRUGOTHER -containing preparations.",mechanism,tetracyclines,magnesium
"Absorption of  DRUG1  is impaired by  DRUGOTHER  containing  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER , and  DRUG2 -containing preparations.",mechanism,tetracyclines,iron
"Absorption of  DRUGOTHER  is impaired by  DRUG1  containing  DRUG2 ,  DRUGOTHER  or  DRUGOTHER , and  DRUGOTHER -containing preparations.",negative,antacids,aluminum
"Absorption of  DRUGOTHER  is impaired by  DRUG1  containing  DRUGOTHER ,  DRUG2  or  DRUGOTHER , and  DRUGOTHER -containing preparations.",negative,antacids,calcium
"Absorption of  DRUGOTHER  is impaired by  DRUG1  containing  DRUGOTHER ,  DRUGOTHER  or  DRUG2 , and  DRUGOTHER -containing preparations.",negative,antacids,magnesium
"Absorption of  DRUGOTHER  is impaired by  DRUG1  containing  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER , and  DRUG2 -containing preparations.",negative,antacids,iron
"Absorption of  DRUGOTHER  is impaired by  DRUGOTHER  containing  DRUG1 ,  DRUG2  or  DRUGOTHER , and  DRUGOTHER -containing preparations.",negative,aluminum,calcium
"Absorption of  DRUGOTHER  is impaired by  DRUGOTHER  containing  DRUG1 ,  DRUGOTHER  or  DRUG2 , and  DRUGOTHER -containing preparations.",negative,aluminum,magnesium
"Absorption of  DRUGOTHER  is impaired by  DRUGOTHER  containing  DRUG1 ,  DRUGOTHER  or  DRUGOTHER , and  DRUG2 -containing preparations.",negative,aluminum,iron
"Absorption of  DRUGOTHER  is impaired by  DRUGOTHER  containing  DRUGOTHER ,  DRUG1  or  DRUG2 , and  DRUGOTHER -containing preparations.",negative,calcium,magnesium
"Absorption of  DRUGOTHER  is impaired by  DRUGOTHER  containing  DRUGOTHER ,  DRUG1  or  DRUGOTHER , and  DRUG2 -containing preparations.",negative,calcium,iron
"Absorption of  DRUGOTHER  is impaired by  DRUGOTHER  containing  DRUGOTHER ,  DRUGOTHER  or  DRUG1 , and  DRUG2 -containing preparations.",negative,magnesium,iron
The concurrent use of  DRUG1  and  DRUG2  has been reported to result in fatal renal toxicity.,effect,tetracycline,methoxyflurane
Concurrent use of  DRUG1  with oral  DRUG2  may render oral  DRUGOTHER  less effective.,effect,tetracyclines,contraceptives
Concurrent use of  DRUG1  with oral  DRUGOTHER  may render oral  DRUG2  less effective.,negative,tetracyclines,contraceptives
Concurrent use of  DRUGOTHER  with oral  DRUG1  may render oral  DRUG2  less effective.,negative,contraceptives,contraceptives
Concomitant administration of  DRUG1  and  DRUG2  has been associated with erythema and histamine-like flushing and anaphylactoid reactions.,effect,vancomycin,anesthetic agents
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER , when indicated, requires careful monitoring.",negative,amphotericin B,aminoglycosides
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER , when indicated, requires careful monitoring.",negative,amphotericin B,bacitracin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER , when indicated, requires careful monitoring.",negative,amphotericin B,polymyxin B
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER , when indicated, requires careful monitoring.",negative,amphotericin B,colistin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER , when indicated, requires careful monitoring.",negative,amphotericin B,viomycin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 , when indicated, requires careful monitoring.",negative,amphotericin B,cisplatin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER , when indicated, requires careful monitoring.",negative,aminoglycosides,bacitracin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER , when indicated, requires careful monitoring.",negative,aminoglycosides,polymyxin B
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER , when indicated, requires careful monitoring.",negative,aminoglycosides,colistin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER , when indicated, requires careful monitoring.",negative,aminoglycosides,viomycin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 , when indicated, requires careful monitoring.",negative,aminoglycosides,cisplatin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER , when indicated, requires careful monitoring.",negative,bacitracin,polymyxin B
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER , when indicated, requires careful monitoring.",negative,bacitracin,colistin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER , when indicated, requires careful monitoring.",negative,bacitracin,viomycin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 , when indicated, requires careful monitoring.",negative,bacitracin,cisplatin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER , when indicated, requires careful monitoring.",negative,polymyxin B,colistin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER , when indicated, requires careful monitoring.",negative,polymyxin B,viomycin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 , when indicated, requires careful monitoring.",negative,polymyxin B,cisplatin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , or  DRUGOTHER , when indicated, requires careful monitoring.",negative,colistin,viomycin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , or  DRUG2 , when indicated, requires careful monitoring.",negative,colistin,cisplatin
"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , or  DRUG2 , when indicated, requires careful monitoring.",negative,viomycin,cisplatin
"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with  DRUG1  with and without  DRUG2  or  DRUGOTHER .",effect,TRENTAL,anticoagulants
"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with  DRUG1  with and without  DRUGOTHER  or  DRUG2 .",effect,TRENTAL,platelet aggregation inhibitors
"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with  DRUGOTHER  with and without  DRUG1  or  DRUG2 .",negative,anticoagulants,platelet aggregation inhibitors
Concomitant administration of  DRUG1  and  DRUG2 -containing drugs leads to increased  DRUGOTHER  levels and  DRUGOTHER  toxicity in some individuals.,mechanism,TRENTAL,theophylline
Concomitant administration of  DRUG1  and  DRUGOTHER -containing drugs leads to increased  DRUG2  levels and  DRUGOTHER  toxicity in some individuals.,negative,TRENTAL,theophylline
Concomitant administration of  DRUG1  and  DRUGOTHER -containing drugs leads to increased  DRUGOTHER  levels and  DRUG2  toxicity in some individuals.,negative,TRENTAL,theophylline
Concomitant administration of  DRUGOTHER  and  DRUG1 -containing drugs leads to increased  DRUG2  levels and  DRUGOTHER  toxicity in some individuals.,negative,theophylline,theophylline
Concomitant administration of  DRUGOTHER  and  DRUG1 -containing drugs leads to increased  DRUGOTHER  levels and  DRUG2  toxicity in some individuals.,negative,theophylline,theophylline
Concomitant administration of  DRUGOTHER  and  DRUGOTHER -containing drugs leads to increased  DRUG1  levels and  DRUG2  toxicity in some individuals.,negative,theophylline,theophylline
" DRUG1  has been used concurrently with  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , without observed problems.",negative,TRENTAL,antihypertensive drugs
" DRUG1  has been used concurrently with  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , without observed problems.",negative,TRENTAL,beta blockers
" DRUG1  has been used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , without observed problems.",negative,TRENTAL,digitalis
" DRUG1  has been used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER , without observed problems.",negative,TRENTAL,diuretics
" DRUG1  has been used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER , without observed problems.",negative,TRENTAL,antidiabetic agents
" DRUG1  has been used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 , without observed problems.",negative,TRENTAL,antiarrhythmics
" DRUGOTHER  has been used concurrently with  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , without observed problems.",negative,antihypertensive drugs,beta blockers
" DRUGOTHER  has been used concurrently with  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , without observed problems.",negative,antihypertensive drugs,digitalis
" DRUGOTHER  has been used concurrently with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER , without observed problems.",negative,antihypertensive drugs,diuretics
" DRUGOTHER  has been used concurrently with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER , without observed problems.",negative,antihypertensive drugs,antidiabetic agents
" DRUGOTHER  has been used concurrently with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 , without observed problems.",negative,antihypertensive drugs,antiarrhythmics
" DRUGOTHER  has been used concurrently with  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , without observed problems.",negative,beta blockers,digitalis
" DRUGOTHER  has been used concurrently with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER , without observed problems.",negative,beta blockers,diuretics
" DRUGOTHER  has been used concurrently with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER , without observed problems.",negative,beta blockers,antidiabetic agents
" DRUGOTHER  has been used concurrently with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 , without observed problems.",negative,beta blockers,antiarrhythmics
" DRUGOTHER  has been used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER , without observed problems.",negative,digitalis,diuretics
" DRUGOTHER  has been used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER , without observed problems.",negative,digitalis,antidiabetic agents
" DRUGOTHER  has been used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 , without observed problems.",negative,digitalis,antiarrhythmics
" DRUGOTHER  has been used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER , without observed problems.",negative,diuretics,antidiabetic agents
" DRUGOTHER  has been used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 , without observed problems.",negative,diuretics,antiarrhythmics
" DRUGOTHER  has been used concurrently with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 , without observed problems.",negative,antidiabetic agents,antiarrhythmics
" DRUG1  may decrease the effectiveness of oral  DRUG2 , certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,Barbiturates,contraceptives
" DRUG1  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,Barbiturates,antibiotics
" DRUG1  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,Barbiturates,quinidine
" DRUG1  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,Barbiturates,theophylline
" DRUG1  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",int,Barbiturates,corticosteroids
" DRUG1  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",int,Barbiturates,anticoagulants
" DRUG1  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",int,Barbiturates,beta blockers
" DRUGOTHER  may decrease the effectiveness of oral  DRUG1 , certain  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,contraceptives,antibiotics
" DRUGOTHER  may decrease the effectiveness of oral  DRUG1 , certain  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,contraceptives,quinidine
" DRUGOTHER  may decrease the effectiveness of oral  DRUG1 , certain  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,contraceptives,theophylline
" DRUGOTHER  may decrease the effectiveness of oral  DRUG1 , certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,contraceptives,corticosteroids
" DRUGOTHER  may decrease the effectiveness of oral  DRUG1 , certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,contraceptives,anticoagulants
" DRUGOTHER  may decrease the effectiveness of oral  DRUG1 , certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,contraceptives,beta blockers
" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,antibiotics,quinidine
" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,antibiotics,theophylline
" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,antibiotics,corticosteroids
" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,antibiotics,anticoagulants
" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,antibiotics,beta blockers
" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,quinidine,theophylline
" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,quinidine,corticosteroids
" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,quinidine,anticoagulants
" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,quinidine,beta blockers
" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,theophylline,corticosteroids
" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,theophylline,anticoagulants
" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,theophylline,beta blockers
" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER .",negative,corticosteroids,anticoagulants
" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 .",negative,corticosteroids,beta blockers
" DRUGOTHER  may decrease the effectiveness of oral  DRUGOTHER , certain  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 .",negative,anticoagulants,beta blockers
Limited evidence suggests that  DRUG1  may influence the intensity and duration of action of  DRUG2 .,mechanism,ascorbic acid,bishydroxycoumarin
 DRUG1  competes with  DRUG2  for active tubular secretion and thus inhibits the renal excretion of  DRUGOTHER .,mechanism,Probenecid,meropenem
 DRUG1  competes with  DRUGOTHER  for active tubular secretion and thus inhibits the renal excretion of  DRUG2 .,negative,Probenecid,meropenem
 DRUGOTHER  competes with  DRUG1  for active tubular secretion and thus inhibits the renal excretion of  DRUG2 .,negative,meropenem,meropenem
"Therefore, the coadministration of  DRUG1  with  DRUG2  is not recommended.",advise,probenecid,meropenem
There is evidence that  DRUG1  may reduce serum levels of  DRUG2  to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total  DRUGOTHER ).,mechanism,meropenem,valproic acid
There is evidence that  DRUG1  may reduce serum levels of  DRUGOTHER  to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total  DRUG2 ).,negative,meropenem,valproate
There is evidence that  DRUGOTHER  may reduce serum levels of  DRUG1  to subtherapeutic levels (therapeutic range considered to be 50 to 100    g/mL total  DRUG2 ).,negative,valproic acid,valproate
"In addition to bleeding associated with  DRUG1  and  DRUG2 , drugs that alter platelet function (such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may increase the risk of bleeding if administered prior to or after  DRUGOTHER     therapy.",negative,heparin,vitamin K antagonists
"In addition to bleeding associated with  DRUG1  and  DRUGOTHER , drugs that alter platelet function (such as  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) may increase the risk of bleeding if administered prior to or after  DRUGOTHER     therapy.",negative,heparin,aspirin
"In addition to bleeding associated with  DRUG1  and  DRUGOTHER , drugs that alter platelet function (such as  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) may increase the risk of bleeding if administered prior to or after  DRUGOTHER     therapy.",negative,heparin,dipyridamole
"In addition to bleeding associated with  DRUG1  and  DRUGOTHER , drugs that alter platelet function (such as  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) may increase the risk of bleeding if administered prior to or after  DRUGOTHER     therapy.",negative,heparin,abciximab
"In addition to bleeding associated with  DRUG1  and  DRUGOTHER , drugs that alter platelet function (such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may increase the risk of bleeding if administered prior to or after  DRUG2     therapy.",effect,heparin,Retavase
"In addition to bleeding associated with  DRUGOTHER  and  DRUG1 , drugs that alter platelet function (such as  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) may increase the risk of bleeding if administered prior to or after  DRUGOTHER     therapy.",negative,vitamin K antagonists,aspirin
"In addition to bleeding associated with  DRUGOTHER  and  DRUG1 , drugs that alter platelet function (such as  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) may increase the risk of bleeding if administered prior to or after  DRUGOTHER     therapy.",negative,vitamin K antagonists,dipyridamole
"In addition to bleeding associated with  DRUGOTHER  and  DRUG1 , drugs that alter platelet function (such as  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) may increase the risk of bleeding if administered prior to or after  DRUGOTHER     therapy.",negative,vitamin K antagonists,abciximab
"In addition to bleeding associated with  DRUGOTHER  and  DRUG1 , drugs that alter platelet function (such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) may increase the risk of bleeding if administered prior to or after  DRUG2     therapy.",effect,vitamin K antagonists,Retavase
"In addition to bleeding associated with  DRUGOTHER  and  DRUGOTHER , drugs that alter platelet function (such as  DRUG1 ,  DRUG2 , and  DRUGOTHER ) may increase the risk of bleeding if administered prior to or after  DRUGOTHER     therapy.",negative,aspirin,dipyridamole
"In addition to bleeding associated with  DRUGOTHER  and  DRUGOTHER , drugs that alter platelet function (such as  DRUG1 ,  DRUGOTHER , and  DRUG2 ) may increase the risk of bleeding if administered prior to or after  DRUGOTHER     therapy.",negative,aspirin,abciximab
"In addition to bleeding associated with  DRUGOTHER  and  DRUGOTHER , drugs that alter platelet function (such as  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ) may increase the risk of bleeding if administered prior to or after  DRUG2     therapy.",effect,aspirin,Retavase
"In addition to bleeding associated with  DRUGOTHER  and  DRUGOTHER , drugs that alter platelet function (such as  DRUGOTHER ,  DRUG1 , and  DRUG2 ) may increase the risk of bleeding if administered prior to or after  DRUGOTHER     therapy.",negative,dipyridamole,abciximab
"In addition to bleeding associated with  DRUGOTHER  and  DRUGOTHER , drugs that alter platelet function (such as  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ) may increase the risk of bleeding if administered prior to or after  DRUG2     therapy.",effect,dipyridamole,Retavase
"In addition to bleeding associated with  DRUGOTHER  and  DRUGOTHER , drugs that alter platelet function (such as  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ) may increase the risk of bleeding if administered prior to or after  DRUG2     therapy.",effect,abciximab,Retavase
"Because there is a theoretical basis that these effects may be additive, use of  DRUG1 -containing or  DRUG2  (like  DRUGOTHER  or  DRUGOTHER ) and  DRUGOTHER  within 24 hours of each other should be avoided.",negative,ergotamine,ergot-type medications
"Because there is a theoretical basis that these effects may be additive, use of  DRUG1 -containing or  DRUGOTHER  (like  DRUG2  or  DRUGOTHER ) and  DRUGOTHER  within 24 hours of each other should be avoided.",negative,ergotamine,dihydroergotamine
"Because there is a theoretical basis that these effects may be additive, use of  DRUG1 -containing or  DRUGOTHER  (like  DRUGOTHER  or  DRUG2 ) and  DRUGOTHER  within 24 hours of each other should be avoided.",negative,ergotamine,methysergide
"Because there is a theoretical basis that these effects may be additive, use of  DRUG1 -containing or  DRUGOTHER  (like  DRUGOTHER  or  DRUGOTHER ) and  DRUG2  within 24 hours of each other should be avoided.",advise,ergotamine,sumatriptan
"Because there is a theoretical basis that these effects may be additive, use of  DRUGOTHER -containing or  DRUG1  (like  DRUG2  or  DRUGOTHER ) and  DRUGOTHER  within 24 hours of each other should be avoided.",negative,ergot-type medications,dihydroergotamine
"Because there is a theoretical basis that these effects may be additive, use of  DRUGOTHER -containing or  DRUG1  (like  DRUGOTHER  or  DRUG2 ) and  DRUGOTHER  within 24 hours of each other should be avoided.",negative,ergot-type medications,methysergide
"Because there is a theoretical basis that these effects may be additive, use of  DRUGOTHER -containing or  DRUG1  (like  DRUGOTHER  or  DRUGOTHER ) and  DRUG2  within 24 hours of each other should be avoided.",advise,ergot-type medications,sumatriptan
"Because there is a theoretical basis that these effects may be additive, use of  DRUGOTHER -containing or  DRUGOTHER  (like  DRUG1  or  DRUG2 ) and  DRUGOTHER  within 24 hours of each other should be avoided.",negative,dihydroergotamine,methysergide
"Because there is a theoretical basis that these effects may be additive, use of  DRUGOTHER -containing or  DRUGOTHER  (like  DRUG1  or  DRUGOTHER ) and  DRUG2  within 24 hours of each other should be avoided.",advise,dihydroergotamine,sumatriptan
"Because there is a theoretical basis that these effects may be additive, use of  DRUGOTHER -containing or  DRUGOTHER  (like  DRUGOTHER  or  DRUG1 ) and  DRUG2  within 24 hours of each other should be avoided.",advise,methysergide,sumatriptan
" DRUG1  reduce  DRUG2  clearance, significantly increasing systemic exposure.",mechanism,MAO-A inhibitors,sumatriptan
"Therefore, the use of  DRUG1  tablets in patients receiving  DRUG2  is contraindicated .  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",advise,sumatriptan succinate,MAO-A inhibitors
"Therefore, the use of  DRUG1  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUG2  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,sumatriptan succinate,Selective serotonin reuptake inhibitors
"Therefore, the use of  DRUG1  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUGOTHER  ( DRUG2 ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,sumatriptan succinate,SSRIs
"Therefore, the use of  DRUG1  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,sumatriptan succinate,fluoxetine
"Therefore, the use of  DRUG1  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,sumatriptan succinate,fluvoxamine
"Therefore, the use of  DRUG1  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,sumatriptan succinate,paroxetine
"Therefore, the use of  DRUG1  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,sumatriptan succinate,sertraline
"Therefore, the use of  DRUG1  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUG2 .",negative,sumatriptan succinate,sumatriptan
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUG1  is contraindicated .  DRUG2  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,MAO-A inhibitors,Selective serotonin reuptake inhibitors
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUG1  is contraindicated .  DRUGOTHER  ( DRUG2 ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,MAO-A inhibitors,SSRIs
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUG1  is contraindicated .  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,MAO-A inhibitors,fluoxetine
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUG1  is contraindicated .  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,MAO-A inhibitors,fluvoxamine
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUG1  is contraindicated .  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,MAO-A inhibitors,paroxetine
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUG1  is contraindicated .  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,MAO-A inhibitors,sertraline
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUG1  is contraindicated .  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUG2 .",negative,MAO-A inhibitors,sumatriptan
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUG1  ( DRUG2 ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,Selective serotonin reuptake inhibitors,SSRIs
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUG1  ( DRUGOTHER ) (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,Selective serotonin reuptake inhibitors,fluoxetine
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUG1  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,Selective serotonin reuptake inhibitors,fluvoxamine
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUG1  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,Selective serotonin reuptake inhibitors,paroxetine
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUG1  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,Selective serotonin reuptake inhibitors,sertraline
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUG1  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUG2 .",effect,Selective serotonin reuptake inhibitors,sumatriptan
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUGOTHER  ( DRUG1 ) (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,SSRIs,fluoxetine
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUGOTHER  ( DRUG1 ) (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,SSRIs,fluvoxamine
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUGOTHER  ( DRUG1 ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,SSRIs,paroxetine
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUGOTHER  ( DRUG1 ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,SSRIs,sertraline
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUGOTHER  ( DRUG1 ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUG2 .",effect,SSRIs,sumatriptan
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,fluoxetine,fluvoxamine
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,fluoxetine,paroxetine
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,fluoxetine,sertraline
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUG2 .",effect,fluoxetine,sumatriptan
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,fluvoxamine,paroxetine
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,fluvoxamine,sertraline
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUG2 .",effect,fluvoxamine,sumatriptan
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUGOTHER .",negative,paroxetine,sertraline
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUG2 .",effect,paroxetine,sumatriptan
"Therefore, the use of  DRUGOTHER  tablets in patients receiving  DRUGOTHER  is contraindicated .  DRUGOTHER  ( DRUGOTHER ) (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with  DRUG2 .",effect,sertraline,sumatriptan
"If concomitant treatment with  DRUG1  and an  DRUG2  is clinically warranted, appropriate observation of the patient is advised.",advise,sumatriptan,SSRI
"To minimize CNS depression and possible potentiation,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER  should be used with caution.",negative,barbiturates,antihistamines
"To minimize CNS depression and possible potentiation,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER  should be used with caution.",negative,barbiturates,narcotics
"To minimize CNS depression and possible potentiation,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER  should be used with caution.",negative,barbiturates,hypotensive agents
"To minimize CNS depression and possible potentiation,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2  should be used with caution.",negative,barbiturates,phenothiazines
"To minimize CNS depression and possible potentiation,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER  should be used with caution.",negative,antihistamines,narcotics
"To minimize CNS depression and possible potentiation,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER  should be used with caution.",negative,antihistamines,hypotensive agents
"To minimize CNS depression and possible potentiation,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2  should be used with caution.",negative,antihistamines,phenothiazines
"To minimize CNS depression and possible potentiation,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  or  DRUGOTHER  should be used with caution.",negative,narcotics,hypotensive agents
"To minimize CNS depression and possible potentiation,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  or  DRUG2  should be used with caution.",negative,narcotics,phenothiazines
"To minimize CNS depression and possible potentiation,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  or  DRUG2  should be used with caution.",negative,hypotensive agents,phenothiazines
"Because  DRUG1  exhibits some monoamine oxidase inhibitory activity,  DRUG2 ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ) and other drugs and foods with known high  DRUGOTHER  content, such as wine, yogurt, ripe cheese and bananas, should be avoided.",advise,Matulane,sympathomimetic drugs
"Because  DRUG1  exhibits some monoamine oxidase inhibitory activity,  DRUGOTHER ,  DRUG2  drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ) and other drugs and foods with known high  DRUGOTHER  content, such as wine, yogurt, ripe cheese and bananas, should be avoided.",advise,Matulane,tricyclic antidepressant
"Because  DRUG1  exhibits some monoamine oxidase inhibitory activity,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUG2 ,  DRUGOTHER ) and other drugs and foods with known high  DRUGOTHER  content, such as wine, yogurt, ripe cheese and bananas, should be avoided.",advise,Matulane,amitriptyline HCl
"Because  DRUG1  exhibits some monoamine oxidase inhibitory activity,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ,  DRUG2 ) and other drugs and foods with known high  DRUGOTHER  content, such as wine, yogurt, ripe cheese and bananas, should be avoided.",advise,Matulane,imipramine HCl
"Because  DRUG1  exhibits some monoamine oxidase inhibitory activity,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ) and other drugs and foods with known high  DRUG2  content, such as wine, yogurt, ripe cheese and bananas, should be avoided.",advise,Matulane,tyramine
"Because  DRUGOTHER  exhibits some monoamine oxidase inhibitory activity,  DRUG1 ,  DRUG2  drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ) and other drugs and foods with known high  DRUGOTHER  content, such as wine, yogurt, ripe cheese and bananas, should be avoided.",negative,sympathomimetic drugs,tricyclic antidepressant
"Because  DRUGOTHER  exhibits some monoamine oxidase inhibitory activity,  DRUG1 ,  DRUGOTHER  drugs (e.g.,  DRUG2 ,  DRUGOTHER ) and other drugs and foods with known high  DRUGOTHER  content, such as wine, yogurt, ripe cheese and bananas, should be avoided.",negative,sympathomimetic drugs,amitriptyline HCl
"Because  DRUGOTHER  exhibits some monoamine oxidase inhibitory activity,  DRUG1 ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ,  DRUG2 ) and other drugs and foods with known high  DRUGOTHER  content, such as wine, yogurt, ripe cheese and bananas, should be avoided.",negative,sympathomimetic drugs,imipramine HCl
"Because  DRUGOTHER  exhibits some monoamine oxidase inhibitory activity,  DRUG1 ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ) and other drugs and foods with known high  DRUG2  content, such as wine, yogurt, ripe cheese and bananas, should be avoided.",negative,sympathomimetic drugs,tyramine
"Because  DRUGOTHER  exhibits some monoamine oxidase inhibitory activity,  DRUGOTHER ,  DRUG1  drugs (e.g.,  DRUG2 ,  DRUGOTHER ) and other drugs and foods with known high  DRUGOTHER  content, such as wine, yogurt, ripe cheese and bananas, should be avoided.",negative,tricyclic antidepressant,amitriptyline HCl
"Because  DRUGOTHER  exhibits some monoamine oxidase inhibitory activity,  DRUGOTHER ,  DRUG1  drugs (e.g.,  DRUGOTHER ,  DRUG2 ) and other drugs and foods with known high  DRUGOTHER  content, such as wine, yogurt, ripe cheese and bananas, should be avoided.",negative,tricyclic antidepressant,imipramine HCl
"Because  DRUGOTHER  exhibits some monoamine oxidase inhibitory activity,  DRUGOTHER ,  DRUG1  drugs (e.g.,  DRUGOTHER ,  DRUGOTHER ) and other drugs and foods with known high  DRUG2  content, such as wine, yogurt, ripe cheese and bananas, should be avoided.",negative,tricyclic antidepressant,tyramine
"Because  DRUGOTHER  exhibits some monoamine oxidase inhibitory activity,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUG1 ,  DRUG2 ) and other drugs and foods with known high  DRUGOTHER  content, such as wine, yogurt, ripe cheese and bananas, should be avoided.",negative,amitriptyline HCl,imipramine HCl
"Because  DRUGOTHER  exhibits some monoamine oxidase inhibitory activity,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUG1 ,  DRUGOTHER ) and other drugs and foods with known high  DRUG2  content, such as wine, yogurt, ripe cheese and bananas, should be avoided.",negative,amitriptyline HCl,tyramine
"Because  DRUGOTHER  exhibits some monoamine oxidase inhibitory activity,  DRUGOTHER ,  DRUGOTHER  drugs (e.g.,  DRUGOTHER ,  DRUG1 ) and other drugs and foods with known high  DRUG2  content, such as wine, yogurt, ripe cheese and bananas, should be avoided.",negative,imipramine HCl,tyramine
"No cross-resistance with other  DRUG1 , radiotherapy or  DRUG2  has been demonstrated.",negative,chemotherapeutic agents,steroids
 DRUG1    failure in an HIV-positive woman on  DRUG2  therapy resulting in two ectopic pregnancies.,effect,Implanon,antiretroviral
We present an interesting case of an HIV-positive woman on  DRUG1  therapy having tubal pregnancies on two separate occasions with  DRUG2  in place.,effect,antiretroviral,Implanon
"Drugs which may potentiate the myeloproliferative effects of  DRUG1 , such as  DRUG2  and  DRUGOTHER , should be used with caution.",effect,Leukine,lithium
"Drugs which may potentiate the myeloproliferative effects of  DRUG1 , such as  DRUGOTHER  and  DRUG2 , should be used with caution.",effect,Leukine,corticosteroids
"Drugs which may potentiate the myeloproliferative effects of  DRUGOTHER , such as  DRUG1  and  DRUG2 , should be used with caution.",negative,lithium,corticosteroids
Drug-Drug Interactions Effect of  DRUG1     ( DRUG2 ) on the Metabolism of Other Drugs:  DRUGOTHER  is primarily metabolized through hydrolysis by esterases.,negative,Exelon,rivastigmine tartrate
Drug-Drug Interactions Effect of  DRUG1     ( DRUGOTHER ) on the Metabolism of Other Drugs:  DRUG2  is primarily metabolized through hydrolysis by esterases.,negative,Exelon,Rivastigmine
Drug-Drug Interactions Effect of  DRUGOTHER     ( DRUG1 ) on the Metabolism of Other Drugs:  DRUG2  is primarily metabolized through hydrolysis by esterases.,negative,rivastigmine tartrate,Rivastigmine
"No pharmacokinetic interaction was observed between  DRUG1  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  in studies in healthy volunteers.",negative,rivastigmine,digoxin
"No pharmacokinetic interaction was observed between  DRUG1  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER  in studies in healthy volunteers.",negative,rivastigmine,warfarin
"No pharmacokinetic interaction was observed between  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER  in studies in healthy volunteers.",negative,rivastigmine,diazepam
"No pharmacokinetic interaction was observed between  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2  in studies in healthy volunteers.",negative,rivastigmine,fluoxetine
"No pharmacokinetic interaction was observed between  DRUGOTHER  and  DRUG1 ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER  in studies in healthy volunteers.",negative,digoxin,warfarin
"No pharmacokinetic interaction was observed between  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER  in studies in healthy volunteers.",negative,digoxin,diazepam
"No pharmacokinetic interaction was observed between  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2  in studies in healthy volunteers.",negative,digoxin,fluoxetine
"No pharmacokinetic interaction was observed between  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUG2 , or  DRUGOTHER  in studies in healthy volunteers.",negative,warfarin,diazepam
"No pharmacokinetic interaction was observed between  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , or  DRUG2  in studies in healthy volunteers.",negative,warfarin,fluoxetine
"No pharmacokinetic interaction was observed between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , or  DRUG2  in studies in healthy volunteers.",negative,diazepam,fluoxetine
The elevation of prothrombin time induced by  DRUG1  is not affected by administration of  DRUG2 .,negative,warfarin,Exelon
Effect of Other Drugs on the Metabolism of  DRUG1 : Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of  DRUG2 .,negative,Exelon,rivastigmine
"Single dose pharmacokinetic studies demonstrated that the metabolism of  DRUG1  is not significantly affected by concurrent administration of  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,rivastigmine,digoxin
"Single dose pharmacokinetic studies demonstrated that the metabolism of  DRUG1  is not significantly affected by concurrent administration of  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,rivastigmine,warfarin
"Single dose pharmacokinetic studies demonstrated that the metabolism of  DRUG1  is not significantly affected by concurrent administration of  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,rivastigmine,diazepam
"Single dose pharmacokinetic studies demonstrated that the metabolism of  DRUG1  is not significantly affected by concurrent administration of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,rivastigmine,fluoxetine
"Single dose pharmacokinetic studies demonstrated that the metabolism of  DRUGOTHER  is not significantly affected by concurrent administration of  DRUG1 ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,digoxin,warfarin
"Single dose pharmacokinetic studies demonstrated that the metabolism of  DRUGOTHER  is not significantly affected by concurrent administration of  DRUG1 ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,digoxin,diazepam
"Single dose pharmacokinetic studies demonstrated that the metabolism of  DRUGOTHER  is not significantly affected by concurrent administration of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,digoxin,fluoxetine
"Single dose pharmacokinetic studies demonstrated that the metabolism of  DRUGOTHER  is not significantly affected by concurrent administration of  DRUGOTHER ,  DRUG1 ,  DRUG2 , or  DRUGOTHER .",negative,warfarin,diazepam
"Single dose pharmacokinetic studies demonstrated that the metabolism of  DRUGOTHER  is not significantly affected by concurrent administration of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , or  DRUG2 .",negative,warfarin,fluoxetine
"Single dose pharmacokinetic studies demonstrated that the metabolism of  DRUGOTHER  is not significantly affected by concurrent administration of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , or  DRUG2 .",negative,diazepam,fluoxetine
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUG1  were not influenced by commonly prescribed medications such as  DRUG2  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,rivastigmine,antacids
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUG1  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUG2  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,rivastigmine,antihypertensives
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUG1  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUG2  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,rivastigmine,calcium channel blockers
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUG1  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUG2  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,rivastigmine,antidiabetics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUG1  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUG2  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,rivastigmine,nonsteroidal anti-inflammatory drugs
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUG1  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUG2  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,rivastigmine,estrogens
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUG1  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUG2  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,rivastigmine,salicylate analgesics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUG1  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUG2  (n=35), and  DRUGOTHER  (n=15).",negative,rivastigmine,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUG1  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUG2  (n=15).",negative,rivastigmine,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUG1  (n=77),  DRUG2  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,antacids,antihypertensives
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUG1  (n=77),  DRUGOTHER  (n=72),  DRUG2  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,antacids,calcium channel blockers
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUG1  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUG2  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,antacids,antidiabetics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUG1  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUG2  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,antacids,nonsteroidal anti-inflammatory drugs
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUG1  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUG2  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,antacids,estrogens
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUG1  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUG2  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,antacids,salicylate analgesics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUG1  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUG2  (n=35), and  DRUGOTHER  (n=15).",negative,antacids,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUG1  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUG2  (n=15).",negative,antacids,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUG1  (n=72),  DRUG2  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,antihypertensives,calcium channel blockers
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUG1  (n=72),  DRUGOTHER  (n=75),  DRUG2  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,antihypertensives,antidiabetics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUG1  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUG2  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,antihypertensives,nonsteroidal anti-inflammatory drugs
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUG1  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUG2  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,antihypertensives,estrogens
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUG1  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUG2  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,antihypertensives,salicylate analgesics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUG1  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUG2  (n=35), and  DRUGOTHER  (n=15).",negative,antihypertensives,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUG1  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUG2  (n=15).",negative,antihypertensives,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUG1  (n=75),  DRUG2  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,calcium channel blockers,antidiabetics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUG1  (n=75),  DRUGOTHER  (n=21),  DRUG2  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,calcium channel blockers,nonsteroidal anti-inflammatory drugs
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUG1  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUG2  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,calcium channel blockers,estrogens
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUG1  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUG2  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,calcium channel blockers,salicylate analgesics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUG1  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUG2  (n=35), and  DRUGOTHER  (n=15).",negative,calcium channel blockers,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUG1  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUG2  (n=15).",negative,calcium channel blockers,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUG1  (n=21),  DRUG2  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,antidiabetics,nonsteroidal anti-inflammatory drugs
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUG1  (n=21),  DRUGOTHER  (n=79),  DRUG2  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,antidiabetics,estrogens
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUG1  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUG2  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,antidiabetics,salicylate analgesics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUG1  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUG2  (n=35), and  DRUGOTHER  (n=15).",negative,antidiabetics,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUG1  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUG2  (n=15).",negative,antidiabetics,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUG1  (n=79),  DRUG2  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,nonsteroidal anti-inflammatory drugs,estrogens
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUG1  (n=79),  DRUGOTHER  (n=70),  DRUG2  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,nonsteroidal anti-inflammatory drugs,salicylate analgesics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUG1  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUG2  (n=35), and  DRUGOTHER  (n=15).",negative,nonsteroidal anti-inflammatory drugs,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUG1  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUG2  (n=15).",negative,nonsteroidal anti-inflammatory drugs,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUG1  (n=70),  DRUG2  (n=177),  DRUGOTHER  (n=35), and  DRUGOTHER  (n=15).",negative,estrogens,salicylate analgesics
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUG1  (n=70),  DRUGOTHER  (n=177),  DRUG2  (n=35), and  DRUGOTHER  (n=15).",negative,estrogens,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUG1  (n=70),  DRUGOTHER  (n=177),  DRUGOTHER  (n=35), and  DRUG2  (n=15).",negative,estrogens,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUG1  (n=177),  DRUG2  (n=35), and  DRUGOTHER  (n=15).",negative,salicylate analgesics,antianginals
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUG1  (n=177),  DRUGOTHER  (n=35), and  DRUG2  (n=15).",negative,salicylate analgesics,antihistamines
"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of  DRUGOTHER  were not influenced by commonly prescribed medications such as  DRUGOTHER  (n=77),  DRUGOTHER  (n=72),  DRUGOTHER  (n=75),  DRUGOTHER  (n=21),  DRUGOTHER  (n=79),  DRUGOTHER  (n=70),  DRUGOTHER  (n=177),  DRUG1  (n=35), and  DRUG2  (n=15).",negative,antianginals,antihistamines
"Use with  DRUG1 : Because of their mechanism of action,  DRUG2  have the potential to interfere with the activity of  DRUGOTHER .",negative,Anticholinergics,cholinesterase inhibitors
"Use with  DRUG1 : Because of their mechanism of action,  DRUGOTHER  have the potential to interfere with the activity of  DRUG2 .",negative,Anticholinergics,anticholinergic medications
"Use with  DRUGOTHER : Because of their mechanism of action,  DRUG1  have the potential to interfere with the activity of  DRUG2 .",int,cholinesterase inhibitors,anticholinergic medications
"Use with  DRUG1  and Other  DRUG2 : A synergistic effect may be expected when  DRUGOTHER  are given concurrently with  DRUGOTHER , similar  DRUGOTHER  or  DRUGOTHER  such as  DRUGOTHER .",negative,Cholinomimetics,Cholinesterase Inhibitors
"Use with  DRUG1  and Other  DRUGOTHER : A synergistic effect may be expected when  DRUG2  are given concurrently with  DRUGOTHER , similar  DRUGOTHER  or  DRUGOTHER  such as  DRUGOTHER .",negative,Cholinomimetics,cholinesterase inhibitors
"Use with  DRUG1  and Other  DRUGOTHER : A synergistic effect may be expected when  DRUGOTHER  are given concurrently with  DRUG2 , similar  DRUGOTHER  or  DRUGOTHER  such as  DRUGOTHER .",negative,Cholinomimetics,succinylcholine
"Use with  DRUG1  and Other  DRUGOTHER : A synergistic effect may be expected when  DRUGOTHER  are given concurrently with  DRUGOTHER , similar  DRUG2  or  DRUGOTHER  such as  DRUGOTHER .",negative,Cholinomimetics,neuromuscular blocking agents
"Use with  DRUG1  and Other  DRUGOTHER : A synergistic effect may be expected when  DRUGOTHER  are given concurrently with  DRUGOTHER , similar  DRUGOTHER  or  DRUG2  such as  DRUGOTHER .",negative,Cholinomimetics,cholinergic agonists
"Use with  DRUG1  and Other  DRUGOTHER : A synergistic effect may be expected when  DRUGOTHER  are given concurrently with  DRUGOTHER , similar  DRUGOTHER  or  DRUGOTHER  such as  DRUG2 .",negative,Cholinomimetics,bethanechol
"Use with  DRUGOTHER  and Other  DRUG1 : A synergistic effect may be expected when  DRUG2  are given concurrently with  DRUGOTHER , similar  DRUGOTHER  or  DRUGOTHER  such as  DRUGOTHER .",negative,Cholinesterase Inhibitors,cholinesterase inhibitors
"Use with  DRUGOTHER  and Other  DRUG1 : A synergistic effect may be expected when  DRUGOTHER  are given concurrently with  DRUG2 , similar  DRUGOTHER  or  DRUGOTHER  such as  DRUGOTHER .",negative,Cholinesterase Inhibitors,succinylcholine
"Use with  DRUGOTHER  and Other  DRUG1 : A synergistic effect may be expected when  DRUGOTHER  are given concurrently with  DRUGOTHER , similar  DRUG2  or  DRUGOTHER  such as  DRUGOTHER .",negative,Cholinesterase Inhibitors,neuromuscular blocking agents
"Use with  DRUGOTHER  and Other  DRUG1 : A synergistic effect may be expected when  DRUGOTHER  are given concurrently with  DRUGOTHER , similar  DRUGOTHER  or  DRUG2  such as  DRUGOTHER .",negative,Cholinesterase Inhibitors,cholinergic agonists
"Use with  DRUGOTHER  and Other  DRUG1 : A synergistic effect may be expected when  DRUGOTHER  are given concurrently with  DRUGOTHER , similar  DRUGOTHER  or  DRUGOTHER  such as  DRUG2 .",negative,Cholinesterase Inhibitors,bethanechol
"Use with  DRUGOTHER  and Other  DRUGOTHER : A synergistic effect may be expected when  DRUG1  are given concurrently with  DRUG2 , similar  DRUGOTHER  or  DRUGOTHER  such as  DRUGOTHER .",effect,cholinesterase inhibitors,succinylcholine
"Use with  DRUGOTHER  and Other  DRUGOTHER : A synergistic effect may be expected when  DRUG1  are given concurrently with  DRUGOTHER , similar  DRUG2  or  DRUGOTHER  such as  DRUGOTHER .",effect,cholinesterase inhibitors,neuromuscular blocking agents
"Use with  DRUGOTHER  and Other  DRUGOTHER : A synergistic effect may be expected when  DRUG1  are given concurrently with  DRUGOTHER , similar  DRUGOTHER  or  DRUG2  such as  DRUGOTHER .",effect,cholinesterase inhibitors,cholinergic agonists
"Use with  DRUGOTHER  and Other  DRUGOTHER : A synergistic effect may be expected when  DRUG1  are given concurrently with  DRUGOTHER , similar  DRUGOTHER  or  DRUGOTHER  such as  DRUG2 .",effect,cholinesterase inhibitors,bethanechol
"Use with  DRUGOTHER  and Other  DRUGOTHER : A synergistic effect may be expected when  DRUGOTHER  are given concurrently with  DRUG1 , similar  DRUG2  or  DRUGOTHER  such as  DRUGOTHER .",negative,succinylcholine,neuromuscular blocking agents
"Use with  DRUGOTHER  and Other  DRUGOTHER : A synergistic effect may be expected when  DRUGOTHER  are given concurrently with  DRUG1 , similar  DRUGOTHER  or  DRUG2  such as  DRUGOTHER .",negative,succinylcholine,cholinergic agonists
"Use with  DRUGOTHER  and Other  DRUGOTHER : A synergistic effect may be expected when  DRUGOTHER  are given concurrently with  DRUG1 , similar  DRUGOTHER  or  DRUGOTHER  such as  DRUG2 .",negative,succinylcholine,bethanechol
"Use with  DRUGOTHER  and Other  DRUGOTHER : A synergistic effect may be expected when  DRUGOTHER  are given concurrently with  DRUGOTHER , similar  DRUG1  or  DRUG2  such as  DRUGOTHER .",negative,neuromuscular blocking agents,cholinergic agonists
"Use with  DRUGOTHER  and Other  DRUGOTHER : A synergistic effect may be expected when  DRUGOTHER  are given concurrently with  DRUGOTHER , similar  DRUG1  or  DRUGOTHER  such as  DRUG2 .",negative,neuromuscular blocking agents,bethanechol
"Use with  DRUGOTHER  and Other  DRUGOTHER : A synergistic effect may be expected when  DRUGOTHER  are given concurrently with  DRUGOTHER , similar  DRUGOTHER  or  DRUG1  such as  DRUG2 .",negative,cholinergic agonists,bethanechol
The role of p27(Kip1) in  DRUG1 -enhanced  DRUG2  cytotoxicity in human ovarian cancer cells.,effect,dasatinib,paclitaxel
"The effect of  DRUG1 , an inhibitor of Src and Abl kinases, on  DRUG2  sensitivity was measured in ovarian cancer cells and HEY xenografts.",negative,dasatinib,paclitaxel
"The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by  DRUG1  and  DRUG2  were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry.",negative,dasatinib,paclitaxel
HEY cells treated with  DRUG1  plus  DRUG2  formed fewer colonies than did cells treated with either agent alone.,effect,dasatinib,paclitaxel
"Treatment of HEY xenograft-bearing mice with  DRUG1  plus  DRUG2  inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse,  DRUGOTHER  +  DRUGOTHER  vs  DRUGOTHER : 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);",effect,dasatinib,paclitaxel
"Treatment of HEY xenograft-bearing mice with  DRUG1  plus  DRUGOTHER  inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse,  DRUG2  +  DRUGOTHER  vs  DRUGOTHER : 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);",negative,dasatinib,dasatinib
"Treatment of HEY xenograft-bearing mice with  DRUG1  plus  DRUGOTHER  inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse,  DRUGOTHER  +  DRUG2  vs  DRUGOTHER : 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);",negative,dasatinib,paclitaxel
"Treatment of HEY xenograft-bearing mice with  DRUG1  plus  DRUGOTHER  inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse,  DRUGOTHER  +  DRUGOTHER  vs  DRUG2 : 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);",negative,dasatinib,paclitaxel
"Treatment of HEY xenograft-bearing mice with  DRUGOTHER  plus  DRUG1  inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse,  DRUG2  +  DRUGOTHER  vs  DRUGOTHER : 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);",negative,paclitaxel,dasatinib
"Treatment of HEY xenograft-bearing mice with  DRUGOTHER  plus  DRUG1  inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse,  DRUGOTHER  +  DRUG2  vs  DRUGOTHER : 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);",negative,paclitaxel,paclitaxel
"Treatment of HEY xenograft-bearing mice with  DRUGOTHER  plus  DRUG1  inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse,  DRUGOTHER  +  DRUGOTHER  vs  DRUG2 : 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);",negative,paclitaxel,paclitaxel
"Treatment of HEY xenograft-bearing mice with  DRUGOTHER  plus  DRUGOTHER  inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse,  DRUG1  +  DRUG2  vs  DRUGOTHER : 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);",negative,dasatinib,paclitaxel
"Treatment of HEY xenograft-bearing mice with  DRUGOTHER  plus  DRUGOTHER  inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse,  DRUG1  +  DRUGOTHER  vs  DRUG2 : 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);",negative,dasatinib,paclitaxel
"Treatment of HEY xenograft-bearing mice with  DRUGOTHER  plus  DRUGOTHER  inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse,  DRUGOTHER  +  DRUG1  vs  DRUG2 : 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014);",negative,paclitaxel,paclitaxel
 DRUG1  +  DRUG2  vs.,negative,dasatinib,paclitaxel
"The siRNA knockdown of p27(Kip1) decreased  DRUG1 - and  DRUG2 -induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017).",negative,dasatinib,paclitaxel
Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that  DRUG1 -mediated induction of p27(Kip1) enhanced  DRUG2 -induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression.,effect,dasatinib,paclitaxel
Inhibition of Src family and Abl kinases with either siRNAs or  DRUG1  enhances  DRUG2  sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.,effect,dasatinib,paclitaxel
"In the present study, we tested whether the highly specific metabotropic glutamate receptor 5 antagonist,  DRUG1 , reduces dopaminergic and noradrenergic neuronal loss in monkeys rendered parkinsonian by chronic treatment with low doses of  DRUG2 .",negative,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"Weekly intramuscular  DRUG1  injections (0.2-0.5 mg/kg body weight), in combination with daily administration of  DRUG2  or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( DRUGOTHER / DRUGOTHER  versus  DRUGOTHER /vehicle).",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"Weekly intramuscular  DRUG1  injections (0.2-0.5 mg/kg body weight), in combination with daily administration of  DRUGOTHER  or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( DRUG2 / DRUGOTHER  versus  DRUGOTHER /vehicle).",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"Weekly intramuscular  DRUG1  injections (0.2-0.5 mg/kg body weight), in combination with daily administration of  DRUGOTHER  or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( DRUGOTHER / DRUG2  versus  DRUGOTHER /vehicle).",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"Weekly intramuscular  DRUG1  injections (0.2-0.5 mg/kg body weight), in combination with daily administration of  DRUGOTHER  or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( DRUGOTHER / DRUGOTHER  versus  DRUG2 /vehicle).",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"Weekly intramuscular  DRUGOTHER  injections (0.2-0.5 mg/kg body weight), in combination with daily administration of  DRUG1  or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( DRUG2 / DRUGOTHER  versus  DRUGOTHER /vehicle).",negative,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"Weekly intramuscular  DRUGOTHER  injections (0.2-0.5 mg/kg body weight), in combination with daily administration of  DRUG1  or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( DRUGOTHER / DRUG2  versus  DRUGOTHER /vehicle).",negative,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"Weekly intramuscular  DRUGOTHER  injections (0.2-0.5 mg/kg body weight), in combination with daily administration of  DRUG1  or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( DRUGOTHER / DRUGOTHER  versus  DRUG2 /vehicle).",negative,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"Weekly intramuscular  DRUGOTHER  injections (0.2-0.5 mg/kg body weight), in combination with daily administration of  DRUGOTHER  or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( DRUG1 / DRUG2  versus  DRUGOTHER /vehicle).",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"Weekly intramuscular  DRUGOTHER  injections (0.2-0.5 mg/kg body weight), in combination with daily administration of  DRUGOTHER  or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( DRUG1 / DRUGOTHER  versus  DRUG2 /vehicle).",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"Weekly intramuscular  DRUGOTHER  injections (0.2-0.5 mg/kg body weight), in combination with daily administration of  DRUGOTHER  or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( DRUGOTHER / DRUG1  versus  DRUG2 /vehicle).",negative,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"After 21 weeks of  DRUG1  treatment, all  DRUG2 /vehicle-treated animals displayed parkinsonian symptoms, whereas none of the  DRUGOTHER / DRUGOTHER -treated monkeys were significantly affected.",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"After 21 weeks of  DRUG1  treatment, all  DRUGOTHER /vehicle-treated animals displayed parkinsonian symptoms, whereas none of the  DRUG2 / DRUGOTHER -treated monkeys were significantly affected.",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"After 21 weeks of  DRUG1  treatment, all  DRUGOTHER /vehicle-treated animals displayed parkinsonian symptoms, whereas none of the  DRUGOTHER / DRUG2 -treated monkeys were significantly affected.",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"After 21 weeks of  DRUGOTHER  treatment, all  DRUG1 /vehicle-treated animals displayed parkinsonian symptoms, whereas none of the  DRUG2 / DRUGOTHER -treated monkeys were significantly affected.",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"After 21 weeks of  DRUGOTHER  treatment, all  DRUG1 /vehicle-treated animals displayed parkinsonian symptoms, whereas none of the  DRUGOTHER / DRUG2 -treated monkeys were significantly affected.",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"After 21 weeks of  DRUGOTHER  treatment, all  DRUGOTHER /vehicle-treated animals displayed parkinsonian symptoms, whereas none of the  DRUG1 / DRUG2 -treated monkeys were significantly affected.",effect,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in  DRUG1 / DRUG2 -treated animals than in  DRUGOTHER /vehicle-treated monkeys.",effect,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in  DRUG1 / DRUGOTHER -treated animals than in  DRUG2 /vehicle-treated monkeys.",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in  DRUGOTHER / DRUG1 -treated animals than in  DRUG2 /vehicle-treated monkeys.",negative,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
The  DRUG1  treatment also had a significant effect on the  DRUG2 -induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups.,effect,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"In  DRUG1 /vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in  DRUG2 / DRUGOTHER -treated monkeys.",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"In  DRUG1 /vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in  DRUGOTHER / DRUG2 -treated monkeys.",negative,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"In  DRUGOTHER /vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in  DRUG1 / DRUG2 -treated monkeys.",effect,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine"
"Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist,  DRUG1 , significantly reduces  DRUG2  toxicity towards dopaminergic and noradrenergic cell groups in non-human primates.",effect,"3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine","1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
"When  DRUG1  and  DRUG2  are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when  DRUGOTHER  is used alone.",effect,atropine,pralidoxime
"When  DRUG1  and  DRUGOTHER  are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when  DRUG2  is used alone.",negative,atropine,atropine
"When  DRUGOTHER  and  DRUG1  are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when  DRUG2  is used alone.",negative,pralidoxime,atropine
This is especially true if the total dose of  DRUG1  has been large and the administration of  DRUG2  has been delayed.,negative,atropine,pralidoxime
"2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of  DRUG1 : since  DRUG2  are potentiated by the  DRUGOTHER , they should be used cautiously in the treatment of convulsions;",negative,pralidoxime,barbiturates
"2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of  DRUG1 : since  DRUGOTHER  are potentiated by the  DRUG2 , they should be used cautiously in the treatment of convulsions;",negative,pralidoxime,anticholinesterases
"2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of  DRUGOTHER : since  DRUG1  are potentiated by the  DRUG2 , they should be used cautiously in the treatment of convulsions;",effect,barbiturates,anticholinesterases
" DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  should be avoided in patients with organophosphate poisoning.",negative,morphine,theophylline
" DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  should be avoided in patients with organophosphate poisoning.",negative,morphine,aminophylline
" DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  should be avoided in patients with organophosphate poisoning.",negative,morphine,succinylcholine
" DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  should be avoided in patients with organophosphate poisoning.",negative,morphine,reserpine
" DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  should be avoided in patients with organophosphate poisoning.",negative,morphine,phenothiazine-type tranquilizers
" DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  should be avoided in patients with organophosphate poisoning.",negative,theophylline,aminophylline
" DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  should be avoided in patients with organophosphate poisoning.",negative,theophylline,succinylcholine
" DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  should be avoided in patients with organophosphate poisoning.",negative,theophylline,reserpine
" DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  should be avoided in patients with organophosphate poisoning.",negative,theophylline,phenothiazine-type tranquilizers
" DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  should be avoided in patients with organophosphate poisoning.",negative,aminophylline,succinylcholine
" DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  should be avoided in patients with organophosphate poisoning.",negative,aminophylline,reserpine
" DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  should be avoided in patients with organophosphate poisoning.",negative,aminophylline,phenothiazine-type tranquilizers
" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER  should be avoided in patients with organophosphate poisoning.",negative,succinylcholine,reserpine
" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2  should be avoided in patients with organophosphate poisoning.",negative,succinylcholine,phenothiazine-type tranquilizers
" DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2  should be avoided in patients with organophosphate poisoning.",negative,reserpine,phenothiazine-type tranquilizers
" DRUG1  can interact with  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,Mequitazine,CNS depressant
" DRUG1  can interact with  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,Mequitazine,antichlolinergic
" DRUG1  can interact with  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",int,Mequitazine,TCA
" DRUG1  can interact with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",int,Mequitazine,MAOIs
" DRUG1  can interact with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",int,Mequitazine,alcohol
" DRUGOTHER  can interact with  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,CNS depressant,antichlolinergic
" DRUGOTHER  can interact with  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,CNS depressant,TCA
" DRUGOTHER  can interact with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,CNS depressant,MAOIs
" DRUGOTHER  can interact with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,CNS depressant,alcohol
" DRUGOTHER  can interact with  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,antichlolinergic,TCA
" DRUGOTHER  can interact with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,antichlolinergic,MAOIs
" DRUGOTHER  can interact with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,antichlolinergic,alcohol
" DRUGOTHER  can interact with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER .",negative,TCA,MAOIs
" DRUGOTHER  can interact with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 .",negative,TCA,alcohol
" DRUGOTHER  can interact with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 .",negative,MAOIs,alcohol
"The concomitant use of  DRUG1  with other  DRUG2  that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects.",effect,Sanctura,anticholinergic agents
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUG1  have not been conducted,  DRUG2  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ).",negative,Sanctura,Sanctura
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUG1  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ).",negative,Sanctura,digoxin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUG1  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ).",negative,Sanctura,procainamide
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUG1  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ).",negative,Sanctura,pancuronium
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUG1  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ).",negative,Sanctura,morphine
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUG1  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ).",negative,Sanctura,vancomycin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUG1  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ).",negative,Sanctura,metformin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUG1  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ).",negative,Sanctura,tenofovir
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUG1  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ).",mechanism,Sanctura,digoxin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUG1  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ).",mechanism,Sanctura,procainamide
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUG1  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ).",mechanism,Sanctura,pancuronium
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUG1  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ).",mechanism,Sanctura,morphine
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUG1  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ).",mechanism,Sanctura,vancomycin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUG1  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ).",mechanism,Sanctura,metformin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUG1  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ).",mechanism,Sanctura,tenofovir
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ).",negative,digoxin,procainamide
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ).",negative,digoxin,pancuronium
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ).",negative,digoxin,morphine
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ).",negative,digoxin,vancomycin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ).",negative,digoxin,metformin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ).",negative,digoxin,tenofovir
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ).",negative,procainamide,pancuronium
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ).",negative,procainamide,morphine
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ).",negative,procainamide,vancomycin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ).",negative,procainamide,metformin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ).",negative,procainamide,tenofovir
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ).",negative,pancuronium,morphine
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ).",negative,pancuronium,vancomycin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ).",negative,pancuronium,metformin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ).",negative,pancuronium,tenofovir
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ).",negative,morphine,vancomycin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ).",negative,morphine,metformin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ).",negative,morphine,tenofovir
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  and  DRUGOTHER ).",negative,vancomycin,metformin
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUG2 ).",negative,vancomycin,tenofovir
"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with  DRUGOTHER  have not been conducted,  DRUGOTHER  has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g.  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUG2 ).",negative,metformin,tenofovir
Coadministration of  DRUG1  with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of  DRUG2  and/or the coadministered drug due to competition for this elimination pathway.,negative,Sanctura,Sanctura
" DRUG1 : There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of  DRUG2  with the co-administration of 100 mg  DRUGOTHER  for 10 days.",negative,Digoxin,digoxin
" DRUG1 : There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of  DRUGOTHER  with the co-administration of 100 mg  DRUG2  for 10 days.",negative,Digoxin,sitagliptin
" DRUGOTHER : There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of  DRUG1  with the co-administration of 100 mg  DRUG2  for 10 days.",mechanism,digoxin,sitagliptin
No dosage adjustment of  DRUG1  or  DRUG2  is recommended.,negative,digoxin,JANUVIA
" DRUG1 , particularly  DRUG2 , may cause serious cardiac arrhythmias during  DRUGOTHER  anesthesia and therefore should be used only with great caution or not at all.",negative,Vasopressors,metaraminol
" DRUG1 , particularly  DRUGOTHER , may cause serious cardiac arrhythmias during  DRUG2  anesthesia and therefore should be used only with great caution or not at all.",effect,Vasopressors,halothane
" DRUGOTHER , particularly  DRUG1 , may cause serious cardiac arrhythmias during  DRUG2  anesthesia and therefore should be used only with great caution or not at all.",effect,metaraminol,halothane
 DRUG1  - The pressor effect of  DRUG2  is markedly potentiated in patients receiving  DRUGOTHER  ( DRUGOTHER ).,negative,MAO Inhibitors,sympathomimetic pressor amines
 DRUG1  - The pressor effect of  DRUGOTHER  is markedly potentiated in patients receiving  DRUG2  ( DRUGOTHER ).,negative,MAO Inhibitors,monoamine oxidase inhibitors
 DRUG1  - The pressor effect of  DRUGOTHER  is markedly potentiated in patients receiving  DRUGOTHER  ( DRUG2 ).,negative,MAO Inhibitors,MAOI
 DRUGOTHER  - The pressor effect of  DRUG1  is markedly potentiated in patients receiving  DRUG2  ( DRUGOTHER ).,effect,sympathomimetic pressor amines,monoamine oxidase inhibitors
 DRUGOTHER  - The pressor effect of  DRUG1  is markedly potentiated in patients receiving  DRUGOTHER  ( DRUG2 ).,effect,sympathomimetic pressor amines,MAOI
 DRUGOTHER  - The pressor effect of  DRUGOTHER  is markedly potentiated in patients receiving  DRUG1  ( DRUG2 ).,negative,monoamine oxidase inhibitors,MAOI
The pressor response of  DRUG1  may also be potentiated by  DRUG2 .,effect,adrenergic agents,tricyclic antidepressants
"When  DRUG1  is used with other  DRUG2 , potentiation of antihypertensive effect may occur.",effect,methyldopa,antihypertensive drugs
Patients may require reduced doses of  DRUG1  when on  DRUG2 .,advise,anesthetics,methyldopa
When  DRUG1  and  DRUG2  are given concomitantly the patient should be carefully monitored for symptoms of  DRUGOTHER  toxicity.,advise,methyldopa,lithium
When  DRUG1  and  DRUGOTHER  are given concomitantly the patient should be carefully monitored for symptoms of  DRUG2  toxicity.,negative,methyldopa,lithium
When  DRUGOTHER  and  DRUG1  are given concomitantly the patient should be carefully monitored for symptoms of  DRUG2  toxicity.,negative,lithium,lithium
Several studies demonstrate a decrease in the bioavailability of  DRUG1  when it is ingested with  DRUG2  or  DRUGOTHER .,mechanism,methyldopa,ferrous sulfate
Several studies demonstrate a decrease in the bioavailability of  DRUG1  when it is ingested with  DRUGOTHER  or  DRUG2 .,mechanism,methyldopa,ferrous gluconate
Several studies demonstrate a decrease in the bioavailability of  DRUGOTHER  when it is ingested with  DRUG1  or  DRUG2 .,negative,ferrous sulfate,ferrous gluconate
Coadministration of  DRUG1  with  DRUG2  or  DRUGOTHER  is not recommended.,advise,methyldopa,ferrous sulfate
Coadministration of  DRUG1  with  DRUGOTHER  or  DRUG2  is not recommended.,advise,methyldopa,ferrous gluconate
Coadministration of  DRUGOTHER  with  DRUG1  or  DRUG2  is not recommended.,negative,ferrous sulfate,ferrous gluconate
" DRUG1  does not interfere with measurement of  DRUG2  ( DRUGOTHER ), a test for pheochromocytoma, by those methods which convert  DRUGOTHER  to  DRUGOTHER .",negative,Methyldopa,VMA
" DRUG1  does not interfere with measurement of  DRUGOTHER  ( DRUG2 ), a test for pheochromocytoma, by those methods which convert  DRUGOTHER  to  DRUGOTHER .",negative,Methyldopa,vanillylmandelic acid
" DRUG1  does not interfere with measurement of  DRUGOTHER  ( DRUGOTHER ), a test for pheochromocytoma, by those methods which convert  DRUG2  to  DRUGOTHER .",negative,Methyldopa,VMA
" DRUG1  does not interfere with measurement of  DRUGOTHER  ( DRUGOTHER ), a test for pheochromocytoma, by those methods which convert  DRUGOTHER  to  DRUG2 .",negative,Methyldopa,vanillin
" DRUGOTHER  does not interfere with measurement of  DRUG1  ( DRUG2 ), a test for pheochromocytoma, by those methods which convert  DRUGOTHER  to  DRUGOTHER .",negative,VMA,vanillylmandelic acid
" DRUGOTHER  does not interfere with measurement of  DRUG1  ( DRUGOTHER ), a test for pheochromocytoma, by those methods which convert  DRUG2  to  DRUGOTHER .",negative,VMA,VMA
" DRUGOTHER  does not interfere with measurement of  DRUG1  ( DRUGOTHER ), a test for pheochromocytoma, by those methods which convert  DRUGOTHER  to  DRUG2 .",negative,VMA,vanillin
" DRUGOTHER  does not interfere with measurement of  DRUGOTHER  ( DRUG1 ), a test for pheochromocytoma, by those methods which convert  DRUG2  to  DRUGOTHER .",negative,vanillylmandelic acid,VMA
" DRUGOTHER  does not interfere with measurement of  DRUGOTHER  ( DRUG1 ), a test for pheochromocytoma, by those methods which convert  DRUGOTHER  to  DRUG2 .",negative,vanillylmandelic acid,vanillin
" DRUGOTHER  does not interfere with measurement of  DRUGOTHER  ( DRUGOTHER ), a test for pheochromocytoma, by those methods which convert  DRUG1  to  DRUG2 .",negative,VMA,vanillin
Concomitant administrations not recommended:  -  DRUG1  and  DRUG2 : Certain  DRUGOTHER  interact with  DRUGOTHER  and  DRUGOTHER  leading to increased serum concentrations of the latter.,negative,Terfenadine,astemizole
Concomitant administrations not recommended:  -  DRUG1  and  DRUGOTHER : Certain  DRUG2  interact with  DRUGOTHER  and  DRUGOTHER  leading to increased serum concentrations of the latter.,negative,Terfenadine,macrolides
Concomitant administrations not recommended:  -  DRUG1  and  DRUGOTHER : Certain  DRUGOTHER  interact with  DRUG2  and  DRUGOTHER  leading to increased serum concentrations of the latter.,negative,Terfenadine,terfenadine
Concomitant administrations not recommended:  -  DRUG1  and  DRUGOTHER : Certain  DRUGOTHER  interact with  DRUGOTHER  and  DRUG2  leading to increased serum concentrations of the latter.,negative,Terfenadine,astemizole
Concomitant administrations not recommended:  -  DRUGOTHER  and  DRUG1 : Certain  DRUG2  interact with  DRUGOTHER  and  DRUGOTHER  leading to increased serum concentrations of the latter.,negative,astemizole,macrolides
Concomitant administrations not recommended:  -  DRUGOTHER  and  DRUG1 : Certain  DRUGOTHER  interact with  DRUG2  and  DRUGOTHER  leading to increased serum concentrations of the latter.,negative,astemizole,terfenadine
Concomitant administrations not recommended:  -  DRUGOTHER  and  DRUG1 : Certain  DRUGOTHER  interact with  DRUGOTHER  and  DRUG2  leading to increased serum concentrations of the latter.,negative,astemizole,astemizole
Concomitant administrations not recommended:  -  DRUGOTHER  and  DRUGOTHER : Certain  DRUG1  interact with  DRUG2  and  DRUGOTHER  leading to increased serum concentrations of the latter.,int,macrolides,terfenadine
Concomitant administrations not recommended:  -  DRUGOTHER  and  DRUGOTHER : Certain  DRUG1  interact with  DRUGOTHER  and  DRUG2  leading to increased serum concentrations of the latter.,int,macrolides,astemizole
Concomitant administrations not recommended:  -  DRUGOTHER  and  DRUGOTHER : Certain  DRUGOTHER  interact with  DRUG1  and  DRUG2  leading to increased serum concentrations of the latter.,negative,terfenadine,astemizole
"Although such a reaction has not been demonstrated with  DRUG1 , concomitant administration of  DRUG2  with  DRUGOTHER  or  DRUGOTHER  is not recommended.",negative,roxithromycin,roxithromycin
"Although such a reaction has not been demonstrated with  DRUG1 , concomitant administration of  DRUGOTHER  with  DRUG2  or  DRUGOTHER  is not recommended.",negative,roxithromycin,terfenadine
"Although such a reaction has not been demonstrated with  DRUG1 , concomitant administration of  DRUGOTHER  with  DRUGOTHER  or  DRUG2  is not recommended.",negative,roxithromycin,astemizole
"Although such a reaction has not been demonstrated with  DRUGOTHER , concomitant administration of  DRUG1  with  DRUG2  or  DRUGOTHER  is not recommended.",advise,roxithromycin,terfenadine
"Although such a reaction has not been demonstrated with  DRUGOTHER , concomitant administration of  DRUG1  with  DRUGOTHER  or  DRUG2  is not recommended.",advise,roxithromycin,astemizole
"Although such a reaction has not been demonstrated with  DRUGOTHER , concomitant administration of  DRUGOTHER  with  DRUG1  or  DRUG2  is not recommended.",negative,terfenadine,astemizole
"-  DRUG1 ,  DRUG2 : Other drugs such as  DRUGOTHER  or  DRUGOTHER , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some  DRUGOTHER .",negative,Cisapride,pimozide
"-  DRUG1 ,  DRUGOTHER : Other drugs such as  DRUG2  or  DRUGOTHER , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some  DRUGOTHER .",negative,Cisapride,cisapride
"-  DRUG1 ,  DRUGOTHER : Other drugs such as  DRUGOTHER  or  DRUG2 , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some  DRUGOTHER .",negative,Cisapride,pimozide
"-  DRUG1 ,  DRUGOTHER : Other drugs such as  DRUGOTHER  or  DRUGOTHER , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some  DRUG2 .",negative,Cisapride,macrolide antibacterials
"-  DRUGOTHER ,  DRUG1 : Other drugs such as  DRUG2  or  DRUGOTHER , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some  DRUGOTHER .",negative,pimozide,cisapride
"-  DRUGOTHER ,  DRUG1 : Other drugs such as  DRUGOTHER  or  DRUG2 , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some  DRUGOTHER .",negative,pimozide,pimozide
"-  DRUGOTHER ,  DRUG1 : Other drugs such as  DRUGOTHER  or  DRUGOTHER , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some  DRUG2 .",mechanism,pimozide,macrolide antibacterials
"-  DRUGOTHER ,  DRUGOTHER : Other drugs such as  DRUG1  or  DRUG2 , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some  DRUGOTHER .",negative,cisapride,pimozide
"-  DRUGOTHER ,  DRUGOTHER : Other drugs such as  DRUG1  or  DRUGOTHER , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some  DRUG2 .",mechanism,cisapride,macrolide antibacterials
"-  DRUGOTHER ,  DRUGOTHER : Other drugs such as  DRUGOTHER  or  DRUG1 , which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some  DRUG2 .",negative,pimozide,macrolide antibacterials
"Although such a risk is not verified for  DRUG1 , combination of  DRUG2  with such drugs is not recommended.",negative,roxithromycin,roxithromycin
"Drugs that induce hepatic enzymes such as  DRUG1 ,  DRUG2  and  DRUGOTHER  may increase the clearance of  DRUGOTHER  and may require increases in  DRUGOTHER  dose to achieve the desired response.",negative,phenobarbital,phenytoin
"Drugs that induce hepatic enzymes such as  DRUG1 ,  DRUGOTHER  and  DRUG2  may increase the clearance of  DRUGOTHER  and may require increases in  DRUGOTHER  dose to achieve the desired response.",negative,phenobarbital,rifampin
"Drugs that induce hepatic enzymes such as  DRUG1 ,  DRUGOTHER  and  DRUGOTHER  may increase the clearance of  DRUG2  and may require increases in  DRUGOTHER  dose to achieve the desired response.",mechanism,phenobarbital,corticosteroids
"Drugs that induce hepatic enzymes such as  DRUG1 ,  DRUGOTHER  and  DRUGOTHER  may increase the clearance of  DRUGOTHER  and may require increases in  DRUG2  dose to achieve the desired response.",mechanism,phenobarbital,corticosteroid
"Drugs that induce hepatic enzymes such as  DRUGOTHER ,  DRUG1  and  DRUG2  may increase the clearance of  DRUGOTHER  and may require increases in  DRUGOTHER  dose to achieve the desired response.",negative,phenytoin,rifampin
"Drugs that induce hepatic enzymes such as  DRUGOTHER ,  DRUG1  and  DRUGOTHER  may increase the clearance of  DRUG2  and may require increases in  DRUGOTHER  dose to achieve the desired response.",mechanism,phenytoin,corticosteroids
"Drugs that induce hepatic enzymes such as  DRUGOTHER ,  DRUG1  and  DRUGOTHER  may increase the clearance of  DRUGOTHER  and may require increases in  DRUG2  dose to achieve the desired response.",mechanism,phenytoin,corticosteroid
"Drugs that induce hepatic enzymes such as  DRUGOTHER ,  DRUGOTHER  and  DRUG1  may increase the clearance of  DRUG2  and may require increases in  DRUGOTHER  dose to achieve the desired response.",mechanism,rifampin,corticosteroids
"Drugs that induce hepatic enzymes such as  DRUGOTHER ,  DRUGOTHER  and  DRUG1  may increase the clearance of  DRUGOTHER  and may require increases in  DRUG2  dose to achieve the desired response.",mechanism,rifampin,corticosteroid
"Drugs that induce hepatic enzymes such as  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  may increase the clearance of  DRUG1  and may require increases in  DRUG2  dose to achieve the desired response.",negative,corticosteroids,corticosteroid
Drugs such as  DRUG1  and  DRUG2  may inhibit the metabolism of  DRUGOTHER  and thus decrease their clearance.,negative,troleandomycin,ketoconazole
Drugs such as  DRUG1  and  DRUGOTHER  may inhibit the metabolism of  DRUG2  and thus decrease their clearance.,mechanism,troleandomycin,corticosteroids
Drugs such as  DRUGOTHER  and  DRUG1  may inhibit the metabolism of  DRUG2  and thus decrease their clearance.,mechanism,ketoconazole,corticosteroids
 DRUG1  may increase the clearance of chronic high dose  DRUG2 .,mechanism,Corticosteroids,aspirin
This could lead to decreased  DRUG1  serum levels or increase the risk of  DRUG2  toxicity when  DRUGOTHER  is withdrawn.,negative,salicylate,salicylate
This could lead to decreased  DRUG1  serum levels or increase the risk of  DRUGOTHER  toxicity when  DRUG2  is withdrawn.,negative,salicylate,corticosteroid
This could lead to decreased  DRUGOTHER  serum levels or increase the risk of  DRUG1  toxicity when  DRUG2  is withdrawn.,effect,salicylate,corticosteroid
 DRUG1  should be used cautiously in conjunction with  DRUG2  in patients suffering from hypoprothrombinemia.,advise,Aspirin,corticosteroids
The effect of  DRUG1  on oral  DRUG2  is variable.,effect,corticosteroids,anticoagulants
There are reports of enhanced as well as diminished effects of  DRUG1  when given concurrently with  DRUG2 .,effect,anticoagulants,corticosteroids
"Because  DRUG1  is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of  DRUG2 .",negative,ondansetron,ondansetron
" DRUG1 ,  DRUG2 , and  DRUGOTHER : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ), the clearance of  DRUGOTHER  was significantly increased and  DRUGOTHER  blood concentrations were decreased.",negative,Phenytoin,Carbamazepine
" DRUG1 ,  DRUGOTHER , and  DRUG2 : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ), the clearance of  DRUGOTHER  was significantly increased and  DRUGOTHER  blood concentrations were decreased.",negative,Phenytoin,Rifampicin
" DRUG1 ,  DRUGOTHER , and  DRUGOTHER : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ), the clearance of  DRUGOTHER  was significantly increased and  DRUGOTHER  blood concentrations were decreased.",negative,Phenytoin,phenytoin
" DRUG1 ,  DRUGOTHER , and  DRUGOTHER : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ), the clearance of  DRUGOTHER  was significantly increased and  DRUGOTHER  blood concentrations were decreased.",negative,Phenytoin,carbamazepine
" DRUG1 ,  DRUGOTHER , and  DRUGOTHER : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ), the clearance of  DRUGOTHER  was significantly increased and  DRUGOTHER  blood concentrations were decreased.",negative,Phenytoin,rifampicin
" DRUG1 ,  DRUGOTHER , and  DRUGOTHER : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ), the clearance of  DRUG2  was significantly increased and  DRUGOTHER  blood concentrations were decreased.",negative,Phenytoin,ondansetron
" DRUG1 ,  DRUGOTHER , and  DRUGOTHER : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ), the clearance of  DRUGOTHER  was significantly increased and  DRUG2  blood concentrations were decreased.",negative,Phenytoin,ondansetron
" DRUGOTHER ,  DRUG1 , and  DRUG2 : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ), the clearance of  DRUGOTHER  was significantly increased and  DRUGOTHER  blood concentrations were decreased.",negative,Carbamazepine,Rifampicin
" DRUGOTHER ,  DRUG1 , and  DRUGOTHER : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ), the clearance of  DRUGOTHER  was significantly increased and  DRUGOTHER  blood concentrations were decreased.",negative,Carbamazepine,phenytoin
" DRUGOTHER ,  DRUG1 , and  DRUGOTHER : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ), the clearance of  DRUGOTHER  was significantly increased and  DRUGOTHER  blood concentrations were decreased.",negative,Carbamazepine,carbamazepine
" DRUGOTHER ,  DRUG1 , and  DRUGOTHER : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ), the clearance of  DRUGOTHER  was significantly increased and  DRUGOTHER  blood concentrations were decreased.",negative,Carbamazepine,rifampicin
" DRUGOTHER ,  DRUG1 , and  DRUGOTHER : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ), the clearance of  DRUG2  was significantly increased and  DRUGOTHER  blood concentrations were decreased.",negative,Carbamazepine,ondansetron
" DRUGOTHER ,  DRUG1 , and  DRUGOTHER : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ), the clearance of  DRUGOTHER  was significantly increased and  DRUG2  blood concentrations were decreased.",negative,Carbamazepine,ondansetron
" DRUGOTHER ,  DRUGOTHER , and  DRUG1 : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ), the clearance of  DRUGOTHER  was significantly increased and  DRUGOTHER  blood concentrations were decreased.",negative,Rifampicin,phenytoin
" DRUGOTHER ,  DRUGOTHER , and  DRUG1 : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ), the clearance of  DRUGOTHER  was significantly increased and  DRUGOTHER  blood concentrations were decreased.",negative,Rifampicin,carbamazepine
" DRUGOTHER ,  DRUGOTHER , and  DRUG1 : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ), the clearance of  DRUGOTHER  was significantly increased and  DRUGOTHER  blood concentrations were decreased.",negative,Rifampicin,rifampicin
" DRUGOTHER ,  DRUGOTHER , and  DRUG1 : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ), the clearance of  DRUG2  was significantly increased and  DRUGOTHER  blood concentrations were decreased.",negative,Rifampicin,ondansetron
" DRUGOTHER ,  DRUGOTHER , and  DRUG1 : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ), the clearance of  DRUGOTHER  was significantly increased and  DRUG2  blood concentrations were decreased.",negative,Rifampicin,ondansetron
" DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUG1 ,  DRUG2 , and  DRUGOTHER ), the clearance of  DRUGOTHER  was significantly increased and  DRUGOTHER  blood concentrations were decreased.",negative,phenytoin,carbamazepine
" DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUG1 ,  DRUGOTHER , and  DRUG2 ), the clearance of  DRUGOTHER  was significantly increased and  DRUGOTHER  blood concentrations were decreased.",negative,phenytoin,rifampicin
" DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ), the clearance of  DRUG2  was significantly increased and  DRUGOTHER  blood concentrations were decreased.",mechanism,phenytoin,ondansetron
" DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ), the clearance of  DRUGOTHER  was significantly increased and  DRUG2  blood concentrations were decreased.",mechanism,phenytoin,ondansetron
" DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUGOTHER ,  DRUG1 , and  DRUG2 ), the clearance of  DRUGOTHER  was significantly increased and  DRUGOTHER  blood concentrations were decreased.",negative,carbamazepine,rifampicin
" DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ), the clearance of  DRUG2  was significantly increased and  DRUGOTHER  blood concentrations were decreased.",mechanism,carbamazepine,ondansetron
" DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ), the clearance of  DRUGOTHER  was significantly increased and  DRUG2  blood concentrations were decreased.",mechanism,carbamazepine,ondansetron
" DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ), the clearance of  DRUG2  was significantly increased and  DRUGOTHER  blood concentrations were decreased.",mechanism,rifampicin,ondansetron
" DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ), the clearance of  DRUGOTHER  was significantly increased and  DRUG2  blood concentrations were decreased.",mechanism,rifampicin,ondansetron
" DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER : In patients treated with potent inducers of CYP3A4 (i.e.,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ), the clearance of  DRUG1  was significantly increased and  DRUG2  blood concentrations were decreased.",negative,ondansetron,ondansetron
"However, on the basis of available data, no dosage adjustment for  DRUG1  is recommended for patients on these drugs.1,3   DRUG2 : Although no pharmacokinetic drug interaction between  DRUGOTHER  and  DRUGOTHER  has been observed, data from 2 small studies indicate that  DRUGOTHER  may be associated with an increase in patient controlled administration of  DRUGOTHER .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  DRUGOTHER .",negative,ondansetron,Tramadol
"However, on the basis of available data, no dosage adjustment for  DRUG1  is recommended for patients on these drugs.1,3   DRUGOTHER : Although no pharmacokinetic drug interaction between  DRUG2  and  DRUGOTHER  has been observed, data from 2 small studies indicate that  DRUGOTHER  may be associated with an increase in patient controlled administration of  DRUGOTHER .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  DRUGOTHER .",negative,ondansetron,ondansetron
"However, on the basis of available data, no dosage adjustment for  DRUG1  is recommended for patients on these drugs.1,3   DRUGOTHER : Although no pharmacokinetic drug interaction between  DRUGOTHER  and  DRUG2  has been observed, data from 2 small studies indicate that  DRUGOTHER  may be associated with an increase in patient controlled administration of  DRUGOTHER .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  DRUGOTHER .",negative,ondansetron,tramadol
"However, on the basis of available data, no dosage adjustment for  DRUG1  is recommended for patients on these drugs.1,3   DRUGOTHER : Although no pharmacokinetic drug interaction between  DRUGOTHER  and  DRUGOTHER  has been observed, data from 2 small studies indicate that  DRUG2  may be associated with an increase in patient controlled administration of  DRUGOTHER .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  DRUGOTHER .",negative,ondansetron,ondansetron
"However, on the basis of available data, no dosage adjustment for  DRUG1  is recommended for patients on these drugs.1,3   DRUGOTHER : Although no pharmacokinetic drug interaction between  DRUGOTHER  and  DRUGOTHER  has been observed, data from 2 small studies indicate that  DRUGOTHER  may be associated with an increase in patient controlled administration of  DRUG2 .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  DRUGOTHER .",negative,ondansetron,tramadol
"However, on the basis of available data, no dosage adjustment for  DRUG1  is recommended for patients on these drugs.1,3   DRUGOTHER : Although no pharmacokinetic drug interaction between  DRUGOTHER  and  DRUGOTHER  has been observed, data from 2 small studies indicate that  DRUGOTHER  may be associated with an increase in patient controlled administration of  DRUGOTHER .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  DRUG2 .",negative,ondansetron,ondansetron
"However, on the basis of available data, no dosage adjustment for  DRUGOTHER  is recommended for patients on these drugs.1,3   DRUG1 : Although no pharmacokinetic drug interaction between  DRUG2  and  DRUGOTHER  has been observed, data from 2 small studies indicate that  DRUGOTHER  may be associated with an increase in patient controlled administration of  DRUGOTHER .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  DRUGOTHER .",negative,Tramadol,ondansetron
"However, on the basis of available data, no dosage adjustment for  DRUGOTHER  is recommended for patients on these drugs.1,3   DRUG1 : Although no pharmacokinetic drug interaction between  DRUGOTHER  and  DRUG2  has been observed, data from 2 small studies indicate that  DRUGOTHER  may be associated with an increase in patient controlled administration of  DRUGOTHER .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  DRUGOTHER .",negative,Tramadol,tramadol
"However, on the basis of available data, no dosage adjustment for  DRUGOTHER  is recommended for patients on these drugs.1,3   DRUG1 : Although no pharmacokinetic drug interaction between  DRUGOTHER  and  DRUGOTHER  has been observed, data from 2 small studies indicate that  DRUG2  may be associated with an increase in patient controlled administration of  DRUGOTHER .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  DRUGOTHER .",negative,Tramadol,ondansetron
"However, on the basis of available data, no dosage adjustment for  DRUGOTHER  is recommended for patients on these drugs.1,3   DRUG1 : Although no pharmacokinetic drug interaction between  DRUGOTHER  and  DRUGOTHER  has been observed, data from 2 small studies indicate that  DRUGOTHER  may be associated with an increase in patient controlled administration of  DRUG2 .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  DRUGOTHER .",negative,Tramadol,tramadol
"However, on the basis of available data, no dosage adjustment for  DRUGOTHER  is recommended for patients on these drugs.1,3   DRUG1 : Although no pharmacokinetic drug interaction between  DRUGOTHER  and  DRUGOTHER  has been observed, data from 2 small studies indicate that  DRUGOTHER  may be associated with an increase in patient controlled administration of  DRUGOTHER .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  DRUG2 .",negative,Tramadol,ondansetron
"However, on the basis of available data, no dosage adjustment for  DRUGOTHER  is recommended for patients on these drugs.1,3   DRUGOTHER : Although no pharmacokinetic drug interaction between  DRUG1  and  DRUG2  has been observed, data from 2 small studies indicate that  DRUGOTHER  may be associated with an increase in patient controlled administration of  DRUGOTHER .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  DRUGOTHER .",negative,ondansetron,tramadol
"However, on the basis of available data, no dosage adjustment for  DRUGOTHER  is recommended for patients on these drugs.1,3   DRUGOTHER : Although no pharmacokinetic drug interaction between  DRUG1  and  DRUGOTHER  has been observed, data from 2 small studies indicate that  DRUG2  may be associated with an increase in patient controlled administration of  DRUGOTHER .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  DRUGOTHER .",negative,ondansetron,ondansetron
"However, on the basis of available data, no dosage adjustment for  DRUGOTHER  is recommended for patients on these drugs.1,3   DRUGOTHER : Although no pharmacokinetic drug interaction between  DRUG1  and  DRUGOTHER  has been observed, data from 2 small studies indicate that  DRUGOTHER  may be associated with an increase in patient controlled administration of  DRUG2 .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  DRUGOTHER .",negative,ondansetron,tramadol
"However, on the basis of available data, no dosage adjustment for  DRUGOTHER  is recommended for patients on these drugs.1,3   DRUGOTHER : Although no pharmacokinetic drug interaction between  DRUG1  and  DRUGOTHER  has been observed, data from 2 small studies indicate that  DRUGOTHER  may be associated with an increase in patient controlled administration of  DRUGOTHER .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  DRUG2 .",negative,ondansetron,ondansetron
"However, on the basis of available data, no dosage adjustment for  DRUGOTHER  is recommended for patients on these drugs.1,3   DRUGOTHER : Although no pharmacokinetic drug interaction between  DRUGOTHER  and  DRUG1  has been observed, data from 2 small studies indicate that  DRUG2  may be associated with an increase in patient controlled administration of  DRUGOTHER .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  DRUGOTHER .",negative,tramadol,ondansetron
"However, on the basis of available data, no dosage adjustment for  DRUGOTHER  is recommended for patients on these drugs.1,3   DRUGOTHER : Although no pharmacokinetic drug interaction between  DRUGOTHER  and  DRUG1  has been observed, data from 2 small studies indicate that  DRUGOTHER  may be associated with an increase in patient controlled administration of  DRUG2 .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  DRUGOTHER .",negative,tramadol,tramadol
"However, on the basis of available data, no dosage adjustment for  DRUGOTHER  is recommended for patients on these drugs.1,3   DRUGOTHER : Although no pharmacokinetic drug interaction between  DRUGOTHER  and  DRUG1  has been observed, data from 2 small studies indicate that  DRUGOTHER  may be associated with an increase in patient controlled administration of  DRUGOTHER .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  DRUG2 .",negative,tramadol,ondansetron
"However, on the basis of available data, no dosage adjustment for  DRUGOTHER  is recommended for patients on these drugs.1,3   DRUGOTHER : Although no pharmacokinetic drug interaction between  DRUGOTHER  and  DRUGOTHER  has been observed, data from 2 small studies indicate that  DRUG1  may be associated with an increase in patient controlled administration of  DRUG2 .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  DRUGOTHER .",effect,ondansetron,tramadol
"However, on the basis of available data, no dosage adjustment for  DRUGOTHER  is recommended for patients on these drugs.1,3   DRUGOTHER : Although no pharmacokinetic drug interaction between  DRUGOTHER  and  DRUGOTHER  has been observed, data from 2 small studies indicate that  DRUG1  may be associated with an increase in patient controlled administration of  DRUGOTHER .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  DRUG2 .",negative,ondansetron,ondansetron
"However, on the basis of available data, no dosage adjustment for  DRUGOTHER  is recommended for patients on these drugs.1,3   DRUGOTHER : Although no pharmacokinetic drug interaction between  DRUGOTHER  and  DRUGOTHER  has been observed, data from 2 small studies indicate that  DRUGOTHER  may be associated with an increase in patient controlled administration of  DRUG1 .4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by  DRUG2 .",negative,tramadol,ondansetron
"In humans,  DRUG1 ,  DRUG2 , and  DRUGOTHER  do not affect the pharmacokinetics of  DRUGOTHER .",negative,carmustine,etoposide
"In humans,  DRUG1 ,  DRUGOTHER , and  DRUG2  do not affect the pharmacokinetics of  DRUGOTHER .",negative,carmustine,cisplatin
"In humans,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER  do not affect the pharmacokinetics of  DRUG2 .",negative,carmustine,ondansetron
"In humans,  DRUGOTHER ,  DRUG1 , and  DRUG2  do not affect the pharmacokinetics of  DRUGOTHER .",negative,etoposide,cisplatin
"In humans,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER  do not affect the pharmacokinetics of  DRUG2 .",negative,etoposide,ondansetron
"In humans,  DRUGOTHER ,  DRUGOTHER , and  DRUG1  do not affect the pharmacokinetics of  DRUG2 .",negative,cisplatin,ondansetron
 DRUG1  did not increase blood levels of high-dose  DRUG2 .,negative,ondansetron,methotrexate
"The in vitro binding of  DRUG1  to human plasma proteins is unaffected by  DRUG2 , and  DRUGOTHER  does not alter the prothrombin time of normal volunteers.",negative,warfarin,tolmetin
"The in vitro binding of  DRUG1  to human plasma proteins is unaffected by  DRUGOTHER , and  DRUG2  does not alter the prothrombin time of normal volunteers.",negative,warfarin,tolmetin
"The in vitro binding of  DRUGOTHER  to human plasma proteins is unaffected by  DRUG1 , and  DRUG2  does not alter the prothrombin time of normal volunteers.",negative,tolmetin,tolmetin
"However, increased prothrombin time and bleeding have been reported in patients on concomitant  DRUG1  and  DRUG2  therapy.",effect,TOLECTIN,warfarin
"Therefore, caution should be exercised when administering  DRUG1  to patients on  DRUG2 .",advise,TOLECTIN,anticoagulants
In adult diabetic patients under treatment with either  DRUG1  or  DRUG2  there is no change in the clinical effects of either  DRUGOTHER  or the  DRUGOTHER .,negative,sulfonylureas,insulin
In adult diabetic patients under treatment with either  DRUG1  or  DRUGOTHER  there is no change in the clinical effects of either  DRUG2  or the  DRUGOTHER .,negative,sulfonylureas,TOLECTIN
In adult diabetic patients under treatment with either  DRUG1  or  DRUGOTHER  there is no change in the clinical effects of either  DRUGOTHER  or the  DRUG2 .,negative,sulfonylureas,hypoglycemic agents
In adult diabetic patients under treatment with either  DRUGOTHER  or  DRUG1  there is no change in the clinical effects of either  DRUG2  or the  DRUGOTHER .,negative,insulin,TOLECTIN
In adult diabetic patients under treatment with either  DRUGOTHER  or  DRUG1  there is no change in the clinical effects of either  DRUGOTHER  or the  DRUG2 .,negative,insulin,hypoglycemic agents
In adult diabetic patients under treatment with either  DRUGOTHER  or  DRUGOTHER  there is no change in the clinical effects of either  DRUG1  or the  DRUG2 .,negative,TOLECTIN,hypoglycemic agents
Caution should be used if  DRUG1  is administered concomitantly with  DRUG2 .,advise,TOLECTIN,methotrexate
" DRUG1  and other  DRUG2  have been reported to reduce the tubular secretion of  DRUGOTHER  in an animal model, possibly enhancing the toxicity of  DRUGOTHER .",negative,TOLECTIN,nonsteroidal anti-inflammatory drugs
" DRUG1  and other  DRUGOTHER  have been reported to reduce the tubular secretion of  DRUG2  in an animal model, possibly enhancing the toxicity of  DRUGOTHER .",mechanism,TOLECTIN,methotrexate
" DRUG1  and other  DRUGOTHER  have been reported to reduce the tubular secretion of  DRUGOTHER  in an animal model, possibly enhancing the toxicity of  DRUG2 .",negative,TOLECTIN,methotrexate
" DRUGOTHER  and other  DRUG1  have been reported to reduce the tubular secretion of  DRUG2  in an animal model, possibly enhancing the toxicity of  DRUGOTHER .",mechanism,nonsteroidal anti-inflammatory drugs,methotrexate
" DRUGOTHER  and other  DRUG1  have been reported to reduce the tubular secretion of  DRUGOTHER  in an animal model, possibly enhancing the toxicity of  DRUG2 .",negative,nonsteroidal anti-inflammatory drugs,methotrexate
" DRUGOTHER  and other  DRUGOTHER  have been reported to reduce the tubular secretion of  DRUG1  in an animal model, possibly enhancing the toxicity of  DRUG2 .",negative,methotrexate,methotrexate
Prothrombin time or other suitable anticoagulation test should be monitored if  DRUG1  is administered with  DRUG2 .,advise,tigecycline,warfarin
Concurrent use of  DRUG1  with oral  DRUG2  may render oral  DRUGOTHER  less effective.,effect,antibacterial drugs,contraceptives
Concurrent use of  DRUG1  with oral  DRUGOTHER  may render oral  DRUG2  less effective.,negative,antibacterial drugs,contraceptives
Concurrent use of  DRUGOTHER  with oral  DRUG1  may render oral  DRUG2  less effective.,negative,contraceptives,contraceptives
 DRUG1 / DRUG2 :  DRUGOTHER / DRUGOTHER  does not influence the pharmacokinetics of  DRUGOTHER  in healthy volunteers (N= 10).,negative,Carbidopa,Levodopa
 DRUG1 / DRUGOTHER :  DRUG2 / DRUGOTHER  does not influence the pharmacokinetics of  DRUGOTHER  in healthy volunteers (N= 10).,negative,Carbidopa,Carbidopa
 DRUG1 / DRUGOTHER :  DRUGOTHER / DRUG2  does not influence the pharmacokinetics of  DRUGOTHER  in healthy volunteers (N= 10).,negative,Carbidopa,Levodopa
 DRUG1 / DRUGOTHER :  DRUGOTHER / DRUGOTHER  does not influence the pharmacokinetics of  DRUG2  in healthy volunteers (N= 10).,negative,Carbidopa,pramipexole
 DRUGOTHER / DRUG1 :  DRUG2 / DRUGOTHER  does not influence the pharmacokinetics of  DRUGOTHER  in healthy volunteers (N= 10).,negative,Levodopa,Carbidopa
 DRUGOTHER / DRUG1 :  DRUGOTHER / DRUG2  does not influence the pharmacokinetics of  DRUGOTHER  in healthy volunteers (N= 10).,negative,Levodopa,Levodopa
 DRUGOTHER / DRUG1 :  DRUGOTHER / DRUGOTHER  does not influence the pharmacokinetics of  DRUG2  in healthy volunteers (N= 10).,negative,Levodopa,pramipexole
 DRUGOTHER / DRUGOTHER :  DRUG1 / DRUG2  does not influence the pharmacokinetics of  DRUGOTHER  in healthy volunteers (N= 10).,negative,Carbidopa,Levodopa
 DRUGOTHER / DRUGOTHER :  DRUG1 / DRUGOTHER  does not influence the pharmacokinetics of  DRUG2  in healthy volunteers (N= 10).,negative,Carbidopa,pramipexole
 DRUGOTHER / DRUGOTHER :  DRUGOTHER / DRUG1  does not influence the pharmacokinetics of  DRUG2  in healthy volunteers (N= 10).,negative,Levodopa,pramipexole
" DRUG1 : In healthy volunteers (N= 11),  DRUG2  did not influence the pharmacokinetics of  DRUGOTHER .",negative,Selegiline,selegiline
" DRUG1 : In healthy volunteers (N= 11),  DRUGOTHER  did not influence the pharmacokinetics of  DRUG2 .",negative,Selegiline,pramipexole
" DRUGOTHER : In healthy volunteers (N= 11),  DRUG1  did not influence the pharmacokinetics of  DRUG2 .",negative,selegiline,pramipexole
 DRUG1 : Population pharmacokinetic analysis suggests that  DRUG2  is unlikely to alter the oral clearance of  DRUGOTHER  (N= 54).,negative,Amantadine,amantadine
 DRUG1 : Population pharmacokinetic analysis suggests that  DRUGOTHER  is unlikely to alter the oral clearance of  DRUG2  (N= 54).,negative,Amantadine,pramipexole
 DRUGOTHER : Population pharmacokinetic analysis suggests that  DRUG1  is unlikely to alter the oral clearance of  DRUG2  (N= 54).,negative,amantadine,pramipexole
" DRUG1 :  DRUG2 , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in  DRUGOTHER  AUC and a 40% increase in half-life (N= 12).",negative,Cimetidine,Cimetidine
" DRUG1 :  DRUGOTHER , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in  DRUG2  AUC and a 40% increase in half-life (N= 12).",negative,Cimetidine,pramipexole
" DRUGOTHER :  DRUG1 , a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in  DRUG2  AUC and a 40% increase in half-life (N= 12).",mechanism,Cimetidine,pramipexole
" DRUG1 :  DRUG2 , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence  DRUGOTHER  pharmacokinetics (N= 12).",negative,Probenecid,Probenecid
" DRUG1 :  DRUGOTHER , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence  DRUG2  pharmacokinetics (N= 12).",negative,Probenecid,pramipexole
" DRUGOTHER :  DRUG1 , a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence  DRUG2  pharmacokinetics (N= 12).",negative,Probenecid,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,cimetidine,ranitidine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,cimetidine,diltiazem
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,cimetidine,triamterene
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,cimetidine,verapamil
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,cimetidine,quinidine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,cimetidine,quinine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUG2  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",mechanism,cimetidine,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,cimetidine,cephalosporins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,cimetidine,penicillins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,cimetidine,indomethacin
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,cimetidine,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,cimetidine,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUG2 .",negative,cimetidine,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,ranitidine,diltiazem
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,ranitidine,triamterene
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,ranitidine,verapamil
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,ranitidine,quinidine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,ranitidine,quinine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUG2  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",mechanism,ranitidine,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,ranitidine,cephalosporins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,ranitidine,penicillins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,ranitidine,indomethacin
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,ranitidine,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,ranitidine,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUG2 .",negative,ranitidine,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,diltiazem,triamterene
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,diltiazem,verapamil
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,diltiazem,quinidine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,diltiazem,quinine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUG2  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",mechanism,diltiazem,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,diltiazem,cephalosporins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,diltiazem,penicillins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,diltiazem,indomethacin
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,diltiazem,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,diltiazem,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUG2 .",negative,diltiazem,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,triamterene,verapamil
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,triamterene,quinidine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,triamterene,quinine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUG2  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",mechanism,triamterene,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,triamterene,cephalosporins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,triamterene,penicillins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,triamterene,indomethacin
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,triamterene,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,triamterene,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUG2 .",negative,triamterene,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,verapamil,quinidine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,verapamil,quinine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUG2  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",mechanism,verapamil,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,verapamil,cephalosporins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,verapamil,penicillins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,verapamil,indomethacin
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,verapamil,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,verapamil,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUG2 .",negative,verapamil,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,quinidine,quinine
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ) decreases the oral clearance of  DRUG2  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",mechanism,quinidine,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,quinidine,cephalosporins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,quinidine,penicillins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,quinidine,indomethacin
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,quinidine,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,quinidine,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUG2 .",negative,quinidine,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ) decreases the oral clearance of  DRUG2  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",mechanism,quinine,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,quinine,cephalosporins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,quinine,penicillins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,quinine,indomethacin
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,quinine,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,quinine,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUG2 .",negative,quinine,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUG1  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,pramipexole,cephalosporins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUG1  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,pramipexole,penicillins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUG1  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,pramipexole,indomethacin
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUG1  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,pramipexole,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUG1  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,pramipexole,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUG1  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUG2 .",negative,pramipexole,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,cephalosporins,penicillins
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,cephalosporins,indomethacin
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,cephalosporins,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,cephalosporins,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUG2 .",mechanism,cephalosporins,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,penicillins,indomethacin
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,penicillins,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,penicillins,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUG2 .",mechanism,penicillins,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,indomethacin,hydrochlorothiazide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,indomethacin,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUG2 .",mechanism,indomethacin,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 ) are likely to have little effect on the oral clearance of  DRUGOTHER .",negative,hydrochlorothiazide,chlorpropamide
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ) are likely to have little effect on the oral clearance of  DRUG2 .",mechanism,hydrochlorothiazide,pramipexole
"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) decreases the oral clearance of  DRUGOTHER  by about 20%, while those secreted by the anionic transport system (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ) are likely to have little effect on the oral clearance of  DRUG2 .",mechanism,chlorpropamide,pramipexole
CYP interactions: Inhibitors of cytochrome P450 enzymes would not be expected to affect  DRUG1  elimination because  DRUG2  is not appreciably metabolized by these enzymes in vivo or in vitro.,negative,pramipexole,pramipexole
" DRUG1 : Since  DRUG2  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,Dopamine antagonists,pramipexole
" DRUG1 : Since  DRUGOTHER  is a  DRUG2 , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,Dopamine antagonists,dopamine agonist
" DRUG1 : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUG2 , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,Dopamine antagonists,dopamine antagonists
" DRUG1 : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,Dopamine antagonists,neuroleptics
" DRUG1 : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,Dopamine antagonists,phenothiazines
" DRUG1 : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,Dopamine antagonists,butyrophenones
" DRUG1 : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,Dopamine antagonists,thioxanthenes
" DRUG1 : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2 , may diminish the effectiveness of  DRUGOTHER .",negative,Dopamine antagonists,metoclopramide
" DRUG1 : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUG2 .",negative,Dopamine antagonists,MIRAPEX
" DRUGOTHER : Since  DRUG1  is a  DRUG2 , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,pramipexole,dopamine agonist
" DRUGOTHER : Since  DRUG1  is a  DRUGOTHER , it is possible that  DRUG2 , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,pramipexole,dopamine antagonists
" DRUGOTHER : Since  DRUG1  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,pramipexole,neuroleptics
" DRUGOTHER : Since  DRUG1  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,pramipexole,phenothiazines
" DRUGOTHER : Since  DRUG1  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,pramipexole,butyrophenones
" DRUGOTHER : Since  DRUG1  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,pramipexole,thioxanthenes
" DRUGOTHER : Since  DRUG1  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2 , may diminish the effectiveness of  DRUGOTHER .",negative,pramipexole,metoclopramide
" DRUGOTHER : Since  DRUG1  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUG2 .",negative,pramipexole,MIRAPEX
" DRUGOTHER : Since  DRUGOTHER  is a  DRUG1 , it is possible that  DRUG2 , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,dopamine agonist,dopamine antagonists
" DRUGOTHER : Since  DRUGOTHER  is a  DRUG1 , it is possible that  DRUGOTHER , such as the  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,dopamine agonist,neuroleptics
" DRUGOTHER : Since  DRUGOTHER  is a  DRUG1 , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,dopamine agonist,phenothiazines
" DRUGOTHER : Since  DRUGOTHER  is a  DRUG1 , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,dopamine agonist,butyrophenones
" DRUGOTHER : Since  DRUGOTHER  is a  DRUG1 , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,dopamine agonist,thioxanthenes
" DRUGOTHER : Since  DRUGOTHER  is a  DRUG1 , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2 , may diminish the effectiveness of  DRUGOTHER .",negative,dopamine agonist,metoclopramide
" DRUGOTHER : Since  DRUGOTHER  is a  DRUG1 , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUG2 .",negative,dopamine agonist,MIRAPEX
" DRUGOTHER : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUG1 , such as the  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,dopamine antagonists,neuroleptics
" DRUGOTHER : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUG1 , such as the  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,dopamine antagonists,phenothiazines
" DRUGOTHER : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUG1 , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,dopamine antagonists,butyrophenones
" DRUGOTHER : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUG1 , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,dopamine antagonists,thioxanthenes
" DRUGOTHER : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUG1 , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2 , may diminish the effectiveness of  DRUGOTHER .",negative,dopamine antagonists,metoclopramide
" DRUGOTHER : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUG1 , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUG2 .",effect,dopamine antagonists,MIRAPEX
" DRUGOTHER : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUG1  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,neuroleptics,phenothiazines
" DRUGOTHER : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUG1  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,neuroleptics,butyrophenones
" DRUGOTHER : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,neuroleptics,thioxanthenes
" DRUGOTHER : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2 , may diminish the effectiveness of  DRUGOTHER .",negative,neuroleptics,metoclopramide
" DRUGOTHER : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUG2 .",effect,neuroleptics,MIRAPEX
" DRUGOTHER : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUG1 ,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,phenothiazines,butyrophenones
" DRUGOTHER : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,phenothiazines,thioxanthenes
" DRUGOTHER : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2 , may diminish the effectiveness of  DRUGOTHER .",negative,phenothiazines,metoclopramide
" DRUGOTHER : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUG2 .",effect,phenothiazines,MIRAPEX
" DRUGOTHER : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUG2 ) or  DRUGOTHER , may diminish the effectiveness of  DRUGOTHER .",negative,butyrophenones,thioxanthenes
" DRUGOTHER : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ) or  DRUG2 , may diminish the effectiveness of  DRUGOTHER .",negative,butyrophenones,metoclopramide
" DRUGOTHER : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ) or  DRUGOTHER , may diminish the effectiveness of  DRUG2 .",effect,butyrophenones,MIRAPEX
" DRUGOTHER : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ) or  DRUG2 , may diminish the effectiveness of  DRUGOTHER .",negative,thioxanthenes,metoclopramide
" DRUGOTHER : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ) or  DRUGOTHER , may diminish the effectiveness of  DRUG2 .",effect,thioxanthenes,MIRAPEX
" DRUGOTHER : Since  DRUGOTHER  is a  DRUGOTHER , it is possible that  DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUG1 , may diminish the effectiveness of  DRUG2 .",effect,metoclopramide,MIRAPEX
In vivo CYP3A activity is significantly lower in  DRUG1 -treated as compared with  DRUG2 -treated renal allograft recipients.,negative,cyclosporine,tacrolimus
In vitro studies have identified  DRUG1  and  DRUG2  as CYP3A inhibitors.,negative,cyclosporine,tacrolimus
"Systemic and apparent oral  DRUG1  clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in  DRUG2 -treated patients (n = 20) than in matched  DRUGOTHER -treated patients (n = 20).",mechanism,midazolam,cyclosporine
"Systemic and apparent oral  DRUG1  clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in  DRUGOTHER -treated patients (n = 20) than in matched  DRUG2 -treated patients (n = 20).",negative,midazolam,tacrolimus
"Systemic and apparent oral  DRUGOTHER  clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in  DRUG1 -treated patients (n = 20) than in matched  DRUG2 -treated patients (n = 20).",negative,cyclosporine,tacrolimus
The latter displayed  DRUG1  clearances similar to those in two larger cohorts of nonmatched  DRUG2 -treated patients (n = 58 and n = 80) and to those receiving a  DRUGOTHER -free regimen (n = 6).,negative,midazolam,tacrolimus
The latter displayed  DRUG1  clearances similar to those in two larger cohorts of nonmatched  DRUGOTHER -treated patients (n = 58 and n = 80) and to those receiving a  DRUG2 -free regimen (n = 6).,negative,midazolam,calcineurin inhibitor
The latter displayed  DRUGOTHER  clearances similar to those in two larger cohorts of nonmatched  DRUG1 -treated patients (n = 58 and n = 80) and to those receiving a  DRUG2 -free regimen (n = 6).,negative,tacrolimus,calcineurin inhibitor
"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving  DRUG1  than in those receiving  DRUG2 , indicating that, at the doses generally used in clinical practice,  DRUGOTHER  is the stronger of the two with respect to CYP3A inhibition.",negative,cyclosporine,tacrolimus
"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving  DRUG1  than in those receiving  DRUGOTHER , indicating that, at the doses generally used in clinical practice,  DRUG2  is the stronger of the two with respect to CYP3A inhibition.",negative,cyclosporine,cyclosporine
"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving  DRUGOTHER  than in those receiving  DRUG1 , indicating that, at the doses generally used in clinical practice,  DRUG2  is the stronger of the two with respect to CYP3A inhibition.",negative,tacrolimus,cyclosporine
 DRUG1  may reverse the analgesic activity of  DRUG2 .,effect,Methysergide,narcotic analgesics
"Concurrent use with  DRUG1  including  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  (e.g. smoking) may result in enhanced vasoconstriction.",negative,vasoconstrictor agents,ergot alkaloids
"Concurrent use with  DRUG1  including  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  (e.g. smoking) may result in enhanced vasoconstriction.",negative,vasoconstrictor agents,sumatriptan
"Concurrent use with  DRUG1  including  DRUGOTHER ,  DRUGOTHER , and  DRUG2  (e.g. smoking) may result in enhanced vasoconstriction.",negative,vasoconstrictor agents,nicotine
"Concurrent use with  DRUGOTHER  including  DRUG1 ,  DRUG2 , and  DRUGOTHER  (e.g. smoking) may result in enhanced vasoconstriction.",negative,ergot alkaloids,sumatriptan
"Concurrent use with  DRUGOTHER  including  DRUG1 ,  DRUGOTHER , and  DRUG2  (e.g. smoking) may result in enhanced vasoconstriction.",negative,ergot alkaloids,nicotine
"Concurrent use with  DRUGOTHER  including  DRUGOTHER ,  DRUG1 , and  DRUG2  (e.g. smoking) may result in enhanced vasoconstriction.",negative,sumatriptan,nicotine
Caution is recommended when administering  DRUG1  with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g.  DRUG2 ).,advise,NEXAVAR,irinotecan
Concomitant treatment with  DRUG1  resulted in a 21% increase in the AUC of  DRUG2 .,mechanism,NEXAVAR,doxorubicin
Caution is recommended when administering  DRUG1  with  DRUG2 .,advise,doxorubicin,NEXAVAR
" DRUG1 , an  DRUG2 , is the standard hormone treatment for breast cancer.",negative,Tamoxifen,estrogen antagonist
 DRUG1  and  DRUG2  reduce the plasma concentration of  DRUGOTHER  by about 50%.,negative,Paroxetine,fluoxetine
 DRUG1  and  DRUGOTHER  reduce the plasma concentration of  DRUG2  by about 50%.,mechanism,Paroxetine,endoxifen
 DRUGOTHER  and  DRUG1  reduce the plasma concentration of  DRUG2  by about 50%.,mechanism,fluoxetine,endoxifen
"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with  DRUG1  for breast cancer, especially  DRUG2  such as  DRUGOTHER  and  DRUGOTHER .",advise,tamoxifen,SSRI antidepressants
"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with  DRUG1  for breast cancer, especially  DRUGOTHER  such as  DRUG2  and  DRUGOTHER .",advise,tamoxifen,paroxetine
"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with  DRUG1  for breast cancer, especially  DRUGOTHER  such as  DRUGOTHER  and  DRUG2 .",advise,tamoxifen,fluoxetine
"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with  DRUGOTHER  for breast cancer, especially  DRUG1  such as  DRUG2  and  DRUGOTHER .",negative,SSRI antidepressants,paroxetine
"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with  DRUGOTHER  for breast cancer, especially  DRUG1  such as  DRUGOTHER  and  DRUG2 .",negative,SSRI antidepressants,fluoxetine
"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with  DRUGOTHER  for breast cancer, especially  DRUGOTHER  such as  DRUG1  and  DRUG2 .",negative,paroxetine,fluoxetine
"Depression does not always require  DRUG1  therapy, and  DRUG2  have no proven preventive impact on hot flushes linked to the menopause.",negative,antidepressant drug,antidepressants
"If in certain cases, an  DRUG1  is considered necessary, it may be advisable to replace  DRUG2  with  DRUGOTHER .",advise,antidepressant,tamoxifen
"If in certain cases, an  DRUG1  is considered necessary, it may be advisable to replace  DRUGOTHER  with  DRUG2 .",negative,antidepressant,anastrozole
"If in certain cases, an  DRUGOTHER  is considered necessary, it may be advisable to replace  DRUG1  with  DRUG2 .",negative,tamoxifen,anastrozole
"In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving  DRUG1 , treatment with  DRUG2  once weekly for 4 weeks was associated with a mean increase of 16% in  DRUGOTHER  AUC;",mechanism,methadone,PEG-Intron
"In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving  DRUG1 , treatment with  DRUGOTHER  once weekly for 4 weeks was associated with a mean increase of 16% in  DRUG2  AUC;",negative,methadone,methadone
"In a pharmacokinetic study of 18 chronic hepatitis C patients concomitantly receiving  DRUGOTHER , treatment with  DRUG1  once weekly for 4 weeks was associated with a mean increase of 16% in  DRUG2  AUC;",negative,PEG-Intron,methadone
 DRUG1  does not inhibit the absorption of 5 milligrams of  DRUG2  or  DRUGOTHER  at doses less than 800 milligrams in nonpregnant women.,negative,Calcium,nonheme iron
 DRUG1  does not inhibit the absorption of 5 milligrams of  DRUGOTHER  or  DRUG2  at doses less than 800 milligrams in nonpregnant women.,negative,Calcium,heme iron
 DRUGOTHER  does not inhibit the absorption of 5 milligrams of  DRUG1  or  DRUG2  at doses less than 800 milligrams in nonpregnant women.,negative,nonheme iron,heme iron
 DRUG1  is the only known component in the diet that may affect absorption of both  DRUG2  and  DRUGOTHER .,mechanism,Calcium,nonheme iron
 DRUG1  is the only known component in the diet that may affect absorption of both  DRUGOTHER  and  DRUG2 .,mechanism,Calcium,heme iron
 DRUGOTHER  is the only known component in the diet that may affect absorption of both  DRUG1  and  DRUG2 .,negative,nonheme iron,heme iron
"However, the evidence for a  DRUG1  effect on  DRUG2  absorption mainly comes from studies that did not isolate the effect of  DRUGOTHER  from that of other dietary components, because it was detected in single-meal studies.",mechanism,calcium,iron
"However, the evidence for a  DRUG1  effect on  DRUGOTHER  absorption mainly comes from studies that did not isolate the effect of  DRUG2  from that of other dietary components, because it was detected in single-meal studies.",negative,calcium,calcium
"However, the evidence for a  DRUGOTHER  effect on  DRUG1  absorption mainly comes from studies that did not isolate the effect of  DRUG2  from that of other dietary components, because it was detected in single-meal studies.",negative,iron,calcium
Our objective was to establish potential effects of  DRUG1  on absorption of  DRUG2  and  DRUGOTHER  and the dose response for this effect in the absence of a meal.,negative,calcium,nonheme iron
Our objective was to establish potential effects of  DRUG1  on absorption of  DRUGOTHER  and  DRUG2  and the dose response for this effect in the absence of a meal.,negative,calcium,heme iron
Our objective was to establish potential effects of  DRUGOTHER  on absorption of  DRUG1  and  DRUG2  and the dose response for this effect in the absence of a meal.,negative,nonheme iron,heme iron
We evaluated the effects of  DRUG1  doses between 200 and 1500 mg on absorption of 5 mg  DRUG2  (as  DRUGOTHER ).,negative,calcium,nonheme iron
We evaluated the effects of  DRUG1  doses between 200 and 1500 mg on absorption of 5 mg  DRUGOTHER  (as  DRUG2 ).,negative,calcium,ferrous sulfate
We evaluated the effects of  DRUGOTHER  doses between 200 and 1500 mg on absorption of 5 mg  DRUG1  (as  DRUG2 ).,negative,nonheme iron,ferrous sulfate
We also evaluated the effects of  DRUG1  doses between 200 and 800 mg on absorption of 5 mg  DRUG2  [as concentrated RBC (CRBC)].,negative,calcium,heme iron
 DRUG1  was administered as  DRUG2  in all studies and  DRUGOTHER  were ingested on an empty stomach.,negative,Calcium,calcium chloride
 DRUG1  was administered as  DRUGOTHER  in all studies and  DRUG2  were ingested on an empty stomach.,negative,Calcium,minerals
 DRUGOTHER  was administered as  DRUG1  in all studies and  DRUG2  were ingested on an empty stomach.,negative,calcium chloride,minerals
 DRUG1  doses   1000 mg diminished  DRUG2  absorption by an average of 49.6%.,mechanism,Calcium,nonheme iron
A  DRUG1  dose of 800 mg diminished absorption of 5 mg  DRUG2  by 37.7%.,mechanism,calcium,heme iron
"In conclusion, we demonstrated an isolated effect of  DRUG1  (as chloride) on absorption of 5 mg of iron provided as  DRUG2  (as sulfate) and  DRUGOTHER  (as CRBC) iron.",mechanism,calcium,nonheme iron
"In conclusion, we demonstrated an isolated effect of  DRUG1  (as chloride) on absorption of 5 mg of iron provided as  DRUGOTHER  (as sulfate) and  DRUG2  (as CRBC) iron.",mechanism,calcium,heme iron
"In conclusion, we demonstrated an isolated effect of  DRUGOTHER  (as chloride) on absorption of 5 mg of iron provided as  DRUG1  (as sulfate) and  DRUG2  (as CRBC) iron.",negative,nonheme iron,heme iron
 DRUG1  ( DRUG2 )--better than  DRUGOTHER  ( DRUGOTHER ),negative,Ticagrelor,Brilinta
 DRUG1  ( DRUGOTHER )--better than  DRUG2  ( DRUGOTHER ),negative,Ticagrelor,clopidogrel
 DRUG1  ( DRUGOTHER )--better than  DRUGOTHER  ( DRUG2 ),negative,Ticagrelor,Plavix
 DRUGOTHER  ( DRUG1 )--better than  DRUG2  ( DRUGOTHER ),negative,Brilinta,clopidogrel
 DRUGOTHER  ( DRUG1 )--better than  DRUGOTHER  ( DRUG2 ),negative,Brilinta,Plavix
 DRUGOTHER  ( DRUGOTHER )--better than  DRUG1  ( DRUG2 ),negative,clopidogrel,Plavix
"The FDA has approved  DRUG1  ( DRUG2 -AstraZeneca), an oral  DRUGOTHER , for use with low-dose  DRUGOTHER  to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).",negative,ticagrelor,Brilinta
"The FDA has approved  DRUG1  ( DRUGOTHER -AstraZeneca), an oral  DRUG2 , for use with low-dose  DRUGOTHER  to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).",negative,ticagrelor,antiplatelet drug
"The FDA has approved  DRUG1  ( DRUGOTHER -AstraZeneca), an oral  DRUGOTHER , for use with low-dose  DRUG2  to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).",effect,ticagrelor,aspirin
"The FDA has approved  DRUGOTHER  ( DRUG1 -AstraZeneca), an oral  DRUG2 , for use with low-dose  DRUGOTHER  to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).",negative,Brilinta,antiplatelet drug
"The FDA has approved  DRUGOTHER  ( DRUG1 -AstraZeneca), an oral  DRUGOTHER , for use with low-dose  DRUG2  to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).",effect,Brilinta,aspirin
"The FDA has approved  DRUGOTHER  ( DRUGOTHER -AstraZeneca), an oral  DRUG1 , for use with low-dose  DRUG2  to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).",negative,antiplatelet drug,aspirin
It will compete with  DRUG1  ( DRUG2 ) and  DRUGOTHER  ( DRUGOTHER ) for such use.,negative,clopidogrel,Plavix
It will compete with  DRUG1  ( DRUGOTHER ) and  DRUG2  ( DRUGOTHER ) for such use.,negative,clopidogrel,prasugrel
It will compete with  DRUG1  ( DRUGOTHER ) and  DRUGOTHER  ( DRUG2 ) for such use.,negative,clopidogrel,Effient
It will compete with  DRUGOTHER  ( DRUG1 ) and  DRUG2  ( DRUGOTHER ) for such use.,negative,Plavix,prasugrel
It will compete with  DRUGOTHER  ( DRUG1 ) and  DRUGOTHER  ( DRUG2 ) for such use.,negative,Plavix,Effient
It will compete with  DRUGOTHER  ( DRUGOTHER ) and  DRUG1  ( DRUG2 ) for such use.,negative,prasugrel,Effient
Preliminary evidence suggests that  DRUG1  inhibits  DRUG2  metabolism and may result in an increase in plasma concentrations of  DRUGOTHER .,mechanism,cimetidine,mebendazole
Preliminary evidence suggests that  DRUG1  inhibits  DRUGOTHER  metabolism and may result in an increase in plasma concentrations of  DRUG2 .,negative,cimetidine,mebendazole
Preliminary evidence suggests that  DRUGOTHER  inhibits  DRUG1  metabolism and may result in an increase in plasma concentrations of  DRUG2 .,negative,mebendazole,mebendazole
" DRUG1 , particularly  DRUG2 , may cause serious cardiac arrhythmias during  DRUGOTHER  anesthesia and therefore should be used only with great caution or not at all.",negative,Vasopressors,metaraminol
" DRUG1 , particularly  DRUGOTHER , may cause serious cardiac arrhythmias during  DRUG2  anesthesia and therefore should be used only with great caution or not at all.",effect,Vasopressors,halothane
" DRUGOTHER , particularly  DRUG1 , may cause serious cardiac arrhythmias during  DRUG2  anesthesia and therefore should be used only with great caution or not at all.",effect,metaraminol,halothane
 DRUG1 : The pressor effect of  DRUG2  is markedly potentiated in patients receiving  DRUGOTHER  ( DRUGOTHER ).,negative,MAO Inhibitors,sympathomimetic pressor amines
 DRUG1 : The pressor effect of  DRUGOTHER  is markedly potentiated in patients receiving  DRUG2  ( DRUGOTHER ).,negative,MAO Inhibitors,monoamine oxidase inhibitors
 DRUG1 : The pressor effect of  DRUGOTHER  is markedly potentiated in patients receiving  DRUGOTHER  ( DRUG2 ).,negative,MAO Inhibitors,MAOI
 DRUGOTHER : The pressor effect of  DRUG1  is markedly potentiated in patients receiving  DRUG2  ( DRUGOTHER ).,effect,sympathomimetic pressor amines,monoamine oxidase inhibitors
 DRUGOTHER : The pressor effect of  DRUG1  is markedly potentiated in patients receiving  DRUGOTHER  ( DRUG2 ).,effect,sympathomimetic pressor amines,MAOI
 DRUGOTHER : The pressor effect of  DRUGOTHER  is markedly potentiated in patients receiving  DRUG1  ( DRUG2 ).,negative,monoamine oxidase inhibitors,MAOI
The pressor response of  DRUG1  may also be potentiated by  DRUG2 .,effect,adrenergic agents,tricyclic antidepressants
There is usually complete cross-resistance between  DRUG1  ( DRUG2 ) and  DRUGOTHER  brand  DRUGOTHER .,negative,PURINETHOL,mercaptopurine
There is usually complete cross-resistance between  DRUG1  ( DRUGOTHER ) and  DRUG2  brand  DRUGOTHER .,effect,PURINETHOL,TABLOID
There is usually complete cross-resistance between  DRUG1  ( DRUGOTHER ) and  DRUGOTHER  brand  DRUG2 .,effect,PURINETHOL,Thioguanine
There is usually complete cross-resistance between  DRUGOTHER  ( DRUG1 ) and  DRUG2  brand  DRUGOTHER .,effect,mercaptopurine,TABLOID
There is usually complete cross-resistance between  DRUGOTHER  ( DRUG1 ) and  DRUGOTHER  brand  DRUG2 .,effect,mercaptopurine,Thioguanine
There is usually complete cross-resistance between  DRUGOTHER  ( DRUGOTHER ) and  DRUG1  brand  DRUG2 .,negative,TABLOID,Thioguanine
"As there is in vitro evidence that  DRUG1  (e.g.,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent  DRUGOTHER  therapy.",negative,aminosalicylate derivatives,olsalazine
"As there is in vitro evidence that  DRUG1  (e.g.,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent  DRUGOTHER  therapy.",negative,aminosalicylate derivatives,mesalazine
"As there is in vitro evidence that  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent  DRUGOTHER  therapy.",negative,aminosalicylate derivatives,sulphasalazine
"As there is in vitro evidence that  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent  DRUG2  therapy.",mechanism,aminosalicylate derivatives,thioguanine
"As there is in vitro evidence that  DRUGOTHER  (e.g.,  DRUG1 ,  DRUG2 , or  DRUGOTHER ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent  DRUGOTHER  therapy.",negative,olsalazine,mesalazine
"As there is in vitro evidence that  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER , or  DRUG2 ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent  DRUGOTHER  therapy.",negative,olsalazine,sulphasalazine
"As there is in vitro evidence that  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER , or  DRUGOTHER ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent  DRUG2  therapy.",mechanism,olsalazine,thioguanine
"As there is in vitro evidence that  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 , or  DRUG2 ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent  DRUGOTHER  therapy.",negative,mesalazine,sulphasalazine
"As there is in vitro evidence that  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 , or  DRUGOTHER ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent  DRUG2  therapy.",mechanism,mesalazine,thioguanine
"As there is in vitro evidence that  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER , or  DRUG1 ) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent  DRUG2  therapy.",mechanism,sulphasalazine,thioguanine
"The following agents may increase certain actions or side effects of  DRUG1 :  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",effect,anticholinergic drugs,amantadine
"The following agents may increase certain actions or side effects of  DRUG1 :  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",effect,anticholinergic drugs,antiarrhythmic agents of class I
"The following agents may increase certain actions or side effects of  DRUG1 :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",effect,anticholinergic drugs,quinidine
"The following agents may increase certain actions or side effects of  DRUG1 :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",effect,anticholinergic drugs,antihistamines
"The following agents may increase certain actions or side effects of  DRUG1 :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",effect,anticholinergic drugs,antipsychotic agents
"The following agents may increase certain actions or side effects of  DRUG1 :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",effect,anticholinergic drugs,phenothiazines
"The following agents may increase certain actions or side effects of  DRUG1 :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",effect,anticholinergic drugs,benzodiazepines
"The following agents may increase certain actions or side effects of  DRUG1 :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",effect,anticholinergic drugs,MAO inhibitors
"The following agents may increase certain actions or side effects of  DRUG1 :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",effect,anticholinergic drugs,narcotic analgesics
"The following agents may increase certain actions or side effects of  DRUG1 :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",effect,anticholinergic drugs,meperidine
"The following agents may increase certain actions or side effects of  DRUG1 :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",effect,anticholinergic drugs,nitrates
"The following agents may increase certain actions or side effects of  DRUG1 :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",effect,anticholinergic drugs,nitrites
"The following agents may increase certain actions or side effects of  DRUG1 :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other drugs having anticholinergic activity.",effect,anticholinergic drugs,sympathomimetic agents
"The following agents may increase certain actions or side effects of  DRUG1 :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other drugs having anticholinergic activity.",effect,anticholinergic drugs,tricyclic antidepressants
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUG1 ,  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,amantadine,antiarrhythmic agents of class I
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUG1 ,  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,amantadine,quinidine
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,amantadine,antihistamines
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,amantadine,antipsychotic agents
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,amantadine,phenothiazines
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,amantadine,benzodiazepines
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,amantadine,MAO inhibitors
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,amantadine,narcotic analgesics
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,amantadine,meperidine
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,amantadine,nitrates
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,amantadine,nitrites
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,amantadine,sympathomimetic agents
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other drugs having anticholinergic activity.",negative,amantadine,tricyclic antidepressants
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUG1  (e.g.,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antiarrhythmic agents of class I,quinidine
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antiarrhythmic agents of class I,antihistamines
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antiarrhythmic agents of class I,antipsychotic agents
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antiarrhythmic agents of class I,phenothiazines
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antiarrhythmic agents of class I,benzodiazepines
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antiarrhythmic agents of class I,MAO inhibitors
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antiarrhythmic agents of class I,narcotic analgesics
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antiarrhythmic agents of class I,meperidine
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antiarrhythmic agents of class I,nitrates
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antiarrhythmic agents of class I,nitrites
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antiarrhythmic agents of class I,sympathomimetic agents
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other drugs having anticholinergic activity.",negative,antiarrhythmic agents of class I,tricyclic antidepressants
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,quinidine,antihistamines
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,quinidine,antipsychotic agents
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,quinidine,phenothiazines
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,quinidine,benzodiazepines
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,quinidine,MAO inhibitors
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,quinidine,narcotic analgesics
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,quinidine,meperidine
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,quinidine,nitrates
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,quinidine,nitrites
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,quinidine,sympathomimetic agents
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other drugs having anticholinergic activity.",negative,quinidine,tricyclic antidepressants
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1 ,  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antihistamines,antipsychotic agents
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antihistamines,phenothiazines
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antihistamines,benzodiazepines
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antihistamines,MAO inhibitors
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antihistamines,narcotic analgesics
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antihistamines,meperidine
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antihistamines,nitrates
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antihistamines,nitrites
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antihistamines,sympathomimetic agents
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other drugs having anticholinergic activity.",negative,antihistamines,tricyclic antidepressants
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG1  (e.g.,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antipsychotic agents,phenothiazines
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antipsychotic agents,benzodiazepines
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antipsychotic agents,MAO inhibitors
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antipsychotic agents,narcotic analgesics
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antipsychotic agents,meperidine
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antipsychotic agents,nitrates
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antipsychotic agents,nitrites
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,antipsychotic agents,sympathomimetic agents
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other drugs having anticholinergic activity.",negative,antipsychotic agents,tricyclic antidepressants
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,phenothiazines,benzodiazepines
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,phenothiazines,MAO inhibitors
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,phenothiazines,narcotic analgesics
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,phenothiazines,meperidine
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,phenothiazines,nitrates
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,phenothiazines,nitrites
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,phenothiazines,sympathomimetic agents
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other drugs having anticholinergic activity.",negative,phenothiazines,tricyclic antidepressants
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1 ,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,benzodiazepines,MAO inhibitors
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,benzodiazepines,narcotic analgesics
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,benzodiazepines,meperidine
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,benzodiazepines,nitrates
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,benzodiazepines,nitrites
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,benzodiazepines,sympathomimetic agents
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other drugs having anticholinergic activity.",negative,benzodiazepines,tricyclic antidepressants
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUG2  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,MAO inhibitors,narcotic analgesics
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (e.g.,  DRUG2 ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,MAO inhibitors,meperidine
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,MAO inhibitors,nitrates
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,MAO inhibitors,nitrites
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,MAO inhibitors,sympathomimetic agents
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other drugs having anticholinergic activity.",negative,MAO inhibitors,tricyclic antidepressants
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (e.g.,  DRUG2 ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,narcotic analgesics,meperidine
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,narcotic analgesics,nitrates
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,narcotic analgesics,nitrites
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,narcotic analgesics,sympathomimetic agents
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other drugs having anticholinergic activity.",negative,narcotic analgesics,tricyclic antidepressants
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUG2  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,meperidine,nitrates
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,meperidine,nitrites
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,meperidine,sympathomimetic agents
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ),  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other drugs having anticholinergic activity.",negative,meperidine,tricyclic antidepressants
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,nitrates,nitrites
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,nitrates,sympathomimetic agents
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other drugs having anticholinergic activity.",negative,nitrates,tricyclic antidepressants
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUG1 ,  DRUG2 ,  DRUGOTHER , and other drugs having anticholinergic activity.",negative,nitrites,sympathomimetic agents
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUG2 , and other drugs having anticholinergic activity.",negative,nitrites,tricyclic antidepressants
"The following agents may increase certain actions or side effects of  DRUGOTHER :  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ),  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUG2 , and other drugs having anticholinergic activity.",negative,sympathomimetic agents,tricyclic antidepressants
 DRUG1  antagonize the effects of  DRUG2 .,effect,Anticholinergics,antiglaucoma agents
 DRUG1  in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as  DRUG2 .,effect,Anticholinergic drugs,corticosteroids
" DRUG1  may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of  DRUG2 ;",mechanism,Anticholinergic agents,digoxin
" DRUG1  may antagonize the effects of drugs that alter gastrointestinal motility, such as  DRUG2 .",effect,Anticholinergic drugs,metoclopramide
"Because  DRUG1  may interfere with the absorption of  DRUG2 , simultaneous use of these drugs should be avoided.",mechanism,antacids,anticholinergic agents
Administration of  DRUG1  in combination with  DRUG2  resulted in a two-fold decrease in  DRUGOTHER  clearance in a non-human primate study and in a 1.5-fold increase in  DRUGOTHER  serum levels in clinical studies.,mechanism,paclitaxel,HERCEPTIN
Administration of  DRUG1  in combination with  DRUGOTHER  resulted in a two-fold decrease in  DRUG2  clearance in a non-human primate study and in a 1.5-fold increase in  DRUGOTHER  serum levels in clinical studies.,negative,paclitaxel,HERCEPTIN
Administration of  DRUG1  in combination with  DRUGOTHER  resulted in a two-fold decrease in  DRUGOTHER  clearance in a non-human primate study and in a 1.5-fold increase in  DRUG2  serum levels in clinical studies.,negative,paclitaxel,HERCEPTIN
Administration of  DRUGOTHER  in combination with  DRUG1  resulted in a two-fold decrease in  DRUG2  clearance in a non-human primate study and in a 1.5-fold increase in  DRUGOTHER  serum levels in clinical studies.,negative,HERCEPTIN,HERCEPTIN
Administration of  DRUGOTHER  in combination with  DRUG1  resulted in a two-fold decrease in  DRUGOTHER  clearance in a non-human primate study and in a 1.5-fold increase in  DRUG2  serum levels in clinical studies.,negative,HERCEPTIN,HERCEPTIN
Administration of  DRUGOTHER  in combination with  DRUGOTHER  resulted in a two-fold decrease in  DRUG1  clearance in a non-human primate study and in a 1.5-fold increase in  DRUG2  serum levels in clinical studies.,negative,HERCEPTIN,HERCEPTIN
An inhibitor of CYP2C8 (such as  DRUG1 ) may increase the AUC of  DRUG2  and an inducer of CYP2C8 (such as  DRUGOTHER ) may decrease the AUC of  DRUGOTHER .,mechanism,gemfibrozil,rosiglitazone
An inhibitor of CYP2C8 (such as  DRUG1 ) may increase the AUC of  DRUGOTHER  and an inducer of CYP2C8 (such as  DRUG2 ) may decrease the AUC of  DRUGOTHER .,negative,gemfibrozil,rifampin
An inhibitor of CYP2C8 (such as  DRUG1 ) may increase the AUC of  DRUGOTHER  and an inducer of CYP2C8 (such as  DRUGOTHER ) may decrease the AUC of  DRUG2 .,negative,gemfibrozil,rosiglitazone
An inhibitor of CYP2C8 (such as  DRUGOTHER ) may increase the AUC of  DRUG1  and an inducer of CYP2C8 (such as  DRUG2 ) may decrease the AUC of  DRUGOTHER .,negative,rosiglitazone,rifampin
An inhibitor of CYP2C8 (such as  DRUGOTHER ) may increase the AUC of  DRUG1  and an inducer of CYP2C8 (such as  DRUGOTHER ) may decrease the AUC of  DRUG2 .,negative,rosiglitazone,rosiglitazone
An inhibitor of CYP2C8 (such as  DRUGOTHER ) may increase the AUC of  DRUGOTHER  and an inducer of CYP2C8 (such as  DRUG1 ) may decrease the AUC of  DRUG2 .,mechanism,rifampin,rosiglitazone
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUG1  and  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,MYCAMINE,mycophenolate mofetil
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUG1  and  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,MYCAMINE,cyclosporine
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,MYCAMINE,tacrolimus
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,MYCAMINE,prednisolone
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,MYCAMINE,sirolimus
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,MYCAMINE,nifedipine
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,MYCAMINE,fluconazole
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,MYCAMINE,ritonavir
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUG1  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,MYCAMINE,rifampin
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,mycophenolate mofetil,cyclosporine
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,mycophenolate mofetil,tacrolimus
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,mycophenolate mofetil,prednisolone
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,mycophenolate mofetil,sirolimus
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,mycophenolate mofetil,nifedipine
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,mycophenolate mofetil,fluconazole
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,mycophenolate mofetil,ritonavir
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,mycophenolate mofetil,rifampin
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,cyclosporine,tacrolimus
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,cyclosporine,prednisolone
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,cyclosporine,sirolimus
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,cyclosporine,nifedipine
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,cyclosporine,fluconazole
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,cyclosporine,ritonavir
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,cyclosporine,rifampin
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,tacrolimus,prednisolone
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,tacrolimus,sirolimus
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,tacrolimus,nifedipine
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,tacrolimus,fluconazole
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,tacrolimus,ritonavir
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,tacrolimus,rifampin
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,prednisolone,sirolimus
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,prednisolone,nifedipine
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,prednisolone,fluconazole
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,prednisolone,ritonavir
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,prednisolone,rifampin
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,sirolimus,nifedipine
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,sirolimus,fluconazole
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,sirolimus,ritonavir
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,sirolimus,rifampin
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,nifedipine,fluconazole
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,nifedipine,ritonavir
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,nifedipine,rifampin
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER .",negative,fluconazole,ritonavir
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 .",negative,fluconazole,rifampin
"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between  DRUGOTHER  and  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 .",negative,ritonavir,rifampin
"There was no effect of a single dose or multiple doses of  DRUG1  on  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  pharmacokinetics.",negative,MYCAMINE,mycophenolate mofetil
"There was no effect of a single dose or multiple doses of  DRUG1  on  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  pharmacokinetics.",negative,MYCAMINE,cyclosporine
"There was no effect of a single dose or multiple doses of  DRUG1  on  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  pharmacokinetics.",negative,MYCAMINE,tacrolimus
"There was no effect of a single dose or multiple doses of  DRUG1  on  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  pharmacokinetics.",negative,MYCAMINE,prednisolone
"There was no effect of a single dose or multiple doses of  DRUG1  on  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  pharmacokinetics.",negative,MYCAMINE,fluconazole
"There was no effect of a single dose or multiple doses of  DRUGOTHER  on  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  pharmacokinetics.",negative,mycophenolate mofetil,cyclosporine
"There was no effect of a single dose or multiple doses of  DRUGOTHER  on  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  pharmacokinetics.",negative,mycophenolate mofetil,tacrolimus
"There was no effect of a single dose or multiple doses of  DRUGOTHER  on  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  pharmacokinetics.",negative,mycophenolate mofetil,prednisolone
"There was no effect of a single dose or multiple doses of  DRUGOTHER  on  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  pharmacokinetics.",negative,mycophenolate mofetil,fluconazole
"There was no effect of a single dose or multiple doses of  DRUGOTHER  on  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  pharmacokinetics.",negative,cyclosporine,tacrolimus
"There was no effect of a single dose or multiple doses of  DRUGOTHER  on  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  pharmacokinetics.",negative,cyclosporine,prednisolone
"There was no effect of a single dose or multiple doses of  DRUGOTHER  on  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  pharmacokinetics.",negative,cyclosporine,fluconazole
"There was no effect of a single dose or multiple doses of  DRUGOTHER  on  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER  pharmacokinetics.",negative,tacrolimus,prednisolone
"There was no effect of a single dose or multiple doses of  DRUGOTHER  on  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2  pharmacokinetics.",negative,tacrolimus,fluconazole
"There was no effect of a single dose or multiple doses of  DRUGOTHER  on  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2  pharmacokinetics.",negative,prednisolone,fluconazole
 DRUG1  AUC was increased by 21% with no effect on Cmax in the presence of steady-state  DRUG2  compared with  DRUGOTHER  alone.,mechanism,Sirolimus,MYCAMINE
 DRUG1  AUC was increased by 21% with no effect on Cmax in the presence of steady-state  DRUGOTHER  compared with  DRUG2  alone.,negative,Sirolimus,sirolimus
 DRUGOTHER  AUC was increased by 21% with no effect on Cmax in the presence of steady-state  DRUG1  compared with  DRUG2  alone.,negative,MYCAMINE,sirolimus
" DRUG1  AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state  DRUG2  compared with  DRUGOTHER  alone.",mechanism,Nifedipine,MYCAMINE
" DRUG1  AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state  DRUGOTHER  compared with  DRUG2  alone.",negative,Nifedipine,nifedipine
" DRUGOTHER  AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state  DRUG1  compared with  DRUG2  alone.",negative,MYCAMINE,nifedipine
Patients receiving  DRUG1  or  DRUG2  in combination with  DRUGOTHER  should be monitored for  DRUGOTHER  or  DRUGOTHER  toxicity and  DRUGOTHER  or  DRUGOTHER  dosage should be reduced if necessary.,negative,sirolimus,nifedipine
Patients receiving  DRUG1  or  DRUGOTHER  in combination with  DRUG2  should be monitored for  DRUGOTHER  or  DRUGOTHER  toxicity and  DRUGOTHER  or  DRUGOTHER  dosage should be reduced if necessary.,advise,sirolimus,MYCAMINE
Patients receiving  DRUG1  or  DRUGOTHER  in combination with  DRUGOTHER  should be monitored for  DRUG2  or  DRUGOTHER  toxicity and  DRUGOTHER  or  DRUGOTHER  dosage should be reduced if necessary.,negative,sirolimus,sirolimus
Patients receiving  DRUG1  or  DRUGOTHER  in combination with  DRUGOTHER  should be monitored for  DRUGOTHER  or  DRUG2  toxicity and  DRUGOTHER  or  DRUGOTHER  dosage should be reduced if necessary.,negative,sirolimus,nifedipine
Patients receiving  DRUG1  or  DRUGOTHER  in combination with  DRUGOTHER  should be monitored for  DRUGOTHER  or  DRUGOTHER  toxicity and  DRUG2  or  DRUGOTHER  dosage should be reduced if necessary.,negative,sirolimus,sirolimus
Patients receiving  DRUG1  or  DRUGOTHER  in combination with  DRUGOTHER  should be monitored for  DRUGOTHER  or  DRUGOTHER  toxicity and  DRUGOTHER  or  DRUG2  dosage should be reduced if necessary.,negative,sirolimus,nifedipine
Patients receiving  DRUGOTHER  or  DRUG1  in combination with  DRUG2  should be monitored for  DRUGOTHER  or  DRUGOTHER  toxicity and  DRUGOTHER  or  DRUGOTHER  dosage should be reduced if necessary.,advise,nifedipine,MYCAMINE
Patients receiving  DRUGOTHER  or  DRUG1  in combination with  DRUGOTHER  should be monitored for  DRUG2  or  DRUGOTHER  toxicity and  DRUGOTHER  or  DRUGOTHER  dosage should be reduced if necessary.,negative,nifedipine,sirolimus
Patients receiving  DRUGOTHER  or  DRUG1  in combination with  DRUGOTHER  should be monitored for  DRUGOTHER  or  DRUG2  toxicity and  DRUGOTHER  or  DRUGOTHER  dosage should be reduced if necessary.,negative,nifedipine,nifedipine
Patients receiving  DRUGOTHER  or  DRUG1  in combination with  DRUGOTHER  should be monitored for  DRUGOTHER  or  DRUGOTHER  toxicity and  DRUG2  or  DRUGOTHER  dosage should be reduced if necessary.,negative,nifedipine,sirolimus
Patients receiving  DRUGOTHER  or  DRUG1  in combination with  DRUGOTHER  should be monitored for  DRUGOTHER  or  DRUGOTHER  toxicity and  DRUGOTHER  or  DRUG2  dosage should be reduced if necessary.,negative,nifedipine,nifedipine
Patients receiving  DRUGOTHER  or  DRUGOTHER  in combination with  DRUG1  should be monitored for  DRUG2  or  DRUGOTHER  toxicity and  DRUGOTHER  or  DRUGOTHER  dosage should be reduced if necessary.,negative,MYCAMINE,sirolimus
Patients receiving  DRUGOTHER  or  DRUGOTHER  in combination with  DRUG1  should be monitored for  DRUGOTHER  or  DRUG2  toxicity and  DRUGOTHER  or  DRUGOTHER  dosage should be reduced if necessary.,negative,MYCAMINE,nifedipine
Patients receiving  DRUGOTHER  or  DRUGOTHER  in combination with  DRUG1  should be monitored for  DRUGOTHER  or  DRUGOTHER  toxicity and  DRUG2  or  DRUGOTHER  dosage should be reduced if necessary.,negative,MYCAMINE,sirolimus
Patients receiving  DRUGOTHER  or  DRUGOTHER  in combination with  DRUG1  should be monitored for  DRUGOTHER  or  DRUGOTHER  toxicity and  DRUGOTHER  or  DRUG2  dosage should be reduced if necessary.,negative,MYCAMINE,nifedipine
Patients receiving  DRUGOTHER  or  DRUGOTHER  in combination with  DRUGOTHER  should be monitored for  DRUG1  or  DRUG2  toxicity and  DRUGOTHER  or  DRUGOTHER  dosage should be reduced if necessary.,negative,sirolimus,nifedipine
Patients receiving  DRUGOTHER  or  DRUGOTHER  in combination with  DRUGOTHER  should be monitored for  DRUG1  or  DRUGOTHER  toxicity and  DRUG2  or  DRUGOTHER  dosage should be reduced if necessary.,negative,sirolimus,sirolimus
Patients receiving  DRUGOTHER  or  DRUGOTHER  in combination with  DRUGOTHER  should be monitored for  DRUG1  or  DRUGOTHER  toxicity and  DRUGOTHER  or  DRUG2  dosage should be reduced if necessary.,negative,sirolimus,nifedipine
Patients receiving  DRUGOTHER  or  DRUGOTHER  in combination with  DRUGOTHER  should be monitored for  DRUGOTHER  or  DRUG1  toxicity and  DRUG2  or  DRUGOTHER  dosage should be reduced if necessary.,negative,nifedipine,sirolimus
Patients receiving  DRUGOTHER  or  DRUGOTHER  in combination with  DRUGOTHER  should be monitored for  DRUGOTHER  or  DRUG1  toxicity and  DRUGOTHER  or  DRUG2  dosage should be reduced if necessary.,negative,nifedipine,nifedipine
Patients receiving  DRUGOTHER  or  DRUGOTHER  in combination with  DRUGOTHER  should be monitored for  DRUGOTHER  or  DRUGOTHER  toxicity and  DRUG1  or  DRUG2  dosage should be reduced if necessary.,negative,sirolimus,nifedipine
"Concurrent administration of  DRUG1  (e.g.,  DRUG2 ,  DRUGOTHER ) may diminish the bactericidal effects of  DRUGOTHER  by slowing the rate of bacterial growth.",negative,bacteriostatic antibiotics,erythromycin
"Concurrent administration of  DRUG1  (e.g.,  DRUGOTHER ,  DRUG2 ) may diminish the bactericidal effects of  DRUGOTHER  by slowing the rate of bacterial growth.",negative,bacteriostatic antibiotics,tetracycline
"Concurrent administration of  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ) may diminish the bactericidal effects of  DRUG2  by slowing the rate of bacterial growth.",effect,bacteriostatic antibiotics,penicillins
"Concurrent administration of  DRUGOTHER  (e.g.,  DRUG1 ,  DRUG2 ) may diminish the bactericidal effects of  DRUGOTHER  by slowing the rate of bacterial growth.",negative,erythromycin,tetracycline
"Concurrent administration of  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ) may diminish the bactericidal effects of  DRUG2  by slowing the rate of bacterial growth.",effect,erythromycin,penicillins
"Concurrent administration of  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ) may diminish the bactericidal effects of  DRUG2  by slowing the rate of bacterial growth.",effect,tetracycline,penicillins
 DRUG1  blood levels may be prolonged by concurrent administration of  DRUG2  which blocks the renal tubular secretion of  DRUGOTHER .,mechanism,Penicillin,probenecid
 DRUG1  blood levels may be prolonged by concurrent administration of  DRUGOTHER  which blocks the renal tubular secretion of  DRUG2 .,negative,Penicillin,penicillins
 DRUGOTHER  blood levels may be prolonged by concurrent administration of  DRUG1  which blocks the renal tubular secretion of  DRUG2 .,negative,probenecid,penicillins
Displacement of  DRUG1  from plasma protein binding sites will elevate the level of free  DRUG2  in the serum.,negative,penicillin,penicillin
" DRUG1  are capable of potentiating  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , etc.)",effect,Phenothiazines,CNS depressants
" DRUG1  are capable of potentiating  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , etc.)",effect,Phenothiazines,barbiturates
" DRUG1  are capable of potentiating  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , etc.)",effect,Phenothiazines,anesthetics
" DRUG1  are capable of potentiating  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , etc.)",effect,Phenothiazines,opiates
" DRUG1  are capable of potentiating  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , etc.)",effect,Phenothiazines,alcohol
" DRUGOTHER  are capable of potentiating  DRUG1  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , etc.)",negative,CNS depressants,barbiturates
" DRUGOTHER  are capable of potentiating  DRUG1  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , etc.)",negative,CNS depressants,anesthetics
" DRUGOTHER  are capable of potentiating  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , etc.)",negative,CNS depressants,opiates
" DRUGOTHER  are capable of potentiating  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , etc.)",negative,CNS depressants,alcohol
" DRUGOTHER  are capable of potentiating  DRUGOTHER  (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , etc.)",negative,barbiturates,anesthetics
" DRUGOTHER  are capable of potentiating  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , etc.)",negative,barbiturates,opiates
" DRUGOTHER  are capable of potentiating  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , etc.)",negative,barbiturates,alcohol
" DRUGOTHER  are capable of potentiating  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , etc.)",negative,anesthetics,opiates
" DRUGOTHER  are capable of potentiating  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , etc.)",negative,anesthetics,alcohol
" DRUGOTHER  are capable of potentiating  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , etc.)",negative,opiates,alcohol
as well as  DRUG1  and  DRUG2 .,negative,atropine,phosphorous insecticides
"Catecholamine-depleting drugs (e.g.,  DRUG1 ) may have an additive effect when given with  DRUG2 .",effect,reserpine,beta-blocking agents
" DRUG1  has been used with a variety of  DRUG2 , including  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  without unexpected adverse interactions.",negative,Pindolol,antihypertensive agents
" DRUG1  has been used with a variety of  DRUGOTHER , including  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  without unexpected adverse interactions.",negative,Pindolol,hydrochlorothiazide
" DRUG1  has been used with a variety of  DRUGOTHER , including  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  without unexpected adverse interactions.",negative,Pindolol,hydralazine
" DRUG1  has been used with a variety of  DRUGOTHER , including  DRUGOTHER ,  DRUGOTHER , and  DRUG2  without unexpected adverse interactions.",negative,Pindolol,guanethidine
" DRUGOTHER  has been used with a variety of  DRUG1 , including  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  without unexpected adverse interactions.",negative,antihypertensive agents,hydrochlorothiazide
" DRUGOTHER  has been used with a variety of  DRUG1 , including  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  without unexpected adverse interactions.",negative,antihypertensive agents,hydralazine
" DRUGOTHER  has been used with a variety of  DRUG1 , including  DRUGOTHER ,  DRUGOTHER , and  DRUG2  without unexpected adverse interactions.",negative,antihypertensive agents,guanethidine
" DRUGOTHER  has been used with a variety of  DRUGOTHER , including  DRUG1 ,  DRUG2 , and  DRUGOTHER  without unexpected adverse interactions.",negative,hydrochlorothiazide,hydralazine
" DRUGOTHER  has been used with a variety of  DRUGOTHER , including  DRUG1 ,  DRUGOTHER , and  DRUG2  without unexpected adverse interactions.",negative,hydrochlorothiazide,guanethidine
" DRUGOTHER  has been used with a variety of  DRUGOTHER , including  DRUGOTHER ,  DRUG1 , and  DRUG2  without unexpected adverse interactions.",negative,hydralazine,guanethidine
 DRUG1  has been shown to increase serum  DRUG2  levels when both drugs are co-administered.,mechanism,Pindolol,thioridazine
 DRUG1  at a Dose of 10 mg Once Daily Dosed to Pharmacokinetic Steady State  - did not cause clinically significant changes in the kinetics of a single intravenous dose of  DRUG2  (predominantly a cytochrome P450 1A2 substrate).,negative,Montelukast,theophylline
- did not change the pharmacokinetic profile of  DRUG1  (a substrate of cytochromes P450 2A6 and 2C9) or influence the effect of a single 30-mg oral dose of  DRUG2  on prothrombin time or the INR (International Normalized Ratio).,negative,warfarin,warfarin
"- did not change the plasma concentration profile of  DRUG1  (a substrate of cytochrome P450 3A4) or  DRUG2 , its carboxylated metabolite, and did not prolong the QTc interval following co-administration with  DRUGOTHER  60 mg twice daily.",negative,terfenadine,fexofenadine
"- did not change the plasma concentration profile of  DRUG1  (a substrate of cytochrome P450 3A4) or  DRUGOTHER , its carboxylated metabolite, and did not prolong the QTc interval following co-administration with  DRUG2  60 mg twice daily.",negative,terfenadine,terfenadine
"- did not change the plasma concentration profile of  DRUGOTHER  (a substrate of cytochrome P450 3A4) or  DRUG1 , its carboxylated metabolite, and did not prolong the QTc interval following co-administration with  DRUG2  60 mg twice daily.",negative,fexofenadine,terfenadine
 DRUG1  at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral  DRUG2  containing  DRUGOTHER  1 mg/ethinyl  DRUGOTHER  35 mcg.,negative,Montelukast,contraceptive
 DRUG1  at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral  DRUGOTHER  containing  DRUG2  1 mg/ethinyl  DRUGOTHER  35 mcg.,negative,Montelukast,norethindrone
 DRUG1  at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral  DRUGOTHER  containing  DRUGOTHER  1 mg/ethinyl  DRUG2  35 mcg.,negative,Montelukast,estradiol
 DRUGOTHER  at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral  DRUG1  containing  DRUG2  1 mg/ethinyl  DRUGOTHER  35 mcg.,negative,contraceptive,norethindrone
 DRUGOTHER  at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral  DRUG1  containing  DRUGOTHER  1 mg/ethinyl  DRUG2  35 mcg.,negative,contraceptive,estradiol
 DRUGOTHER  at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral  DRUGOTHER  containing  DRUG1  1 mg/ethinyl  DRUG2  35 mcg.,negative,norethindrone,estradiol
- did not cause any clinically significant change in plasma profiles of  DRUG1  or  DRUG2  following administration of either oral  DRUGOTHER  or intravenous  DRUGOTHER .,negative,prednisone,prednisolone
- did not cause any clinically significant change in plasma profiles of  DRUG1  or  DRUGOTHER  following administration of either oral  DRUG2  or intravenous  DRUGOTHER .,negative,prednisone,prednisone
- did not cause any clinically significant change in plasma profiles of  DRUG1  or  DRUGOTHER  following administration of either oral  DRUGOTHER  or intravenous  DRUG2 .,negative,prednisone,prednisolone
- did not cause any clinically significant change in plasma profiles of  DRUGOTHER  or  DRUG1  following administration of either oral  DRUG2  or intravenous  DRUGOTHER .,negative,prednisolone,prednisone
- did not cause any clinically significant change in plasma profiles of  DRUGOTHER  or  DRUG1  following administration of either oral  DRUGOTHER  or intravenous  DRUG2 .,negative,prednisolone,prednisolone
- did not cause any clinically significant change in plasma profiles of  DRUGOTHER  or  DRUGOTHER  following administration of either oral  DRUG1  or intravenous  DRUG2 .,negative,prednisone,prednisolone
" DRUG1 , which induces hepatic metabolism, decreased the AUC of  DRUG2  approximately 40% following a single 10-mg dose of  DRUGOTHER .",negative,Phenobarbital,montelukast
" DRUG1 , which induces hepatic metabolism, decreased the AUC of  DRUGOTHER  approximately 40% following a single 10-mg dose of  DRUG2 .",negative,Phenobarbital,montelukast
" DRUGOTHER , which induces hepatic metabolism, decreased the AUC of  DRUG1  approximately 40% following a single 10-mg dose of  DRUG2 .",negative,montelukast,montelukast
"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as  DRUG1  or  DRUG2 , are co-administered with  DRUGOTHER .",negative,phenobarbital,rifampin
"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as  DRUG1  or  DRUGOTHER , are co-administered with  DRUG2 .",advise,phenobarbital,montelukast
"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as  DRUGOTHER  or  DRUG1 , are co-administered with  DRUG2 .",advise,rifampin,montelukast
"In drug-interaction studies, the recommended clinical dose of  DRUG1  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,montelukast,theophylline
"In drug-interaction studies, the recommended clinical dose of  DRUG1  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,montelukast,prednisone
"In drug-interaction studies, the recommended clinical dose of  DRUG1  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,montelukast,prednisolone
"In drug-interaction studies, the recommended clinical dose of  DRUG1  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,montelukast,contraceptives
"In drug-interaction studies, the recommended clinical dose of  DRUG1  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER  ( DRUG2  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,montelukast,norethindrone
"In drug-interaction studies, the recommended clinical dose of  DRUG1  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUG2  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,montelukast,ethinyl estradiol
"In drug-interaction studies, the recommended clinical dose of  DRUG1  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,montelukast,terfenadine
"In drug-interaction studies, the recommended clinical dose of  DRUG1  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,montelukast,digoxin
"In drug-interaction studies, the recommended clinical dose of  DRUG1  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,montelukast,warfarin
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUG1 ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,theophylline,prednisone
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUG1 ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,theophylline,prednisolone
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,theophylline,contraceptives
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER  ( DRUG2  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,theophylline,norethindrone
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUG2  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,theophylline,ethinyl estradiol
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,theophylline,terfenadine
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,theophylline,digoxin
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,theophylline,warfarin
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUG1 ,  DRUG2 , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,prednisone,prednisolone
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUG2  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,prednisone,contraceptives
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUGOTHER  ( DRUG2  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,prednisone,norethindrone
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUG2  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,prednisone,ethinyl estradiol
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,prednisone,terfenadine
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,prednisone,digoxin
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,prednisone,warfarin
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUG2  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,prednisolone,contraceptives
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUGOTHER  ( DRUG2  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,prednisolone,norethindrone
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUG2  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,prednisolone,ethinyl estradiol
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,prednisolone,terfenadine
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,prednisolone,digoxin
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,prednisolone,warfarin
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG1  ( DRUG2  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,contraceptives,norethindrone
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG1  ( DRUGOTHER  1 mg/ DRUG2  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,contraceptives,ethinyl estradiol
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG1  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,contraceptives,terfenadine
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG1  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,contraceptives,digoxin
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG1  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,contraceptives,warfarin
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER  ( DRUG1  1 mg/ DRUG2  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,norethindrone,ethinyl estradiol
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER  ( DRUG1  1 mg/ DRUGOTHER  35 mcg),  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,norethindrone,terfenadine
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER  ( DRUG1  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,norethindrone,digoxin
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER  ( DRUG1  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,norethindrone,warfarin
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUG1  35 mcg),  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,ethinyl estradiol,terfenadine
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUG1  35 mcg),  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,ethinyl estradiol,digoxin
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUG1  35 mcg),  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,ethinyl estradiol,warfarin
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUG1 ,  DRUG2 , and  DRUGOTHER .",negative,terfenadine,digoxin
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUG1 ,  DRUGOTHER , and  DRUG2 .",negative,terfenadine,warfarin
"In drug-interaction studies, the recommended clinical dose of  DRUGOTHER  did not have clinically important effects on the pharmacokinetics of the following drugs:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER  ( DRUGOTHER  1 mg/ DRUGOTHER  35 mcg),  DRUGOTHER ,  DRUG1 , and  DRUG2 .",negative,digoxin,warfarin
"These medications included  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,thyroid hormones,sedative hypnotics
"These medications included  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,thyroid hormones,non-steroidal anti-inflammatory agents
"These medications included  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,thyroid hormones,benzodiazepines
"These medications included  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,thyroid hormones,decongestants
"These medications included  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,sedative hypnotics,non-steroidal anti-inflammatory agents
"These medications included  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,sedative hypnotics,benzodiazepines
"These medications included  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,sedative hypnotics,decongestants
"These medications included  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER .",negative,non-steroidal anti-inflammatory agents,benzodiazepines
"These medications included  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 .",negative,non-steroidal anti-inflammatory agents,decongestants
"These medications included  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 .",negative,benzodiazepines,decongestants
" DRUG1 , which induces hepatic metabolism, decreased the AUC of  DRUG2  approximately 40% following a single 10-mg dose of  DRUGOTHER .",negative,Phenobarbital,montelukast
" DRUG1 , which induces hepatic metabolism, decreased the AUC of  DRUGOTHER  approximately 40% following a single 10-mg dose of  DRUG2 .",negative,Phenobarbital,montelukast
" DRUGOTHER , which induces hepatic metabolism, decreased the AUC of  DRUG1  approximately 40% following a single 10-mg dose of  DRUG2 .",negative,montelukast,montelukast
"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as  DRUG1  or  DRUG2 , are co-administered with  DRUGOTHER .",negative,phenobarbital,rifampin
"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as  DRUG1  or  DRUGOTHER , are co-administered with  DRUG2 .",advise,phenobarbital,montelukast
"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as  DRUGOTHER  or  DRUG1 , are co-administered with  DRUG2 .",advise,rifampin,montelukast
No pharmacokinetic interaction between 85 mg/m2  DRUG1  and infusional  DRUG2  has been observed in patients treated every 2 weeks.,negative,ELOXATIN,5-FU
Increases of  DRUG1  plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2  DRUG2  dosed every 3 weeks.,mechanism,5-FU,ELOXATIN
 DRUG1  Reports suggest that  DRUG2  may diminish the antihypertensive effect of  DRUGOTHER .,negative,ACE inhibitors,NSAIDs
 DRUG1  Reports suggest that  DRUGOTHER  may diminish the antihypertensive effect of  DRUG2 .,negative,ACE inhibitors,angiotensin-converting enzyme (ACE) inhibitors
 DRUGOTHER  Reports suggest that  DRUG1  may diminish the antihypertensive effect of  DRUG2 .,effect,NSAIDs,angiotensin-converting enzyme (ACE) inhibitors
This interaction should be given consideration in patients taking  DRUG1  concomitantly with  DRUG2 .,advise,NSAIDs,ACE inhibitors
 DRUG1 : Concomitant administration of  DRUG2  (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of  DRUGOTHER .,negative,Aspirin,aspirin
 DRUG1 : Concomitant administration of  DRUGOTHER  (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of  DRUG2 .,negative,Aspirin,meloxicam
 DRUGOTHER : Concomitant administration of  DRUG1  (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of  DRUG2 .,mechanism,aspirin,meloxicam
"however, as with other  DRUG1 , concomitant administration of  DRUG2  and  DRUGOTHER  is not generally recommended because of the potential for increased adverse effects.",negative,NSAIDs,meloxicam
"however, as with other  DRUG1 , concomitant administration of  DRUGOTHER  and  DRUG2  is not generally recommended because of the potential for increased adverse effects.",advise,NSAIDs,aspirin
"however, as with other  DRUGOTHER , concomitant administration of  DRUG1  and  DRUG2  is not generally recommended because of the potential for increased adverse effects.",advise,meloxicam,aspirin
"Concomitant administration of low-dose  DRUG1  with  DRUG2  may result in an increased rate of GI ulceration or other complications, compared to use of  DRUGOTHER  alone.",effect,aspirin,MOBIC
"Concomitant administration of low-dose  DRUG1  with  DRUGOTHER  may result in an increased rate of GI ulceration or other complications, compared to use of  DRUG2  alone.",negative,aspirin,MOBIC
"Concomitant administration of low-dose  DRUGOTHER  with  DRUG1  may result in an increased rate of GI ulceration or other complications, compared to use of  DRUG2  alone.",negative,MOBIC,MOBIC
 DRUG1  is not a substitute for  DRUG2  for cardiovascular prophylaxis.,negative,MOBIC,aspirin
 DRUG1 : Pretreatment for four days with  DRUG2  significantly increased the clearance of  DRUGOTHER  by 50%.,negative,Cholestyramine,cholestyramine
 DRUG1 : Pretreatment for four days with  DRUGOTHER  significantly increased the clearance of  DRUG2  by 50%.,negative,Cholestyramine,meloxicam
 DRUGOTHER : Pretreatment for four days with  DRUG1  significantly increased the clearance of  DRUG2  by 50%.,mechanism,cholestyramine,meloxicam
 DRUG1 : Concomitant administration of 200 mg  DRUG2  QID did not alter the single-dose pharmacokinetics of 30 mg  DRUGOTHER .,negative,Cimetidine,cimetidine
 DRUG1 : Concomitant administration of 200 mg  DRUGOTHER  QID did not alter the single-dose pharmacokinetics of 30 mg  DRUG2 .,negative,Cimetidine,meloxicam
 DRUGOTHER : Concomitant administration of 200 mg  DRUG1  QID did not alter the single-dose pharmacokinetics of 30 mg  DRUG2 .,negative,cimetidine,meloxicam
 DRUG1 :  DRUG2  15 mg once daily for 7 days did not alter the plasma concentration profile of  DRUGOTHER  after b-acetyldigoxin administration for 7 days at clinical doses.,negative,Digoxin,Meloxicam
 DRUG1 :  DRUGOTHER  15 mg once daily for 7 days did not alter the plasma concentration profile of  DRUG2  after b-acetyldigoxin administration for 7 days at clinical doses.,negative,Digoxin,digoxin
 DRUGOTHER :  DRUG1  15 mg once daily for 7 days did not alter the plasma concentration profile of  DRUG2  after b-acetyldigoxin administration for 7 days at clinical doses.,negative,Meloxicam,digoxin
In vitro testing found no protein binding drug interaction between  DRUG1  and  DRUG2 .,negative,digoxin,meloxicam
" DRUG1 : Clinical studies, as well as post-marketing observations, have shown that  DRUG2  can reduce the natriuretic effect of  DRUGOTHER  and  DRUGOTHER  in some patients.",negative,Furosemide,NSAIDs
" DRUG1 : Clinical studies, as well as post-marketing observations, have shown that  DRUGOTHER  can reduce the natriuretic effect of  DRUG2  and  DRUGOTHER  in some patients.",negative,Furosemide,furosemide
" DRUG1 : Clinical studies, as well as post-marketing observations, have shown that  DRUGOTHER  can reduce the natriuretic effect of  DRUGOTHER  and  DRUG2  in some patients.",negative,Furosemide,thiazide diuretics
" DRUGOTHER : Clinical studies, as well as post-marketing observations, have shown that  DRUG1  can reduce the natriuretic effect of  DRUG2  and  DRUGOTHER  in some patients.",effect,NSAIDs,furosemide
" DRUGOTHER : Clinical studies, as well as post-marketing observations, have shown that  DRUG1  can reduce the natriuretic effect of  DRUGOTHER  and  DRUG2  in some patients.",effect,NSAIDs,thiazide diuretics
" DRUGOTHER : Clinical studies, as well as post-marketing observations, have shown that  DRUGOTHER  can reduce the natriuretic effect of  DRUG1  and  DRUG2  in some patients.",negative,furosemide,thiazide diuretics
Studies with  DRUG1  agents and  DRUG2  have not demonstrated a reduction in natriuretic effect.,negative,furosemide,meloxicam
 DRUG1 : single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of  DRUG2 .,negative,Furosemide,meloxicam
"Nevertheless, during concomitant therapy with  DRUG1  and  DRUG2 , patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy.",advise,furosemide,MOBIC
" DRUG1 : In clinical trials,  DRUG2  have produced an elevation of plasma  DRUGOTHER  levels and a reduction in renal  DRUGOTHER  clearance.",negative,Lithium,NSAIDs
" DRUG1 : In clinical trials,  DRUGOTHER  have produced an elevation of plasma  DRUG2  levels and a reduction in renal  DRUGOTHER  clearance.",negative,Lithium,lithium
" DRUG1 : In clinical trials,  DRUGOTHER  have produced an elevation of plasma  DRUGOTHER  levels and a reduction in renal  DRUG2  clearance.",negative,Lithium,lithium
" DRUGOTHER : In clinical trials,  DRUG1  have produced an elevation of plasma  DRUG2  levels and a reduction in renal  DRUGOTHER  clearance.",mechanism,NSAIDs,lithium
" DRUGOTHER : In clinical trials,  DRUG1  have produced an elevation of plasma  DRUGOTHER  levels and a reduction in renal  DRUG2  clearance.",negative,NSAIDs,lithium
" DRUGOTHER : In clinical trials,  DRUGOTHER  have produced an elevation of plasma  DRUG1  levels and a reduction in renal  DRUG2  clearance.",negative,lithium,lithium
"In a study conducted in healthy subjects, mean pre-dose  DRUG1  concentration and AUC were increased by 21% in subjects receiving  DRUG2  doses ranging from 804 to 1072 mg BID with  DRUGOTHER  15 mg QD as compared to subjects receiving  DRUGOTHER  alone.",negative,lithium,lithium
"In a study conducted in healthy subjects, mean pre-dose  DRUG1  concentration and AUC were increased by 21% in subjects receiving  DRUGOTHER  doses ranging from 804 to 1072 mg BID with  DRUG2  15 mg QD as compared to subjects receiving  DRUGOTHER  alone.",negative,lithium,meloxicam
"In a study conducted in healthy subjects, mean pre-dose  DRUG1  concentration and AUC were increased by 21% in subjects receiving  DRUGOTHER  doses ranging from 804 to 1072 mg BID with  DRUGOTHER  15 mg QD as compared to subjects receiving  DRUG2  alone.",negative,lithium,lithium
"In a study conducted in healthy subjects, mean pre-dose  DRUGOTHER  concentration and AUC were increased by 21% in subjects receiving  DRUG1  doses ranging from 804 to 1072 mg BID with  DRUG2  15 mg QD as compared to subjects receiving  DRUGOTHER  alone.",mechanism,lithium,meloxicam
"In a study conducted in healthy subjects, mean pre-dose  DRUGOTHER  concentration and AUC were increased by 21% in subjects receiving  DRUG1  doses ranging from 804 to 1072 mg BID with  DRUGOTHER  15 mg QD as compared to subjects receiving  DRUG2  alone.",negative,lithium,lithium
"In a study conducted in healthy subjects, mean pre-dose  DRUGOTHER  concentration and AUC were increased by 21% in subjects receiving  DRUGOTHER  doses ranging from 804 to 1072 mg BID with  DRUG1  15 mg QD as compared to subjects receiving  DRUG2  alone.",negative,meloxicam,lithium
Patients on  DRUG1  treatment should be closely monitored when  DRUG2  is introduced or withdrawn.,advise,lithium,MOBIC
 DRUG1 : A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of  DRUG2  on the pharmacokinetics of  DRUGOTHER  taken once weekly.,negative,Methotrexate,meloxicam
 DRUG1 : A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of  DRUGOTHER  on the pharmacokinetics of  DRUG2  taken once weekly.,negative,Methotrexate,methotrexate
 DRUGOTHER : A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of  DRUG1  on the pharmacokinetics of  DRUG2  taken once weekly.,negative,meloxicam,methotrexate
 DRUG1  did not have a significant effect on the pharmacokinetics of single doses of  DRUG2 .,negative,Meloxicam,methotrexate
"In vitro,  DRUG1  did not displace  DRUG2  from its human serum binding sites.",negative,methotrexate,meloxicam
" DRUG1 : Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing  DRUG2  therapy in patients receiving  DRUGOTHER  or similar agents, since these patients are at an increased risk of bleeding.",negative,Warfarin,MOBIC
" DRUG1 : Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing  DRUGOTHER  therapy in patients receiving  DRUG2  or similar agents, since these patients are at an increased risk of bleeding.",negative,Warfarin,warfarin
" DRUGOTHER : Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing  DRUG1  therapy in patients receiving  DRUG2  or similar agents, since these patients are at an increased risk of bleeding.",advise,MOBIC,warfarin
The effect of  DRUG1  on the anticoagulant effect of  DRUG2  was studied in a group of healthy subjects receiving daily doses of  DRUGOTHER  that produced an INR (International Normalized Ratio) between 1.2 and 1.8.,negative,meloxicam,warfarin
The effect of  DRUG1  on the anticoagulant effect of  DRUGOTHER  was studied in a group of healthy subjects receiving daily doses of  DRUG2  that produced an INR (International Normalized Ratio) between 1.2 and 1.8.,negative,meloxicam,warfarin
The effect of  DRUGOTHER  on the anticoagulant effect of  DRUG1  was studied in a group of healthy subjects receiving daily doses of  DRUG2  that produced an INR (International Normalized Ratio) between 1.2 and 1.8.,negative,warfarin,warfarin
"In these subjects,  DRUG1  did not alter  DRUG2  pharmacokinetics and the average anticoagulant effect of  DRUGOTHER  as determined by prothrombin time.",negative,meloxicam,warfarin
"In these subjects,  DRUG1  did not alter  DRUGOTHER  pharmacokinetics and the average anticoagulant effect of  DRUG2  as determined by prothrombin time.",negative,meloxicam,warfarin
"In these subjects,  DRUGOTHER  did not alter  DRUG1  pharmacokinetics and the average anticoagulant effect of  DRUG2  as determined by prothrombin time.",negative,warfarin,warfarin
Caution should be used when administering  DRUG1  with  DRUG2  since patients on  DRUGOTHER  may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,advise,MOBIC,warfarin
Caution should be used when administering  DRUG1  with  DRUGOTHER  since patients on  DRUG2  may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,negative,MOBIC,warfarin
Caution should be used when administering  DRUGOTHER  with  DRUG1  since patients on  DRUG2  may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,negative,warfarin,warfarin
The effects of  DRUG1  on gastrointestinal motility are antagonized by  DRUG2  and  DRUGOTHER .,effect,metoclopramide,anticholinergic drugs
The effects of  DRUG1  on gastrointestinal motility are antagonized by  DRUGOTHER  and  DRUG2 .,effect,metoclopramide,narcotic analgesics
The effects of  DRUGOTHER  on gastrointestinal motility are antagonized by  DRUG1  and  DRUG2 .,negative,anticholinergic drugs,narcotic analgesics
"Additive sedative effects can occur when  DRUG1  is given with  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",effect,metoclopramide,alcohol
"Additive sedative effects can occur when  DRUG1  is given with  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",effect,metoclopramide,sedatives
"Additive sedative effects can occur when  DRUG1  is given with  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",effect,metoclopramide,hypnotics
"Additive sedative effects can occur when  DRUG1  is given with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",effect,metoclopramide,narcotics
"Additive sedative effects can occur when  DRUG1  is given with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",effect,metoclopramide,tranquilizers
"Additive sedative effects can occur when  DRUGOTHER  is given with  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,alcohol,sedatives
"Additive sedative effects can occur when  DRUGOTHER  is given with  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,alcohol,hypnotics
"Additive sedative effects can occur when  DRUGOTHER  is given with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,alcohol,narcotics
"Additive sedative effects can occur when  DRUGOTHER  is given with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,alcohol,tranquilizers
"Additive sedative effects can occur when  DRUGOTHER  is given with  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,sedatives,hypnotics
"Additive sedative effects can occur when  DRUGOTHER  is given with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,sedatives,narcotics
"Additive sedative effects can occur when  DRUGOTHER  is given with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,sedatives,tranquilizers
"Additive sedative effects can occur when  DRUGOTHER  is given with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , or  DRUGOTHER .",negative,hypnotics,narcotics
"Additive sedative effects can occur when  DRUGOTHER  is given with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , or  DRUG2 .",negative,hypnotics,tranquilizers
"Additive sedative effects can occur when  DRUGOTHER  is given with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , or  DRUG2 .",negative,narcotics,tranquilizers
"The finding that  DRUG1  releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving  DRUG2 .",advise,metoclopramide,monoamine oxi-dase inhibitors
"Absorption of drugs from the stomach may be diminished (e.g.,  DRUG1 ) by  DRUG2 , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",mechanism,digoxin,metoclopramide
"Absorption of drugs from the stomach may be diminished (e.g.,  DRUG1 ) by  DRUGOTHER , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,digoxin,acetaminophen
"Absorption of drugs from the stomach may be diminished (e.g.,  DRUG1 ) by  DRUGOTHER , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,digoxin,tetracycline
"Absorption of drugs from the stomach may be diminished (e.g.,  DRUG1 ) by  DRUGOTHER , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,digoxin,levodopa
"Absorption of drugs from the stomach may be diminished (e.g.,  DRUG1 ) by  DRUGOTHER , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,digoxin,ethanol
"Absorption of drugs from the stomach may be diminished (e.g.,  DRUG1 ) by  DRUGOTHER , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,digoxin,cyclosporine
"Absorption of drugs from the stomach may be diminished (e.g.,  DRUGOTHER ) by  DRUG1 , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",mechanism,metoclopramide,acetaminophen
"Absorption of drugs from the stomach may be diminished (e.g.,  DRUGOTHER ) by  DRUG1 , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,metoclopramide,tetracycline
"Absorption of drugs from the stomach may be diminished (e.g.,  DRUGOTHER ) by  DRUG1 , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,metoclopramide,levodopa
"Absorption of drugs from the stomach may be diminished (e.g.,  DRUGOTHER ) by  DRUG1 , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,metoclopramide,ethanol
"Absorption of drugs from the stomach may be diminished (e.g.,  DRUGOTHER ) by  DRUG1 , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,metoclopramide,cyclosporine
"Absorption of drugs from the stomach may be diminished (e.g.,  DRUGOTHER ) by  DRUGOTHER , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,acetaminophen,tetracycline
"Absorption of drugs from the stomach may be diminished (e.g.,  DRUGOTHER ) by  DRUGOTHER , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,acetaminophen,levodopa
"Absorption of drugs from the stomach may be diminished (e.g.,  DRUGOTHER ) by  DRUGOTHER , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,acetaminophen,ethanol
"Absorption of drugs from the stomach may be diminished (e.g.,  DRUGOTHER ) by  DRUGOTHER , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,acetaminophen,cyclosporine
"Absorption of drugs from the stomach may be diminished (e.g.,  DRUGOTHER ) by  DRUGOTHER , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,tetracycline,levodopa
"Absorption of drugs from the stomach may be diminished (e.g.,  DRUGOTHER ) by  DRUGOTHER , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,tetracycline,ethanol
"Absorption of drugs from the stomach may be diminished (e.g.,  DRUGOTHER ) by  DRUGOTHER , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,tetracycline,cyclosporine
"Absorption of drugs from the stomach may be diminished (e.g.,  DRUGOTHER ) by  DRUGOTHER , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ).",negative,levodopa,ethanol
"Absorption of drugs from the stomach may be diminished (e.g.,  DRUGOTHER ) by  DRUGOTHER , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ).",negative,levodopa,cyclosporine
"Absorption of drugs from the stomach may be diminished (e.g.,  DRUGOTHER ) by  DRUGOTHER , whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ).",negative,ethanol,cyclosporine
"Because the action of  DRUG1  will influence the delivery of food to the intestines and thus the rate of absorption,  DRUG2  dosage or timing of dosage may require adjustment.",advise,metoclopramide,insulin
patients receiving  DRUG1  and  DRUG2  should have more frequent monitoring of neutrophil counts.,advise,lithium,Neulasta
 DRUG1  (oral): The activity of oral  DRUG2  may be potentiated by anti-vitamin-K activity attributed to  DRUGOTHER .,negative,Anticoagulants,anticoagulants
 DRUG1  (oral): The activity of oral  DRUGOTHER  may be potentiated by anti-vitamin-K activity attributed to  DRUG2 .,negative,Anticoagulants,methimazole
 DRUGOTHER  (oral): The activity of oral  DRUG1  may be potentiated by anti-vitamin-K activity attributed to  DRUG2 .,effect,anticoagulants,methimazole
 DRUG1 : Serum digitalis levels may be increased when hyperthyroid patients on a stable  DRUG2  regimen become euthyroid;,negative,Digitalis glycosides,digitalis glycoside
 DRUG1 :  DRUG2  clearance may decrease when hyperthyroid patients on a stable  DRUGOTHER  regimen become euthyroid;,negative,Theophylline,Theophylline
 DRUG1 :  DRUGOTHER  clearance may decrease when hyperthyroid patients on a stable  DRUG2  regimen become euthyroid;,negative,Theophylline,theophylline
 DRUGOTHER :  DRUG1  clearance may decrease when hyperthyroid patients on a stable  DRUG2  regimen become euthyroid;,negative,Theophylline,theophylline
 DRUG1  AND OTHER  DRUG2  WILL BE ADDITIVE TO  DRUGOTHER  AND MAY INCREASE PLASMA CONCENTRATIONS OF  DRUGOTHER  TO TOXIC LEVELS.,negative,ASPIRIN,SALICYLATE DRUGS
 DRUG1  AND OTHER  DRUGOTHER  WILL BE ADDITIVE TO  DRUG2  AND MAY INCREASE PLASMA CONCENTRATIONS OF  DRUGOTHER  TO TOXIC LEVELS.,effect,ASPIRIN,DISALCID
 DRUG1  AND OTHER  DRUGOTHER  WILL BE ADDITIVE TO  DRUGOTHER  AND MAY INCREASE PLASMA CONCENTRATIONS OF  DRUG2  TO TOXIC LEVELS.,negative,ASPIRIN,SALICYLIC ACID
 DRUGOTHER  AND OTHER  DRUG1  WILL BE ADDITIVE TO  DRUG2  AND MAY INCREASE PLASMA CONCENTRATIONS OF  DRUGOTHER  TO TOXIC LEVELS.,effect,SALICYLATE DRUGS,DISALCID
 DRUGOTHER  AND OTHER  DRUG1  WILL BE ADDITIVE TO  DRUGOTHER  AND MAY INCREASE PLASMA CONCENTRATIONS OF  DRUG2  TO TOXIC LEVELS.,negative,SALICYLATE DRUGS,SALICYLIC ACID
 DRUGOTHER  AND OTHER  DRUGOTHER  WILL BE ADDITIVE TO  DRUG1  AND MAY INCREASE PLASMA CONCENTRATIONS OF  DRUG2  TO TOXIC LEVELS.,negative,DISALCID,SALICYLIC ACID
 DRUG1  given concomitantly with  DRUG2  may predispose to systemic bleeding.,effect,Salicylates,anticoagulant drugs
 DRUG1  may enhance the hypoglycemic effect of oral  DRUG2  of the sulfonylurea class.,effect,Salicylates,antidiabetic drugs
" DRUG1  competes with a number of drugs for protein binding sites, notably  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",mechanism,Salicylate,penicillin
" DRUG1  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",mechanism,Salicylate,thiopental
" DRUG1  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",mechanism,Salicylate,thyroxine
" DRUG1  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",mechanism,Salicylate,triiodothyronine
" DRUG1  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",mechanism,Salicylate,phenytoin
" DRUG1  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",mechanism,Salicylate,sulfinpyrazone
" DRUG1  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",mechanism,Salicylate,naproxen
" DRUG1  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and possibly  DRUGOTHER .",mechanism,Salicylate,warfarin
" DRUG1  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and possibly  DRUGOTHER .",mechanism,Salicylate,methotrexate
" DRUG1  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUG2 .",mechanism,Salicylate,corticosteroids
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,penicillin,thiopental
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,penicillin,thyroxine
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,penicillin,triiodothyronine
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,penicillin,phenytoin
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,penicillin,sulfinpyrazone
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,penicillin,naproxen
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,penicillin,warfarin
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and possibly  DRUGOTHER .",negative,penicillin,methotrexate
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUG2 .",negative,penicillin,corticosteroids
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,thiopental,thyroxine
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,thiopental,triiodothyronine
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,thiopental,phenytoin
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,thiopental,sulfinpyrazone
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,thiopental,naproxen
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,thiopental,warfarin
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and possibly  DRUGOTHER .",negative,thiopental,methotrexate
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUG2 .",negative,thiopental,corticosteroids
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,thyroxine,triiodothyronine
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,thyroxine,phenytoin
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,thyroxine,sulfinpyrazone
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,thyroxine,naproxen
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,thyroxine,warfarin
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and possibly  DRUGOTHER .",negative,thyroxine,methotrexate
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUG2 .",negative,thyroxine,corticosteroids
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,triiodothyronine,phenytoin
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,triiodothyronine,sulfinpyrazone
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,triiodothyronine,naproxen
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,triiodothyronine,warfarin
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and possibly  DRUGOTHER .",negative,triiodothyronine,methotrexate
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUG2 .",negative,triiodothyronine,corticosteroids
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,phenytoin,sulfinpyrazone
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,phenytoin,naproxen
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,phenytoin,warfarin
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and possibly  DRUGOTHER .",negative,phenytoin,methotrexate
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUG2 .",negative,phenytoin,corticosteroids
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,sulfinpyrazone,naproxen
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,sulfinpyrazone,warfarin
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and possibly  DRUGOTHER .",negative,sulfinpyrazone,methotrexate
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUG2 .",negative,sulfinpyrazone,corticosteroids
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and possibly  DRUGOTHER .",negative,naproxen,warfarin
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and possibly  DRUGOTHER .",negative,naproxen,methotrexate
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and possibly  DRUG2 .",negative,naproxen,corticosteroids
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and possibly  DRUGOTHER .",negative,warfarin,methotrexate
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and possibly  DRUG2 .",negative,warfarin,corticosteroids
" DRUGOTHER  competes with a number of drugs for protein binding sites, notably  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and possibly  DRUG2 .",negative,methotrexate,corticosteroids
Drugs Affecting Hepatic Metabolism The metabolism and pharmacokinetics of  DRUG1     ( DRUG2 ) Orally Disintegrating Tablets may be affected by the induction or inhibition of drug-metab-olizing enzymes.,negative,REMERON SolTab,mirtazapine
"While in vitro studies have shown that  DRUG1  is not a potent inhibitor of any of these enzymes, an indication that  DRUG2  is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of  DRUGOTHER  with most other drugs metabolized by these enzymes has not been formally studied.",negative,mirtazapine,mirtazapine
"While in vitro studies have shown that  DRUG1  is not a potent inhibitor of any of these enzymes, an indication that  DRUGOTHER  is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of  DRUG2  with most other drugs metabolized by these enzymes has not been formally studied.",negative,mirtazapine,REMERON SolTab
"While in vitro studies have shown that  DRUGOTHER  is not a potent inhibitor of any of these enzymes, an indication that  DRUG1  is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of  DRUG2  with most other drugs metabolized by these enzymes has not been formally studied.",negative,mirtazapine,REMERON SolTab
 DRUG1 : Concomitant administration of  DRUG2  (equivalent to 60 g) had a minimal effect on plasma levels of  DRUGOTHER  (15 mg) in 6 healthy male subjects.,negative,Alcohol,alcohol
 DRUG1 : Concomitant administration of  DRUGOTHER  (equivalent to 60 g) had a minimal effect on plasma levels of  DRUG2  (15 mg) in 6 healthy male subjects.,negative,Alcohol,mirtazapine
 DRUGOTHER : Concomitant administration of  DRUG1  (equivalent to 60 g) had a minimal effect on plasma levels of  DRUG2  (15 mg) in 6 healthy male subjects.,mechanism,alcohol,mirtazapine
"However, the impairment of cognitive and motor skills produced by  DRUG1     were shown to be additive with those produced by  DRUG2 .",effect,REMERON,alcohol
"Accordingly, patients should be advised to avoid  DRUG1  while taking  DRUG2 .  DRUGOTHER : Concomitant administration of  DRUGOTHER  (15 mg) had a minimal effect on plasma levels of  DRUGOTHER  (15 mg) in 12 healthy subjects.",advise,alcohol,REMERON SolTab
"Accordingly, patients should be advised to avoid  DRUG1  while taking  DRUGOTHER .  DRUG2 : Concomitant administration of  DRUGOTHER  (15 mg) had a minimal effect on plasma levels of  DRUGOTHER  (15 mg) in 12 healthy subjects.",negative,alcohol,Diazepam
"Accordingly, patients should be advised to avoid  DRUG1  while taking  DRUGOTHER .  DRUGOTHER : Concomitant administration of  DRUG2  (15 mg) had a minimal effect on plasma levels of  DRUGOTHER  (15 mg) in 12 healthy subjects.",negative,alcohol,diazepam
"Accordingly, patients should be advised to avoid  DRUG1  while taking  DRUGOTHER .  DRUGOTHER : Concomitant administration of  DRUGOTHER  (15 mg) had a minimal effect on plasma levels of  DRUG2  (15 mg) in 12 healthy subjects.",negative,alcohol,mirtazapine
"Accordingly, patients should be advised to avoid  DRUGOTHER  while taking  DRUG1 .  DRUG2 : Concomitant administration of  DRUGOTHER  (15 mg) had a minimal effect on plasma levels of  DRUGOTHER  (15 mg) in 12 healthy subjects.",negative,REMERON SolTab,Diazepam
"Accordingly, patients should be advised to avoid  DRUGOTHER  while taking  DRUG1 .  DRUGOTHER : Concomitant administration of  DRUG2  (15 mg) had a minimal effect on plasma levels of  DRUGOTHER  (15 mg) in 12 healthy subjects.",negative,REMERON SolTab,diazepam
"Accordingly, patients should be advised to avoid  DRUGOTHER  while taking  DRUG1 .  DRUGOTHER : Concomitant administration of  DRUGOTHER  (15 mg) had a minimal effect on plasma levels of  DRUG2  (15 mg) in 12 healthy subjects.",negative,REMERON SolTab,mirtazapine
"Accordingly, patients should be advised to avoid  DRUGOTHER  while taking  DRUGOTHER .  DRUG1 : Concomitant administration of  DRUG2  (15 mg) had a minimal effect on plasma levels of  DRUGOTHER  (15 mg) in 12 healthy subjects.",negative,Diazepam,diazepam
"Accordingly, patients should be advised to avoid  DRUGOTHER  while taking  DRUGOTHER .  DRUG1 : Concomitant administration of  DRUGOTHER  (15 mg) had a minimal effect on plasma levels of  DRUG2  (15 mg) in 12 healthy subjects.",negative,Diazepam,mirtazapine
"Accordingly, patients should be advised to avoid  DRUGOTHER  while taking  DRUGOTHER .  DRUGOTHER : Concomitant administration of  DRUG1  (15 mg) had a minimal effect on plasma levels of  DRUG2  (15 mg) in 12 healthy subjects.",mechanism,diazepam,mirtazapine
"However, the impairment of motor skills produced by  DRUG1  has been shown to be additive with those caused by  DRUG2 .",effect,REMERON,diazepam
"Accordingly, patients should be advised to avoid  DRUG1  and other similar drugs while taking  DRUG2 .",advise,diazepam,REMERON SolTab
 DRUG1  locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with  DRUG2 .,negative,Amphetamine,quinpirole
The objective was to analyze the effects of neonatal  DRUG1  treatment on effects of  DRUG2  in adolescent rats using locomotor sensitization and conditioned place preference procedures.,negative,quinpirole,amphetamine
"In female rats, neonatal  DRUG1  treatment enhanced  DRUG2  locomotor sensitization compared with  DRUGOTHER -free controls sensitized to  DRUGOTHER .",effect,quinpirole,amphetamine
"In female rats, neonatal  DRUG1  treatment enhanced  DRUGOTHER  locomotor sensitization compared with  DRUG2 -free controls sensitized to  DRUGOTHER .",negative,quinpirole,quinpirole
"In female rats, neonatal  DRUG1  treatment enhanced  DRUGOTHER  locomotor sensitization compared with  DRUGOTHER -free controls sensitized to  DRUG2 .",negative,quinpirole,amphetamine
"In female rats, neonatal  DRUGOTHER  treatment enhanced  DRUG1  locomotor sensitization compared with  DRUG2 -free controls sensitized to  DRUGOTHER .",negative,amphetamine,quinpirole
"In female rats, neonatal  DRUGOTHER  treatment enhanced  DRUG1  locomotor sensitization compared with  DRUGOTHER -free controls sensitized to  DRUG2 .",negative,amphetamine,amphetamine
"In female rats, neonatal  DRUGOTHER  treatment enhanced  DRUGOTHER  locomotor sensitization compared with  DRUG1 -free controls sensitized to  DRUG2 .",negative,quinpirole,amphetamine
"Male rats demonstrated sensitization to  DRUG1 , although this was muted compared with female rats, and were unaffected by neonatal  DRUG2 .",negative,amphetamine,quinpirole
"Rats treated with neonatal  DRUG1  enhanced time spent in the  DRUG2 -paired context compared with  DRUGOTHER -free controls conditioned with  DRUGOTHER , but only female controls conditioned with  DRUGOTHER  spent more time in the drug-paired context compared with saline-treated controls.",negative,quinpirole,amphetamine
"Rats treated with neonatal  DRUG1  enhanced time spent in the  DRUGOTHER -paired context compared with  DRUG2 -free controls conditioned with  DRUGOTHER , but only female controls conditioned with  DRUGOTHER  spent more time in the drug-paired context compared with saline-treated controls.",negative,quinpirole,quinpirole
"Rats treated with neonatal  DRUG1  enhanced time spent in the  DRUGOTHER -paired context compared with  DRUGOTHER -free controls conditioned with  DRUG2 , but only female controls conditioned with  DRUGOTHER  spent more time in the drug-paired context compared with saline-treated controls.",negative,quinpirole,amphetamine
"Rats treated with neonatal  DRUG1  enhanced time spent in the  DRUGOTHER -paired context compared with  DRUGOTHER -free controls conditioned with  DRUGOTHER , but only female controls conditioned with  DRUG2  spent more time in the drug-paired context compared with saline-treated controls.",negative,quinpirole,amphetamine
"Rats treated with neonatal  DRUGOTHER  enhanced time spent in the  DRUG1 -paired context compared with  DRUG2 -free controls conditioned with  DRUGOTHER , but only female controls conditioned with  DRUGOTHER  spent more time in the drug-paired context compared with saline-treated controls.",negative,amphetamine,quinpirole
"Rats treated with neonatal  DRUGOTHER  enhanced time spent in the  DRUG1 -paired context compared with  DRUGOTHER -free controls conditioned with  DRUG2 , but only female controls conditioned with  DRUGOTHER  spent more time in the drug-paired context compared with saline-treated controls.",negative,amphetamine,amphetamine
"Rats treated with neonatal  DRUGOTHER  enhanced time spent in the  DRUG1 -paired context compared with  DRUGOTHER -free controls conditioned with  DRUGOTHER , but only female controls conditioned with  DRUG2  spent more time in the drug-paired context compared with saline-treated controls.",negative,amphetamine,amphetamine
"Rats treated with neonatal  DRUGOTHER  enhanced time spent in the  DRUGOTHER -paired context compared with  DRUG1 -free controls conditioned with  DRUG2 , but only female controls conditioned with  DRUGOTHER  spent more time in the drug-paired context compared with saline-treated controls.",negative,quinpirole,amphetamine
"Rats treated with neonatal  DRUGOTHER  enhanced time spent in the  DRUGOTHER -paired context compared with  DRUG1 -free controls conditioned with  DRUGOTHER , but only female controls conditioned with  DRUG2  spent more time in the drug-paired context compared with saline-treated controls.",negative,quinpirole,amphetamine
"Rats treated with neonatal  DRUGOTHER  enhanced time spent in the  DRUGOTHER -paired context compared with  DRUGOTHER -free controls conditioned with  DRUG1 , but only female controls conditioned with  DRUG2  spent more time in the drug-paired context compared with saline-treated controls.",negative,amphetamine,amphetamine
 DRUG1 - DRUG2  interaction and associated gastrointestinal bleeding risk in a case-control study.,negative,Antidepressant,warfarin
We sought to evaluate whether initiation of an  DRUG1  increases the risk of hospitalization for gastrointestinal bleeding in  DRUG2  users.,negative,antidepressant,warfarin
"In total, 430,455  DRUG1  users contributed 407,370 person-years of  DRUG2  use.",negative,warfarin,warfarin
" DRUG1  users had an increased odds ratio of gastrointestinal bleeding upon initiation of  DRUG2  (OR   =   1.73 [95% CI, 1.25-2.38]),  DRUGOTHER  (OR   =   1.63 [95% CI, 1.11-2.38]),  DRUGOTHER  (OR   =   1.64 [95% CI, 1.27-2.12]),  DRUGOTHER  (OR   =   1.47 [95% CI, 1.02-2.11]).",effect,Warfarin,citalopram
" DRUG1  users had an increased odds ratio of gastrointestinal bleeding upon initiation of  DRUGOTHER  (OR   =   1.73 [95% CI, 1.25-2.38]),  DRUG2  (OR   =   1.63 [95% CI, 1.11-2.38]),  DRUGOTHER  (OR   =   1.64 [95% CI, 1.27-2.12]),  DRUGOTHER  (OR   =   1.47 [95% CI, 1.02-2.11]).",effect,Warfarin,fluoxetine
" DRUG1  users had an increased odds ratio of gastrointestinal bleeding upon initiation of  DRUGOTHER  (OR   =   1.73 [95% CI, 1.25-2.38]),  DRUGOTHER  (OR   =   1.63 [95% CI, 1.11-2.38]),  DRUG2  (OR   =   1.64 [95% CI, 1.27-2.12]),  DRUGOTHER  (OR   =   1.47 [95% CI, 1.02-2.11]).",effect,Warfarin,paroxetine
" DRUG1  users had an increased odds ratio of gastrointestinal bleeding upon initiation of  DRUGOTHER  (OR   =   1.73 [95% CI, 1.25-2.38]),  DRUGOTHER  (OR   =   1.63 [95% CI, 1.11-2.38]),  DRUGOTHER  (OR   =   1.64 [95% CI, 1.27-2.12]),  DRUG2  (OR   =   1.47 [95% CI, 1.02-2.11]).",effect,Warfarin,amitriptyline
" DRUGOTHER  users had an increased odds ratio of gastrointestinal bleeding upon initiation of  DRUG1  (OR   =   1.73 [95% CI, 1.25-2.38]),  DRUG2  (OR   =   1.63 [95% CI, 1.11-2.38]),  DRUGOTHER  (OR   =   1.64 [95% CI, 1.27-2.12]),  DRUGOTHER  (OR   =   1.47 [95% CI, 1.02-2.11]).",negative,citalopram,fluoxetine
" DRUGOTHER  users had an increased odds ratio of gastrointestinal bleeding upon initiation of  DRUG1  (OR   =   1.73 [95% CI, 1.25-2.38]),  DRUGOTHER  (OR   =   1.63 [95% CI, 1.11-2.38]),  DRUG2  (OR   =   1.64 [95% CI, 1.27-2.12]),  DRUGOTHER  (OR   =   1.47 [95% CI, 1.02-2.11]).",negative,citalopram,paroxetine
" DRUGOTHER  users had an increased odds ratio of gastrointestinal bleeding upon initiation of  DRUG1  (OR   =   1.73 [95% CI, 1.25-2.38]),  DRUGOTHER  (OR   =   1.63 [95% CI, 1.11-2.38]),  DRUGOTHER  (OR   =   1.64 [95% CI, 1.27-2.12]),  DRUG2  (OR   =   1.47 [95% CI, 1.02-2.11]).",negative,citalopram,amitriptyline
" DRUGOTHER  users had an increased odds ratio of gastrointestinal bleeding upon initiation of  DRUGOTHER  (OR   =   1.73 [95% CI, 1.25-2.38]),  DRUG1  (OR   =   1.63 [95% CI, 1.11-2.38]),  DRUG2  (OR   =   1.64 [95% CI, 1.27-2.12]),  DRUGOTHER  (OR   =   1.47 [95% CI, 1.02-2.11]).",negative,fluoxetine,paroxetine
" DRUGOTHER  users had an increased odds ratio of gastrointestinal bleeding upon initiation of  DRUGOTHER  (OR   =   1.73 [95% CI, 1.25-2.38]),  DRUG1  (OR   =   1.63 [95% CI, 1.11-2.38]),  DRUGOTHER  (OR   =   1.64 [95% CI, 1.27-2.12]),  DRUG2  (OR   =   1.47 [95% CI, 1.02-2.11]).",negative,fluoxetine,amitriptyline
" DRUGOTHER  users had an increased odds ratio of gastrointestinal bleeding upon initiation of  DRUGOTHER  (OR   =   1.73 [95% CI, 1.25-2.38]),  DRUGOTHER  (OR   =   1.63 [95% CI, 1.11-2.38]),  DRUG1  (OR   =   1.64 [95% CI, 1.27-2.12]),  DRUG2  (OR   =   1.47 [95% CI, 1.02-2.11]).",negative,paroxetine,amitriptyline
"Also  DRUG1 , which is not believed to interact with  DRUG2 , increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]).",effect,mirtazapine,warfarin
" DRUG1  users who initiated  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  had an increased risk of hospitalization for gastrointestinal bleeding.",effect,Warfarin,citalopram
" DRUG1  users who initiated  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  had an increased risk of hospitalization for gastrointestinal bleeding.",effect,Warfarin,fluoxetine
" DRUG1  users who initiated  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER  had an increased risk of hospitalization for gastrointestinal bleeding.",effect,Warfarin,paroxetine
" DRUG1  users who initiated  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER  had an increased risk of hospitalization for gastrointestinal bleeding.",effect,Warfarin,amitriptyline
" DRUG1  users who initiated  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2  had an increased risk of hospitalization for gastrointestinal bleeding.",effect,Warfarin,mirtazapine
" DRUGOTHER  users who initiated  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  had an increased risk of hospitalization for gastrointestinal bleeding.",negative,citalopram,fluoxetine
" DRUGOTHER  users who initiated  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER  had an increased risk of hospitalization for gastrointestinal bleeding.",negative,citalopram,paroxetine
" DRUGOTHER  users who initiated  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER  had an increased risk of hospitalization for gastrointestinal bleeding.",negative,citalopram,amitriptyline
" DRUGOTHER  users who initiated  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2  had an increased risk of hospitalization for gastrointestinal bleeding.",negative,citalopram,mirtazapine
" DRUGOTHER  users who initiated  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER  had an increased risk of hospitalization for gastrointestinal bleeding.",negative,fluoxetine,paroxetine
" DRUGOTHER  users who initiated  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER  had an increased risk of hospitalization for gastrointestinal bleeding.",negative,fluoxetine,amitriptyline
" DRUGOTHER  users who initiated  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2  had an increased risk of hospitalization for gastrointestinal bleeding.",negative,fluoxetine,mirtazapine
" DRUGOTHER  users who initiated  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , or  DRUGOTHER  had an increased risk of hospitalization for gastrointestinal bleeding.",negative,paroxetine,amitriptyline
" DRUGOTHER  users who initiated  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , or  DRUG2  had an increased risk of hospitalization for gastrointestinal bleeding.",negative,paroxetine,mirtazapine
" DRUGOTHER  users who initiated  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , or  DRUG2  had an increased risk of hospitalization for gastrointestinal bleeding.",negative,amitriptyline,mirtazapine
 DRUG1  may accentuate the orthostatic hypotension that may occur with  DRUG2 .,effect,Thiazide diuretics,phenothiazines
Antihypertensive effects of  DRUG1  and related compounds may be counteracted when  DRUG2  are used concomitantly.,effect,guanethidine,phenothiazines
Concomitant administration of  DRUG1  with  DRUG2  results in increased plasma levels of both drugs.,mechanism,propranolol,phenothiazines
Prevention of emergence agitation in seven children receiving low-dose  DRUG1  and  DRUG2  total intravenous anesthesia.,negative,ketamine,propofol
We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose  DRUG1  in conjunction with  DRUG2  for total intravenous anesthesia (TIVA) repeatedly for radiation therapy.,negative,ketamine,propofol
EA signs were observed in all 7 patients in association with  DRUG1  TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose  DRUG2  was added to  DRUGOTHER .,negative,propofol,ketamine
EA signs were observed in all 7 patients in association with  DRUG1  TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose  DRUGOTHER  was added to  DRUG2 .,negative,propofol,propofol
EA signs were observed in all 7 patients in association with  DRUGOTHER  TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose  DRUG1  was added to  DRUG2 .,negative,ketamine,propofol
"Based on this experience, we suggest that low-dose  DRUG1  added to  DRUG2  may be associated with prevention of EA in children with a history of EA with  DRUGOTHER  TIVA.",effect,ketamine,propofol
"Based on this experience, we suggest that low-dose  DRUG1  added to  DRUGOTHER  may be associated with prevention of EA in children with a history of EA with  DRUG2  TIVA.",negative,ketamine,propofol
"Based on this experience, we suggest that low-dose  DRUGOTHER  added to  DRUG1  may be associated with prevention of EA in children with a history of EA with  DRUG2  TIVA.",negative,propofol,propofol
"Catecholamine-depleting drugs (e.g.,  DRUG1 ) may have an additive effect when given with  DRUG2 .",effect,reserpine,beta-blocking agents
The interaction of  DRUG1  ( DRUG2 ) with other drugs has not been studied in humans.,negative,CYLERT,pemoline
Decreased seizure threshold has been reported in patients receiving  DRUG1  concomitantly with  DRUG2 .,effect,CYLERT,antiepileptic medications
 DRUG1   DRUG2  may increase sensitivity to oral  DRUGOTHER .,negative,Anticoagulants,Anabolic steroids
 DRUG1   DRUGOTHER  may increase sensitivity to oral  DRUG2 .,negative,Anticoagulants,anticoagulants
 DRUGOTHER   DRUG1  may increase sensitivity to oral  DRUG2 .,effect,Anabolic steroids,anticoagulants
" DRUG1 : A multidose study of  DRUG2 , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with  DRUGOTHER , resulted in a mean increase in  DRUGOTHER  half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in  DRUGOTHER  half-life and AUC were also detected.",negative,Warfarin,oxandrolone
" DRUG1 : A multidose study of  DRUGOTHER , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with  DRUG2 , resulted in a mean increase in  DRUGOTHER  half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in  DRUGOTHER  half-life and AUC were also detected.",negative,Warfarin,warfarin
" DRUG1 : A multidose study of  DRUGOTHER , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with  DRUGOTHER , resulted in a mean increase in  DRUG2  half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in  DRUGOTHER  half-life and AUC were also detected.",negative,Warfarin,S-warfarin
" DRUG1 : A multidose study of  DRUGOTHER , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with  DRUGOTHER , resulted in a mean increase in  DRUGOTHER  half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in  DRUG2  half-life and AUC were also detected.",negative,Warfarin,R-warfarin
" DRUGOTHER : A multidose study of  DRUG1 , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with  DRUG2 , resulted in a mean increase in  DRUGOTHER  half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in  DRUGOTHER  half-life and AUC were also detected.",mechanism,oxandrolone,warfarin
" DRUGOTHER : A multidose study of  DRUG1 , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with  DRUGOTHER , resulted in a mean increase in  DRUG2  half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in  DRUGOTHER  half-life and AUC were also detected.",negative,oxandrolone,S-warfarin
" DRUGOTHER : A multidose study of  DRUG1 , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with  DRUGOTHER , resulted in a mean increase in  DRUGOTHER  half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in  DRUG2  half-life and AUC were also detected.",negative,oxandrolone,R-warfarin
" DRUGOTHER : A multidose study of  DRUGOTHER , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with  DRUG1 , resulted in a mean increase in  DRUG2  half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in  DRUGOTHER  half-life and AUC were also detected.",negative,warfarin,S-warfarin
" DRUGOTHER : A multidose study of  DRUGOTHER , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with  DRUG1 , resulted in a mean increase in  DRUGOTHER  half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in  DRUG2  half-life and AUC were also detected.",negative,warfarin,R-warfarin
" DRUGOTHER : A multidose study of  DRUGOTHER , given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with  DRUGOTHER , resulted in a mean increase in  DRUG1  half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in  DRUG2  half-life and AUC were also detected.",negative,S-warfarin,R-warfarin
"A 5.5-fold decrease in the mean  DRUG1  dose from 6.13 mg/day to 1.13 mg/day (approximately 80-85% reduction of  DRUG2  dose), was necessary to maintain a target INR of 1.5.",negative,warfarin,warfarin
"When  DRUG1  therapy is initiated in a patient already receiving treatment with  DRUG2 , the INR or prothrombin time (PT) should be monitored closely and the dose of  DRUGOTHER  adjusted as necessary until a stable target INR or PT has been achieved.",advise,oxandrolone,warfarin
"When  DRUG1  therapy is initiated in a patient already receiving treatment with  DRUGOTHER , the INR or prothrombin time (PT) should be monitored closely and the dose of  DRUG2  adjusted as necessary until a stable target INR or PT has been achieved.",negative,oxandrolone,warfarin
"When  DRUGOTHER  therapy is initiated in a patient already receiving treatment with  DRUG1 , the INR or prothrombin time (PT) should be monitored closely and the dose of  DRUG2  adjusted as necessary until a stable target INR or PT has been achieved.",negative,warfarin,warfarin
"Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the  DRUG1  dosage if indicated are recommended when the  DRUG2  dose is changed or discontinued.",advise,warfarin,oxandrolone
Oral  DRUG1   DRUG2  may inhibit the metabolism of oral  DRUGOTHER .,negative,hypoglycemic agents,Oxandrolone
Oral  DRUG1   DRUGOTHER  may inhibit the metabolism of oral  DRUG2 .,negative,hypoglycemic agents,hypoglycemic agents
Oral  DRUGOTHER   DRUG1  may inhibit the metabolism of oral  DRUG2 .,mechanism,Oxandrolone,hypoglycemic agents
" DRUG1  or  DRUG2  In patients with edema, concomitant administration with  DRUGOTHER  or  DRUGOTHER  may increase the edema.",negative,Adrenal steroids,ACTH
" DRUG1  or  DRUGOTHER  In patients with edema, concomitant administration with  DRUG2  or  DRUGOTHER  may increase the edema.",negative,Adrenal steroids,adrenal cortical steroids
" DRUG1  or  DRUGOTHER  In patients with edema, concomitant administration with  DRUGOTHER  or  DRUG2  may increase the edema.",negative,Adrenal steroids,ACTH
" DRUGOTHER  or  DRUG1  In patients with edema, concomitant administration with  DRUG2  or  DRUGOTHER  may increase the edema.",negative,ACTH,adrenal cortical steroids
" DRUGOTHER  or  DRUG1  In patients with edema, concomitant administration with  DRUGOTHER  or  DRUG2  may increase the edema.",negative,ACTH,ACTH
" DRUGOTHER  or  DRUGOTHER  In patients with edema, concomitant administration with  DRUG1  or  DRUG2  may increase the edema.",negative,adrenal cortical steroids,ACTH
" DRUG1  may increase the effects of  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",effect,Sulfoxone,barbiturates
" DRUG1  may increase the effects of  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",effect,Sulfoxone,tolbutamide
" DRUG1  may increase the effects of  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",effect,Sulfoxone,uricosurics
" DRUGOTHER  may increase the effects of  DRUG1 ,  DRUG2 , and  DRUGOTHER .",negative,barbiturates,tolbutamide
" DRUGOTHER  may increase the effects of  DRUG1 ,  DRUGOTHER , and  DRUG2 .",negative,barbiturates,uricosurics
" DRUGOTHER  may increase the effects of  DRUGOTHER ,  DRUG1 , and  DRUG2 .",negative,tolbutamide,uricosurics
"It may also interact with  DRUG1  (increased thrombocytopenia),  DRUG2  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,thiazides,cyclosporine
"It may also interact with  DRUG1  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUG2  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,thiazides,sulfonylurea agents
"It may also interact with  DRUG1  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUG2  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,thiazides,warfarin
"It may also interact with  DRUG1  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUG2  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,thiazides,methotrexate
"It may also interact with  DRUG1  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUG2 ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,thiazides,methotrexate
"It may also interact with  DRUG1  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUG2  (decreased hepatic clearance of  DRUGOTHER ).",negative,thiazides,phenytoin
"It may also interact with  DRUG1  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUG2 ).",negative,thiazides,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUG1  (increased nephrotoxicity),  DRUG2  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,cyclosporine,sulfonylurea agents
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUG1  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUG2  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,cyclosporine,warfarin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUG1  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUG2  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,cyclosporine,methotrexate
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUG1  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUG2 ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,cyclosporine,methotrexate
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUG1  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUG2  (decreased hepatic clearance of  DRUGOTHER ).",negative,cyclosporine,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUG1  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUG2 ).",negative,cyclosporine,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUG1  (increased hypoglycemic response),  DRUG2  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,sulfonylurea agents,warfarin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUG1  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUG2  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,sulfonylurea agents,methotrexate
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUG1  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUG2 ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,sulfonylurea agents,methotrexate
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUG1  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUG2  (decreased hepatic clearance of  DRUGOTHER ).",negative,sulfonylurea agents,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUG1  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUG2 ).",negative,sulfonylurea agents,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUG1  (increased anticoagulant effect),  DRUG2  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,warfarin,methotrexate
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUG1  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUG2 ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,warfarin,methotrexate
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUG1  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUG2  (decreased hepatic clearance of  DRUGOTHER ).",negative,warfarin,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUG1  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUG2 ).",negative,warfarin,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUG1  (decreased renal excretion of  DRUG2 ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,methotrexate,methotrexate
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUG1  (decreased renal excretion of  DRUGOTHER ),  DRUG2  (decreased hepatic clearance of  DRUGOTHER ).",negative,methotrexate,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUG1  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUG2 ).",negative,methotrexate,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUG1 ),  DRUG2  (decreased hepatic clearance of  DRUGOTHER ).",negative,methotrexate,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUG1 ),  DRUGOTHER  (decreased hepatic clearance of  DRUG2 ).",negative,methotrexate,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUG1  (decreased hepatic clearance of  DRUG2 ).",negative,phenytoin,phenytoin
 DRUG1 : Excessive reductions in blood pressure may occur in patients on diuretic therapy when  DRUG2  are started.,negative,Diuretics,ACE inhibitors
"The possibility of hypotensive effects with  DRUG1     can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with  DRUG2    . If this is not possible, the starting dose of  DRUGOTHER  should be reduced..",negative,UNIVASC,UNIVASC
"The possibility of hypotensive effects with  DRUG1     can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with  DRUGOTHER    . If this is not possible, the starting dose of  DRUG2  should be reduced..",negative,UNIVASC,moexpril
"The possibility of hypotensive effects with  DRUGOTHER     can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with  DRUG1    . If this is not possible, the starting dose of  DRUG2  should be reduced..",negative,UNIVASC,moexpril
 DRUG1  Supplements and  DRUG2 :  DRUGOTHER     can increase serum potassium because it decreases aldosterone secretion.,negative,Potassium,Potassium-Sparing Diuretics
 DRUG1  Supplements and  DRUGOTHER :  DRUG2     can increase serum potassium because it decreases aldosterone secretion.,negative,Potassium,UNIVASC
 DRUGOTHER  Supplements and  DRUG1 :  DRUG2     can increase serum potassium because it decreases aldosterone secretion.,negative,Potassium-Sparing Diuretics,UNIVASC
"Use of  DRUG1  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  supplements concomitantly with  DRUGOTHER  can increase the risk of hyperkalemia.",negative,potassium-sparing diuretics,spironolactone
"Use of  DRUG1  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER  supplements concomitantly with  DRUGOTHER  can increase the risk of hyperkalemia.",negative,potassium-sparing diuretics,triamterene
"Use of  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER  supplements concomitantly with  DRUGOTHER  can increase the risk of hyperkalemia.",negative,potassium-sparing diuretics,amiloride
"Use of  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2  supplements concomitantly with  DRUGOTHER  can increase the risk of hyperkalemia.",negative,potassium-sparing diuretics,potassium
"Use of  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  supplements concomitantly with  DRUG2  can increase the risk of hyperkalemia.",effect,potassium-sparing diuretics,ACE inhibitors
"Use of  DRUGOTHER  ( DRUG1 ,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER  supplements concomitantly with  DRUGOTHER  can increase the risk of hyperkalemia.",negative,spironolactone,triamterene
"Use of  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER  supplements concomitantly with  DRUGOTHER  can increase the risk of hyperkalemia.",negative,spironolactone,amiloride
"Use of  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2  supplements concomitantly with  DRUGOTHER  can increase the risk of hyperkalemia.",negative,spironolactone,potassium
"Use of  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  supplements concomitantly with  DRUG2  can increase the risk of hyperkalemia.",effect,spironolactone,ACE inhibitors
"Use of  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUG2 ) or  DRUGOTHER  supplements concomitantly with  DRUGOTHER  can increase the risk of hyperkalemia.",negative,triamterene,amiloride
"Use of  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ) or  DRUG2  supplements concomitantly with  DRUGOTHER  can increase the risk of hyperkalemia.",negative,triamterene,potassium
"Use of  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ) or  DRUGOTHER  supplements concomitantly with  DRUG2  can increase the risk of hyperkalemia.",effect,triamterene,ACE inhibitors
"Use of  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ) or  DRUG2  supplements concomitantly with  DRUGOTHER  can increase the risk of hyperkalemia.",negative,amiloride,potassium
"Use of  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ) or  DRUGOTHER  supplements concomitantly with  DRUG2  can increase the risk of hyperkalemia.",effect,amiloride,ACE inhibitors
"Use of  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUG1  supplements concomitantly with  DRUG2  can increase the risk of hyperkalemia.",effect,potassium,ACE inhibitors
Oral  DRUG1 : Interaction studies with  DRUG2  failed to identify any clinically important effect on the serum concentrations of the  DRUGOTHER  or on its anticoagulant effect.,negative,Anticoagulants,warfarin
Oral  DRUG1 : Interaction studies with  DRUGOTHER  failed to identify any clinically important effect on the serum concentrations of the  DRUG2  or on its anticoagulant effect.,negative,Anticoagulants,anticoagulant
Oral  DRUGOTHER : Interaction studies with  DRUG1  failed to identify any clinically important effect on the serum concentrations of the  DRUG2  or on its anticoagulant effect.,negative,warfarin,anticoagulant
 DRUG1 : Increased serum  DRUG2  levels and symptoms of  DRUGOTHER  toxicity have been reported in patients receiving  DRUGOTHER  during therapy with  DRUGOTHER .,negative,Lithium,lithium
 DRUG1 : Increased serum  DRUGOTHER  levels and symptoms of  DRUG2  toxicity have been reported in patients receiving  DRUGOTHER  during therapy with  DRUGOTHER .,negative,Lithium,lithium
 DRUG1 : Increased serum  DRUGOTHER  levels and symptoms of  DRUGOTHER  toxicity have been reported in patients receiving  DRUG2  during therapy with  DRUGOTHER .,negative,Lithium,ACE inhibitors
 DRUG1 : Increased serum  DRUGOTHER  levels and symptoms of  DRUGOTHER  toxicity have been reported in patients receiving  DRUGOTHER  during therapy with  DRUG2 .,negative,Lithium,lithium
 DRUGOTHER : Increased serum  DRUG1  levels and symptoms of  DRUG2  toxicity have been reported in patients receiving  DRUGOTHER  during therapy with  DRUGOTHER .,negative,lithium,lithium
 DRUGOTHER : Increased serum  DRUG1  levels and symptoms of  DRUGOTHER  toxicity have been reported in patients receiving  DRUG2  during therapy with  DRUGOTHER .,negative,lithium,ACE inhibitors
 DRUGOTHER : Increased serum  DRUG1  levels and symptoms of  DRUGOTHER  toxicity have been reported in patients receiving  DRUGOTHER  during therapy with  DRUG2 .,negative,lithium,lithium
 DRUGOTHER : Increased serum  DRUGOTHER  levels and symptoms of  DRUG1  toxicity have been reported in patients receiving  DRUG2  during therapy with  DRUGOTHER .,negative,lithium,ACE inhibitors
 DRUGOTHER : Increased serum  DRUGOTHER  levels and symptoms of  DRUG1  toxicity have been reported in patients receiving  DRUGOTHER  during therapy with  DRUG2 .,negative,lithium,lithium
 DRUGOTHER : Increased serum  DRUGOTHER  levels and symptoms of  DRUGOTHER  toxicity have been reported in patients receiving  DRUG1  during therapy with  DRUG2 .,effect,ACE inhibitors,lithium
"If a  DRUG1  is also used, the risk of  DRUG2  toxicity may be increased.",effect,diuretic,lithium
"Other Agents: No clinically important pharmacokinetic interactions occurred when  DRUG1     was administered concomitantly with  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,UNIVASC,hydrochlorothiazide
"Other Agents: No clinically important pharmacokinetic interactions occurred when  DRUG1     was administered concomitantly with  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,UNIVASC,digoxin
"Other Agents: No clinically important pharmacokinetic interactions occurred when  DRUG1     was administered concomitantly with  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,UNIVASC,cimetidine
"Other Agents: No clinically important pharmacokinetic interactions occurred when  DRUGOTHER     was administered concomitantly with  DRUG1 ,  DRUG2 , or  DRUGOTHER .",negative,hydrochlorothiazide,digoxin
"Other Agents: No clinically important pharmacokinetic interactions occurred when  DRUGOTHER     was administered concomitantly with  DRUG1 ,  DRUGOTHER , or  DRUG2 .",negative,hydrochlorothiazide,cimetidine
"Other Agents: No clinically important pharmacokinetic interactions occurred when  DRUGOTHER     was administered concomitantly with  DRUGOTHER ,  DRUG1 , or  DRUG2 .",negative,digoxin,cimetidine
" DRUG1     has been used in clinical trials concomitantly with  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and cholesterol-lowering agents.",negative,UNIVASC,calcium-channel-blocking agents
" DRUG1     has been used in clinical trials concomitantly with  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and cholesterol-lowering agents.",negative,UNIVASC,diuretics
" DRUG1     has been used in clinical trials concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER , and cholesterol-lowering agents.",negative,UNIVASC,H2 blockers
" DRUG1     has been used in clinical trials concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER , and cholesterol-lowering agents.",negative,UNIVASC,digoxin
" DRUG1     has been used in clinical trials concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 , and cholesterol-lowering agents.",negative,UNIVASC,hypoglycemic agents
" DRUGOTHER     has been used in clinical trials concomitantly with  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUGOTHER , and cholesterol-lowering agents.",negative,calcium-channel-blocking agents,diuretics
" DRUGOTHER     has been used in clinical trials concomitantly with  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER , and cholesterol-lowering agents.",negative,calcium-channel-blocking agents,H2 blockers
" DRUGOTHER     has been used in clinical trials concomitantly with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER , and cholesterol-lowering agents.",negative,calcium-channel-blocking agents,digoxin
" DRUGOTHER     has been used in clinical trials concomitantly with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 , and cholesterol-lowering agents.",negative,calcium-channel-blocking agents,hypoglycemic agents
" DRUGOTHER     has been used in clinical trials concomitantly with  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , oral  DRUGOTHER , and cholesterol-lowering agents.",negative,diuretics,H2 blockers
" DRUGOTHER     has been used in clinical trials concomitantly with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , oral  DRUGOTHER , and cholesterol-lowering agents.",negative,diuretics,digoxin
" DRUGOTHER     has been used in clinical trials concomitantly with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , oral  DRUG2 , and cholesterol-lowering agents.",negative,diuretics,hypoglycemic agents
" DRUGOTHER     has been used in clinical trials concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , oral  DRUGOTHER , and cholesterol-lowering agents.",negative,H2 blockers,digoxin
" DRUGOTHER     has been used in clinical trials concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , oral  DRUG2 , and cholesterol-lowering agents.",negative,H2 blockers,hypoglycemic agents
" DRUGOTHER     has been used in clinical trials concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , oral  DRUG2 , and cholesterol-lowering agents.",negative,digoxin,hypoglycemic agents
"Co-administration of oral  DRUG1  200 mg twice daily increased  DRUG2  geometric mean AUC(0-24) and Cmax by 81% after topical application of  DRUGOTHER  ointment, 1% on the abraded skin of healthy adult males.",negative,ketoconazole,retapamulin
"Co-administration of oral  DRUG1  200 mg twice daily increased  DRUGOTHER  geometric mean AUC(0-24) and Cmax by 81% after topical application of  DRUG2  ointment, 1% on the abraded skin of healthy adult males.",mechanism,ketoconazole,retapamulin
"Co-administration of oral  DRUGOTHER  200 mg twice daily increased  DRUG1  geometric mean AUC(0-24) and Cmax by 81% after topical application of  DRUG2  ointment, 1% on the abraded skin of healthy adult males.",negative,retapamulin,retapamulin
"Due to low systemic exposure to  DRUG1  following topical application in patients, dosage adjustments for  DRUG2  are unnecessary when co-administered with CYP3A4 inhibitors, such as  DRUGOTHER .",negative,retapamulin,retapamulin
"Due to low systemic exposure to  DRUG1  following topical application in patients, dosage adjustments for  DRUGOTHER  are unnecessary when co-administered with CYP3A4 inhibitors, such as  DRUG2 .",negative,retapamulin,ketoconazole
"Due to low systemic exposure to  DRUGOTHER  following topical application in patients, dosage adjustments for  DRUG1  are unnecessary when co-administered with CYP3A4 inhibitors, such as  DRUG2 .",negative,retapamulin,ketoconazole
"Based on in vitro P450 inhibition studies and the low systemic exposure observed following topical application of  DRUG1 ,  DRUG2  is unlikely to affect the metabolism of other P450 substrates.",negative,ALTABAX,retapamulin
Patients receiving  DRUG1  and  DRUG2  generally should not be treated with  DRUGOTHER .,negative,antibiotics,sulfonamides
Patients receiving  DRUG1  and  DRUGOTHER  generally should not be treated with  DRUG2 .,advise,antibiotics,ganglion blockers
Patients receiving  DRUGOTHER  and  DRUG1  generally should not be treated with  DRUG2 .,advise,sulfonamides,ganglion blockers
"The action of  DRUG1  may be potentiated by anesthesia, other  DRUG2  and  DRUGOTHER .",effect,Mecamylamine,antihypertensive drugs
"The action of  DRUG1  may be potentiated by anesthesia, other  DRUGOTHER  and  DRUG2 .",effect,Mecamylamine,alcohol
"The action of  DRUGOTHER  may be potentiated by anesthesia, other  DRUG1  and  DRUG2 .",negative,antihypertensive drugs,alcohol
" DRUG1 : Absorption of a single dose of  DRUG2  was decreased when administered to 12 stable renal transplant patients also taking  DRUGOTHER - DRUGOTHER  containing  DRUGOTHER  (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when  DRUGOTHER  was administered alone under fasting conditions.",negative,Antacids,Myfortic
" DRUG1 : Absorption of a single dose of  DRUGOTHER  was decreased when administered to 12 stable renal transplant patients also taking  DRUG2 - DRUGOTHER  containing  DRUGOTHER  (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when  DRUGOTHER  was administered alone under fasting conditions.",negative,Antacids,magnesium
" DRUG1 : Absorption of a single dose of  DRUGOTHER  was decreased when administered to 12 stable renal transplant patients also taking  DRUGOTHER - DRUG2  containing  DRUGOTHER  (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when  DRUGOTHER  was administered alone under fasting conditions.",negative,Antacids,aluminum
" DRUG1 : Absorption of a single dose of  DRUGOTHER  was decreased when administered to 12 stable renal transplant patients also taking  DRUGOTHER - DRUGOTHER  containing  DRUG2  (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when  DRUGOTHER  was administered alone under fasting conditions.",negative,Antacids,antacids
" DRUG1 : Absorption of a single dose of  DRUGOTHER  was decreased when administered to 12 stable renal transplant patients also taking  DRUGOTHER - DRUGOTHER  containing  DRUGOTHER  (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when  DRUG2  was administered alone under fasting conditions.",negative,Antacids,Myfortic
" DRUGOTHER : Absorption of a single dose of  DRUG1  was decreased when administered to 12 stable renal transplant patients also taking  DRUG2 - DRUGOTHER  containing  DRUGOTHER  (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when  DRUGOTHER  was administered alone under fasting conditions.",mechanism,Myfortic,magnesium
" DRUGOTHER : Absorption of a single dose of  DRUG1  was decreased when administered to 12 stable renal transplant patients also taking  DRUGOTHER - DRUG2  containing  DRUGOTHER  (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when  DRUGOTHER  was administered alone under fasting conditions.",mechanism,Myfortic,aluminum
" DRUGOTHER : Absorption of a single dose of  DRUG1  was decreased when administered to 12 stable renal transplant patients also taking  DRUGOTHER - DRUGOTHER  containing  DRUG2  (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when  DRUGOTHER  was administered alone under fasting conditions.",negative,Myfortic,antacids
" DRUGOTHER : Absorption of a single dose of  DRUG1  was decreased when administered to 12 stable renal transplant patients also taking  DRUGOTHER - DRUGOTHER  containing  DRUGOTHER  (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when  DRUG2  was administered alone under fasting conditions.",negative,Myfortic,Myfortic
" DRUGOTHER : Absorption of a single dose of  DRUGOTHER  was decreased when administered to 12 stable renal transplant patients also taking  DRUG1 - DRUG2  containing  DRUGOTHER  (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when  DRUGOTHER  was administered alone under fasting conditions.",negative,magnesium,aluminum
" DRUGOTHER : Absorption of a single dose of  DRUGOTHER  was decreased when administered to 12 stable renal transplant patients also taking  DRUG1 - DRUGOTHER  containing  DRUG2  (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when  DRUGOTHER  was administered alone under fasting conditions.",negative,magnesium,antacids
" DRUGOTHER : Absorption of a single dose of  DRUGOTHER  was decreased when administered to 12 stable renal transplant patients also taking  DRUG1 - DRUGOTHER  containing  DRUGOTHER  (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when  DRUG2  was administered alone under fasting conditions.",negative,magnesium,Myfortic
" DRUGOTHER : Absorption of a single dose of  DRUGOTHER  was decreased when administered to 12 stable renal transplant patients also taking  DRUGOTHER - DRUG1  containing  DRUG2  (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when  DRUGOTHER  was administered alone under fasting conditions.",negative,aluminum,antacids
" DRUGOTHER : Absorption of a single dose of  DRUGOTHER  was decreased when administered to 12 stable renal transplant patients also taking  DRUGOTHER - DRUG1  containing  DRUGOTHER  (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when  DRUG2  was administered alone under fasting conditions.",negative,aluminum,Myfortic
" DRUGOTHER : Absorption of a single dose of  DRUGOTHER  was decreased when administered to 12 stable renal transplant patients also taking  DRUGOTHER - DRUGOTHER  containing  DRUG1  (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when  DRUG2  was administered alone under fasting conditions.",negative,antacids,Myfortic
It is recommended that  DRUG1  and  DRUG2  not be administered simultaneously.,advise,Myfortic,antacids
" DRUG1 : When studied in stable renal transplant patients,  DRUG2 , USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of  DRUGOTHER .",negative,Cyclosporine,cyclosporine
" DRUG1 : When studied in stable renal transplant patients,  DRUGOTHER , USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of  DRUG2 .",negative,Cyclosporine,Myfortic
" DRUGOTHER : When studied in stable renal transplant patients,  DRUG1 , USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of  DRUG2 .",negative,cyclosporine,Myfortic
 DRUG1 / DRUG2 : may be taken with  DRUGOTHER ;,negative,Acyclovir,Ganciclovir
 DRUG1 / DRUGOTHER : may be taken with  DRUG2 ;,negative,Acyclovir,Myfortic
 DRUGOTHER / DRUG1 : may be taken with  DRUG2 ;,negative,Ganciclovir,Myfortic
"Both  DRUG1 / DRUG2  and  DRUGOTHER  concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.",negative,acyclovir,ganciclovir
"Both  DRUG1 / DRUGOTHER  and  DRUG2  concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.",negative,acyclovir,MPAG
"Both  DRUGOTHER / DRUG1  and  DRUG2  concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two.",negative,ganciclovir,MPAG
" DRUG1 / DRUG2 : Given that  DRUGOTHER  and  DRUGOTHER  inhibit purine metabolism, it is recommended that  DRUGOTHER  not be administered concomitantly with  DRUGOTHER  or  DRUGOTHER .",negative,Azathioprine,Mycophenolate Mofetil
" DRUG1 / DRUGOTHER : Given that  DRUG2  and  DRUGOTHER  inhibit purine metabolism, it is recommended that  DRUGOTHER  not be administered concomitantly with  DRUGOTHER  or  DRUGOTHER .",negative,Azathioprine,azathioprine
" DRUG1 / DRUGOTHER : Given that  DRUGOTHER  and  DRUG2  inhibit purine metabolism, it is recommended that  DRUGOTHER  not be administered concomitantly with  DRUGOTHER  or  DRUGOTHER .",negative,Azathioprine,mycophenolate mofetil
" DRUG1 / DRUGOTHER : Given that  DRUGOTHER  and  DRUGOTHER  inhibit purine metabolism, it is recommended that  DRUG2  not be administered concomitantly with  DRUGOTHER  or  DRUGOTHER .",negative,Azathioprine,Myfortic
" DRUG1 / DRUGOTHER : Given that  DRUGOTHER  and  DRUGOTHER  inhibit purine metabolism, it is recommended that  DRUGOTHER  not be administered concomitantly with  DRUG2  or  DRUGOTHER .",negative,Azathioprine,azathioprine
" DRUG1 / DRUGOTHER : Given that  DRUGOTHER  and  DRUGOTHER  inhibit purine metabolism, it is recommended that  DRUGOTHER  not be administered concomitantly with  DRUGOTHER  or  DRUG2 .",negative,Azathioprine,mycophenolate mofetil
" DRUGOTHER / DRUG1 : Given that  DRUG2  and  DRUGOTHER  inhibit purine metabolism, it is recommended that  DRUGOTHER  not be administered concomitantly with  DRUGOTHER  or  DRUGOTHER .",negative,Mycophenolate Mofetil,azathioprine
" DRUGOTHER / DRUG1 : Given that  DRUGOTHER  and  DRUG2  inhibit purine metabolism, it is recommended that  DRUGOTHER  not be administered concomitantly with  DRUGOTHER  or  DRUGOTHER .",negative,Mycophenolate Mofetil,mycophenolate mofetil
" DRUGOTHER / DRUG1 : Given that  DRUGOTHER  and  DRUGOTHER  inhibit purine metabolism, it is recommended that  DRUG2  not be administered concomitantly with  DRUGOTHER  or  DRUGOTHER .",negative,Mycophenolate Mofetil,Myfortic
" DRUGOTHER / DRUG1 : Given that  DRUGOTHER  and  DRUGOTHER  inhibit purine metabolism, it is recommended that  DRUGOTHER  not be administered concomitantly with  DRUG2  or  DRUGOTHER .",negative,Mycophenolate Mofetil,azathioprine
" DRUGOTHER / DRUG1 : Given that  DRUGOTHER  and  DRUGOTHER  inhibit purine metabolism, it is recommended that  DRUGOTHER  not be administered concomitantly with  DRUGOTHER  or  DRUG2 .",negative,Mycophenolate Mofetil,mycophenolate mofetil
" DRUGOTHER / DRUGOTHER : Given that  DRUG1  and  DRUG2  inhibit purine metabolism, it is recommended that  DRUGOTHER  not be administered concomitantly with  DRUGOTHER  or  DRUGOTHER .",negative,azathioprine,mycophenolate mofetil
" DRUGOTHER / DRUGOTHER : Given that  DRUG1  and  DRUGOTHER  inhibit purine metabolism, it is recommended that  DRUG2  not be administered concomitantly with  DRUGOTHER  or  DRUGOTHER .",negative,azathioprine,Myfortic
" DRUGOTHER / DRUGOTHER : Given that  DRUG1  and  DRUGOTHER  inhibit purine metabolism, it is recommended that  DRUGOTHER  not be administered concomitantly with  DRUG2  or  DRUGOTHER .",negative,azathioprine,azathioprine
" DRUGOTHER / DRUGOTHER : Given that  DRUG1  and  DRUGOTHER  inhibit purine metabolism, it is recommended that  DRUGOTHER  not be administered concomitantly with  DRUGOTHER  or  DRUG2 .",negative,azathioprine,mycophenolate mofetil
" DRUGOTHER / DRUGOTHER : Given that  DRUGOTHER  and  DRUG1  inhibit purine metabolism, it is recommended that  DRUG2  not be administered concomitantly with  DRUGOTHER  or  DRUGOTHER .",negative,mycophenolate mofetil,Myfortic
" DRUGOTHER / DRUGOTHER : Given that  DRUGOTHER  and  DRUG1  inhibit purine metabolism, it is recommended that  DRUGOTHER  not be administered concomitantly with  DRUG2  or  DRUGOTHER .",negative,mycophenolate mofetil,azathioprine
" DRUGOTHER / DRUGOTHER : Given that  DRUGOTHER  and  DRUG1  inhibit purine metabolism, it is recommended that  DRUGOTHER  not be administered concomitantly with  DRUGOTHER  or  DRUG2 .",negative,mycophenolate mofetil,mycophenolate mofetil
" DRUGOTHER / DRUGOTHER : Given that  DRUGOTHER  and  DRUGOTHER  inhibit purine metabolism, it is recommended that  DRUG1  not be administered concomitantly with  DRUG2  or  DRUGOTHER .",advise,Myfortic,azathioprine
" DRUGOTHER / DRUGOTHER : Given that  DRUGOTHER  and  DRUGOTHER  inhibit purine metabolism, it is recommended that  DRUG1  not be administered concomitantly with  DRUGOTHER  or  DRUG2 .",advise,Myfortic,mycophenolate mofetil
" DRUGOTHER / DRUGOTHER : Given that  DRUGOTHER  and  DRUGOTHER  inhibit purine metabolism, it is recommended that  DRUGOTHER  not be administered concomitantly with  DRUG1  or  DRUG2 .",negative,azathioprine,mycophenolate mofetil
 DRUG1  and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce  DRUG2  exposure when coadministered with  DRUGOTHER .,negative,Cholestyramine,MPA
 DRUG1  and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce  DRUGOTHER  exposure when coadministered with  DRUG2 .,negative,Cholestyramine,mycophenolate mofetil
 DRUGOTHER  and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce  DRUG1  exposure when coadministered with  DRUG2 .,negative,MPA,mycophenolate mofetil
"Therefore, do not administer  DRUG1  with  DRUG2  or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral  DRUGOTHER , because of the potential to reduce the efficacy of  DRUGOTHER .",advise,Myfortic,cholestyramine
"Therefore, do not administer  DRUG1  with  DRUGOTHER  or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral  DRUG2 , because of the potential to reduce the efficacy of  DRUGOTHER .",advise,Myfortic,activated charcoal
"Therefore, do not administer  DRUG1  with  DRUGOTHER  or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral  DRUGOTHER , because of the potential to reduce the efficacy of  DRUG2 .",negative,Myfortic,Myfortic
"Therefore, do not administer  DRUGOTHER  with  DRUG1  or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral  DRUG2 , because of the potential to reduce the efficacy of  DRUGOTHER .",negative,cholestyramine,activated charcoal
"Therefore, do not administer  DRUGOTHER  with  DRUG1  or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral  DRUGOTHER , because of the potential to reduce the efficacy of  DRUG2 .",negative,cholestyramine,Myfortic
"Therefore, do not administer  DRUGOTHER  with  DRUGOTHER  or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral  DRUG1 , because of the potential to reduce the efficacy of  DRUG2 .",negative,activated charcoal,Myfortic
"Oral  DRUG1 : Given the different metabolism of  DRUG2  and oral  DRUGOTHER , no drug interaction between these two classes of drug is expected.",negative,Contraceptives,Myfortic
"Oral  DRUG1 : Given the different metabolism of  DRUGOTHER  and oral  DRUG2 , no drug interaction between these two classes of drug is expected.",negative,Contraceptives,contraceptives
"Oral  DRUGOTHER : Given the different metabolism of  DRUG1  and oral  DRUG2 , no drug interaction between these two classes of drug is expected.",negative,Myfortic,contraceptives
"However, in a drug-drug interaction study, mean  DRUG1  AUC was decreased by 15% when coadministered with  DRUG2 .",mechanism,levonorgesterol,mycophenolate mofetil
"Therefore, it is recommended that oral  DRUG1  are co- administered with  DRUG2  with caution and additional birth control methods be considered.",advise,contraceptives,Myfortic
" DRUG1 : During treatment with  DRUG2 , the use of  DRUGOTHER  should be avoided and patients should be advised that vaccinations may be less effective.",negative,Live Vaccines,Myfortic
" DRUG1 : During treatment with  DRUGOTHER , the use of  DRUG2  should be avoided and patients should be advised that vaccinations may be less effective.",negative,Live Vaccines,live attenuated vaccines
" DRUGOTHER : During treatment with  DRUG1 , the use of  DRUG2  should be avoided and patients should be advised that vaccinations may be less effective.",advise,Myfortic,live attenuated vaccines
Interference of  DRUG1  hydrolysis may lead to less  DRUG2  available for absorption.,negative,MPAG,MPA
"CYP3A4 Inhibitors:  DRUG1 , an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of  DRUG2  when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions).",mechanism,Ketoconazole,tolterodine
"For patients receiving  DRUG1  or other potent CYP3A4 inhibitors such as other  DRUG2  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,ketoconazole,azole antifungals
"For patients receiving  DRUG1  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,ketoconazole,itraconazole
"For patients receiving  DRUG1  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,ketoconazole,miconazole
"For patients receiving  DRUG1  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,ketoconazole,macrolide antibiotics
"For patients receiving  DRUG1  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,ketoconazole,erythromycin
"For patients receiving  DRUG1  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,ketoconazole,clarithromycin
"For patients receiving  DRUG1  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,ketoconazole,cyclosporine
"For patients receiving  DRUG1  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  or  DRUG2 , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,ketoconazole,vinblastine
"For patients receiving  DRUG1  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUG2  is 2 mg daily.",advise,ketoconazole,DETROL LA
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUG1  (eg,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,azole antifungals,itraconazole
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUG1  (eg,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,azole antifungals,miconazole
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,azole antifungals,macrolide antibiotics
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,azole antifungals,erythromycin
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,azole antifungals,clarithromycin
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,azole antifungals,cyclosporine
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  or  DRUG2 , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,azole antifungals,vinblastine
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUG2  is 2 mg daily.",advise,azole antifungals,DETROL LA
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUG1 ,  DRUG2 ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,itraconazole,miconazole
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER ) or  DRUG2  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,itraconazole,macrolide antibiotics
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,itraconazole,erythromycin
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,itraconazole,clarithromycin
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,itraconazole,cyclosporine
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  or  DRUG2 , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,itraconazole,vinblastine
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUG2  is 2 mg daily.",advise,itraconazole,DETROL LA
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1 ) or  DRUG2  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,miconazole,macrolide antibiotics
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1 ) or  DRUGOTHER  (eg,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,miconazole,erythromycin
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1 ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,miconazole,clarithromycin
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1 ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,miconazole,cyclosporine
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1 ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  or  DRUG2 , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,miconazole,vinblastine
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1 ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUG2  is 2 mg daily.",advise,miconazole,DETROL LA
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUG1  (eg,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,macrolide antibiotics,erythromycin
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUG1  (eg,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,macrolide antibiotics,clarithromycin
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,macrolide antibiotics,cyclosporine
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  or  DRUG2 , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,macrolide antibiotics,vinblastine
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUG2  is 2 mg daily.",advise,macrolide antibiotics,DETROL LA
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUG1 ,  DRUG2 ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,erythromycin,clarithromycin
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER ) or  DRUG2  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,erythromycin,cyclosporine
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER ) or  DRUGOTHER  or  DRUG2 , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,erythromycin,vinblastine
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUG2  is 2 mg daily.",advise,erythromycin,DETROL LA
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1 ) or  DRUG2  or  DRUGOTHER , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,clarithromycin,cyclosporine
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1 ) or  DRUGOTHER  or  DRUG2 , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,clarithromycin,vinblastine
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1 ) or  DRUGOTHER  or  DRUGOTHER , the recommended dose of  DRUG2  is 2 mg daily.",advise,clarithromycin,DETROL LA
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUG1  or  DRUG2 , the recommended dose of  DRUGOTHER  is 2 mg daily.",negative,cyclosporine,vinblastine
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUG1  or  DRUGOTHER , the recommended dose of  DRUG2  is 2 mg daily.",advise,cyclosporine,DETROL LA
"For patients receiving  DRUGOTHER  or other potent CYP3A4 inhibitors such as other  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  or  DRUG1 , the recommended dose of  DRUG2  is 2 mg daily.",advise,vinblastine,DETROL LA
" DRUG1 , such as the  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ) or  DRUGOTHER , ordinarily should not be administered concurrently with  DRUGOTHER  (a  DRUGOTHER );",negative,Dopamine antagonists,neuroleptics
" DRUG1 , such as the  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER  ) or  DRUGOTHER , ordinarily should not be administered concurrently with  DRUGOTHER  (a  DRUGOTHER );",negative,Dopamine antagonists,phenothiazines
" DRUG1 , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER  ) or  DRUGOTHER , ordinarily should not be administered concurrently with  DRUGOTHER  (a  DRUGOTHER );",negative,Dopamine antagonists,butyrophenones
" DRUG1 , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2  ) or  DRUGOTHER , ordinarily should not be administered concurrently with  DRUGOTHER  (a  DRUGOTHER );",negative,Dopamine antagonists,thioxanthines
" DRUG1 , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ) or  DRUG2 , ordinarily should not be administered concurrently with  DRUGOTHER  (a  DRUGOTHER );",negative,Dopamine antagonists,metoclopramide
" DRUG1 , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ) or  DRUGOTHER , ordinarily should not be administered concurrently with  DRUG2  (a  DRUGOTHER );",advise,Dopamine antagonists,Permax
" DRUG1 , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ) or  DRUGOTHER , ordinarily should not be administered concurrently with  DRUGOTHER  (a  DRUG2 );",negative,Dopamine antagonists,dopamine agonist
" DRUGOTHER , such as the  DRUG1  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER  ) or  DRUGOTHER , ordinarily should not be administered concurrently with  DRUGOTHER  (a  DRUGOTHER );",negative,neuroleptics,phenothiazines
" DRUGOTHER , such as the  DRUG1  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER  ) or  DRUGOTHER , ordinarily should not be administered concurrently with  DRUGOTHER  (a  DRUGOTHER );",negative,neuroleptics,butyrophenones
" DRUGOTHER , such as the  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2  ) or  DRUGOTHER , ordinarily should not be administered concurrently with  DRUGOTHER  (a  DRUGOTHER );",negative,neuroleptics,thioxanthines
" DRUGOTHER , such as the  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ) or  DRUG2 , ordinarily should not be administered concurrently with  DRUGOTHER  (a  DRUGOTHER );",negative,neuroleptics,metoclopramide
" DRUGOTHER , such as the  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ) or  DRUGOTHER , ordinarily should not be administered concurrently with  DRUG2  (a  DRUGOTHER );",advise,neuroleptics,Permax
" DRUGOTHER , such as the  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ) or  DRUGOTHER , ordinarily should not be administered concurrently with  DRUGOTHER  (a  DRUG2 );",negative,neuroleptics,dopamine agonist
" DRUGOTHER , such as the  DRUGOTHER  ( DRUG1 ,  DRUG2 ,  DRUGOTHER  ) or  DRUGOTHER , ordinarily should not be administered concurrently with  DRUGOTHER  (a  DRUGOTHER );",negative,phenothiazines,butyrophenones
" DRUGOTHER , such as the  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUG2  ) or  DRUGOTHER , ordinarily should not be administered concurrently with  DRUGOTHER  (a  DRUGOTHER );",negative,phenothiazines,thioxanthines
" DRUGOTHER , such as the  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER  ) or  DRUG2 , ordinarily should not be administered concurrently with  DRUGOTHER  (a  DRUGOTHER );",negative,phenothiazines,metoclopramide
" DRUGOTHER , such as the  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER  ) or  DRUGOTHER , ordinarily should not be administered concurrently with  DRUG2  (a  DRUGOTHER );",advise,phenothiazines,Permax
" DRUGOTHER , such as the  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER  ) or  DRUGOTHER , ordinarily should not be administered concurrently with  DRUGOTHER  (a  DRUG2 );",negative,phenothiazines,dopamine agonist
" DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUG2  ) or  DRUGOTHER , ordinarily should not be administered concurrently with  DRUGOTHER  (a  DRUGOTHER );",negative,butyrophenones,thioxanthines
" DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER  ) or  DRUG2 , ordinarily should not be administered concurrently with  DRUGOTHER  (a  DRUGOTHER );",negative,butyrophenones,metoclopramide
" DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER  ) or  DRUGOTHER , ordinarily should not be administered concurrently with  DRUG2  (a  DRUGOTHER );",advise,butyrophenones,Permax
" DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER  ) or  DRUGOTHER , ordinarily should not be administered concurrently with  DRUGOTHER  (a  DRUG2 );",negative,butyrophenones,dopamine agonist
" DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1  ) or  DRUG2 , ordinarily should not be administered concurrently with  DRUGOTHER  (a  DRUGOTHER );",negative,thioxanthines,metoclopramide
" DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1  ) or  DRUGOTHER , ordinarily should not be administered concurrently with  DRUG2  (a  DRUGOTHER );",advise,thioxanthines,Permax
" DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1  ) or  DRUGOTHER , ordinarily should not be administered concurrently with  DRUGOTHER  (a  DRUG2 );",negative,thioxanthines,dopamine agonist
" DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ) or  DRUG1 , ordinarily should not be administered concurrently with  DRUG2  (a  DRUGOTHER );",advise,metoclopramide,Permax
" DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ) or  DRUG1 , ordinarily should not be administered concurrently with  DRUGOTHER  (a  DRUG2 );",negative,metoclopramide,dopamine agonist
" DRUGOTHER , such as the  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  ) or  DRUGOTHER , ordinarily should not be administered concurrently with  DRUG1  (a  DRUG2 );",negative,Permax,dopamine agonist
"Because  DRUG1  is approximately 90% bound to plasma proteins, caution should be exercised if  DRUG2  is coadministered with other drugs known to affect protein binding.",negative,pergolide mesylate,pergolide mesylate
Other  DRUG1  should not be used concomitantly with  DRUG2  because they may have additive effects.,advise,short-acting beta adrenergic aerosol bronchodilators,MAXAIR AUTOHALER
[Interaction between  DRUG1  and  DRUG2 ].,negative,clopidogrel,proton pump inhibitors
The drug interaction between  DRUG1  and  DRUG2  has been the subject of much study in recent years.,negative,proton pump inhibitors,clopidogrel
Contradictory results regarding the effect of  DRUG1  on platelet reactivity and on clinical outcome in  DRUG2 -treated patients have been reported in literature.,negative,proton pump inhibitors,clopidogrel
"Concomitant use of  DRUG1  and  DRUG2  was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by  DRUGOTHER  of CYP2C19, a cytochrome P450 (CYP) enzyme.",mechanism,omeprazole,clopidogrel
"Concomitant use of  DRUG1  and  DRUGOTHER  was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by  DRUG2  of CYP2C19, a cytochrome P450 (CYP) enzyme.",negative,omeprazole,omeprazole
"Concomitant use of  DRUGOTHER  and  DRUG1  was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by  DRUG2  of CYP2C19, a cytochrome P450 (CYP) enzyme.",negative,clopidogrel,omeprazole
 DRUG1  has a much weaker effect on  DRUG2 's pharmacokinetics and on platelet reactivity during concomitant use.,mechanism,Pantoprazole,clopidogrel
The influence of the other  DRUG1  when used simultaneously with  DRUG2  has not yet been investigated in adequately randomized studies.,negative,proton pump inhibitors,clopidogrel
Regulatory agencies state that the combination of  DRUG1  and the CYP2C19 inhibitors  DRUG2  and  DRUGOTHER  should be avoided.,advise,clopidogrel,omeprazole
Regulatory agencies state that the combination of  DRUG1  and the CYP2C19 inhibitors  DRUGOTHER  and  DRUG2  should be avoided.,advise,clopidogrel,esomeprazole
Regulatory agencies state that the combination of  DRUGOTHER  and the CYP2C19 inhibitors  DRUG1  and  DRUG2  should be avoided.,negative,omeprazole,esomeprazole
"To date, there is no conclusive evidence of a clinically-relevant interaction between any of the  DRUG1  and  DRUG2 .",negative,proton pump inhibitors,clopidogrel
" DRUG1  should be used with caution in patients receiving other local  DRUG2  or agents structurally related to  DRUGOTHER , since the toxic effects of these drugs are additive.",advise,Ropivacaine,anesthetics
" DRUG1  should be used with caution in patients receiving other local  DRUGOTHER  or agents structurally related to  DRUG2 , since the toxic effects of these drugs are additive.",negative,Ropivacaine,amide-type local anesthetics
" DRUGOTHER  should be used with caution in patients receiving other local  DRUG1  or agents structurally related to  DRUG2 , since the toxic effects of these drugs are additive.",negative,anesthetics,amide-type local anesthetics
"In vivo, the plasma clearance of  DRUG1  was reduced by 70% during coadministration of  DRUG2  (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor.",mechanism,ropivacaine,fluvoxamine
"Thus strong inhibitors of cytochrome P4501A2, such as  DRUG1 , given concomitantly during administration of  DRUG2 , can interact with  DRUGOTHER  leading to increased  DRUGOTHER  plasma levels.",int,fluvoxamine,Ropivacaine
"Thus strong inhibitors of cytochrome P4501A2, such as  DRUG1 , given concomitantly during administration of  DRUGOTHER , can interact with  DRUG2  leading to increased  DRUGOTHER  plasma levels.",negative,fluvoxamine,Ropivacaine
"Thus strong inhibitors of cytochrome P4501A2, such as  DRUG1 , given concomitantly during administration of  DRUGOTHER , can interact with  DRUGOTHER  leading to increased  DRUG2  plasma levels.",negative,fluvoxamine,ropivacaine
"Thus strong inhibitors of cytochrome P4501A2, such as  DRUGOTHER , given concomitantly during administration of  DRUG1 , can interact with  DRUG2  leading to increased  DRUGOTHER  plasma levels.",negative,Ropivacaine,Ropivacaine
"Thus strong inhibitors of cytochrome P4501A2, such as  DRUGOTHER , given concomitantly during administration of  DRUG1 , can interact with  DRUGOTHER  leading to increased  DRUG2  plasma levels.",negative,Ropivacaine,ropivacaine
"Thus strong inhibitors of cytochrome P4501A2, such as  DRUGOTHER , given concomitantly during administration of  DRUGOTHER , can interact with  DRUG1  leading to increased  DRUG2  plasma levels.",negative,Ropivacaine,ropivacaine
Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as  DRUG1  and  DRUG2  may also occur.,negative,theophylline,imipramine
"Coadministration of a selective and potent inhibitor of CYP3A4,  DRUG1  (100 mg bid for 2 days with  DRUG2  infusion administered 1 hour after  DRUGOTHER ) caused a 15% reduction in in-vivo plasma clearance of  DRUGOTHER .",negative,ketoconazole,ropivacaine
"Coadministration of a selective and potent inhibitor of CYP3A4,  DRUG1  (100 mg bid for 2 days with  DRUGOTHER  infusion administered 1 hour after  DRUG2 ) caused a 15% reduction in in-vivo plasma clearance of  DRUGOTHER .",negative,ketoconazole,ketoconazole
"Coadministration of a selective and potent inhibitor of CYP3A4,  DRUG1  (100 mg bid for 2 days with  DRUGOTHER  infusion administered 1 hour after  DRUGOTHER ) caused a 15% reduction in in-vivo plasma clearance of  DRUG2 .",mechanism,ketoconazole,ropivacaine
"Coadministration of a selective and potent inhibitor of CYP3A4,  DRUGOTHER  (100 mg bid for 2 days with  DRUG1  infusion administered 1 hour after  DRUG2 ) caused a 15% reduction in in-vivo plasma clearance of  DRUGOTHER .",negative,ropivacaine,ketoconazole
"Coadministration of a selective and potent inhibitor of CYP3A4,  DRUGOTHER  (100 mg bid for 2 days with  DRUG1  infusion administered 1 hour after  DRUGOTHER ) caused a 15% reduction in in-vivo plasma clearance of  DRUG2 .",negative,ropivacaine,ropivacaine
"Coadministration of a selective and potent inhibitor of CYP3A4,  DRUGOTHER  (100 mg bid for 2 days with  DRUGOTHER  infusion administered 1 hour after  DRUG1 ) caused a 15% reduction in in-vivo plasma clearance of  DRUG2 .",negative,ketoconazole,ropivacaine
Exposure to oral  DRUG1  is unaffected by  DRUG2  but greatly increased by  DRUGOTHER .,negative,S-ketamine,itraconazole
Exposure to oral  DRUG1  is unaffected by  DRUGOTHER  but greatly increased by  DRUG2 .,effect,S-ketamine,ticlopidine
Exposure to oral  DRUGOTHER  is unaffected by  DRUG1  but greatly increased by  DRUG2 .,negative,itraconazole,ticlopidine
This study examined drug-drug interactions of oral  DRUG1  with the cytochrome P450 (CYP) 2B6 inhibitor  DRUG2  and the CYP3A inhibitor  DRUGOTHER .,negative,S-ketamine,ticlopidine
This study examined drug-drug interactions of oral  DRUG1  with the cytochrome P450 (CYP) 2B6 inhibitor  DRUGOTHER  and the CYP3A inhibitor  DRUG2 .,negative,S-ketamine,itraconazole
This study examined drug-drug interactions of oral  DRUGOTHER  with the cytochrome P450 (CYP) 2B6 inhibitor  DRUG1  and the CYP3A inhibitor  DRUG2 .,negative,ticlopidine,itraconazole
"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg  DRUG1  after pretreatments with oral  DRUG2  (250 mg twice daily),  DRUGOTHER  (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks.",negative,S-ketamine,ticlopidine
"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg  DRUG1  after pretreatments with oral  DRUGOTHER  (250 mg twice daily),  DRUG2  (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks.",negative,S-ketamine,itraconazole
"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg  DRUGOTHER  after pretreatments with oral  DRUG1  (250 mg twice daily),  DRUG2  (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks.",negative,ticlopidine,itraconazole
" DRUG1  treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral  DRUG2  by 2.4-fold, whereas  DRUGOTHER  treatment did not increase the exposure to  DRUGOTHER .",mechanism,Ticlopidine,ketamine
" DRUG1  treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral  DRUGOTHER  by 2.4-fold, whereas  DRUG2  treatment did not increase the exposure to  DRUGOTHER .",negative,Ticlopidine,itraconazole
" DRUG1  treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral  DRUGOTHER  by 2.4-fold, whereas  DRUGOTHER  treatment did not increase the exposure to  DRUG2 .",negative,Ticlopidine,S-ketamine
" DRUGOTHER  treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral  DRUG1  by 2.4-fold, whereas  DRUG2  treatment did not increase the exposure to  DRUGOTHER .",negative,ketamine,itraconazole
" DRUGOTHER  treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral  DRUG1  by 2.4-fold, whereas  DRUGOTHER  treatment did not increase the exposure to  DRUG2 .",negative,ketamine,S-ketamine
" DRUGOTHER  treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral  DRUGOTHER  by 2.4-fold, whereas  DRUG1  treatment did not increase the exposure to  DRUG2 .",negative,itraconazole,S-ketamine
The ratio of  DRUG1  AUC(0-   ) to  DRUG2  AUC(0-   ) was significantly decreased in the  DRUGOTHER  (P &lt; 0.001) and  DRUGOTHER  phases (P = 0.006) as compared to placebo.,negative,norketamine,ketamine
The ratio of  DRUG1  AUC(0-   ) to  DRUGOTHER  AUC(0-   ) was significantly decreased in the  DRUG2  (P &lt; 0.001) and  DRUGOTHER  phases (P = 0.006) as compared to placebo.,negative,norketamine,ticlopidine
The ratio of  DRUG1  AUC(0-   ) to  DRUGOTHER  AUC(0-   ) was significantly decreased in the  DRUGOTHER  (P &lt; 0.001) and  DRUG2  phases (P = 0.006) as compared to placebo.,negative,norketamine,itraconazole
The ratio of  DRUGOTHER  AUC(0-   ) to  DRUG1  AUC(0-   ) was significantly decreased in the  DRUG2  (P &lt; 0.001) and  DRUGOTHER  phases (P = 0.006) as compared to placebo.,negative,ketamine,ticlopidine
The ratio of  DRUGOTHER  AUC(0-   ) to  DRUG1  AUC(0-   ) was significantly decreased in the  DRUGOTHER  (P &lt; 0.001) and  DRUG2  phases (P = 0.006) as compared to placebo.,negative,ketamine,itraconazole
The ratio of  DRUGOTHER  AUC(0-   ) to  DRUGOTHER  AUC(0-   ) was significantly decreased in the  DRUG1  (P &lt; 0.001) and  DRUG2  phases (P = 0.006) as compared to placebo.,negative,ticlopidine,itraconazole
"In the  DRUG1  and  DRUG2  phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05).",negative,ticlopidine,itraconazole
The findings suggest that the dosage of  DRUG1  should be reduced in patients receiving  DRUG2 .,advise,S-ketamine,ticlopidine
"The induction dose requirements of  DRUG1  Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with  DRUG2  (eg,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , etc.)",effect,DIPRIVAN,narcotics
"The induction dose requirements of  DRUG1  Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with  DRUGOTHER  (eg,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER , etc.)",effect,DIPRIVAN,morphine
"The induction dose requirements of  DRUG1  Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER , etc.)",effect,DIPRIVAN,meperidine
"The induction dose requirements of  DRUG1  Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 , etc.)",effect,DIPRIVAN,fentanyl
"The induction dose requirements of  DRUGOTHER  Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with  DRUG1  (eg,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER , etc.)",negative,narcotics,morphine
"The induction dose requirements of  DRUGOTHER  Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with  DRUG1  (eg,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER , etc.)",negative,narcotics,meperidine
"The induction dose requirements of  DRUGOTHER  Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 , etc.)",negative,narcotics,fentanyl
"The induction dose requirements of  DRUGOTHER  Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with  DRUGOTHER  (eg,  DRUG1 ,  DRUG2 , and  DRUGOTHER , etc.)",negative,morphine,meperidine
"The induction dose requirements of  DRUGOTHER  Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER , and  DRUG2 , etc.)",negative,morphine,fentanyl
"The induction dose requirements of  DRUGOTHER  Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1 , and  DRUG2 , etc.)",negative,meperidine,fentanyl
"and combinations of  DRUG1  and  DRUG2  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , etc.).",negative,opioids,sedatives
"and combinations of  DRUG1  and  DRUGOTHER  (eg,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , etc.).",negative,opioids,benzodiazepines
"and combinations of  DRUG1  and  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , etc.).",negative,opioids,barbiturates
"and combinations of  DRUG1  and  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , etc.).",negative,opioids,chloral hydrate
"and combinations of  DRUG1  and  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , etc.).",negative,opioids,droperidol
"and combinations of  DRUGOTHER  and  DRUG1  (eg,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , etc.).",negative,sedatives,benzodiazepines
"and combinations of  DRUGOTHER  and  DRUG1  (eg,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , etc.).",negative,sedatives,barbiturates
"and combinations of  DRUGOTHER  and  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , etc.).",negative,sedatives,chloral hydrate
"and combinations of  DRUGOTHER  and  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , etc.).",negative,sedatives,droperidol
"and combinations of  DRUGOTHER  and  DRUGOTHER  (eg,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , etc.).",negative,benzodiazepines,barbiturates
"and combinations of  DRUGOTHER  and  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , etc.).",negative,benzodiazepines,chloral hydrate
"and combinations of  DRUGOTHER  and  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , etc.).",negative,benzodiazepines,droperidol
"and combinations of  DRUGOTHER  and  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , etc.).",negative,barbiturates,chloral hydrate
"and combinations of  DRUGOTHER  and  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , etc.).",negative,barbiturates,droperidol
"and combinations of  DRUGOTHER  and  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , etc.).",negative,chloral hydrate,droperidol
"During maintenance of anesthesia or sedation, the rate of  DRUG1  Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental  DRUG2  (eg,  DRUGOTHER  or  DRUGOTHER ).",advise,DIPRIVAN,analgesic agents
"During maintenance of anesthesia or sedation, the rate of  DRUG1  Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental  DRUGOTHER  (eg,  DRUG2  or  DRUGOTHER ).",advise,DIPRIVAN,nitrous oxide
"During maintenance of anesthesia or sedation, the rate of  DRUG1  Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental  DRUGOTHER  (eg,  DRUGOTHER  or  DRUG2 ).",advise,DIPRIVAN,opioids
"During maintenance of anesthesia or sedation, the rate of  DRUGOTHER  Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental  DRUG1  (eg,  DRUG2  or  DRUGOTHER ).",negative,analgesic agents,nitrous oxide
"During maintenance of anesthesia or sedation, the rate of  DRUGOTHER  Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental  DRUG1  (eg,  DRUGOTHER  or  DRUG2 ).",negative,analgesic agents,opioids
"During maintenance of anesthesia or sedation, the rate of  DRUGOTHER  Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental  DRUGOTHER  (eg,  DRUG1  or  DRUG2 ).",negative,nitrous oxide,opioids
"The concurrent administration of potent inhalational agents (eg,  DRUG1 ,  DRUG2 , and  DRUGOTHER ) during maintenance with  DRUGOTHER  Injectable Emulsion has not been extensively evaluated.",negative,isoflurane,enflurane
"The concurrent administration of potent inhalational agents (eg,  DRUG1 ,  DRUGOTHER , and  DRUG2 ) during maintenance with  DRUGOTHER  Injectable Emulsion has not been extensively evaluated.",negative,isoflurane,halothane
"The concurrent administration of potent inhalational agents (eg,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ) during maintenance with  DRUG2  Injectable Emulsion has not been extensively evaluated.",negative,isoflurane,DIPRIVAN
"The concurrent administration of potent inhalational agents (eg,  DRUGOTHER ,  DRUG1 , and  DRUG2 ) during maintenance with  DRUGOTHER  Injectable Emulsion has not been extensively evaluated.",negative,enflurane,halothane
"The concurrent administration of potent inhalational agents (eg,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ) during maintenance with  DRUG2  Injectable Emulsion has not been extensively evaluated.",negative,enflurane,DIPRIVAN
"The concurrent administration of potent inhalational agents (eg,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ) during maintenance with  DRUG2  Injectable Emulsion has not been extensively evaluated.",negative,halothane,DIPRIVAN
" DRUG1  Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used  DRUG2  (eg,  DRUGOTHER  and  DRUGOTHER ).",negative,DIPRIVAN,neuromuscular blocking agents
" DRUG1  Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used  DRUGOTHER  (eg,  DRUG2  and  DRUGOTHER ).",negative,DIPRIVAN,succinylcholine
" DRUG1  Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used  DRUGOTHER  (eg,  DRUGOTHER  and  DRUG2 ).",negative,DIPRIVAN,nondepolarizing muscle relaxants
" DRUGOTHER  Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used  DRUG1  (eg,  DRUG2  and  DRUGOTHER ).",negative,neuromuscular blocking agents,succinylcholine
" DRUGOTHER  Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used  DRUG1  (eg,  DRUGOTHER  and  DRUG2 ).",negative,neuromuscular blocking agents,nondepolarizing muscle relaxants
" DRUGOTHER  Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used  DRUGOTHER  (eg,  DRUG1  and  DRUG2 ).",negative,succinylcholine,nondepolarizing muscle relaxants
"No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of  DRUG1 , inhalational agents,  DRUG2 , and local  DRUGOTHER ) have been observed.",negative,muscle relaxants,analgesic agents
"No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of  DRUG1 , inhalational agents,  DRUGOTHER , and local  DRUG2 ) have been observed.",negative,muscle relaxants,anesthetic agents
"No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of  DRUGOTHER , inhalational agents,  DRUG1 , and local  DRUG2 ) have been observed.",negative,analgesic agents,anesthetic agents
" DRUG1  may compete with other drugs, such as  DRUG2 , for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels.",mechanism,Thiabendazole,theophylline
"Therefore, when concomitant use of  DRUG1  and  DRUG2  is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds.",advise,thiabendazole,xanthine derivatives
"Due to its effects on gastric emptying,  DRUG1  therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g.,  DRUG2  such as  DRUGOTHER ) and agents that slow the intestinal absorption of nutrients (e.g.,  DRUGOTHER ).",advise,SYMLIN,anticholinergic agents
"Due to its effects on gastric emptying,  DRUG1  therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g.,  DRUGOTHER  such as  DRUG2 ) and agents that slow the intestinal absorption of nutrients (e.g.,  DRUGOTHER ).",advise,SYMLIN,atropine
"Due to its effects on gastric emptying,  DRUG1  therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g.,  DRUGOTHER  such as  DRUGOTHER ) and agents that slow the intestinal absorption of nutrients (e.g.,  DRUG2 ).",advise,SYMLIN,alpha glucosidase inhibitors
"Due to its effects on gastric emptying,  DRUGOTHER  therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g.,  DRUG1  such as  DRUG2 ) and agents that slow the intestinal absorption of nutrients (e.g.,  DRUGOTHER ).",negative,anticholinergic agents,atropine
"Due to its effects on gastric emptying,  DRUGOTHER  therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g.,  DRUG1  such as  DRUGOTHER ) and agents that slow the intestinal absorption of nutrients (e.g.,  DRUG2 ).",negative,anticholinergic agents,alpha glucosidase inhibitors
"Due to its effects on gastric emptying,  DRUGOTHER  therapy should not be considered for patients taking drugs that alter gastrointestinal motility (e.g.,  DRUGOTHER  such as  DRUG1 ) and agents that slow the intestinal absorption of nutrients (e.g.,  DRUG2 ).",negative,atropine,alpha glucosidase inhibitors
"When the rapid onset of a concomitant orally administered agent is a critical determinant of effectiveness (such as  DRUG1 ), the agent should be administered at least 1 hour prior to or 2 hours after  DRUG2  injection.",advise,analgesics,SYMLIN
"In clinical trials, the concomitant use of  DRUG1  or  DRUG2  did not alter the adverse event profile of  DRUGOTHER .",negative,sulfonylureas,biguanides
"In clinical trials, the concomitant use of  DRUG1  or  DRUGOTHER  did not alter the adverse event profile of  DRUG2 .",negative,sulfonylureas,SYMLIN
"In clinical trials, the concomitant use of  DRUGOTHER  or  DRUG1  did not alter the adverse event profile of  DRUG2 .",negative,biguanides,SYMLIN
No formal interaction studies have been performed to assess the effect of  DRUG1  on the kinetics of oral  DRUG2 .,negative,SYMLIN,antidiabetic agents
"Mixing  DRUG1  and  DRUG2  The pharmacokinetic parameters of  DRUGOTHER  were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant  DRUGOTHER  immediately prior to injection.",negative,SYMLIN,Insulin
"Mixing  DRUG1  and  DRUGOTHER  The pharmacokinetic parameters of  DRUG2  were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant  DRUGOTHER  immediately prior to injection.",negative,SYMLIN,SYMLIN
"Mixing  DRUG1  and  DRUGOTHER  The pharmacokinetic parameters of  DRUGOTHER  were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant  DRUG2  immediately prior to injection.",negative,SYMLIN,human insulin
"Mixing  DRUGOTHER  and  DRUG1  The pharmacokinetic parameters of  DRUG2  were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant  DRUGOTHER  immediately prior to injection.",negative,Insulin,SYMLIN
"Mixing  DRUGOTHER  and  DRUG1  The pharmacokinetic parameters of  DRUGOTHER  were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant  DRUG2  immediately prior to injection.",negative,Insulin,human insulin
"Mixing  DRUGOTHER  and  DRUGOTHER  The pharmacokinetic parameters of  DRUG1  were altered when mixed with regular, NPH, and 70/30 premixed formulations of recombinant  DRUG2  immediately prior to injection.",mechanism,SYMLIN,human insulin
"Thus,  DRUG1  and  DRUG2  should not be mixed and must be administered separately.",negative,SYMLIN,insulin
Interaction study of  DRUG1  and  DRUG2  with co-administered drugs.,negative,moxifloxacin,lomefloxacin
 DRUG1  and  DRUG2  are  DRUGOTHER  used in treating urinary and respiratory tract infections.,negative,Moxifloxacin,lomefloxacin
 DRUG1  and  DRUGOTHER  are  DRUG2  used in treating urinary and respiratory tract infections.,negative,Moxifloxacin,fluoroquinolone antibiotics
 DRUGOTHER  and  DRUG1  are  DRUG2  used in treating urinary and respiratory tract infections.,negative,lomefloxacin,fluoroquinolone antibiotics
"Being  DRUG1  and lomefloxacin  DRUG2  the interaction study of was carried out with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",negative,moxifloxacin,fluoroquinolones
"Being  DRUG1  and lomefloxacin  DRUGOTHER  the interaction study of was carried out with  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",negative,moxifloxacin,sucralfate
"Being  DRUG1  and lomefloxacin  DRUGOTHER  the interaction study of was carried out with  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER .",negative,moxifloxacin,gelusil
"Being  DRUG1  and lomefloxacin  DRUGOTHER  the interaction study of was carried out with  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER .",negative,moxifloxacin,erythromycin
"Being  DRUG1  and lomefloxacin  DRUGOTHER  the interaction study of was carried out with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 .",negative,moxifloxacin,multi minerals
"Being  DRUGOTHER  and lomefloxacin  DRUG1  the interaction study of was carried out with  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",negative,fluoroquinolones,sucralfate
"Being  DRUGOTHER  and lomefloxacin  DRUG1  the interaction study of was carried out with  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER .",negative,fluoroquinolones,gelusil
"Being  DRUGOTHER  and lomefloxacin  DRUG1  the interaction study of was carried out with  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER .",negative,fluoroquinolones,erythromycin
"Being  DRUGOTHER  and lomefloxacin  DRUG1  the interaction study of was carried out with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 .",negative,fluoroquinolones,multi minerals
"Being  DRUGOTHER  and lomefloxacin  DRUGOTHER  the interaction study of was carried out with  DRUG1 ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER .",negative,sucralfate,gelusil
"Being  DRUGOTHER  and lomefloxacin  DRUGOTHER  the interaction study of was carried out with  DRUG1 ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER .",negative,sucralfate,erythromycin
"Being  DRUGOTHER  and lomefloxacin  DRUGOTHER  the interaction study of was carried out with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 .",negative,sucralfate,multi minerals
"Being  DRUGOTHER  and lomefloxacin  DRUGOTHER  the interaction study of was carried out with  DRUGOTHER ,  DRUG1 ,  DRUG2  and  DRUGOTHER .",negative,gelusil,erythromycin
"Being  DRUGOTHER  and lomefloxacin  DRUGOTHER  the interaction study of was carried out with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUG2 .",negative,gelusil,multi minerals
"Being  DRUGOTHER  and lomefloxacin  DRUGOTHER  the interaction study of was carried out with  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUG2 .",negative,erythromycin,multi minerals
The response of  DRUG1  and  DRUG2  after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector.,negative,moxifloxacin,lomefloxacin
 DRUG1  and  DRUG2  reacts faster with  DRUGOTHER  and  DRUGOTHER  in acidic media whereas with  DRUGOTHER  in basic media and  DRUGOTHER  in neutral media.,negative,Moxifloxacin,Lomefloxacin
 DRUG1  and  DRUGOTHER  reacts faster with  DRUG2  and  DRUGOTHER  in acidic media whereas with  DRUGOTHER  in basic media and  DRUGOTHER  in neutral media.,mechanism,Moxifloxacin,sucralfate
 DRUG1  and  DRUGOTHER  reacts faster with  DRUGOTHER  and  DRUG2  in acidic media whereas with  DRUGOTHER  in basic media and  DRUGOTHER  in neutral media.,mechanism,Moxifloxacin,gelusil
 DRUG1  and  DRUGOTHER  reacts faster with  DRUGOTHER  and  DRUGOTHER  in acidic media whereas with  DRUG2  in basic media and  DRUGOTHER  in neutral media.,mechanism,Moxifloxacin,erythromycin
 DRUG1  and  DRUGOTHER  reacts faster with  DRUGOTHER  and  DRUGOTHER  in acidic media whereas with  DRUGOTHER  in basic media and  DRUG2  in neutral media.,mechanism,Moxifloxacin,multi-minerals
 DRUGOTHER  and  DRUG1  reacts faster with  DRUG2  and  DRUGOTHER  in acidic media whereas with  DRUGOTHER  in basic media and  DRUGOTHER  in neutral media.,mechanism,Lomefloxacin,sucralfate
 DRUGOTHER  and  DRUG1  reacts faster with  DRUGOTHER  and  DRUG2  in acidic media whereas with  DRUGOTHER  in basic media and  DRUGOTHER  in neutral media.,mechanism,Lomefloxacin,gelusil
 DRUGOTHER  and  DRUG1  reacts faster with  DRUGOTHER  and  DRUGOTHER  in acidic media whereas with  DRUG2  in basic media and  DRUGOTHER  in neutral media.,mechanism,Lomefloxacin,erythromycin
 DRUGOTHER  and  DRUG1  reacts faster with  DRUGOTHER  and  DRUGOTHER  in acidic media whereas with  DRUGOTHER  in basic media and  DRUG2  in neutral media.,mechanism,Lomefloxacin,multi-minerals
 DRUGOTHER  and  DRUGOTHER  reacts faster with  DRUG1  and  DRUG2  in acidic media whereas with  DRUGOTHER  in basic media and  DRUGOTHER  in neutral media.,negative,sucralfate,gelusil
 DRUGOTHER  and  DRUGOTHER  reacts faster with  DRUG1  and  DRUGOTHER  in acidic media whereas with  DRUG2  in basic media and  DRUGOTHER  in neutral media.,negative,sucralfate,erythromycin
 DRUGOTHER  and  DRUGOTHER  reacts faster with  DRUG1  and  DRUGOTHER  in acidic media whereas with  DRUGOTHER  in basic media and  DRUG2  in neutral media.,negative,sucralfate,multi-minerals
 DRUGOTHER  and  DRUGOTHER  reacts faster with  DRUGOTHER  and  DRUG1  in acidic media whereas with  DRUG2  in basic media and  DRUGOTHER  in neutral media.,negative,gelusil,erythromycin
 DRUGOTHER  and  DRUGOTHER  reacts faster with  DRUGOTHER  and  DRUG1  in acidic media whereas with  DRUGOTHER  in basic media and  DRUG2  in neutral media.,negative,gelusil,multi-minerals
 DRUGOTHER  and  DRUGOTHER  reacts faster with  DRUGOTHER  and  DRUGOTHER  in acidic media whereas with  DRUG1  in basic media and  DRUG2  in neutral media.,negative,erythromycin,multi-minerals
 DRUG1  may interact with  DRUG2  or  DRUGOTHER  (causing too great a decrease in adrenal function).,int,Trilostane,aminoglutethimide
 DRUG1  may interact with  DRUGOTHER  or  DRUG2  (causing too great a decrease in adrenal function).,int,Trilostane,mitotane
 DRUGOTHER  may interact with  DRUG1  or  DRUG2  (causing too great a decrease in adrenal function).,negative,aminoglutethimide,mitotane
" DRUG1 : Spontaneous adverse reaction reports of patients taking concomitant  DRUG2  with recommended doses of  DRUGOTHER  demonstrate QT interval prolongation and rare serious cardiac events, e.g.",negative,Ketoconazole,ketoconazole
" DRUG1 : Spontaneous adverse reaction reports of patients taking concomitant  DRUGOTHER  with recommended doses of  DRUG2  demonstrate QT interval prolongation and rare serious cardiac events, e.g.",negative,Ketoconazole,terfenadine
" DRUGOTHER : Spontaneous adverse reaction reports of patients taking concomitant  DRUG1  with recommended doses of  DRUG2  demonstrate QT interval prolongation and rare serious cardiac events, e.g.",effect,ketoconazole,terfenadine
"Pharmacokinetic data indicate that  DRUG1  markedly inhibits the metabolism of  DRUG2 , resulting in elevated plasma  DRUGOTHER  levels.",mechanism,ketoconazole,terfenadine
"Pharmacokinetic data indicate that  DRUG1  markedly inhibits the metabolism of  DRUGOTHER , resulting in elevated plasma  DRUG2  levels.",negative,ketoconazole,terfenadine
"Pharmacokinetic data indicate that  DRUGOTHER  markedly inhibits the metabolism of  DRUG1 , resulting in elevated plasma  DRUG2  levels.",negative,terfenadine,terfenadine
Concomitant administration of  DRUG1  and  DRUG2  is contraindicated.,advise,ketoconazole,terfenadine
 DRUG1 : Torsades de pointes and elevated parent  DRUG2  levels have been reported during concomitant use of  DRUGOTHER  and  DRUGOTHER  in clinical trials of  DRUGOTHER  and from foreign post-marketing sources.,negative,Itraconazole,terfenadine
 DRUG1 : Torsades de pointes and elevated parent  DRUGOTHER  levels have been reported during concomitant use of  DRUG2  and  DRUGOTHER  in clinical trials of  DRUGOTHER  and from foreign post-marketing sources.,negative,Itraconazole,terfenadine
 DRUG1 : Torsades de pointes and elevated parent  DRUGOTHER  levels have been reported during concomitant use of  DRUGOTHER  and  DRUG2  in clinical trials of  DRUGOTHER  and from foreign post-marketing sources.,negative,Itraconazole,itraconazole
 DRUG1 : Torsades de pointes and elevated parent  DRUGOTHER  levels have been reported during concomitant use of  DRUGOTHER  and  DRUGOTHER  in clinical trials of  DRUG2  and from foreign post-marketing sources.,negative,Itraconazole,itraconazole
 DRUGOTHER : Torsades de pointes and elevated parent  DRUG1  levels have been reported during concomitant use of  DRUG2  and  DRUGOTHER  in clinical trials of  DRUGOTHER  and from foreign post-marketing sources.,negative,terfenadine,terfenadine
 DRUGOTHER : Torsades de pointes and elevated parent  DRUG1  levels have been reported during concomitant use of  DRUGOTHER  and  DRUG2  in clinical trials of  DRUGOTHER  and from foreign post-marketing sources.,negative,terfenadine,itraconazole
 DRUGOTHER : Torsades de pointes and elevated parent  DRUG1  levels have been reported during concomitant use of  DRUGOTHER  and  DRUGOTHER  in clinical trials of  DRUG2  and from foreign post-marketing sources.,negative,terfenadine,itraconazole
 DRUGOTHER : Torsades de pointes and elevated parent  DRUGOTHER  levels have been reported during concomitant use of  DRUG1  and  DRUG2  in clinical trials of  DRUGOTHER  and from foreign post-marketing sources.,mechanism,terfenadine,itraconazole
 DRUGOTHER : Torsades de pointes and elevated parent  DRUGOTHER  levels have been reported during concomitant use of  DRUG1  and  DRUGOTHER  in clinical trials of  DRUG2  and from foreign post-marketing sources.,negative,terfenadine,itraconazole
 DRUGOTHER : Torsades de pointes and elevated parent  DRUGOTHER  levels have been reported during concomitant use of  DRUGOTHER  and  DRUG1  in clinical trials of  DRUG2  and from foreign post-marketing sources.,negative,itraconazole,itraconazole
Concomitant administration of  DRUG1  and  DRUG2  is contraindicated.,advise,itraconazole,terfenadine
"Due to the chemical similarity of other  DRUG1  (including  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) to  DRUGOTHER , and  DRUGOTHER , concomitant use of these products with  DRUGOTHER  is not recommended pending full examination of potential interactions.",negative,azole-type antifungal agents,fluconazole
"Due to the chemical similarity of other  DRUG1  (including  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) to  DRUGOTHER , and  DRUGOTHER , concomitant use of these products with  DRUGOTHER  is not recommended pending full examination of potential interactions.",negative,azole-type antifungal agents,metronidazole
"Due to the chemical similarity of other  DRUG1  (including  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) to  DRUGOTHER , and  DRUGOTHER , concomitant use of these products with  DRUGOTHER  is not recommended pending full examination of potential interactions.",negative,azole-type antifungal agents,miconazole
"Due to the chemical similarity of other  DRUG1  (including  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) to  DRUG2 , and  DRUGOTHER , concomitant use of these products with  DRUGOTHER  is not recommended pending full examination of potential interactions.",negative,azole-type antifungal agents,ketoconazole
"Due to the chemical similarity of other  DRUG1  (including  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) to  DRUGOTHER , and  DRUG2 , concomitant use of these products with  DRUGOTHER  is not recommended pending full examination of potential interactions.",negative,azole-type antifungal agents,itraconazole
"Due to the chemical similarity of other  DRUG1  (including  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) to  DRUGOTHER , and  DRUGOTHER , concomitant use of these products with  DRUG2  is not recommended pending full examination of potential interactions.",advise,azole-type antifungal agents,terfenadine
"Due to the chemical similarity of other  DRUGOTHER  (including  DRUG1 ,  DRUG2 , and  DRUGOTHER ) to  DRUGOTHER , and  DRUGOTHER , concomitant use of these products with  DRUGOTHER  is not recommended pending full examination of potential interactions.",negative,fluconazole,metronidazole
"Due to the chemical similarity of other  DRUGOTHER  (including  DRUG1 ,  DRUGOTHER , and  DRUG2 ) to  DRUGOTHER , and  DRUGOTHER , concomitant use of these products with  DRUGOTHER  is not recommended pending full examination of potential interactions.",negative,fluconazole,miconazole
"Due to the chemical similarity of other  DRUGOTHER  (including  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ) to  DRUG2 , and  DRUGOTHER , concomitant use of these products with  DRUGOTHER  is not recommended pending full examination of potential interactions.",negative,fluconazole,ketoconazole
"Due to the chemical similarity of other  DRUGOTHER  (including  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ) to  DRUGOTHER , and  DRUG2 , concomitant use of these products with  DRUGOTHER  is not recommended pending full examination of potential interactions.",negative,fluconazole,itraconazole
"Due to the chemical similarity of other  DRUGOTHER  (including  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ) to  DRUGOTHER , and  DRUGOTHER , concomitant use of these products with  DRUG2  is not recommended pending full examination of potential interactions.",advise,fluconazole,terfenadine
"Due to the chemical similarity of other  DRUGOTHER  (including  DRUGOTHER ,  DRUG1 , and  DRUG2 ) to  DRUGOTHER , and  DRUGOTHER , concomitant use of these products with  DRUGOTHER  is not recommended pending full examination of potential interactions.",negative,metronidazole,miconazole
"Due to the chemical similarity of other  DRUGOTHER  (including  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ) to  DRUG2 , and  DRUGOTHER , concomitant use of these products with  DRUGOTHER  is not recommended pending full examination of potential interactions.",negative,metronidazole,ketoconazole
"Due to the chemical similarity of other  DRUGOTHER  (including  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ) to  DRUGOTHER , and  DRUG2 , concomitant use of these products with  DRUGOTHER  is not recommended pending full examination of potential interactions.",negative,metronidazole,itraconazole
"Due to the chemical similarity of other  DRUGOTHER  (including  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ) to  DRUGOTHER , and  DRUGOTHER , concomitant use of these products with  DRUG2  is not recommended pending full examination of potential interactions.",advise,metronidazole,terfenadine
"Due to the chemical similarity of other  DRUGOTHER  (including  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ) to  DRUG2 , and  DRUGOTHER , concomitant use of these products with  DRUGOTHER  is not recommended pending full examination of potential interactions.",negative,miconazole,ketoconazole
"Due to the chemical similarity of other  DRUGOTHER  (including  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ) to  DRUGOTHER , and  DRUG2 , concomitant use of these products with  DRUGOTHER  is not recommended pending full examination of potential interactions.",negative,miconazole,itraconazole
"Due to the chemical similarity of other  DRUGOTHER  (including  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ) to  DRUGOTHER , and  DRUGOTHER , concomitant use of these products with  DRUG2  is not recommended pending full examination of potential interactions.",advise,miconazole,terfenadine
"Due to the chemical similarity of other  DRUGOTHER  (including  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) to  DRUG1 , and  DRUG2 , concomitant use of these products with  DRUGOTHER  is not recommended pending full examination of potential interactions.",negative,ketoconazole,itraconazole
"Due to the chemical similarity of other  DRUGOTHER  (including  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) to  DRUG1 , and  DRUGOTHER , concomitant use of these products with  DRUG2  is not recommended pending full examination of potential interactions.",negative,ketoconazole,terfenadine
"Due to the chemical similarity of other  DRUGOTHER  (including  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) to  DRUGOTHER , and  DRUG1 , concomitant use of these products with  DRUG2  is not recommended pending full examination of potential interactions.",negative,itraconazole,terfenadine
" DRUG1 : Clinical drug interaction studies indicate that  DRUG2  and  DRUGOTHER  can exert an effect on  DRUGOTHER  metabolism by a mechanism which may be similar to that of  DRUGOTHER , but to a lesser extent.",negative,Macrolides,erythromycin
" DRUG1 : Clinical drug interaction studies indicate that  DRUGOTHER  and  DRUG2  can exert an effect on  DRUGOTHER  metabolism by a mechanism which may be similar to that of  DRUGOTHER , but to a lesser extent.",negative,Macrolides,clarithromycin
" DRUG1 : Clinical drug interaction studies indicate that  DRUGOTHER  and  DRUGOTHER  can exert an effect on  DRUG2  metabolism by a mechanism which may be similar to that of  DRUGOTHER , but to a lesser extent.",negative,Macrolides,terfenadine
" DRUG1 : Clinical drug interaction studies indicate that  DRUGOTHER  and  DRUGOTHER  can exert an effect on  DRUGOTHER  metabolism by a mechanism which may be similar to that of  DRUG2 , but to a lesser extent.",negative,Macrolides,ketoconazole
" DRUGOTHER : Clinical drug interaction studies indicate that  DRUG1  and  DRUG2  can exert an effect on  DRUGOTHER  metabolism by a mechanism which may be similar to that of  DRUGOTHER , but to a lesser extent.",negative,erythromycin,clarithromycin
" DRUGOTHER : Clinical drug interaction studies indicate that  DRUG1  and  DRUGOTHER  can exert an effect on  DRUG2  metabolism by a mechanism which may be similar to that of  DRUGOTHER , but to a lesser extent.",mechanism,erythromycin,terfenadine
" DRUGOTHER : Clinical drug interaction studies indicate that  DRUG1  and  DRUGOTHER  can exert an effect on  DRUGOTHER  metabolism by a mechanism which may be similar to that of  DRUG2 , but to a lesser extent.",negative,erythromycin,ketoconazole
" DRUGOTHER : Clinical drug interaction studies indicate that  DRUGOTHER  and  DRUG1  can exert an effect on  DRUG2  metabolism by a mechanism which may be similar to that of  DRUGOTHER , but to a lesser extent.",mechanism,clarithromycin,terfenadine
" DRUGOTHER : Clinical drug interaction studies indicate that  DRUGOTHER  and  DRUG1  can exert an effect on  DRUGOTHER  metabolism by a mechanism which may be similar to that of  DRUG2 , but to a lesser extent.",negative,clarithromycin,ketoconazole
" DRUGOTHER : Clinical drug interaction studies indicate that  DRUGOTHER  and  DRUGOTHER  can exert an effect on  DRUG1  metabolism by a mechanism which may be similar to that of  DRUG2 , but to a lesser extent.",negative,terfenadine,ketoconazole
"A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving  DRUG1  or  DRUG2 .",negative,erythromycin,troleandomycin
"Concomitant administration of  DRUG1  with  DRUG2 ,  DRUGOTHER , or  DRUGOTHER  is contraindicated: Pending full characterization of potential interactions, concomitant administration of  DRUGOTHER  with other  DRUGOTHER , including  DRUGOTHER , is not recommended.",advise,terfenadine,clarithromycin
"Concomitant administration of  DRUG1  with  DRUGOTHER ,  DRUG2 , or  DRUGOTHER  is contraindicated: Pending full characterization of potential interactions, concomitant administration of  DRUGOTHER  with other  DRUGOTHER , including  DRUGOTHER , is not recommended.",advise,terfenadine,erythromycin
"Concomitant administration of  DRUG1  with  DRUGOTHER ,  DRUGOTHER , or  DRUG2  is contraindicated: Pending full characterization of potential interactions, concomitant administration of  DRUGOTHER  with other  DRUGOTHER , including  DRUGOTHER , is not recommended.",advise,terfenadine,troleandomycin
"Concomitant administration of  DRUG1  with  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  is contraindicated: Pending full characterization of potential interactions, concomitant administration of  DRUG2  with other  DRUGOTHER , including  DRUGOTHER , is not recommended.",negative,terfenadine,terfenadine
"Concomitant administration of  DRUG1  with  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  is contraindicated: Pending full characterization of potential interactions, concomitant administration of  DRUGOTHER  with other  DRUG2 , including  DRUGOTHER , is not recommended.",negative,terfenadine,macrolide antibiotics
"Concomitant administration of  DRUG1  with  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  is contraindicated: Pending full characterization of potential interactions, concomitant administration of  DRUGOTHER  with other  DRUGOTHER , including  DRUG2 , is not recommended.",negative,terfenadine,azithromycin
"Concomitant administration of  DRUGOTHER  with  DRUG1 ,  DRUG2 , or  DRUGOTHER  is contraindicated: Pending full characterization of potential interactions, concomitant administration of  DRUGOTHER  with other  DRUGOTHER , including  DRUGOTHER , is not recommended.",negative,clarithromycin,erythromycin
"Concomitant administration of  DRUGOTHER  with  DRUG1 ,  DRUGOTHER , or  DRUG2  is contraindicated: Pending full characterization of potential interactions, concomitant administration of  DRUGOTHER  with other  DRUGOTHER , including  DRUGOTHER , is not recommended.",negative,clarithromycin,troleandomycin
"Concomitant administration of  DRUGOTHER  with  DRUG1 ,  DRUGOTHER , or  DRUGOTHER  is contraindicated: Pending full characterization of potential interactions, concomitant administration of  DRUG2  with other  DRUGOTHER , including  DRUGOTHER , is not recommended.",negative,clarithromycin,terfenadine
"Concomitant administration of  DRUGOTHER  with  DRUG1 ,  DRUGOTHER , or  DRUGOTHER  is contraindicated: Pending full characterization of potential interactions, concomitant administration of  DRUGOTHER  with other  DRUG2 , including  DRUGOTHER , is not recommended.",negative,clarithromycin,macrolide antibiotics
"Concomitant administration of  DRUGOTHER  with  DRUG1 ,  DRUGOTHER , or  DRUGOTHER  is contraindicated: Pending full characterization of potential interactions, concomitant administration of  DRUGOTHER  with other  DRUGOTHER , including  DRUG2 , is not recommended.",negative,clarithromycin,azithromycin
"Concomitant administration of  DRUGOTHER  with  DRUGOTHER ,  DRUG1 , or  DRUG2  is contraindicated: Pending full characterization of potential interactions, concomitant administration of  DRUGOTHER  with other  DRUGOTHER , including  DRUGOTHER , is not recommended.",negative,erythromycin,troleandomycin
"Concomitant administration of  DRUGOTHER  with  DRUGOTHER ,  DRUG1 , or  DRUGOTHER  is contraindicated: Pending full characterization of potential interactions, concomitant administration of  DRUG2  with other  DRUGOTHER , including  DRUGOTHER , is not recommended.",negative,erythromycin,terfenadine
"Concomitant administration of  DRUGOTHER  with  DRUGOTHER ,  DRUG1 , or  DRUGOTHER  is contraindicated: Pending full characterization of potential interactions, concomitant administration of  DRUGOTHER  with other  DRUG2 , including  DRUGOTHER , is not recommended.",negative,erythromycin,macrolide antibiotics
"Concomitant administration of  DRUGOTHER  with  DRUGOTHER ,  DRUG1 , or  DRUGOTHER  is contraindicated: Pending full characterization of potential interactions, concomitant administration of  DRUGOTHER  with other  DRUGOTHER , including  DRUG2 , is not recommended.",negative,erythromycin,azithromycin
"Concomitant administration of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER , or  DRUG1  is contraindicated: Pending full characterization of potential interactions, concomitant administration of  DRUG2  with other  DRUGOTHER , including  DRUGOTHER , is not recommended.",negative,troleandomycin,terfenadine
"Concomitant administration of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER , or  DRUG1  is contraindicated: Pending full characterization of potential interactions, concomitant administration of  DRUGOTHER  with other  DRUG2 , including  DRUGOTHER , is not recommended.",negative,troleandomycin,macrolide antibiotics
"Concomitant administration of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER , or  DRUG1  is contraindicated: Pending full characterization of potential interactions, concomitant administration of  DRUGOTHER  with other  DRUGOTHER , including  DRUG2 , is not recommended.",negative,troleandomycin,azithromycin
"Concomitant administration of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  is contraindicated: Pending full characterization of potential interactions, concomitant administration of  DRUG1  with other  DRUG2 , including  DRUGOTHER , is not recommended.",advise,terfenadine,macrolide antibiotics
"Concomitant administration of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  is contraindicated: Pending full characterization of potential interactions, concomitant administration of  DRUG1  with other  DRUGOTHER , including  DRUG2 , is not recommended.",advise,terfenadine,azithromycin
"Concomitant administration of  DRUGOTHER  with  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER  is contraindicated: Pending full characterization of potential interactions, concomitant administration of  DRUGOTHER  with other  DRUG1 , including  DRUG2 , is not recommended.",negative,macrolide antibiotics,azithromycin
Studies to evaluate potential interactions of  DRUG1  with  DRUG2  are in progress.,negative,terfenadine,azithromycin
"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when  DRUG1  is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ).",advise,midazolam,azole antimycotics
"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when  DRUG1  is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ).",advise,midazolam,protease inhibitors
"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when  DRUG1  is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ).",advise,midazolam,calcium channel antagonists
"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when  DRUG1  is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ).",advise,midazolam,macrolide antibiotics
"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when  DRUGOTHER  is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ).",negative,azole antimycotics,protease inhibitors
"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when  DRUGOTHER  is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ).",negative,azole antimycotics,calcium channel antagonists
"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when  DRUGOTHER  is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ).",negative,azole antimycotics,macrolide antibiotics
"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when  DRUGOTHER  is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER ).",negative,protease inhibitors,calcium channel antagonists
"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when  DRUGOTHER  is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 ).",negative,protease inhibitors,macrolide antibiotics
"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when  DRUGOTHER  is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 ).",negative,calcium channel antagonists,macrolide antibiotics
"Drugs such as  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  were shown to significantly increase the C max and AUC of orally administered  DRUGOTHER .",negative,erythromycin,diltiazem
"Drugs such as  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  were shown to significantly increase the C max and AUC of orally administered  DRUGOTHER .",negative,erythromycin,verapamil
"Drugs such as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  were shown to significantly increase the C max and AUC of orally administered  DRUGOTHER .",negative,erythromycin,ketoconazole
"Drugs such as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  were shown to significantly increase the C max and AUC of orally administered  DRUGOTHER .",negative,erythromycin,fluconazole
"Drugs such as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  were shown to significantly increase the C max and AUC of orally administered  DRUGOTHER .",negative,erythromycin,itraconazole
"Drugs such as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  were shown to significantly increase the C max and AUC of orally administered  DRUG2 .",mechanism,erythromycin,midazolam
"Drugs such as  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  were shown to significantly increase the C max and AUC of orally administered  DRUGOTHER .",negative,diltiazem,verapamil
"Drugs such as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  were shown to significantly increase the C max and AUC of orally administered  DRUGOTHER .",negative,diltiazem,ketoconazole
"Drugs such as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  were shown to significantly increase the C max and AUC of orally administered  DRUGOTHER .",negative,diltiazem,fluconazole
"Drugs such as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  were shown to significantly increase the C max and AUC of orally administered  DRUGOTHER .",negative,diltiazem,itraconazole
"Drugs such as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  were shown to significantly increase the C max and AUC of orally administered  DRUG2 .",mechanism,diltiazem,midazolam
"Drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  were shown to significantly increase the C max and AUC of orally administered  DRUGOTHER .",negative,verapamil,ketoconazole
"Drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  were shown to significantly increase the C max and AUC of orally administered  DRUGOTHER .",negative,verapamil,fluconazole
"Drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  were shown to significantly increase the C max and AUC of orally administered  DRUGOTHER .",negative,verapamil,itraconazole
"Drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  were shown to significantly increase the C max and AUC of orally administered  DRUG2 .",mechanism,verapamil,midazolam
"Drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  and  DRUGOTHER  were shown to significantly increase the C max and AUC of orally administered  DRUGOTHER .",negative,ketoconazole,fluconazole
"Drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUG2  were shown to significantly increase the C max and AUC of orally administered  DRUGOTHER .",negative,ketoconazole,itraconazole
"Drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER  were shown to significantly increase the C max and AUC of orally administered  DRUG2 .",mechanism,ketoconazole,midazolam
"Drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUG2  were shown to significantly increase the C max and AUC of orally administered  DRUGOTHER .",negative,fluconazole,itraconazole
"Drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER  were shown to significantly increase the C max and AUC of orally administered  DRUG2 .",mechanism,fluconazole,midazolam
"Drugs such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1  were shown to significantly increase the C max and AUC of orally administered  DRUG2 .",mechanism,itraconazole,midazolam
"Although not studied, the potent cytochrome P450 3A4 inhibitors  DRUG1  and  DRUG2  may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of  DRUGOTHER .",negative,ritonavir,nelfinavir
"Although not studied, the potent cytochrome P450 3A4 inhibitors  DRUG1  and  DRUGOTHER  may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of  DRUG2 .",mechanism,ritonavir,midazolam
"Although not studied, the potent cytochrome P450 3A4 inhibitors  DRUGOTHER  and  DRUG1  may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of  DRUG2 .",mechanism,nelfinavir,midazolam
"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as  DRUG1 ,  DRUG2 , and  DRUGOTHER , induce metabolism and caused a markedly decreased C max and AUC of oral  DRUGOTHER  in adult studies.",negative,rifampin,carbamazepine
"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as  DRUG1 ,  DRUGOTHER , and  DRUG2 , induce metabolism and caused a markedly decreased C max and AUC of oral  DRUGOTHER  in adult studies.",negative,rifampin,phenytoin
"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as  DRUG1 ,  DRUGOTHER , and  DRUGOTHER , induce metabolism and caused a markedly decreased C max and AUC of oral  DRUG2  in adult studies.",mechanism,rifampin,midazolam
"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as  DRUGOTHER ,  DRUG1 , and  DRUG2 , induce metabolism and caused a markedly decreased C max and AUC of oral  DRUGOTHER  in adult studies.",negative,carbamazepine,phenytoin
"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as  DRUGOTHER ,  DRUG1 , and  DRUGOTHER , induce metabolism and caused a markedly decreased C max and AUC of oral  DRUG2  in adult studies.",mechanism,carbamazepine,midazolam
"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as  DRUGOTHER ,  DRUGOTHER , and  DRUG1 , induce metabolism and caused a markedly decreased C max and AUC of oral  DRUG2  in adult studies.",mechanism,phenytoin,midazolam
The difficulty in achieving adequate sedation may have been the result of decreased absorption of the  DRUG1  due to both the gastrointestinal effects and stimulant effects of  DRUG2 .,negative,sedatives,methylphenidate
"The sedative effect of  DRUG1  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUG2  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",effect,VERSED Syrup,narcotics
"The sedative effect of  DRUG1  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",effect,VERSED Syrup,morphine
"The sedative effect of  DRUG1  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",effect,VERSED Syrup,meperidine
"The sedative effect of  DRUG1  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",effect,VERSED Syrup,fentanyl
"The sedative effect of  DRUG1  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",effect,VERSED Syrup,propofol
"The sedative effect of  DRUG1  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",effect,VERSED Syrup,ketamine
"The sedative effect of  DRUG1  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER .",effect,VERSED Syrup,nitrous oxide
"The sedative effect of  DRUG1  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER .",effect,VERSED Syrup,secobarbital
"The sedative effect of  DRUG1  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 .",effect,VERSED Syrup,droperidol
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUG1  (eg,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",negative,narcotics,morphine
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUG1  (eg,  DRUGOTHER ,  DRUG2  and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",negative,narcotics,meperidine
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",negative,narcotics,fentanyl
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",negative,narcotics,propofol
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",negative,narcotics,ketamine
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER .",negative,narcotics,nitrous oxide
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER .",negative,narcotics,secobarbital
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUG1  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 .",negative,narcotics,droperidol
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUG1 ,  DRUG2  and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",negative,morphine,meperidine
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER  and  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",negative,morphine,fentanyl
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",negative,morphine,propofol
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",negative,morphine,ketamine
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER .",negative,morphine,nitrous oxide
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER .",negative,morphine,secobarbital
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 .",negative,morphine,droperidol
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1  and  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",negative,meperidine,fentanyl
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",negative,meperidine,propofol
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",negative,meperidine,ketamine
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER .",negative,meperidine,nitrous oxide
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER .",negative,meperidine,secobarbital
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUG1  and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 .",negative,meperidine,droperidol
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",negative,fentanyl,propofol
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",negative,fentanyl,ketamine
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER .",negative,fentanyl,nitrous oxide
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER .",negative,fentanyl,secobarbital
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 .",negative,fentanyl,droperidol
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ),  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",negative,propofol,ketamine
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER .",negative,propofol,nitrous oxide
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER .",negative,propofol,secobarbital
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 .",negative,propofol,droperidol
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER .",negative,ketamine,nitrous oxide
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER .",negative,ketamine,secobarbital
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 .",negative,ketamine,droperidol
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  and  DRUGOTHER .",negative,nitrous oxide,secobarbital
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUG2 .",negative,nitrous oxide,droperidol
"The sedative effect of  DRUGOTHER  is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly  DRUGOTHER  (eg,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUG2 .",negative,secobarbital,droperidol
"No significant adverse interactions with common premedications (such as  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other  DRUGOTHER ) or local  DRUGOTHER  have been observed.",negative,atropine,scopolamine
"No significant adverse interactions with common premedications (such as  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other  DRUGOTHER ) or local  DRUGOTHER  have been observed.",negative,atropine,glycopyrrolate
"No significant adverse interactions with common premedications (such as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other  DRUGOTHER ) or local  DRUGOTHER  have been observed.",negative,atropine,diazepam
"No significant adverse interactions with common premedications (such as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other  DRUGOTHER ) or local  DRUGOTHER  have been observed.",negative,atropine,hydroxyzine
"No significant adverse interactions with common premedications (such as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other  DRUG2 ) or local  DRUGOTHER  have been observed.",negative,atropine,muscle relaxants
"No significant adverse interactions with common premedications (such as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other  DRUGOTHER ) or local  DRUG2  have been observed.",negative,atropine,anesthetics
"No significant adverse interactions with common premedications (such as  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and other  DRUGOTHER ) or local  DRUGOTHER  have been observed.",negative,scopolamine,glycopyrrolate
"No significant adverse interactions with common premedications (such as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and other  DRUGOTHER ) or local  DRUGOTHER  have been observed.",negative,scopolamine,diazepam
"No significant adverse interactions with common premedications (such as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and other  DRUGOTHER ) or local  DRUGOTHER  have been observed.",negative,scopolamine,hydroxyzine
"No significant adverse interactions with common premedications (such as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other  DRUG2 ) or local  DRUGOTHER  have been observed.",negative,scopolamine,muscle relaxants
"No significant adverse interactions with common premedications (such as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other  DRUGOTHER ) or local  DRUG2  have been observed.",negative,scopolamine,anesthetics
"No significant adverse interactions with common premedications (such as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and other  DRUGOTHER ) or local  DRUGOTHER  have been observed.",negative,glycopyrrolate,diazepam
"No significant adverse interactions with common premedications (such as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and other  DRUGOTHER ) or local  DRUGOTHER  have been observed.",negative,glycopyrrolate,hydroxyzine
"No significant adverse interactions with common premedications (such as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and other  DRUG2 ) or local  DRUGOTHER  have been observed.",negative,glycopyrrolate,muscle relaxants
"No significant adverse interactions with common premedications (such as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and other  DRUGOTHER ) or local  DRUG2  have been observed.",negative,glycopyrrolate,anesthetics
"No significant adverse interactions with common premedications (such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and other  DRUGOTHER ) or local  DRUGOTHER  have been observed.",negative,diazepam,hydroxyzine
"No significant adverse interactions with common premedications (such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and other  DRUG2 ) or local  DRUGOTHER  have been observed.",negative,diazepam,muscle relaxants
"No significant adverse interactions with common premedications (such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and other  DRUGOTHER ) or local  DRUG2  have been observed.",negative,diazepam,anesthetics
"No significant adverse interactions with common premedications (such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and other  DRUG2 ) or local  DRUGOTHER  have been observed.",negative,hydroxyzine,muscle relaxants
"No significant adverse interactions with common premedications (such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and other  DRUGOTHER ) or local  DRUG2  have been observed.",negative,hydroxyzine,anesthetics
"No significant adverse interactions with common premedications (such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and other  DRUG1 ) or local  DRUG2  have been observed.",negative,muscle relaxants,anesthetics
Caution should be observed in administering  DRUG1  to patients receiving  DRUG2  or  DRUGOTHER  because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.,advise,DEMSER,phenothiazines
Caution should be observed in administering  DRUG1  to patients receiving  DRUGOTHER  or  DRUG2  because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.,advise,DEMSER,haloperidol
Caution should be observed in administering  DRUGOTHER  to patients receiving  DRUG1  or  DRUG2  because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis.,negative,phenothiazines,haloperidol
Concurrent use of  DRUG1  with  DRUG2  or other  DRUGOTHER  can increase their sedative effects.,effect,DEMSER,alcohol
Concurrent use of  DRUG1  with  DRUGOTHER  or other  DRUG2  can increase their sedative effects.,effect,DEMSER,CNS depressants
Concurrent use of  DRUGOTHER  with  DRUG1  or other  DRUG2  can increase their sedative effects.,negative,alcohol,CNS depressants
Reduced absorption of  DRUG1  and  DRUG2  have been reported when those agents were administered concomitantly with  DRUGOTHER .,negative,folic acid,digoxin
Reduced absorption of  DRUG1  and  DRUGOTHER  have been reported when those agents were administered concomitantly with  DRUG2 .,mechanism,folic acid,sulfasalazine
Reduced absorption of  DRUGOTHER  and  DRUG1  have been reported when those agents were administered concomitantly with  DRUG2 .,mechanism,digoxin,sulfasalazine
"When daily doses of  DRUG1  2 g and weekly doses of  DRUG2  7.5 mg were coadministered to 15 rheumatoid arthritis patients in a drug-drug interaction study, the pharmacokinetic disposition of the drugs was not altered.",negative,sulfasalazine,methotrexate
Daily doses of  DRUG1  2 g (maximum 3 g) and weekly doses of  DRUG2  7.5 mg (maximum 15 mg) were administered alone or in combination to 310 rheumatoid arthritis patients in two controlled 52-week clinical studies.,negative,sulfasalazine,methotrexate
"In elderly patients concurrently receiving certain  DRUG1 , primarily  DRUG2 , an increased incidence of thrombopenia with purpura has been reported.",negative,diuretics,thiazides
It has been reported that  DRUG1  may prolong the prothrombin time in patients who are receiving the  DRUG2   DRUGOTHER .,negative,sulfamethoxazole,anticoagulant
It has been reported that  DRUG1  may prolong the prothrombin time in patients who are receiving the  DRUGOTHER   DRUG2 .,effect,sulfamethoxazole,warfarin
It has been reported that  DRUGOTHER  may prolong the prothrombin time in patients who are receiving the  DRUG1   DRUG2 .,negative,anticoagulant,warfarin
 DRUG1  may inhibit the hepatic metabolism of  DRUG2 .,mechanism,Sulfamethoxazole,phenytoin
"At a 1.6-g dose,  DRUG1  produced a slight but significant increase in the half-life of  DRUG2  but did not produce a corresponding decrease in the metabolic clearance rate.",mechanism,sulfamethoxazole,phenytoin
" DRUG1  can also displace  DRUG2  from plasma protein-binding sites, thus increasing free  DRUGOTHER  concentrations.",mechanism,Sulfonamides,methotrexate
" DRUG1  can also displace  DRUGOTHER  from plasma protein-binding sites, thus increasing free  DRUG2  concentrations.",negative,Sulfonamides,methotrexate
" DRUGOTHER  can also displace  DRUG1  from plasma protein-binding sites, thus increasing free  DRUG2  concentrations.",negative,methotrexate,methotrexate
"If  DRUG1  replacement is required, the  DRUG2  dose should be carefully adjusted.",negative,glucocorticoid,glucocorticoid
Limited published data indicate that  DRUG1  treatment increases cytochrome P450 (CP450) mediated  DRUG2  clearance in man.,mechanism,GH,antipyrine
"These data suggest that  DRUG1  administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",mechanism,GH,corticosteroids
"These data suggest that  DRUG1  administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",mechanism,GH,sex steroids
"These data suggest that  DRUG1  administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",mechanism,GH,anticonvulsants
"These data suggest that  DRUG1  administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",mechanism,GH,cyclosporin
"These data suggest that  DRUGOTHER  administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,corticosteroids,sex steroids
"These data suggest that  DRUGOTHER  administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,corticosteroids,anticonvulsants
"These data suggest that  DRUGOTHER  administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,corticosteroids,cyclosporin
"These data suggest that  DRUGOTHER  administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ).",negative,sex steroids,anticonvulsants
"These data suggest that  DRUGOTHER  administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ).",negative,sex steroids,cyclosporin
"These data suggest that  DRUGOTHER  administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ).",negative,anticonvulsants,cyclosporin
 DRUG1  enhances  DRUG2 -mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.,effect,Lapatinib,herceptin
"Although it was previously reported that  DRUG1  combined with  DRUG2  improved the progression-free survival rate compared with  DRUGOTHER  alone for patients with  DRUGOTHER -refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",effect,lapatinib,Herceptin
"Although it was previously reported that  DRUG1  combined with  DRUGOTHER  improved the progression-free survival rate compared with  DRUG2  alone for patients with  DRUGOTHER -refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",negative,lapatinib,lapatinib
"Although it was previously reported that  DRUG1  combined with  DRUGOTHER  improved the progression-free survival rate compared with  DRUGOTHER  alone for patients with  DRUG2 -refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",negative,lapatinib,Herceptin
"Although it was previously reported that  DRUGOTHER  combined with  DRUG1  improved the progression-free survival rate compared with  DRUG2  alone for patients with  DRUGOTHER -refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",negative,Herceptin,lapatinib
"Although it was previously reported that  DRUGOTHER  combined with  DRUG1  improved the progression-free survival rate compared with  DRUGOTHER  alone for patients with  DRUG2 -refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",negative,Herceptin,Herceptin
"Although it was previously reported that  DRUGOTHER  combined with  DRUGOTHER  improved the progression-free survival rate compared with  DRUG1  alone for patients with  DRUG2 -refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.",negative,lapatinib,Herceptin
"We evaluated how  DRUG1  interacts with  DRUG2  in HER2-positive breast cancer, with a particular focus on  DRUGOTHER -mediated antibody-dependent cellular cytotoxicity (ADCC).",negative,lapatinib,Herceptin
"We evaluated how  DRUG1  interacts with  DRUGOTHER  in HER2-positive breast cancer, with a particular focus on  DRUG2 -mediated antibody-dependent cellular cytotoxicity (ADCC).",negative,lapatinib,Herceptin
"We evaluated how  DRUGOTHER  interacts with  DRUG1  in HER2-positive breast cancer, with a particular focus on  DRUG2 -mediated antibody-dependent cellular cytotoxicity (ADCC).",negative,Herceptin,Herceptin
"In an in vitro assay,  DRUG1  induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of  DRUG2 -mediated ADCC.",effect,lapatinib,Herceptin
"Furthermore, we present a case report in which a second  DRUG1  treatment following  DRUG2  resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer.",effect,Herceptin,lapatinib
 DRUG1  may have the potential to convert  DRUG2 -refractory to  DRUGOTHER -sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.,negative,Lapatinib,Herceptin
 DRUG1  may have the potential to convert  DRUGOTHER -refractory to  DRUG2 -sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.,negative,Lapatinib,Herceptin
 DRUGOTHER  may have the potential to convert  DRUG1 -refractory to  DRUG2 -sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.,negative,Herceptin,Herceptin
"A multiple dose drug-drug interaction study demonstrated that  DRUG1  approximately doubled  DRUG2  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",mechanism,ketoconazole,paricalcitol
"A multiple dose drug-drug interaction study demonstrated that  DRUG1  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUG2  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,paricalcitol
"A multiple dose drug-drug interaction study demonstrated that  DRUG1  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUG2  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,ketoconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUG1  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUG2  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,paricalcitol
"A multiple dose drug-drug interaction study demonstrated that  DRUG1  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUG2  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,ketoconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUG1  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,atazanavir
"A multiple dose drug-drug interaction study demonstrated that  DRUG1  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,clarithromycin
"A multiple dose drug-drug interaction study demonstrated that  DRUG1  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,indinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUG1  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,itraconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUG1  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,nefazodone
"A multiple dose drug-drug interaction study demonstrated that  DRUG1  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUG1  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,ritonavir
"A multiple dose drug-drug interaction study demonstrated that  DRUG1  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,saquinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUG1  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER .",negative,ketoconazole,telithromycin
"A multiple dose drug-drug interaction study demonstrated that  DRUG1  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 .",negative,ketoconazole,voriconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUG1  AUC0-   . Since  DRUG2  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,paricalcitol
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUG1  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUG2  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,ketoconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUG1  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUG2  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,paricalcitol
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUG1  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUG2  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,ketoconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUG1  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,atazanavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUG1  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,clarithromycin
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUG1  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,indinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUG1  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,itraconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUG1  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,nefazodone
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUG1  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUG1  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,ritonavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUG1  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,saquinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUG1  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER .",negative,paricalcitol,telithromycin
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUG1  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 .",negative,paricalcitol,voriconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUG1  is partially metabolized by CYP3A and  DRUG2  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,ketoconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUG1  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUG2  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,paricalcitol
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUG1  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUG2  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,ketoconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUG1  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,atazanavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUG1  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,clarithromycin
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUG1  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,indinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUG1  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,itraconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUG1  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,nefazodone
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUG1  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUG1  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,ritonavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUG1  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER .",negative,paricalcitol,saquinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUG1  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER .",negative,paricalcitol,telithromycin
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUG1  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 .",negative,paricalcitol,voriconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUG1  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUG2  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,paricalcitol
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUG1  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUG2  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,ketoconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUG1  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,atazanavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUG1  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,clarithromycin
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUG1  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,indinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUG1  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,itraconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUG1  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,nefazodone
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUG1  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUG1  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,ritonavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUG1  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,saquinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUG1  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER .",negative,ketoconazole,telithromycin
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUG1  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 .",negative,ketoconazole,voriconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUG1  with  DRUG2  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",advise,paricalcitol,ketoconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUG1  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",advise,paricalcitol,atazanavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUG1  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",advise,paricalcitol,clarithromycin
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUG1  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",advise,paricalcitol,indinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUG1  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",advise,paricalcitol,itraconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUG1  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",advise,paricalcitol,nefazodone
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUG1  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",advise,paricalcitol,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUG1  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",advise,paricalcitol,ritonavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUG1  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER .",advise,paricalcitol,saquinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUG1  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER .",advise,paricalcitol,telithromycin
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUG1  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 .",advise,paricalcitol,voriconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUG1  and other strong P450 3A inhibitors including  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,atazanavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUG1  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,clarithromycin
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUG1  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,indinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUG1  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,itraconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUG1  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,nefazodone
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUG1  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUG1  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,ritonavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUG1  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER .",negative,ketoconazole,saquinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUG1  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER .",negative,ketoconazole,telithromycin
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUG1  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 .",negative,ketoconazole,voriconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,atazanavir,clarithromycin
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,atazanavir,indinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,atazanavir,itraconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,atazanavir,nefazodone
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,atazanavir,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,atazanavir,ritonavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER .",negative,atazanavir,saquinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER .",negative,atazanavir,telithromycin
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 .",negative,atazanavir,voriconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,clarithromycin,indinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,clarithromycin,itraconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,clarithromycin,nefazodone
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,clarithromycin,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,clarithromycin,ritonavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER .",negative,clarithromycin,saquinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER .",negative,clarithromycin,telithromycin
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 .",negative,clarithromycin,voriconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,indinavir,itraconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,indinavir,nefazodone
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,indinavir,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,indinavir,ritonavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER .",negative,indinavir,saquinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER .",negative,indinavir,telithromycin
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 .",negative,indinavir,voriconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,itraconazole,nefazodone
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,itraconazole,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,itraconazole,ritonavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER .",negative,itraconazole,saquinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER .",negative,itraconazole,telithromycin
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 .",negative,itraconazole,voriconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,nefazodone,nelfinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,nefazodone,ritonavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER .",negative,nefazodone,saquinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER .",negative,nefazodone,telithromycin
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 .",negative,nefazodone,voriconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER .",negative,nelfinavir,ritonavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER .",negative,nelfinavir,saquinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER .",negative,nelfinavir,telithromycin
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 .",negative,nelfinavir,voriconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER .",negative,ritonavir,saquinavir
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER .",negative,ritonavir,telithromycin
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 .",negative,ritonavir,voriconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  or  DRUGOTHER .",negative,saquinavir,telithromycin
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  or  DRUG2 .",negative,saquinavir,voriconazole
"A multiple dose drug-drug interaction study demonstrated that  DRUGOTHER  approximately doubled  DRUGOTHER  AUC0-   . Since  DRUGOTHER  is partially metabolized by CYP3A and  DRUGOTHER  le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing  DRUGOTHER  with  DRUGOTHER  and other strong P450 3A inhibitors including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  or  DRUG2 .",negative,telithromycin,voriconazole
"Dose adjustment of  DRUG1  Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as  DRUG2 .",advise,Zemplar,ketoconazole
"Drugs that impair intestinal absorption of  DRUG1 , such as  DRUG2 , may interfere with the absorption of  DRUGOTHER  Capsules.",mechanism,fat-soluble vitamins,cholestyramine
"Drugs that impair intestinal absorption of  DRUG1 , such as  DRUGOTHER , may interfere with the absorption of  DRUG2  Capsules.",negative,fat-soluble vitamins,Zemplar
"Drugs that impair intestinal absorption of  DRUGOTHER , such as  DRUG1 , may interfere with the absorption of  DRUG2  Capsules.",mechanism,cholestyramine,Zemplar
Enhancement of humoral immune responses to inactivated Newcastle disease and  DRUG1  by oral administration of  DRUG2  in chickens.,negative,avian influenza vaccines,ginseng stem-and-leaf saponins
The objective of this study was to evaluate the effect of oral administration of  DRUG1  ( DRUG2 ) on the humoral immune responses of chickens to inactivated ND and  DRUGOTHER   DRUGOTHER .,negative,ginseng stem-and-leaf saponins,GSLS
The objective of this study was to evaluate the effect of oral administration of  DRUG1  ( DRUGOTHER ) on the humoral immune responses of chickens to inactivated ND and  DRUGOTHER   DRUG2 .,negative,ginseng stem-and-leaf saponins,inactivated ND vaccines
The objective of this study was to evaluate the effect of oral administration of  DRUG1  ( DRUGOTHER ) on the humoral immune responses of chickens to inactivated ND and  DRUG2   DRUGOTHER .,negative,ginseng stem-and-leaf saponins,inactivated AI vaccines
The objective of this study was to evaluate the effect of oral administration of  DRUGOTHER  ( DRUG1 ) on the humoral immune responses of chickens to inactivated ND and  DRUGOTHER   DRUG2 .,negative,GSLS,inactivated ND vaccines
The objective of this study was to evaluate the effect of oral administration of  DRUGOTHER  ( DRUG1 ) on the humoral immune responses of chickens to inactivated ND and  DRUG2   DRUGOTHER .,negative,GSLS,inactivated AI vaccines
The objective of this study was to evaluate the effect of oral administration of  DRUGOTHER  ( DRUGOTHER ) on the humoral immune responses of chickens to inactivated ND and  DRUG2   DRUG1 .,negative,inactivated ND vaccines,inactivated AI vaccines
"In experiment 1, oral administration of  DRUG1  at a dose of 5 mg/kg of BW for 7 d on the immune response in chickens intramuscularly injected with  DRUG2  was evaluated.",negative,GSLS,inactivated ND vaccine
"In experiment 2, the same regimen of  DRUG1  was administered to chickens inoculated with  DRUG2 , and an enhanced serum antibody response to AI vaccination was also observed.",effect,GSLS,inactivated AI vaccines
"Considering the safety of  DRUG1 , because no adverse effect was found throughout the experiments,  DRUG2  may be a promising oral adjuvant to improve immunization in poultry.",negative,GSLS,GSLS
" DRUG1  may enhance the sedative effects of  DRUG2  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",effect,Triprolidine,central nervous system depressants
" DRUG1  may enhance the sedative effects of  DRUGOTHER  including  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",effect,Triprolidine,alcohol
" DRUG1  may enhance the sedative effects of  DRUGOTHER  including  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",effect,Triprolidine,barbiturates
" DRUG1  may enhance the sedative effects of  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",effect,Triprolidine,hypnotics
" DRUG1  may enhance the sedative effects of  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",effect,Triprolidine,narcotic analgesics
" DRUG1  may enhance the sedative effects of  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",effect,Triprolidine,sedatives
" DRUG1  may enhance the sedative effects of  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",effect,Triprolidine,tranquillisers
" DRUGOTHER  may enhance the sedative effects of  DRUG1  including  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,central nervous system depressants,alcohol
" DRUGOTHER  may enhance the sedative effects of  DRUG1  including  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,central nervous system depressants,barbiturates
" DRUGOTHER  may enhance the sedative effects of  DRUG1  including  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,central nervous system depressants,hypnotics
" DRUGOTHER  may enhance the sedative effects of  DRUG1  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,central nervous system depressants,narcotic analgesics
" DRUGOTHER  may enhance the sedative effects of  DRUG1  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,central nervous system depressants,sedatives
" DRUGOTHER  may enhance the sedative effects of  DRUG1  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,central nervous system depressants,tranquillisers
" DRUGOTHER  may enhance the sedative effects of  DRUGOTHER  including  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,alcohol,barbiturates
" DRUGOTHER  may enhance the sedative effects of  DRUGOTHER  including  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,alcohol,hypnotics
" DRUGOTHER  may enhance the sedative effects of  DRUGOTHER  including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,alcohol,narcotic analgesics
" DRUGOTHER  may enhance the sedative effects of  DRUGOTHER  including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,alcohol,sedatives
" DRUGOTHER  may enhance the sedative effects of  DRUGOTHER  including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,alcohol,tranquillisers
" DRUGOTHER  may enhance the sedative effects of  DRUGOTHER  including  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,barbiturates,hypnotics
" DRUGOTHER  may enhance the sedative effects of  DRUGOTHER  including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,barbiturates,narcotic analgesics
" DRUGOTHER  may enhance the sedative effects of  DRUGOTHER  including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,barbiturates,sedatives
" DRUGOTHER  may enhance the sedative effects of  DRUGOTHER  including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,barbiturates,tranquillisers
" DRUGOTHER  may enhance the sedative effects of  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,hypnotics,narcotic analgesics
" DRUGOTHER  may enhance the sedative effects of  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,hypnotics,sedatives
" DRUGOTHER  may enhance the sedative effects of  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,hypnotics,tranquillisers
" DRUGOTHER  may enhance the sedative effects of  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER .",negative,narcotic analgesics,sedatives
" DRUGOTHER  may enhance the sedative effects of  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 .",negative,narcotic analgesics,tranquillisers
" DRUGOTHER  may enhance the sedative effects of  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 .",negative,sedatives,tranquillisers
"The effects of  DRUG1 , such as  DRUG2  and  DRUGOTHER  may be enhanced by the concomitant administration of  DRUGOTHER .",negative,anticholinergic drugs,atropine
"The effects of  DRUG1 , such as  DRUGOTHER  and  DRUG2  may be enhanced by the concomitant administration of  DRUGOTHER .",negative,anticholinergic drugs,tricyclic antidepressants
"The effects of  DRUG1 , such as  DRUGOTHER  and  DRUGOTHER  may be enhanced by the concomitant administration of  DRUG2 .",effect,anticholinergic drugs,triprolidine
"The effects of  DRUGOTHER , such as  DRUG1  and  DRUG2  may be enhanced by the concomitant administration of  DRUGOTHER .",negative,atropine,tricyclic antidepressants
"The effects of  DRUGOTHER , such as  DRUG1  and  DRUGOTHER  may be enhanced by the concomitant administration of  DRUG2 .",effect,atropine,triprolidine
"The effects of  DRUGOTHER , such as  DRUGOTHER  and  DRUG1  may be enhanced by the concomitant administration of  DRUG2 .",effect,tricyclic antidepressants,triprolidine
"Since  DRUG1  is metabolized by a P450 enzyme system, drugs that induce or inhibit this drug metabolizing enzyme system may elicit important drug-drug interactions that may alter  DRUG2  plasma concentrations.",negative,trimetrexate,trimetrexate
"Agents that might be coadministered with  DRUG1  in AIDS patients for other indications that could elicit this activity include  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",effect,trimetrexate,erythromycin
"Agents that might be coadministered with  DRUG1  in AIDS patients for other indications that could elicit this activity include  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",effect,trimetrexate,rifampin
"Agents that might be coadministered with  DRUG1  in AIDS patients for other indications that could elicit this activity include  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",effect,trimetrexate,rifabutin
"Agents that might be coadministered with  DRUG1  in AIDS patients for other indications that could elicit this activity include  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",effect,trimetrexate,ketoconazole
"Agents that might be coadministered with  DRUG1  in AIDS patients for other indications that could elicit this activity include  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",effect,trimetrexate,fluconazole
"Agents that might be coadministered with  DRUGOTHER  in AIDS patients for other indications that could elicit this activity include  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,erythromycin,rifampin
"Agents that might be coadministered with  DRUGOTHER  in AIDS patients for other indications that could elicit this activity include  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,erythromycin,rifabutin
"Agents that might be coadministered with  DRUGOTHER  in AIDS patients for other indications that could elicit this activity include  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,erythromycin,ketoconazole
"Agents that might be coadministered with  DRUGOTHER  in AIDS patients for other indications that could elicit this activity include  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,erythromycin,fluconazole
"Agents that might be coadministered with  DRUGOTHER  in AIDS patients for other indications that could elicit this activity include  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,rifampin,rifabutin
"Agents that might be coadministered with  DRUGOTHER  in AIDS patients for other indications that could elicit this activity include  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,rifampin,ketoconazole
"Agents that might be coadministered with  DRUGOTHER  in AIDS patients for other indications that could elicit this activity include  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,rifampin,fluconazole
"Agents that might be coadministered with  DRUGOTHER  in AIDS patients for other indications that could elicit this activity include  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER .",negative,rifabutin,ketoconazole
"Agents that might be coadministered with  DRUGOTHER  in AIDS patients for other indications that could elicit this activity include  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 .",negative,rifabutin,fluconazole
"Agents that might be coadministered with  DRUGOTHER  in AIDS patients for other indications that could elicit this activity include  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 .",negative,ketoconazole,fluconazole
In vitro perfusion of isolated rat liver has shown that  DRUG1  caused a significant reduction in  DRUG2  metabolism and that  DRUGOTHER  altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.,mechanism,cimetidine,trimetrexate
In vitro perfusion of isolated rat liver has shown that  DRUG1  caused a significant reduction in  DRUGOTHER  metabolism and that  DRUG2  altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.,negative,cimetidine,acetaminophen
In vitro perfusion of isolated rat liver has shown that  DRUGOTHER  caused a significant reduction in  DRUG1  metabolism and that  DRUG2  altered the relative concentration of trimetrexate metabolites possibly by competing for sulfate metabolites.,negative,trimetrexate,acetaminophen
"Based on an in vitro rat liver model, nitrogen substituted  DRUG1  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) were potent, non-competitive inhibitors of  DRUGOTHER  metabolism.",negative,imidazole drugs,clotrimazole
"Based on an in vitro rat liver model, nitrogen substituted  DRUG1  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) were potent, non-competitive inhibitors of  DRUGOTHER  metabolism.",negative,imidazole drugs,ketoconazole
"Based on an in vitro rat liver model, nitrogen substituted  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) were potent, non-competitive inhibitors of  DRUGOTHER  metabolism.",negative,imidazole drugs,miconazole
"Based on an in vitro rat liver model, nitrogen substituted  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) were potent, non-competitive inhibitors of  DRUG2  metabolism.",mechanism,imidazole drugs,trimetrexate
"Based on an in vitro rat liver model, nitrogen substituted  DRUGOTHER  ( DRUG1 ,  DRUG2 ,  DRUGOTHER ) were potent, non-competitive inhibitors of  DRUGOTHER  metabolism.",negative,clotrimazole,ketoconazole
"Based on an in vitro rat liver model, nitrogen substituted  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUG2 ) were potent, non-competitive inhibitors of  DRUGOTHER  metabolism.",negative,clotrimazole,miconazole
"Based on an in vitro rat liver model, nitrogen substituted  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ) were potent, non-competitive inhibitors of  DRUG2  metabolism.",mechanism,clotrimazole,trimetrexate
"Based on an in vitro rat liver model, nitrogen substituted  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUG2 ) were potent, non-competitive inhibitors of  DRUGOTHER  metabolism.",negative,ketoconazole,miconazole
"Based on an in vitro rat liver model, nitrogen substituted  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ) were potent, non-competitive inhibitors of  DRUG2  metabolism.",mechanism,ketoconazole,trimetrexate
"Based on an in vitro rat liver model, nitrogen substituted  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ) were potent, non-competitive inhibitors of  DRUG2  metabolism.",mechanism,miconazole,trimetrexate
Improved parathyroid hormone control by  DRUG1  is associated with reduction in  DRUG2  requirement in patients with end-stage renal disease.,negative,cinacalcet,darbepoetin
"Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to  DRUG1  ( DRUG2 ) resistance.",negative,erythropoietin,EPO
"Medical treatment with  DRUG1  is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on  DRUG2  dosing is unknown.",negative,cinacalcet,darbepoetin
The primary objective of the study was to ascertain the difference in  DRUG1  responsiveness before and after 12 months of  DRUG2  therapy.,negative,darbepoetin,cinacalcet
Reduction of PTH by  DRUG1  is associated with a decrease in  DRUG2  requirement.,effect,cinacalcet,darbepoetin
" DRUG1  should be used with care in patients taking other drugs that are capable of causing CNS effects such as  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",advise,Scopolamine,sedatives
" DRUG1  should be used with care in patients taking other drugs that are capable of causing CNS effects such as  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",advise,Scopolamine,tranquilizers
" DRUG1  should be used with care in patients taking other drugs that are capable of causing CNS effects such as  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",advise,Scopolamine,alcohol
" DRUGOTHER  should be used with care in patients taking other drugs that are capable of causing CNS effects such as  DRUG1 ,  DRUG2 , or  DRUGOTHER .",negative,sedatives,tranquilizers
" DRUGOTHER  should be used with care in patients taking other drugs that are capable of causing CNS effects such as  DRUG1 ,  DRUGOTHER , or  DRUG2 .",negative,sedatives,alcohol
" DRUGOTHER  should be used with care in patients taking other drugs that are capable of causing CNS effects such as  DRUGOTHER ,  DRUG1 , or  DRUG2 .",negative,tranquilizers,alcohol
"e.g., other  DRUG1 ,  DRUG2  (including  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER .",negative,belladonna alkaloids,antihistamines
"e.g., other  DRUG1 ,  DRUGOTHER  (including  DRUG2 ),  DRUGOTHER , and  DRUGOTHER .",negative,belladonna alkaloids,meclizine
"e.g., other  DRUG1 ,  DRUGOTHER  (including  DRUGOTHER ),  DRUG2 , and  DRUGOTHER .",negative,belladonna alkaloids,tricyclic antidepressants
"e.g., other  DRUG1 ,  DRUGOTHER  (including  DRUGOTHER ),  DRUGOTHER , and  DRUG2 .",negative,belladonna alkaloids,muscle relaxants
"e.g., other  DRUGOTHER ,  DRUG1  (including  DRUG2 ),  DRUGOTHER , and  DRUGOTHER .",negative,antihistamines,meclizine
"e.g., other  DRUGOTHER ,  DRUG1  (including  DRUGOTHER ),  DRUG2 , and  DRUGOTHER .",negative,antihistamines,tricyclic antidepressants
"e.g., other  DRUGOTHER ,  DRUG1  (including  DRUGOTHER ),  DRUGOTHER , and  DRUG2 .",negative,antihistamines,muscle relaxants
"e.g., other  DRUGOTHER ,  DRUGOTHER  (including  DRUG1 ),  DRUG2 , and  DRUGOTHER .",negative,meclizine,tricyclic antidepressants
"e.g., other  DRUGOTHER ,  DRUGOTHER  (including  DRUG1 ),  DRUGOTHER , and  DRUG2 .",negative,meclizine,muscle relaxants
"e.g., other  DRUGOTHER ,  DRUGOTHER  (including  DRUGOTHER ),  DRUG1 , and  DRUG2 .",negative,tricyclic antidepressants,muscle relaxants
Distinct synergistic action of  DRUG1  and  DRUG2  against Pseudomonas aeruginosa.,negative,piperacillin,methylglyoxal
"Results revealed that the strains were resistant to many drugs at high levels, only  DRUG1 ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  showed resistances at comparatively lower levels.",negative,piperacillin,carbenicillin
"Results revealed that the strains were resistant to many drugs at high levels, only  DRUG1 ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  showed resistances at comparatively lower levels.",negative,piperacillin,amikacin
"Results revealed that the strains were resistant to many drugs at high levels, only  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  showed resistances at comparatively lower levels.",negative,piperacillin,ciprofloxacin
"Results revealed that the strains were resistant to many drugs at high levels, only  DRUGOTHER ,  DRUG1 ,  DRUG2  and  DRUGOTHER  showed resistances at comparatively lower levels.",negative,carbenicillin,amikacin
"Results revealed that the strains were resistant to many drugs at high levels, only  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUG2  showed resistances at comparatively lower levels.",negative,carbenicillin,ciprofloxacin
"Results revealed that the strains were resistant to many drugs at high levels, only  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUG2  showed resistances at comparatively lower levels.",negative,amikacin,ciprofloxacin
Distinct and statistically significant synergism was observed between  DRUG1  and  DRUG2  by disc diffusion tests when compared with their individual effects.,effect,methylglyoxal,piperacillin
Synergism was also noted when  DRUG1  was combined with  DRUG2  and  DRUGOTHER .,effect,methylglyoxal,carbenicillin
Synergism was also noted when  DRUG1  was combined with  DRUGOTHER  and  DRUG2 .,effect,methylglyoxal,amikacin
Synergism was also noted when  DRUGOTHER  was combined with  DRUG1  and  DRUG2 .,negative,carbenicillin,amikacin
" DRUG1  should be used with caution in digitalized patients, since the combination of  DRUG2  and  DRUGOTHER  may cause ectopic arrhythmias.",negative,ARAMINE,digitalis
" DRUG1  should be used with caution in digitalized patients, since the combination of  DRUGOTHER  and  DRUG2  may cause ectopic arrhythmias.",negative,ARAMINE,sympathomimetic amines
" DRUGOTHER  should be used with caution in digitalized patients, since the combination of  DRUG1  and  DRUG2  may cause ectopic arrhythmias.",effect,digitalis,sympathomimetic amines
 DRUG1  or  DRUG2  may potentiate the action of  DRUGOTHER .,negative,Monoamine oxidase inhibitors,tricyclic antidepressants
 DRUG1  or  DRUGOTHER  may potentiate the action of  DRUG2 .,effect,Monoamine oxidase inhibitors,sympathomimetic amines
 DRUGOTHER  or  DRUG1  may potentiate the action of  DRUG2 .,effect,tricyclic antidepressants,sympathomimetic amines
"Caution is advised for patients receiving high-dose  DRUG1  and  DRUG2  concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose  DRUGOTHER  and  DRUGOTHER .",advise,aspirin,methazolamide
"Caution is advised for patients receiving high-dose  DRUG1  and  DRUGOTHER  concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose  DRUG2  and  DRUGOTHER .",negative,aspirin,aspirin
"Caution is advised for patients receiving high-dose  DRUG1  and  DRUGOTHER  concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose  DRUGOTHER  and  DRUG2 .",negative,aspirin,carbonic anhydrase inhibitors
"Caution is advised for patients receiving high-dose  DRUGOTHER  and  DRUG1  concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose  DRUG2  and  DRUGOTHER .",negative,methazolamide,aspirin
"Caution is advised for patients receiving high-dose  DRUGOTHER  and  DRUG1  concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose  DRUGOTHER  and  DRUG2 .",negative,methazolamide,carbonic anhydrase inhibitors
"Caution is advised for patients receiving high-dose  DRUGOTHER  and  DRUGOTHER  concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose  DRUG1  and  DRUG2 .",effect,aspirin,carbonic anhydrase inhibitors
" DRUG1  may be used with  DRUG2 ,  DRUGOTHER  and other  DRUGOTHER , and with other  DRUGOTHER .",negative,Pyrimethamine,sulfonamides
" DRUG1  may be used with  DRUGOTHER ,  DRUG2  and other  DRUGOTHER , and with other  DRUGOTHER .",negative,Pyrimethamine,quinine
" DRUG1  may be used with  DRUGOTHER ,  DRUGOTHER  and other  DRUG2 , and with other  DRUGOTHER .",negative,Pyrimethamine,antimalarials
" DRUG1  may be used with  DRUGOTHER ,  DRUGOTHER  and other  DRUGOTHER , and with other  DRUG2 .",negative,Pyrimethamine,antibiotics
" DRUGOTHER  may be used with  DRUG1 ,  DRUG2  and other  DRUGOTHER , and with other  DRUGOTHER .",negative,sulfonamides,quinine
" DRUGOTHER  may be used with  DRUG1 ,  DRUGOTHER  and other  DRUG2 , and with other  DRUGOTHER .",negative,sulfonamides,antimalarials
" DRUGOTHER  may be used with  DRUG1 ,  DRUGOTHER  and other  DRUGOTHER , and with other  DRUG2 .",negative,sulfonamides,antibiotics
" DRUGOTHER  may be used with  DRUGOTHER ,  DRUG1  and other  DRUG2 , and with other  DRUGOTHER .",negative,quinine,antimalarials
" DRUGOTHER  may be used with  DRUGOTHER ,  DRUG1  and other  DRUGOTHER , and with other  DRUG2 .",negative,quinine,antibiotics
" DRUGOTHER  may be used with  DRUGOTHER ,  DRUGOTHER  and other  DRUG1 , and with other  DRUG2 .",negative,antimalarials,antibiotics
 DRUG1  ( DRUG2 ) should be administered until normal hematopoiesis is restored.,negative,Folinic acid,leucovorin
Mild hepatotoxicity has been reported in some patients when  DRUG1  and  DRUG2  were administered concomitantly.,effect,lorazepam,pyrimethamine
Acromegalic patients with diabetes mellitus being treated with  DRUG1  and/or oral  DRUG2  agents may require dose reductions of these therapeutic agents after the initiation of therapy with  DRUGOTHER .,negative,insulin,hypoglycemic
Acromegalic patients with diabetes mellitus being treated with  DRUG1  and/or oral  DRUGOTHER  agents may require dose reductions of these therapeutic agents after the initiation of therapy with  DRUG2 .,advise,insulin,SOMAVERT
Acromegalic patients with diabetes mellitus being treated with  DRUGOTHER  and/or oral  DRUG1  agents may require dose reductions of these therapeutic agents after the initiation of therapy with  DRUG2 .,advise,hypoglycemic,SOMAVERT
"In clinical studies, patients on  DRUG1  often needed higher serum  DRUG2  concentrations to achieve appropriate IGF-I suppression compared with patients not receiving  DRUGOTHER .",mechanism,opioids,pegvisomant
"In clinical studies, patients on  DRUG1  often needed higher serum  DRUGOTHER  concentrations to achieve appropriate IGF-I suppression compared with patients not receiving  DRUG2 .",negative,opioids,opioids
"In clinical studies, patients on  DRUGOTHER  often needed higher serum  DRUG1  concentrations to achieve appropriate IGF-I suppression compared with patients not receiving  DRUG2 .",negative,pegvisomant,opioids
Interactions for  DRUG1  ( DRUG2 ):   DRUGOTHER  - impairs the intestinal absorption of  DRUGOTHER ,negative,Vitamin B2,Riboflavin
Interactions for  DRUG1  ( DRUGOTHER ):   DRUG2  - impairs the intestinal absorption of  DRUGOTHER ,negative,Vitamin B2,Alcohol
Interactions for  DRUG1  ( DRUGOTHER ):   DRUGOTHER  - impairs the intestinal absorption of  DRUG2 ,negative,Vitamin B2,riboflavin
Interactions for  DRUGOTHER  ( DRUG1 ):   DRUG2  - impairs the intestinal absorption of  DRUGOTHER ,negative,Riboflavin,Alcohol
Interactions for  DRUGOTHER  ( DRUG1 ):   DRUGOTHER  - impairs the intestinal absorption of  DRUG2 ,negative,Riboflavin,riboflavin
Interactions for  DRUGOTHER  ( DRUGOTHER ):   DRUG1  - impairs the intestinal absorption of  DRUG2 ,mechanism,Alcohol,riboflavin
 DRUG1  - concurrent use decreases gastrointestinal absorption of  DRUG2 ;,mechanism,Probenecid,riboflavin
requirements for  DRUG1  may be increased in patients receiving  DRUG2 .,effect,riboflavin,probenecid
 DRUG1 :  DRUG2  causes a 60% reduction in the absorption and enterohepatic cycling of  DRUGOTHER  and should not be coadministered with  DRUGOTHER .,negative,Cholestyramine,Cholestyramine
 DRUG1 :  DRUGOTHER  causes a 60% reduction in the absorption and enterohepatic cycling of  DRUG2  and should not be coadministered with  DRUGOTHER .,negative,Cholestyramine,raloxifene
 DRUG1 :  DRUGOTHER  causes a 60% reduction in the absorption and enterohepatic cycling of  DRUGOTHER  and should not be coadministered with  DRUG2 .,negative,Cholestyramine,EVISTA
 DRUGOTHER :  DRUG1  causes a 60% reduction in the absorption and enterohepatic cycling of  DRUG2  and should not be coadministered with  DRUGOTHER .,mechanism,Cholestyramine,raloxifene
 DRUGOTHER :  DRUG1  causes a 60% reduction in the absorption and enterohepatic cycling of  DRUGOTHER  and should not be coadministered with  DRUG2 .,advise,Cholestyramine,EVISTA
 DRUGOTHER :  DRUGOTHER  causes a 60% reduction in the absorption and enterohepatic cycling of  DRUG1  and should not be coadministered with  DRUG2 .,negative,raloxifene,EVISTA
 DRUG1 : The coadministration of  DRUG2  and  DRUGOTHER  has not been assessed under chronic conditions.,negative,Warfarin,EVISTA
 DRUG1 : The coadministration of  DRUGOTHER  and  DRUG2  has not been assessed under chronic conditions.,negative,Warfarin,warfarin
 DRUGOTHER : The coadministration of  DRUG1  and  DRUG2  has not been assessed under chronic conditions.,negative,EVISTA,warfarin
"If  DRUG1  is given concurrently with  DRUG2 , prothrombin time should be monitored.",advise,EVISTA,warfarin
"In vitro,  DRUG1  did not affect the binding of  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,raloxifene,warfarin
"In vitro,  DRUG1  did not affect the binding of  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,raloxifene,phenytoin
"In vitro,  DRUG1  did not affect the binding of  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,raloxifene,tamoxifen
"In vitro,  DRUGOTHER  did not affect the binding of  DRUG1 ,  DRUG2 , or  DRUGOTHER .",negative,warfarin,phenytoin
"In vitro,  DRUGOTHER  did not affect the binding of  DRUG1 ,  DRUGOTHER , or  DRUG2 .",negative,warfarin,tamoxifen
"In vitro,  DRUGOTHER  did not affect the binding of  DRUGOTHER ,  DRUG1 , or  DRUG2 .",negative,phenytoin,tamoxifen
"Caution should be used when  DRUG1  is coadministered with other highly protein-bound drugs, such as  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",advise,EVISTA,clofibrate
"Caution should be used when  DRUG1  is coadministered with other highly protein-bound drugs, such as  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",advise,EVISTA,indomethacin
"Caution should be used when  DRUG1  is coadministered with other highly protein-bound drugs, such as  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",advise,EVISTA,naproxen
"Caution should be used when  DRUG1  is coadministered with other highly protein-bound drugs, such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",advise,EVISTA,ibuprofen
"Caution should be used when  DRUG1  is coadministered with other highly protein-bound drugs, such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",advise,EVISTA,diazepam
"Caution should be used when  DRUG1  is coadministered with other highly protein-bound drugs, such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",advise,EVISTA,diazoxide
"Caution should be used when  DRUGOTHER  is coadministered with other highly protein-bound drugs, such as  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,clofibrate,indomethacin
"Caution should be used when  DRUGOTHER  is coadministered with other highly protein-bound drugs, such as  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,clofibrate,naproxen
"Caution should be used when  DRUGOTHER  is coadministered with other highly protein-bound drugs, such as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,clofibrate,ibuprofen
"Caution should be used when  DRUGOTHER  is coadministered with other highly protein-bound drugs, such as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,clofibrate,diazepam
"Caution should be used when  DRUGOTHER  is coadministered with other highly protein-bound drugs, such as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,clofibrate,diazoxide
"Caution should be used when  DRUGOTHER  is coadministered with other highly protein-bound drugs, such as  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,indomethacin,naproxen
"Caution should be used when  DRUGOTHER  is coadministered with other highly protein-bound drugs, such as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,indomethacin,ibuprofen
"Caution should be used when  DRUGOTHER  is coadministered with other highly protein-bound drugs, such as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,indomethacin,diazepam
"Caution should be used when  DRUGOTHER  is coadministered with other highly protein-bound drugs, such as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,indomethacin,diazoxide
"Caution should be used when  DRUGOTHER  is coadministered with other highly protein-bound drugs, such as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,naproxen,ibuprofen
"Caution should be used when  DRUGOTHER  is coadministered with other highly protein-bound drugs, such as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,naproxen,diazepam
"Caution should be used when  DRUGOTHER  is coadministered with other highly protein-bound drugs, such as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,naproxen,diazoxide
"Caution should be used when  DRUGOTHER  is coadministered with other highly protein-bound drugs, such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER .",negative,ibuprofen,diazepam
"Caution should be used when  DRUGOTHER  is coadministered with other highly protein-bound drugs, such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 .",negative,ibuprofen,diazoxide
"Caution should be used when  DRUGOTHER  is coadministered with other highly protein-bound drugs, such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 .",negative,diazepam,diazoxide
"Since  DRUG1  ( DRUG2 ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg  DRUGOTHER  may increase the plasma concentrations of  DRUGOTHER  and  DRUGOTHER ).",negative,Celontin,methsuximide
"Since  DRUG1  ( DRUGOTHER ) may interact with concurrently administered  DRUG2 , periodic serum level determinations of these drugs may be necessary (eg  DRUGOTHER  may increase the plasma concentrations of  DRUGOTHER  and  DRUGOTHER ).",advise,Celontin,antiepileptic drugs
"Since  DRUG1  ( DRUGOTHER ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg  DRUG2  may increase the plasma concentrations of  DRUGOTHER  and  DRUGOTHER ).",negative,Celontin,methsuximide
"Since  DRUG1  ( DRUGOTHER ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg  DRUGOTHER  may increase the plasma concentrations of  DRUG2  and  DRUGOTHER ).",negative,Celontin,phenytoin
"Since  DRUG1  ( DRUGOTHER ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg  DRUGOTHER  may increase the plasma concentrations of  DRUGOTHER  and  DRUG2 ).",negative,Celontin,phenobarbital
"Since  DRUGOTHER  ( DRUG1 ) may interact with concurrently administered  DRUG2 , periodic serum level determinations of these drugs may be necessary (eg  DRUGOTHER  may increase the plasma concentrations of  DRUGOTHER  and  DRUGOTHER ).",advise,methsuximide,antiepileptic drugs
"Since  DRUGOTHER  ( DRUG1 ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg  DRUG2  may increase the plasma concentrations of  DRUGOTHER  and  DRUGOTHER ).",negative,methsuximide,methsuximide
"Since  DRUGOTHER  ( DRUG1 ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg  DRUGOTHER  may increase the plasma concentrations of  DRUG2  and  DRUGOTHER ).",negative,methsuximide,phenytoin
"Since  DRUGOTHER  ( DRUG1 ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg  DRUGOTHER  may increase the plasma concentrations of  DRUGOTHER  and  DRUG2 ).",negative,methsuximide,phenobarbital
"Since  DRUGOTHER  ( DRUGOTHER ) may interact with concurrently administered  DRUG1 , periodic serum level determinations of these drugs may be necessary (eg  DRUG2  may increase the plasma concentrations of  DRUGOTHER  and  DRUGOTHER ).",negative,antiepileptic drugs,methsuximide
"Since  DRUGOTHER  ( DRUGOTHER ) may interact with concurrently administered  DRUG1 , periodic serum level determinations of these drugs may be necessary (eg  DRUGOTHER  may increase the plasma concentrations of  DRUG2  and  DRUGOTHER ).",negative,antiepileptic drugs,phenytoin
"Since  DRUGOTHER  ( DRUGOTHER ) may interact with concurrently administered  DRUG1 , periodic serum level determinations of these drugs may be necessary (eg  DRUGOTHER  may increase the plasma concentrations of  DRUGOTHER  and  DRUG2 ).",negative,antiepileptic drugs,phenobarbital
"Since  DRUGOTHER  ( DRUGOTHER ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg  DRUG1  may increase the plasma concentrations of  DRUG2  and  DRUGOTHER ).",mechanism,methsuximide,phenytoin
"Since  DRUGOTHER  ( DRUGOTHER ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg  DRUG1  may increase the plasma concentrations of  DRUGOTHER  and  DRUG2 ).",mechanism,methsuximide,phenobarbital
"Since  DRUGOTHER  ( DRUGOTHER ) may interact with concurrently administered  DRUGOTHER , periodic serum level determinations of these drugs may be necessary (eg  DRUGOTHER  may increase the plasma concentrations of  DRUG1  and  DRUG2 ).",negative,phenytoin,phenobarbital
" DRUG1  may interact with  DRUG2  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,Methscopolamine,antidepressants
" DRUG1  may interact with  DRUGOTHER  ( DRUG2  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",int,Methscopolamine,tricyclic
" DRUG1  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",int,Methscopolamine,MAO inhibitors
" DRUG1  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",int,Methscopolamine,phenelzine
" DRUG1  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",int,Methscopolamine,linezolid
" DRUG1  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",int,Methscopolamine,tranylcypromine
" DRUG1  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",int,Methscopolamine,isocarboxazid
" DRUG1  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",int,Methscopolamine,selegiline
" DRUG1  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",int,Methscopolamine,furazolidone
" DRUG1  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",int,Methscopolamine,quinidine
" DRUG1  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",int,Methscopolamine,amantadine
" DRUG1  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",int,Methscopolamine,antihistamines
" DRUG1  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",int,Methscopolamine,diphenhydramine
" DRUG1  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUG2 ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",int,Methscopolamine,anticholinergics
" DRUG1  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUG2  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",int,Methscopolamine,potassium chloride
" DRUG1  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",int,Methscopolamine,antacids
" DRUG1  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",int,Methscopolamine,absorbent-type anti-diarrhea medicines
" DRUG1  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",int,Methscopolamine,kaolin
" DRUG1  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",int,Methscopolamine,pectin
" DRUG1  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",int,Methscopolamine,phenothiazines
" DRUG1  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ).",int,Methscopolamine,chlorpromazine
" DRUG1  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ).",int,Methscopolamine,promethazine
" DRUGOTHER  may interact with  DRUG1  ( DRUG2  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antidepressants,tricyclic
" DRUGOTHER  may interact with  DRUG1  ( DRUGOTHER  type),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antidepressants,MAO inhibitors
" DRUGOTHER  may interact with  DRUG1  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antidepressants,phenelzine
" DRUGOTHER  may interact with  DRUG1  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antidepressants,linezolid
" DRUGOTHER  may interact with  DRUG1  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antidepressants,tranylcypromine
" DRUGOTHER  may interact with  DRUG1  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antidepressants,isocarboxazid
" DRUGOTHER  may interact with  DRUG1  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antidepressants,selegiline
" DRUGOTHER  may interact with  DRUG1  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antidepressants,furazolidone
" DRUGOTHER  may interact with  DRUG1  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antidepressants,quinidine
" DRUGOTHER  may interact with  DRUG1  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antidepressants,amantadine
" DRUGOTHER  may interact with  DRUG1  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antidepressants,antihistamines
" DRUGOTHER  may interact with  DRUG1  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antidepressants,diphenhydramine
" DRUGOTHER  may interact with  DRUG1  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUG2 ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antidepressants,anticholinergics
" DRUGOTHER  may interact with  DRUG1  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUG2  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antidepressants,potassium chloride
" DRUGOTHER  may interact with  DRUG1  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antidepressants,antacids
" DRUGOTHER  may interact with  DRUG1  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antidepressants,absorbent-type anti-diarrhea medicines
" DRUGOTHER  may interact with  DRUG1  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antidepressants,kaolin
" DRUGOTHER  may interact with  DRUG1  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antidepressants,pectin
" DRUGOTHER  may interact with  DRUG1  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antidepressants,phenothiazines
" DRUGOTHER  may interact with  DRUG1  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ).",negative,antidepressants,chlorpromazine
" DRUGOTHER  may interact with  DRUG1  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ).",negative,antidepressants,promethazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUG1  type),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tricyclic,MAO inhibitors
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUG1  type),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tricyclic,phenelzine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUG1  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tricyclic,linezolid
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUG1  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tricyclic,tranylcypromine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUG1  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tricyclic,isocarboxazid
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUG1  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tricyclic,selegiline
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUG1  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tricyclic,furazolidone
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUG1  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tricyclic,quinidine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUG1  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tricyclic,amantadine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUG1  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tricyclic,antihistamines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUG1  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tricyclic,diphenhydramine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUG1  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUG2 ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tricyclic,anticholinergics
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUG1  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUG2  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tricyclic,potassium chloride
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUG1  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tricyclic,antacids
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUG1  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tricyclic,absorbent-type anti-diarrhea medicines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUG1  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tricyclic,kaolin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUG1  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tricyclic,pectin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUG1  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tricyclic,phenothiazines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUG1  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ).",negative,tricyclic,chlorpromazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUG1  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ).",negative,tricyclic,promethazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUG1  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,MAO inhibitors,phenelzine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUG1  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,MAO inhibitors,linezolid
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,MAO inhibitors,tranylcypromine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,MAO inhibitors,isocarboxazid
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,MAO inhibitors,selegiline
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,MAO inhibitors,furazolidone
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,MAO inhibitors,quinidine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,MAO inhibitors,amantadine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,MAO inhibitors,antihistamines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,MAO inhibitors,diphenhydramine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUG2 ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,MAO inhibitors,anticholinergics
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUG2  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,MAO inhibitors,potassium chloride
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,MAO inhibitors,antacids
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,MAO inhibitors,absorbent-type anti-diarrhea medicines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,MAO inhibitors,kaolin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,MAO inhibitors,pectin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,MAO inhibitors,phenothiazines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ).",negative,MAO inhibitors,chlorpromazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ).",negative,MAO inhibitors,promethazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,phenelzine,linezolid
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,phenelzine,tranylcypromine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,phenelzine,isocarboxazid
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,phenelzine,selegiline
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,phenelzine,furazolidone
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,phenelzine,quinidine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,phenelzine,amantadine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,phenelzine,antihistamines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,phenelzine,diphenhydramine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUG2 ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,phenelzine,anticholinergics
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUG2  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,phenelzine,potassium chloride
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,phenelzine,antacids
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,phenelzine,absorbent-type anti-diarrhea medicines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,phenelzine,kaolin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,phenelzine,pectin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,phenelzine,phenothiazines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ).",negative,phenelzine,chlorpromazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ).",negative,phenelzine,promethazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,linezolid,tranylcypromine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,linezolid,isocarboxazid
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,linezolid,selegiline
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,linezolid,furazolidone
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,linezolid,quinidine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,linezolid,amantadine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,linezolid,antihistamines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,linezolid,diphenhydramine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUG2 ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,linezolid,anticholinergics
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUG2  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,linezolid,potassium chloride
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,linezolid,antacids
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,linezolid,absorbent-type anti-diarrhea medicines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,linezolid,kaolin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,linezolid,pectin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,linezolid,phenothiazines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ).",negative,linezolid,chlorpromazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ).",negative,linezolid,promethazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tranylcypromine,isocarboxazid
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tranylcypromine,selegiline
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tranylcypromine,furazolidone
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tranylcypromine,quinidine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tranylcypromine,amantadine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tranylcypromine,antihistamines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tranylcypromine,diphenhydramine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUG2 ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tranylcypromine,anticholinergics
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUG2  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tranylcypromine,potassium chloride
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tranylcypromine,antacids
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tranylcypromine,absorbent-type anti-diarrhea medicines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tranylcypromine,kaolin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tranylcypromine,pectin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,tranylcypromine,phenothiazines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ).",negative,tranylcypromine,chlorpromazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ).",negative,tranylcypromine,promethazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,isocarboxazid,selegiline
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,isocarboxazid,furazolidone
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,isocarboxazid,quinidine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,isocarboxazid,amantadine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,isocarboxazid,antihistamines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,isocarboxazid,diphenhydramine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUG2 ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,isocarboxazid,anticholinergics
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUG2  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,isocarboxazid,potassium chloride
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,isocarboxazid,antacids
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,isocarboxazid,absorbent-type anti-diarrhea medicines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,isocarboxazid,kaolin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,isocarboxazid,pectin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,isocarboxazid,phenothiazines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ).",negative,isocarboxazid,chlorpromazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ).",negative,isocarboxazid,promethazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,selegiline,furazolidone
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,selegiline,quinidine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,selegiline,amantadine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,selegiline,antihistamines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,selegiline,diphenhydramine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUG2 ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,selegiline,anticholinergics
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUG2  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,selegiline,potassium chloride
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,selegiline,antacids
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,selegiline,absorbent-type anti-diarrhea medicines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,selegiline,kaolin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,selegiline,pectin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,selegiline,phenothiazines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ).",negative,selegiline,chlorpromazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ).",negative,selegiline,promethazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,furazolidone,quinidine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,furazolidone,amantadine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,furazolidone,antihistamines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,furazolidone,diphenhydramine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUG2 ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,furazolidone,anticholinergics
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUG2  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,furazolidone,potassium chloride
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,furazolidone,antacids
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,furazolidone,absorbent-type anti-diarrhea medicines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,furazolidone,kaolin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,furazolidone,pectin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,furazolidone,phenothiazines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ).",negative,furazolidone,chlorpromazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ).",negative,furazolidone,promethazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,quinidine,amantadine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,quinidine,antihistamines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,quinidine,diphenhydramine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUG2 ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,quinidine,anticholinergics
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUG2  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,quinidine,potassium chloride
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,quinidine,antacids
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,quinidine,absorbent-type anti-diarrhea medicines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,quinidine,kaolin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,quinidine,pectin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,quinidine,phenothiazines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ).",negative,quinidine,chlorpromazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ).",negative,quinidine,promethazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUG2  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,amantadine,antihistamines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (e.g.,  DRUG2 ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,amantadine,diphenhydramine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUG2 ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,amantadine,anticholinergics
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUG2  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,amantadine,potassium chloride
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,amantadine,antacids
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,amantadine,absorbent-type anti-diarrhea medicines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,amantadine,kaolin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,amantadine,pectin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,amantadine,phenothiazines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ).",negative,amantadine,chlorpromazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ).",negative,amantadine,promethazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (e.g.,  DRUG2 ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antihistamines,diphenhydramine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ), other  DRUG2 ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antihistamines,anticholinergics
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUG2  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antihistamines,potassium chloride
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antihistamines,antacids
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antihistamines,absorbent-type anti-diarrhea medicines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antihistamines,kaolin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antihistamines,pectin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antihistamines,phenothiazines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ).",negative,antihistamines,chlorpromazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ).",negative,antihistamines,promethazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ), other  DRUG2 ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,diphenhydramine,anticholinergics
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ), other  DRUGOTHER ,  DRUG2  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,diphenhydramine,potassium chloride
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,diphenhydramine,antacids
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,diphenhydramine,absorbent-type anti-diarrhea medicines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,diphenhydramine,kaolin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,diphenhydramine,pectin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,diphenhydramine,phenothiazines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ).",negative,diphenhydramine,chlorpromazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ).",negative,diphenhydramine,promethazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUG1 ,  DRUG2  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,anticholinergics,potassium chloride
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUG1 ,  DRUGOTHER  supplements,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,anticholinergics,antacids
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUG1 ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,anticholinergics,absorbent-type anti-diarrhea medicines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUG1 ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,anticholinergics,kaolin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUG1 ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,anticholinergics,pectin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUG1 ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,anticholinergics,phenothiazines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUG1 ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ).",negative,anticholinergics,chlorpromazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUG1 ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ).",negative,anticholinergics,promethazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUG1  supplements,  DRUG2 ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,potassium chloride,antacids
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUG1  supplements,  DRUGOTHER ,  DRUG2  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,potassium chloride,absorbent-type anti-diarrhea medicines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUG1  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG2 - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,potassium chloride,kaolin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUG1  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,potassium chloride,pectin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUG1  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,potassium chloride,phenothiazines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUG1  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ).",negative,potassium chloride,chlorpromazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUG1  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ).",negative,potassium chloride,promethazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUG1 ,  DRUG2  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antacids,absorbent-type anti-diarrhea medicines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUG1 ,  DRUGOTHER  (e.g.,  DRUG2 - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antacids,kaolin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antacids,pectin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,antacids,phenothiazines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ).",negative,antacids,chlorpromazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUG1 ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ).",negative,antacids,promethazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUG1  (e.g.,  DRUG2 - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,absorbent-type anti-diarrhea medicines,kaolin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER - DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,absorbent-type anti-diarrhea medicines,pectin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,absorbent-type anti-diarrhea medicines,phenothiazines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ).",negative,absorbent-type anti-diarrhea medicines,chlorpromazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUG1  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ).",negative,absorbent-type anti-diarrhea medicines,promethazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 - DRUG2 ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,kaolin,pectin
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 - DRUGOTHER ),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,kaolin,phenothiazines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ).",negative,kaolin,chlorpromazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUG1 - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ).",negative,kaolin,promethazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUG1 ),  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ).",negative,pectin,phenothiazines
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUG1 ),  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ).",negative,pectin,chlorpromazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUG1 ),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ).",negative,pectin,promethazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUG1  (e.g.,  DRUG2 ,  DRUGOTHER ).",negative,phenothiazines,chlorpromazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUG1  (e.g.,  DRUGOTHER ,  DRUG2 ).",negative,phenothiazines,promethazine
" DRUGOTHER  may interact with  DRUGOTHER  ( DRUGOTHER  type),  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER ), other  DRUGOTHER ,  DRUGOTHER  supplements,  DRUGOTHER ,  DRUGOTHER  (e.g.,  DRUGOTHER - DRUGOTHER ),  DRUGOTHER  (e.g.,  DRUG1 ,  DRUG2 ).",negative,chlorpromazine,promethazine
 DRUG1  should be administered with caution to patients taking  DRUG2  because of the possibility of conduction disturbances.,advise,Pilocarpine,beta adrenergic antagonists
"These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g.,  DRUG1 , inhaled  DRUG2 ).",negative,atropine,ipratropium
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUG1 , artificial tears,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,acetylsalicylic acid,calcium
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUG1 , artificial tears,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,acetylsalicylic acid,conjugated estrogens
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUG1 , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,acetylsalicylic acid,hydroxychloroquine sulfate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUG1 , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,acetylsalicylic acid,ibuprofen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUG1 , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,acetylsalicylic acid,levothyroxine sodium
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUG1 , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,acetylsalicylic acid,medroxyprogesterone acetate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUG1 , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,acetylsalicylic acid,methotrexate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUG1 , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,acetylsalicylic acid,multivitamins
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUG1 , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,acetylsalicylic acid,naproxen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUG1 , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,acetylsalicylic acid,omeprazole
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUG1 , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,acetylsalicylic acid,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUG1 , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,acetylsalicylic acid,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,calcium,conjugated estrogens
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,calcium,hydroxychloroquine sulfate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,calcium,ibuprofen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,calcium,levothyroxine sodium
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,calcium,medroxyprogesterone acetate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,calcium,methotrexate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,calcium,multivitamins
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,calcium,naproxen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,calcium,omeprazole
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,calcium,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,calcium,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,conjugated estrogens,hydroxychloroquine sulfate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,conjugated estrogens,ibuprofen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,conjugated estrogens,levothyroxine sodium
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,conjugated estrogens,medroxyprogesterone acetate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,conjugated estrogens,methotrexate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,conjugated estrogens,multivitamins
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,conjugated estrogens,naproxen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,conjugated estrogens,omeprazole
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,conjugated estrogens,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,conjugated estrogens,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,hydroxychloroquine sulfate,ibuprofen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,hydroxychloroquine sulfate,levothyroxine sodium
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,hydroxychloroquine sulfate,medroxyprogesterone acetate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,hydroxychloroquine sulfate,methotrexate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,hydroxychloroquine sulfate,multivitamins
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,hydroxychloroquine sulfate,naproxen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,hydroxychloroquine sulfate,omeprazole
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,hydroxychloroquine sulfate,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,hydroxychloroquine sulfate,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,ibuprofen,levothyroxine sodium
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,ibuprofen,medroxyprogesterone acetate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,ibuprofen,methotrexate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,ibuprofen,multivitamins
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,ibuprofen,naproxen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,ibuprofen,omeprazole
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,ibuprofen,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,ibuprofen,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,levothyroxine sodium,medroxyprogesterone acetate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,levothyroxine sodium,methotrexate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,levothyroxine sodium,multivitamins
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,levothyroxine sodium,naproxen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,levothyroxine sodium,omeprazole
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,levothyroxine sodium,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,levothyroxine sodium,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,medroxyprogesterone acetate,methotrexate
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,medroxyprogesterone acetate,multivitamins
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,medroxyprogesterone acetate,naproxen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,medroxyprogesterone acetate,omeprazole
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,medroxyprogesterone acetate,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,medroxyprogesterone acetate,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,methotrexate,multivitamins
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,methotrexate,naproxen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,methotrexate,omeprazole
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,methotrexate,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,methotrexate,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,multivitamins,naproxen
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,multivitamins,omeprazole
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,multivitamins,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,multivitamins,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,naproxen,omeprazole
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,naproxen,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,naproxen,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER .",negative,omeprazole,paracetamol
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 .",negative,omeprazole,prednisone
"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies:  DRUGOTHER , artificial tears,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 .",negative,paracetamol,prednisone
Administration of  DRUG1  decreases oral clearance of  DRUG2  by about 5%.,mechanism,valproic acid,temozolomide
Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between  DRUG1  capsules and other  DRUG2  have not been determined.,negative,FLOMAX,alpha-adrenergic blocking agents
"However, interactions may be expected and  DRUG1  capsules should NOT be used in combination with other  DRUG2 .",advise,FLOMAX,alpha-adrenergic blocking agents
The pharmacokinetic interaction between  DRUG1  and  DRUG2  capsules was investigated.,negative,cimetidine,FLOMAX
"Therefore,  DRUG1  capsules should be used with caution in combination with  DRUG2 , particularly at doses higher than 0.4 mg.",advise,FLOMAX,cimetidine
Results from limited in vitro and in vivo drug-drug interaction studies between  DRUG1  and  DRUG2  are inconclusive.,negative,tamsulosin HCI,warfarin
"Therefore, caution should be exercised with concomitant administration of  DRUG1  and  DRUG2  capsules.",advise,warfarin,FLOMAX
"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of  DRUG1 ,  DRUG2  and  DRUGOTHER  displaced protein-bound  DRUGOTHER  in fresh human serum to a small but significant extent.",negative,tolbutamide,sodium salicylate
"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of  DRUG1 ,  DRUGOTHER  and  DRUG2  displaced protein-bound  DRUGOTHER  in fresh human serum to a small but significant extent.",negative,tolbutamide,sulfamethizole
"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of  DRUG1 ,  DRUGOTHER  and  DRUGOTHER  displaced protein-bound  DRUG2  in fresh human serum to a small but significant extent.",mechanism,tolbutamide,teniposide
"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of  DRUGOTHER ,  DRUG1  and  DRUG2  displaced protein-bound  DRUGOTHER  in fresh human serum to a small but significant extent.",negative,sodium salicylate,sulfamethizole
"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of  DRUGOTHER ,  DRUG1  and  DRUGOTHER  displaced protein-bound  DRUG2  in fresh human serum to a small but significant extent.",mechanism,sodium salicylate,teniposide
"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of  DRUGOTHER ,  DRUGOTHER  and  DRUG1  displaced protein-bound  DRUG2  in fresh human serum to a small but significant extent.",mechanism,sulfamethizole,teniposide
"Therefore, caution should be used in administering  DRUG1  ( DRUG2  injection) to patients receiving these other agents.",negative,VUMON,teniposide
There was no change in the plasma kinetics of  DRUG1  when coadministered with  DRUG2 .,negative,teniposide,methotrexate
An increase in intracellular levels of  DRUG1  was observed in vitro in the presence of  DRUG2 .,mechanism,methotrexate,teniposide
"When administered concurrently,  DRUG1  may increase the effects of oral  DRUG2 ;",effect,testolactone,anticoagulants
"You cannot take  DRUG1  if you have taken a  DRUG2  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ) in the last 14 days.",advise,mazindol,monoamine oxidase inhibitor
"You cannot take  DRUG1  if you have taken a  DRUGOTHER  ( DRUG2 ) such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ) in the last 14 days.",advise,mazindol,MAOI
"You cannot take  DRUG1  if you have taken a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ) in the last 14 days.",advise,mazindol,isocarboxazid
"You cannot take  DRUG1  if you have taken a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ) in the last 14 days.",advise,mazindol,Marplan
"You cannot take  DRUG1  if you have taken a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ) in the last 14 days.",advise,mazindol,tranylcypromine
"You cannot take  DRUG1  if you have taken a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER ) in the last 14 days.",advise,mazindol,Parnate
"You cannot take  DRUG1  if you have taken a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER ) in the last 14 days.",advise,mazindol,phenelzine
"You cannot take  DRUG1  if you have taken a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 ) in the last 14 days.",advise,mazindol,Nardil
"You cannot take  DRUGOTHER  if you have taken a  DRUG1  ( DRUG2 ) such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ) in the last 14 days.",negative,monoamine oxidase inhibitor,MAOI
"You cannot take  DRUGOTHER  if you have taken a  DRUG1  ( DRUGOTHER ) such as  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ) in the last 14 days.",negative,monoamine oxidase inhibitor,isocarboxazid
"You cannot take  DRUGOTHER  if you have taken a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ) in the last 14 days.",negative,monoamine oxidase inhibitor,Marplan
"You cannot take  DRUGOTHER  if you have taken a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ) in the last 14 days.",negative,monoamine oxidase inhibitor,tranylcypromine
"You cannot take  DRUGOTHER  if you have taken a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER ) in the last 14 days.",negative,monoamine oxidase inhibitor,Parnate
"You cannot take  DRUGOTHER  if you have taken a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER ) in the last 14 days.",negative,monoamine oxidase inhibitor,phenelzine
"You cannot take  DRUGOTHER  if you have taken a  DRUG1  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 ) in the last 14 days.",negative,monoamine oxidase inhibitor,Nardil
"You cannot take  DRUGOTHER  if you have taken a  DRUGOTHER  ( DRUG1 ) such as  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ) in the last 14 days.",negative,MAOI,isocarboxazid
"You cannot take  DRUGOTHER  if you have taken a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ) in the last 14 days.",negative,MAOI,Marplan
"You cannot take  DRUGOTHER  if you have taken a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ) in the last 14 days.",negative,MAOI,tranylcypromine
"You cannot take  DRUGOTHER  if you have taken a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER ) in the last 14 days.",negative,MAOI,Parnate
"You cannot take  DRUGOTHER  if you have taken a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER ) in the last 14 days.",negative,MAOI,phenelzine
"You cannot take  DRUGOTHER  if you have taken a  DRUGOTHER  ( DRUG1 ) such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 ) in the last 14 days.",negative,MAOI,Nardil
"You cannot take  DRUGOTHER  if you have taken a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ) in the last 14 days.",negative,isocarboxazid,Marplan
"You cannot take  DRUGOTHER  if you have taken a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ) in the last 14 days.",negative,isocarboxazid,tranylcypromine
"You cannot take  DRUGOTHER  if you have taken a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER ) in the last 14 days.",negative,isocarboxazid,Parnate
"You cannot take  DRUGOTHER  if you have taken a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER ) in the last 14 days.",negative,isocarboxazid,phenelzine
"You cannot take  DRUGOTHER  if you have taken a  DRUGOTHER  ( DRUGOTHER ) such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 ) in the last 14 days.",negative,isocarboxazid,Nardil
"You cannot take  DRUGOTHER  if you have taken a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ) in the last 14 days.",negative,Marplan,tranylcypromine
"You cannot take  DRUGOTHER  if you have taken a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER ) in the last 14 days.",negative,Marplan,Parnate
"You cannot take  DRUGOTHER  if you have taken a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER ) in the last 14 days.",negative,Marplan,phenelzine
"You cannot take  DRUGOTHER  if you have taken a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 ) in the last 14 days.",negative,Marplan,Nardil
"You cannot take  DRUGOTHER  if you have taken a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER ) in the last 14 days.",negative,tranylcypromine,Parnate
"You cannot take  DRUGOTHER  if you have taken a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER ) in the last 14 days.",negative,tranylcypromine,phenelzine
"You cannot take  DRUGOTHER  if you have taken a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 ) in the last 14 days.",negative,tranylcypromine,Nardil
"You cannot take  DRUGOTHER  if you have taken a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ), or  DRUG2  ( DRUGOTHER ) in the last 14 days.",negative,Parnate,phenelzine
"You cannot take  DRUGOTHER  if you have taken a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ), or  DRUGOTHER  ( DRUG2 ) in the last 14 days.",negative,Parnate,Nardil
"You cannot take  DRUGOTHER  if you have taken a  DRUGOTHER  ( DRUGOTHER ) such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG1  ( DRUG2 ) in the last 14 days.",negative,phenelzine,Nardil
Changes in  DRUG1  and other diabetes drug therapies may be necessary during treatment with  DRUG2 .,advise,insulin,mazindol
 DRUG1  may reduce the effects of  DRUG2  ( DRUGOTHER ).,effect,Mazindol,guanethidine
 DRUG1  may reduce the effects of  DRUGOTHER  ( DRUG2 ).,effect,Mazindol,Ismelin
 DRUGOTHER  may reduce the effects of  DRUG1  ( DRUG2 ).,negative,guanethidine,Ismelin
"Before taking this medication, tell your doctor if you are taking a  DRUG1  such as  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,tricyclic antidepressant,amitriptyline
"Before taking this medication, tell your doctor if you are taking a  DRUG1  such as  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,tricyclic antidepressant,Elavil
"Before taking this medication, tell your doctor if you are taking a  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,tricyclic antidepressant,amoxapine
"Before taking this medication, tell your doctor if you are taking a  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,tricyclic antidepressant,Asendin
"Before taking this medication, tell your doctor if you are taking a  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,tricyclic antidepressant,doxepin
"Before taking this medication, tell your doctor if you are taking a  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,tricyclic antidepressant,Sinequan
"Before taking this medication, tell your doctor if you are taking a  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,tricyclic antidepressant,nortriptyline
"Before taking this medication, tell your doctor if you are taking a  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,tricyclic antidepressant,Pamelor
"Before taking this medication, tell your doctor if you are taking a  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,tricyclic antidepressant,imipramine
"Before taking this medication, tell your doctor if you are taking a  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,tricyclic antidepressant,Tofranil
"Before taking this medication, tell your doctor if you are taking a  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,tricyclic antidepressant,clomipramine
"Before taking this medication, tell your doctor if you are taking a  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,tricyclic antidepressant,Anafranil
"Before taking this medication, tell your doctor if you are taking a  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,tricyclic antidepressant,protriptyline
"Before taking this medication, tell your doctor if you are taking a  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER ).",negative,tricyclic antidepressant,Vivactil
"Before taking this medication, tell your doctor if you are taking a  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER ).",negative,tricyclic antidepressant,desipramine
"Before taking this medication, tell your doctor if you are taking a  DRUG1  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 ).",negative,tricyclic antidepressant,Norpramin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUG1  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amitriptyline,Elavil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amitriptyline,amoxapine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amitriptyline,Asendin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amitriptyline,doxepin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amitriptyline,Sinequan
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amitriptyline,nortriptyline
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amitriptyline,Pamelor
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amitriptyline,imipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amitriptyline,Tofranil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amitriptyline,clomipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amitriptyline,Anafranil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amitriptyline,protriptyline
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amitriptyline,Vivactil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER ).",negative,amitriptyline,desipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 ).",negative,amitriptyline,Norpramin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Elavil,amoxapine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Elavil,Asendin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Elavil,doxepin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Elavil,Sinequan
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Elavil,nortriptyline
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Elavil,Pamelor
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Elavil,imipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Elavil,Tofranil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Elavil,clomipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Elavil,Anafranil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Elavil,protriptyline
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Elavil,Vivactil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER ).",negative,Elavil,desipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 ).",negative,Elavil,Norpramin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amoxapine,Asendin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amoxapine,doxepin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amoxapine,Sinequan
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amoxapine,nortriptyline
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amoxapine,Pamelor
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amoxapine,imipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amoxapine,Tofranil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amoxapine,clomipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amoxapine,Anafranil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amoxapine,protriptyline
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER ).",negative,amoxapine,Vivactil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER ).",negative,amoxapine,desipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 ).",negative,amoxapine,Norpramin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Asendin,doxepin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Asendin,Sinequan
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Asendin,nortriptyline
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Asendin,Pamelor
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Asendin,imipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Asendin,Tofranil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Asendin,clomipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Asendin,Anafranil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Asendin,protriptyline
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Asendin,Vivactil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER ).",negative,Asendin,desipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 ).",negative,Asendin,Norpramin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,doxepin,Sinequan
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,doxepin,nortriptyline
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,doxepin,Pamelor
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,doxepin,imipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,doxepin,Tofranil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,doxepin,clomipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,doxepin,Anafranil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,doxepin,protriptyline
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER ).",negative,doxepin,Vivactil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER ).",negative,doxepin,desipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 ).",negative,doxepin,Norpramin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Sinequan,nortriptyline
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Sinequan,Pamelor
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Sinequan,imipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Sinequan,Tofranil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Sinequan,clomipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Sinequan,Anafranil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Sinequan,protriptyline
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Sinequan,Vivactil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER ).",negative,Sinequan,desipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 ).",negative,Sinequan,Norpramin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,nortriptyline,Pamelor
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,nortriptyline,imipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,nortriptyline,Tofranil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,nortriptyline,clomipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,nortriptyline,Anafranil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,nortriptyline,protriptyline
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER ).",negative,nortriptyline,Vivactil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER ).",negative,nortriptyline,desipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 ).",negative,nortriptyline,Norpramin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Pamelor,imipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Pamelor,Tofranil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Pamelor,clomipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Pamelor,Anafranil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Pamelor,protriptyline
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Pamelor,Vivactil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER ).",negative,Pamelor,desipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 ).",negative,Pamelor,Norpramin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,imipramine,Tofranil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,imipramine,clomipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,imipramine,Anafranil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,imipramine,protriptyline
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER ).",negative,imipramine,Vivactil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER ).",negative,imipramine,desipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 ).",negative,imipramine,Norpramin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUG2  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Tofranil,clomipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Tofranil,Anafranil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Tofranil,protriptyline
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Tofranil,Vivactil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER ).",negative,Tofranil,desipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 ).",negative,Tofranil,Norpramin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUG2 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,clomipramine,Anafranil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,clomipramine,protriptyline
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER ).",negative,clomipramine,Vivactil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER ).",negative,clomipramine,desipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 ).",negative,clomipramine,Norpramin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUG2  ( DRUGOTHER ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Anafranil,protriptyline
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER ).",negative,Anafranil,Vivactil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER ).",negative,Anafranil,desipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ),  DRUGOTHER  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 ).",negative,Anafranil,Norpramin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUG2 ), or  DRUGOTHER  ( DRUGOTHER ).",negative,protriptyline,Vivactil
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ), or  DRUG2  ( DRUGOTHER ).",negative,protriptyline,desipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUG1  ( DRUGOTHER ), or  DRUGOTHER  ( DRUG2 ).",negative,protriptyline,Norpramin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ), or  DRUG2  ( DRUGOTHER ).",negative,Vivactil,desipramine
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUG1 ), or  DRUGOTHER  ( DRUG2 ).",negative,Vivactil,Norpramin
"Before taking this medication, tell your doctor if you are taking a  DRUGOTHER  such as  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ),  DRUGOTHER  ( DRUGOTHER ), or  DRUG1  ( DRUG2 ).",negative,desipramine,Norpramin
Interaction of  DRUG1  with different  DRUG2  is antagonistic in breast but not in other cancer cells.,effect,celecoxib,anti-cancer drugs
This study investigates the ability of  DRUG1  to sensitize cells from different origins to several  DRUG2 .,negative,cyclooxygenase-2 inhibitors,chemotherapeutic agents
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to  DRUG1 ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER     DRUGOTHER  following different incubation schedules were analyzed.",negative,5-FU,cisplatin
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to  DRUG1 ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER     DRUGOTHER  following different incubation schedules were analyzed.",negative,5-FU,doxorubicin
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2     DRUGOTHER  following different incubation schedules were analyzed.",negative,5-FU,etoposide
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER     DRUG2  following different incubation schedules were analyzed.",negative,5-FU,celecoxib
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to  DRUGOTHER ,  DRUG1 ,  DRUG2  and  DRUGOTHER     DRUGOTHER  following different incubation schedules were analyzed.",negative,cisplatin,doxorubicin
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUG2     DRUGOTHER  following different incubation schedules were analyzed.",negative,cisplatin,etoposide
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER     DRUG2  following different incubation schedules were analyzed.",negative,cisplatin,celecoxib
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUG2     DRUGOTHER  following different incubation schedules were analyzed.",negative,doxorubicin,etoposide
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUGOTHER     DRUG2  following different incubation schedules were analyzed.",negative,doxorubicin,celecoxib
"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG1     DRUG2  following different incubation schedules were analyzed.",negative,etoposide,celecoxib
We found antagonism between  DRUG1  and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between  DRUG2  and  DRUGOTHER  in all cell lines except for two combinations in HCT116 cells.,negative,celecoxib,celecoxib
We found antagonism between  DRUG1  and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between  DRUGOTHER  and  DRUG2  in all cell lines except for two combinations in HCT116 cells.,negative,celecoxib,doxorubicin
We found antagonism between  DRUGOTHER  and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between  DRUG1  and  DRUG2  in all cell lines except for two combinations in HCT116 cells.,effect,celecoxib,doxorubicin
"These results, if confirmed in-vivo, indicate that  DRUG1  is not a suitable chemosensitizer for breast cancer or with  DRUG2  for other cancers.",negative,celecoxib,doxorubicin
Synergistic interaction between  DRUG1  and  DRUG2  is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.,int,sunitinib,docetaxel
This study was aimed to investigate the efficacy of single use of  DRUG1  and that of concurrent or sequential administration of  DRUG2  and  DRUGOTHER  in NSCLC cell lines that are resistant to EGFR TKIs.,negative,sunitinib,sunitinib
This study was aimed to investigate the efficacy of single use of  DRUG1  and that of concurrent or sequential administration of  DRUGOTHER  and  DRUG2  in NSCLC cell lines that are resistant to EGFR TKIs.,negative,sunitinib,docetaxel
This study was aimed to investigate the efficacy of single use of  DRUGOTHER  and that of concurrent or sequential administration of  DRUG1  and  DRUG2  in NSCLC cell lines that are resistant to EGFR TKIs.,negative,sunitinib,docetaxel
NSCLC cell lines with EGFR T790M mutation and K-ras mutation were exposed to either  DRUG1  or  DRUG2  or both based on various sequential administrations.,negative,sunitinib,docetaxel
" DRUG1  exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase, whereas  DRUG2  arrested at S phase.",negative,Sunitinib,docetaxel
"Although single or concurrent use of  DRUG1  and  DRUG2  has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity.",effect,sunitinib,docetaxel
"When cells were exposed to  DRUG1  followed by  DRUG2 , synergism was observed.",effect,docetaxel,sunitinib
The molecular basis of this synergism is that the signaling pathways that were initially activated by  DRUG1  exposure were efficiently suppressed by the subsequent exposure to  DRUG2 .,effect,docetaxel,sunitinib
 DRUG1  as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of  DRUG2  followed by  DRUGOTHER  is superior to  DRUGOTHER  followed by  DRUGOTHER  and concurrent administration.,negative,Sunitinib,docetaxel
 DRUG1  as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of  DRUGOTHER  followed by  DRUG2  is superior to  DRUGOTHER  followed by  DRUGOTHER  and concurrent administration.,negative,Sunitinib,sunitinib
 DRUG1  as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of  DRUGOTHER  followed by  DRUGOTHER  is superior to  DRUG2  followed by  DRUGOTHER  and concurrent administration.,negative,Sunitinib,sunitinib
 DRUG1  as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of  DRUGOTHER  followed by  DRUGOTHER  is superior to  DRUGOTHER  followed by  DRUG2  and concurrent administration.,negative,Sunitinib,docetaxel
 DRUGOTHER  as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of  DRUG1  followed by  DRUG2  is superior to  DRUGOTHER  followed by  DRUGOTHER  and concurrent administration.,effect,docetaxel,sunitinib
 DRUGOTHER  as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of  DRUG1  followed by  DRUGOTHER  is superior to  DRUG2  followed by  DRUGOTHER  and concurrent administration.,negative,docetaxel,sunitinib
 DRUGOTHER  as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of  DRUG1  followed by  DRUGOTHER  is superior to  DRUGOTHER  followed by  DRUG2  and concurrent administration.,negative,docetaxel,docetaxel
 DRUGOTHER  as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of  DRUGOTHER  followed by  DRUG1  is superior to  DRUG2  followed by  DRUGOTHER  and concurrent administration.,negative,sunitinib,sunitinib
 DRUGOTHER  as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of  DRUGOTHER  followed by  DRUG1  is superior to  DRUGOTHER  followed by  DRUG2  and concurrent administration.,negative,sunitinib,docetaxel
 DRUGOTHER  as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of  DRUGOTHER  followed by  DRUGOTHER  is superior to  DRUG1  followed by  DRUG2  and concurrent administration.,negative,sunitinib,docetaxel
"Usage with  DRUG1 : Due to the potential for increased CNS depressants effects,  DRUG2  should be used with caution in patients who are currently receiving  DRUGOTHER .",negative,Alcohol,alcohol
"Usage with  DRUG1 : Due to the potential for increased CNS depressants effects,  DRUGOTHER  should be used with caution in patients who are currently receiving  DRUG2 .",negative,Alcohol,pentazocine
"Usage with  DRUGOTHER : Due to the potential for increased CNS depressants effects,  DRUG1  should be used with caution in patients who are currently receiving  DRUG2 .",advise,alcohol,pentazocine
"Coadministration of  DRUG1  with  DRUG2  resulted in increased plasma  DRUGOTHER  concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased  DRUGOTHER  plasma concentrations (31%).",mechanism,TRITEC,clarithromycin
"Coadministration of  DRUG1  with  DRUGOTHER  resulted in increased plasma  DRUG2  concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased  DRUGOTHER  plasma concentrations (31%).",negative,TRITEC,ranitidine
"Coadministration of  DRUG1  with  DRUGOTHER  resulted in increased plasma  DRUGOTHER  concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased  DRUG2  plasma concentrations (31%).",negative,TRITEC,14- hydroxy- clarithromycin
"Coadministration of  DRUGOTHER  with  DRUG1  resulted in increased plasma  DRUG2  concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased  DRUGOTHER  plasma concentrations (31%).",negative,clarithromycin,ranitidine
"Coadministration of  DRUGOTHER  with  DRUG1  resulted in increased plasma  DRUGOTHER  concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased  DRUG2  plasma concentrations (31%).",negative,clarithromycin,14- hydroxy- clarithromycin
"Coadministration of  DRUGOTHER  with  DRUGOTHER  resulted in increased plasma  DRUG1  concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased  DRUG2  plasma concentrations (31%).",negative,ranitidine,14- hydroxy- clarithromycin
Coadministration with  DRUG1  results in a slight decrease in the rate of  DRUG2  absorption that is clinically unimportant.,negative,aspirin,salicylate
Coadministration with a high dose of  DRUG1  (170 mEq) results in a 28% decrease in plasma concentrations of  DRUG2  and may decrease plasma concentrations of bismuth from  DRUGOTHER .,mechanism,antacid,ranitidine
Coadministration with a high dose of  DRUG1  (170 mEq) results in a 28% decrease in plasma concentrations of  DRUGOTHER  and may decrease plasma concentrations of bismuth from  DRUG2 .,mechanism,antacid,TRITEC
Coadministration with a high dose of  DRUGOTHER  (170 mEq) results in a 28% decrease in plasma concentrations of  DRUG1  and may decrease plasma concentrations of bismuth from  DRUG2 .,negative,ranitidine,TRITEC
"For information on drug interactions associated with  DRUG1 , refer to the  DRUG2      package insert.",negative,ranitidine,ZANTAC
 DRUG1  enhances the antinociceptive effect of  DRUG2  in mice.,effect,Ephedrine,dexmedetomidine
The purpose of this study was to evaluate whether the psychostimulant drug  DRUG1  has any effect on  DRUG2 -induced antinociception and locomotor inhibitor activity in mice in acute application.,negative,ephedrine,dexmedetomidine
"saline + saline,  DRUG1  (10   mg/kg) + saline, saline +  DRUG2  (15     g/kg) and  DRUGOTHER  (10   mg/kg) +  DRUGOTHER  (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.",negative,ephedrine,dexmedetomidine
"saline + saline,  DRUG1  (10   mg/kg) + saline, saline +  DRUGOTHER  (15     g/kg) and  DRUG2  (10   mg/kg) +  DRUGOTHER  (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.",negative,ephedrine,ephedrine
"saline + saline,  DRUG1  (10   mg/kg) + saline, saline +  DRUGOTHER  (15     g/kg) and  DRUGOTHER  (10   mg/kg) +  DRUG2  (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.",negative,ephedrine,dexmedetomidine
"saline + saline,  DRUGOTHER  (10   mg/kg) + saline, saline +  DRUG1  (15     g/kg) and  DRUG2  (10   mg/kg) +  DRUGOTHER  (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.",negative,dexmedetomidine,ephedrine
"saline + saline,  DRUGOTHER  (10   mg/kg) + saline, saline +  DRUG1  (15     g/kg) and  DRUGOTHER  (10   mg/kg) +  DRUG2  (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.",negative,dexmedetomidine,dexmedetomidine
"saline + saline,  DRUGOTHER  (10   mg/kg) + saline, saline +  DRUGOTHER  (15     g/kg) and  DRUG1  (10   mg/kg) +  DRUG2  (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests.",negative,ephedrine,dexmedetomidine
"In the hot plate test in mice, co-administration of 15     g/kg  DRUG1  with 10   mg/kg  DRUG2  intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by  DRUGOTHER .",effect,dexmedetomidine,ephedrine
"In the hot plate test in mice, co-administration of 15     g/kg  DRUG1  with 10   mg/kg  DRUGOTHER  intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by  DRUG2 .",negative,dexmedetomidine,dexmedetomidine
"In the hot plate test in mice, co-administration of 15     g/kg  DRUGOTHER  with 10   mg/kg  DRUG1  intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by  DRUG2 .",negative,ephedrine,dexmedetomidine
"At the same time, the locomotor inhibitory effect of  DRUG1  was counteracted by  DRUG2 .",effect,dexmedetomidine,ephedrine
"We concluded that the combined administration of  DRUG1  with  DRUG2  may have beneficial effects in the treatment of pain without causing sedation, which limits the use of  DRUGOTHER  as an  DRUGOTHER  in humans.",effect,dexmedetomidine,ephedrine
"We concluded that the combined administration of  DRUG1  with  DRUGOTHER  may have beneficial effects in the treatment of pain without causing sedation, which limits the use of  DRUG2  as an  DRUGOTHER  in humans.",negative,dexmedetomidine,dexmedetomidine
"We concluded that the combined administration of  DRUG1  with  DRUGOTHER  may have beneficial effects in the treatment of pain without causing sedation, which limits the use of  DRUGOTHER  as an  DRUG2  in humans.",negative,dexmedetomidine,analgesic
"We concluded that the combined administration of  DRUGOTHER  with  DRUG1  may have beneficial effects in the treatment of pain without causing sedation, which limits the use of  DRUG2  as an  DRUGOTHER  in humans.",negative,ephedrine,dexmedetomidine
"We concluded that the combined administration of  DRUGOTHER  with  DRUG1  may have beneficial effects in the treatment of pain without causing sedation, which limits the use of  DRUGOTHER  as an  DRUG2  in humans.",negative,ephedrine,analgesic
"We concluded that the combined administration of  DRUGOTHER  with  DRUGOTHER  may have beneficial effects in the treatment of pain without causing sedation, which limits the use of  DRUG1  as an  DRUG2  in humans.",negative,dexmedetomidine,analgesic
"In clinical studies of  DRUG1 , patients taking  DRUG2  concomitantly with  DRUGOTHER  ( DRUGOTHER    , Genentech),  DRUGOTHER , inhaled  DRUGOTHER , other  DRUGOTHER , or parenteral  DRUGOTHER  demonstrated adverse experience profiles similar to the study population as a whole.",negative,TOBI,TOBI
"In clinical studies of  DRUG1 , patients taking  DRUGOTHER  concomitantly with  DRUG2  ( DRUGOTHER    , Genentech),  DRUGOTHER , inhaled  DRUGOTHER , other  DRUGOTHER , or parenteral  DRUGOTHER  demonstrated adverse experience profiles similar to the study population as a whole.",negative,TOBI,dornase alfa
"In clinical studies of  DRUG1 , patients taking  DRUGOTHER  concomitantly with  DRUGOTHER  ( DRUG2    , Genentech),  DRUGOTHER , inhaled  DRUGOTHER , other  DRUGOTHER , or parenteral  DRUGOTHER  demonstrated adverse experience profiles similar to the study population as a whole.",negative,TOBI,PULMOZYME
"In clinical studies of  DRUG1 , patients taking  DRUGOTHER  concomitantly with  DRUGOTHER  ( DRUGOTHER    , Genentech),  DRUG2 , inhaled  DRUGOTHER , other  DRUGOTHER , or parenteral  DRUGOTHER  demonstrated adverse experience profiles similar to the study population as a whole.",negative,TOBI,(beta)-agonists
"In clinical studies of  DRUG1 , patients taking  DRUGOTHER  concomitantly with  DRUGOTHER  ( DRUGOTHER    , Genentech),  DRUGOTHER , inhaled  DRUG2 , other  DRUGOTHER , or parenteral  DRUGOTHER  demonstrated adverse experience profiles similar to the study population as a whole.",negative,TOBI,corticosteroids
"In clinical studies of  DRUG1 , patients taking  DRUGOTHER  concomitantly with  DRUGOTHER  ( DRUGOTHER    , Genentech),  DRUGOTHER , inhaled  DRUGOTHER , other  DRUG2 , or parenteral  DRUGOTHER  demonstrated adverse experience profiles similar to the study population as a whole.",negative,TOBI,anti-pseudomonal antibiotics
"In clinical studies of  DRUG1 , patients taking  DRUGOTHER  concomitantly with  DRUGOTHER  ( DRUGOTHER    , Genentech),  DRUGOTHER , inhaled  DRUGOTHER , other  DRUGOTHER , or parenteral  DRUG2  demonstrated adverse experience profiles similar to the study population as a whole.",negative,TOBI,aminoglycosides
"In clinical studies of  DRUGOTHER , patients taking  DRUG1  concomitantly with  DRUG2  ( DRUGOTHER    , Genentech),  DRUGOTHER , inhaled  DRUGOTHER , other  DRUGOTHER , or parenteral  DRUGOTHER  demonstrated adverse experience profiles similar to the study population as a whole.",effect,TOBI,dornase alfa
"In clinical studies of  DRUGOTHER , patients taking  DRUG1  concomitantly with  DRUGOTHER  ( DRUG2    , Genentech),  DRUGOTHER , inhaled  DRUGOTHER , other  DRUGOTHER , or parenteral  DRUGOTHER  demonstrated adverse experience profiles similar to the study population as a whole.",effect,TOBI,PULMOZYME
"In clinical studies of  DRUGOTHER , patients taking  DRUG1  concomitantly with  DRUGOTHER  ( DRUGOTHER    , Genentech),  DRUG2 , inhaled  DRUGOTHER , other  DRUGOTHER , or parenteral  DRUGOTHER  demonstrated adverse experience profiles similar to the study population as a whole.",effect,TOBI,(beta)-agonists
"In clinical studies of  DRUGOTHER , patients taking  DRUG1  concomitantly with  DRUGOTHER  ( DRUGOTHER    , Genentech),  DRUGOTHER , inhaled  DRUG2 , other  DRUGOTHER , or parenteral  DRUGOTHER  demonstrated adverse experience profiles similar to the study population as a whole.",effect,TOBI,corticosteroids
"In clinical studies of  DRUGOTHER , patients taking  DRUG1  concomitantly with  DRUGOTHER  ( DRUGOTHER    , Genentech),  DRUGOTHER , inhaled  DRUGOTHER , other  DRUG2 , or parenteral  DRUGOTHER  demonstrated adverse experience profiles similar to the study population as a whole.",effect,TOBI,anti-pseudomonal antibiotics
"In clinical studies of  DRUGOTHER , patients taking  DRUG1  concomitantly with  DRUGOTHER  ( DRUGOTHER    , Genentech),  DRUGOTHER , inhaled  DRUGOTHER , other  DRUGOTHER , or parenteral  DRUG2  demonstrated adverse experience profiles similar to the study population as a whole.",effect,TOBI,aminoglycosides
"In clinical studies of  DRUGOTHER , patients taking  DRUGOTHER  concomitantly with  DRUG1  ( DRUG2    , Genentech),  DRUGOTHER , inhaled  DRUGOTHER , other  DRUGOTHER , or parenteral  DRUGOTHER  demonstrated adverse experience profiles similar to the study population as a whole.",negative,dornase alfa,PULMOZYME
"In clinical studies of  DRUGOTHER , patients taking  DRUGOTHER  concomitantly with  DRUG1  ( DRUGOTHER    , Genentech),  DRUG2 , inhaled  DRUGOTHER , other  DRUGOTHER , or parenteral  DRUGOTHER  demonstrated adverse experience profiles similar to the study population as a whole.",negative,dornase alfa,(beta)-agonists
"In clinical studies of  DRUGOTHER , patients taking  DRUGOTHER  concomitantly with  DRUG1  ( DRUGOTHER    , Genentech),  DRUGOTHER , inhaled  DRUG2 , other  DRUGOTHER , or parenteral  DRUGOTHER  demonstrated adverse experience profiles similar to the study population as a whole.",negative,dornase alfa,corticosteroids
"In clinical studies of  DRUGOTHER , patients taking  DRUGOTHER  concomitantly with  DRUG1  ( DRUGOTHER    , Genentech),  DRUGOTHER , inhaled  DRUGOTHER , other  DRUG2 , or parenteral  DRUGOTHER  demonstrated adverse experience profiles similar to the study population as a whole.",negative,dornase alfa,anti-pseudomonal antibiotics
"In clinical studies of  DRUGOTHER , patients taking  DRUGOTHER  concomitantly with  DRUG1  ( DRUGOTHER    , Genentech),  DRUGOTHER , inhaled  DRUGOTHER , other  DRUGOTHER , or parenteral  DRUG2  demonstrated adverse experience profiles similar to the study population as a whole.",negative,dornase alfa,aminoglycosides
"In clinical studies of  DRUGOTHER , patients taking  DRUGOTHER  concomitantly with  DRUGOTHER  ( DRUG1    , Genentech),  DRUG2 , inhaled  DRUGOTHER , other  DRUGOTHER , or parenteral  DRUGOTHER  demonstrated adverse experience profiles similar to the study population as a whole.",negative,PULMOZYME,(beta)-agonists
"In clinical studies of  DRUGOTHER , patients taking  DRUGOTHER  concomitantly with  DRUGOTHER  ( DRUG1    , Genentech),  DRUGOTHER , inhaled  DRUG2 , other  DRUGOTHER , or parenteral  DRUGOTHER  demonstrated adverse experience profiles similar to the study population as a whole.",negative,PULMOZYME,corticosteroids
"In clinical studies of  DRUGOTHER , patients taking  DRUGOTHER  concomitantly with  DRUGOTHER  ( DRUG1    , Genentech),  DRUGOTHER , inhaled  DRUGOTHER , other  DRUG2 , or parenteral  DRUGOTHER  demonstrated adverse experience profiles similar to the study population as a whole.",negative,PULMOZYME,anti-pseudomonal antibiotics
"In clinical studies of  DRUGOTHER , patients taking  DRUGOTHER  concomitantly with  DRUGOTHER  ( DRUG1    , Genentech),  DRUGOTHER , inhaled  DRUGOTHER , other  DRUGOTHER , or parenteral  DRUG2  demonstrated adverse experience profiles similar to the study population as a whole.",negative,PULMOZYME,aminoglycosides
"In clinical studies of  DRUGOTHER , patients taking  DRUGOTHER  concomitantly with  DRUGOTHER  ( DRUGOTHER    , Genentech),  DRUG1 , inhaled  DRUG2 , other  DRUGOTHER , or parenteral  DRUGOTHER  demonstrated adverse experience profiles similar to the study population as a whole.",negative,(beta)-agonists,corticosteroids
"In clinical studies of  DRUGOTHER , patients taking  DRUGOTHER  concomitantly with  DRUGOTHER  ( DRUGOTHER    , Genentech),  DRUG1 , inhaled  DRUGOTHER , other  DRUG2 , or parenteral  DRUGOTHER  demonstrated adverse experience profiles similar to the study population as a whole.",negative,(beta)-agonists,anti-pseudomonal antibiotics
"In clinical studies of  DRUGOTHER , patients taking  DRUGOTHER  concomitantly with  DRUGOTHER  ( DRUGOTHER    , Genentech),  DRUG1 , inhaled  DRUGOTHER , other  DRUGOTHER , or parenteral  DRUG2  demonstrated adverse experience profiles similar to the study population as a whole.",negative,(beta)-agonists,aminoglycosides
"In clinical studies of  DRUGOTHER , patients taking  DRUGOTHER  concomitantly with  DRUGOTHER  ( DRUGOTHER    , Genentech),  DRUGOTHER , inhaled  DRUG1 , other  DRUG2 , or parenteral  DRUGOTHER  demonstrated adverse experience profiles similar to the study population as a whole.",negative,corticosteroids,anti-pseudomonal antibiotics
"In clinical studies of  DRUGOTHER , patients taking  DRUGOTHER  concomitantly with  DRUGOTHER  ( DRUGOTHER    , Genentech),  DRUGOTHER , inhaled  DRUG1 , other  DRUGOTHER , or parenteral  DRUG2  demonstrated adverse experience profiles similar to the study population as a whole.",negative,corticosteroids,aminoglycosides
"In clinical studies of  DRUGOTHER , patients taking  DRUGOTHER  concomitantly with  DRUGOTHER  ( DRUGOTHER    , Genentech),  DRUGOTHER , inhaled  DRUGOTHER , other  DRUG1 , or parenteral  DRUG2  demonstrated adverse experience profiles similar to the study population as a whole.",negative,anti-pseudomonal antibiotics,aminoglycosides
Some  DRUG1  can enhance  DRUG2  toxicity by altering  DRUGOTHER  concentrations in serum and tissue.,effect,diuretics,aminoglycoside
Some  DRUG1  can enhance  DRUGOTHER  toxicity by altering  DRUG2  concentrations in serum and tissue.,negative,diuretics,antibiotic
Some  DRUGOTHER  can enhance  DRUG1  toxicity by altering  DRUG2  concentrations in serum and tissue.,negative,aminoglycoside,antibiotic
" DRUG1  should not be administered concomitantly with  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",advise,TOBI,ethacrynic acid
" DRUG1  should not be administered concomitantly with  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",advise,TOBI,furosemide
" DRUG1  should not be administered concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",advise,TOBI,urea
" DRUG1  should not be administered concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",advise,TOBI,mannitol
" DRUGOTHER  should not be administered concomitantly with  DRUG1 ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,ethacrynic acid,furosemide
" DRUGOTHER  should not be administered concomitantly with  DRUG1 ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,ethacrynic acid,urea
" DRUGOTHER  should not be administered concomitantly with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,ethacrynic acid,mannitol
" DRUGOTHER  should not be administered concomitantly with  DRUGOTHER ,  DRUG1 ,  DRUG2 , or  DRUGOTHER .",negative,furosemide,urea
" DRUGOTHER  should not be administered concomitantly with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , or  DRUG2 .",negative,furosemide,mannitol
" DRUGOTHER  should not be administered concomitantly with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , or  DRUG2 .",negative,urea,mannitol
"Effect of  DRUG1 -mediated CYP3A4 inhibition on clinical pharmacokinetics of  DRUG2  ( DRUGOTHER ), an orally active  DRUGOTHER .",negative,ketoconazole,panobinostat
"Effect of  DRUG1 -mediated CYP3A4 inhibition on clinical pharmacokinetics of  DRUGOTHER  ( DRUG2 ), an orally active  DRUGOTHER .",negative,ketoconazole,LBH589
"Effect of  DRUG1 -mediated CYP3A4 inhibition on clinical pharmacokinetics of  DRUGOTHER  ( DRUGOTHER ), an orally active  DRUG2 .",negative,ketoconazole,histone deacetylase inhibitor
"Effect of  DRUGOTHER -mediated CYP3A4 inhibition on clinical pharmacokinetics of  DRUG1  ( DRUG2 ), an orally active  DRUGOTHER .",negative,panobinostat,LBH589
"Effect of  DRUGOTHER -mediated CYP3A4 inhibition on clinical pharmacokinetics of  DRUG1  ( DRUGOTHER ), an orally active  DRUG2 .",negative,panobinostat,histone deacetylase inhibitor
"Effect of  DRUGOTHER -mediated CYP3A4 inhibition on clinical pharmacokinetics of  DRUGOTHER  ( DRUG1 ), an orally active  DRUG2 .",negative,LBH589,histone deacetylase inhibitor
"This study evaluated the effect of a potent CYP3A inhibitor,  DRUG1 , on the pharmacokinetics and safety of  DRUG2 .",negative,ketoconazole,panobinostat
"On day 8, a single  DRUG1  dose was co-administered with  DRUG2 .",negative,panobinostat,ketoconazole
"In the presence of  DRUG1 , there was 1.6- and 1.8-fold increase in C (max) and AUC of  DRUG2 , respectively.",mechanism,ketoconazole,panobinostat
Co-administration of  DRUG1  with CYP3A inhibitors is feasible as the observed increase in  DRUG2  PK parameters was not considered clinically relevant.,negative,panobinostat,panobinostat
"Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of  DRUG1  was not studied with CYP3A inhibitors, close monitoring of  DRUG2 -related adverse events is necessary.",negative,panobinostat,panobinostat
To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of  DRUG1  ( DRUG2 ).,negative,adeno-associated virus-2,AAV2
" DRUG1  containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,AAV2,collagenase
" DRUG1  containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,AAV2,hyaluronan lyase
" DRUG1  containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,AAV2,heparinase III
" DRUG1  containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,AAV2,chondroitin ABC lyase
" DRUGOTHER  containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including  DRUG1 ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,collagenase,hyaluronan lyase
" DRUGOTHER  containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including  DRUG1 ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,collagenase,heparinase III
" DRUGOTHER  containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,collagenase,chondroitin ABC lyase
" DRUGOTHER  containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including  DRUGOTHER ,  DRUG1 ,  DRUG2 , or  DRUGOTHER .",negative,hyaluronan lyase,heparinase III
" DRUGOTHER  containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , or  DRUG2 .",negative,hyaluronan lyase,chondroitin ABC lyase
" DRUGOTHER  containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , or  DRUG2 .",negative,heparinase III,chondroitin ABC lyase
The addition of  DRUG1  or  DRUG2  greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina.,negative,heparinase III,chondroitin ABC lyase
 DRUG1  had a limited effect and  DRUG2  was ineffective.,negative,Hyaluronan lyase,collagenase
Electroretinograms survived with higher concentrations of  DRUG1  and  DRUG2  than were required for optimal retinal transduction.,negative,heparinase III,chondroitin ABC lyase
 DRUG1 -mediated retinal transduction is improved by co-injection of  DRUG2  or  DRUGOTHER .,effect,AAV2,heparinase III
 DRUG1 -mediated retinal transduction is improved by co-injection of  DRUGOTHER  or  DRUG2 .,effect,AAV2,chondroitin ABC lyase
 DRUGOTHER -mediated retinal transduction is improved by co-injection of  DRUG1  or  DRUG2 .,negative,heparinase III,chondroitin ABC lyase
 DRUG1  is not known to interact with other drugs including  DRUG2  supplements;,negative,CHEMET,iron
"Concomitant administration of  DRUG1  with other chelation therapy, such as  DRUG2  is not recommended.",advise,CHEMET,CaNa 2 EDTA
 DRUG1 : Concomitant  DRUG2  administration decreased the mean AUC of total  DRUGOTHER  approximately 55%.,negative,Cholestyramine,cholestyramine
 DRUG1 : Concomitant  DRUGOTHER  administration decreased the mean AUC of total  DRUG2  approximately 55%.,negative,Cholestyramine,ezetimibe
 DRUGOTHER : Concomitant  DRUG1  administration decreased the mean AUC of total  DRUG2  approximately 55%.,mechanism,cholestyramine,ezetimibe
The incremental LDL-C reduction due to adding  DRUG1  to  DRUG2  may be reduced by this interaction.,effect,ezetimibe,cholestyramine
 DRUG1 : The safety and effectiveness of  DRUG2  administered with  DRUGOTHER  have not been established.,negative,Fibrates,ezetimibe
 DRUG1 : The safety and effectiveness of  DRUGOTHER  administered with  DRUG2  have not been established.,negative,Fibrates,fibrates
 DRUGOTHER : The safety and effectiveness of  DRUG1  administered with  DRUG2  have not been established.,negative,ezetimibe,fibrates
Co-administration of  DRUG1  with  DRUG2  is not recommended until use in patients is studied.,advise,ZETIA,fibrates
" DRUG1 : In a pharmacokinetic study, concomitant  DRUG2  administration increased total  DRUGOTHER  concentrations approximately 1.5-fold.",negative,Fenofibrate,fenofibrate
" DRUG1 : In a pharmacokinetic study, concomitant  DRUGOTHER  administration increased total  DRUG2  concentrations approximately 1.5-fold.",negative,Fenofibrate,ezetimibe
" DRUGOTHER : In a pharmacokinetic study, concomitant  DRUG1  administration increased total  DRUG2  concentrations approximately 1.5-fold.",mechanism,fenofibrate,ezetimibe
" DRUG1 : In a pharmacokinetic study, concomitant  DRUG2  administration increased total  DRUGOTHER  concentrations approximately 1.7-fold.",negative,Gemfibrozil,gemfibrozil
" DRUG1 : In a pharmacokinetic study, concomitant  DRUGOTHER  administration increased total  DRUG2  concentrations approximately 1.7-fold.",negative,Gemfibrozil,ezetimibe
" DRUGOTHER : In a pharmacokinetic study, concomitant  DRUG1  administration increased total  DRUG2  concentrations approximately 1.7-fold.",negative,gemfibrozil,ezetimibe
" DRUG1 : No clinically significant pharmacokinetic interactions were seen when  DRUG2  was co-administered with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,HMG-CoA reductase inhibitors,ezetimibe
" DRUG1 : No clinically significant pharmacokinetic interactions were seen when  DRUGOTHER  was co-administered with  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,HMG-CoA reductase inhibitors,atorvastatin
" DRUG1 : No clinically significant pharmacokinetic interactions were seen when  DRUGOTHER  was co-administered with  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,HMG-CoA reductase inhibitors,simvastatin
" DRUG1 : No clinically significant pharmacokinetic interactions were seen when  DRUGOTHER  was co-administered with  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,HMG-CoA reductase inhibitors,pravastatin
" DRUG1 : No clinically significant pharmacokinetic interactions were seen when  DRUGOTHER  was co-administered with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,HMG-CoA reductase inhibitors,lovastatin
" DRUG1 : No clinically significant pharmacokinetic interactions were seen when  DRUGOTHER  was co-administered with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,HMG-CoA reductase inhibitors,fluvastatin
" DRUGOTHER : No clinically significant pharmacokinetic interactions were seen when  DRUG1  was co-administered with  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,ezetimibe,atorvastatin
" DRUGOTHER : No clinically significant pharmacokinetic interactions were seen when  DRUG1  was co-administered with  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,ezetimibe,simvastatin
" DRUGOTHER : No clinically significant pharmacokinetic interactions were seen when  DRUG1  was co-administered with  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,ezetimibe,pravastatin
" DRUGOTHER : No clinically significant pharmacokinetic interactions were seen when  DRUG1  was co-administered with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,ezetimibe,lovastatin
" DRUGOTHER : No clinically significant pharmacokinetic interactions were seen when  DRUG1  was co-administered with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,ezetimibe,fluvastatin
" DRUGOTHER : No clinically significant pharmacokinetic interactions were seen when  DRUGOTHER  was co-administered with  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,atorvastatin,simvastatin
" DRUGOTHER : No clinically significant pharmacokinetic interactions were seen when  DRUGOTHER  was co-administered with  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,atorvastatin,pravastatin
" DRUGOTHER : No clinically significant pharmacokinetic interactions were seen when  DRUGOTHER  was co-administered with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,atorvastatin,lovastatin
" DRUGOTHER : No clinically significant pharmacokinetic interactions were seen when  DRUGOTHER  was co-administered with  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,atorvastatin,fluvastatin
" DRUGOTHER : No clinically significant pharmacokinetic interactions were seen when  DRUGOTHER  was co-administered with  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,simvastatin,pravastatin
" DRUGOTHER : No clinically significant pharmacokinetic interactions were seen when  DRUGOTHER  was co-administered with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,simvastatin,lovastatin
" DRUGOTHER : No clinically significant pharmacokinetic interactions were seen when  DRUGOTHER  was co-administered with  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,simvastatin,fluvastatin
" DRUGOTHER : No clinically significant pharmacokinetic interactions were seen when  DRUGOTHER  was co-administered with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , or  DRUGOTHER .",negative,pravastatin,lovastatin
" DRUGOTHER : No clinically significant pharmacokinetic interactions were seen when  DRUGOTHER  was co-administered with  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , or  DRUG2 .",negative,pravastatin,fluvastatin
" DRUGOTHER : No clinically significant pharmacokinetic interactions were seen when  DRUGOTHER  was co-administered with  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , or  DRUG2 .",negative,lovastatin,fluvastatin
" DRUG1 : The total  DRUG2  level increased 12-fold in one renal transplant patient receiving multiple medications, including  DRUGOTHER .",negative,Cyclosporine,ezetimibe
" DRUG1 : The total  DRUGOTHER  level increased 12-fold in one renal transplant patient receiving multiple medications, including  DRUG2 .",negative,Cyclosporine,cyclosporine
" DRUGOTHER : The total  DRUG1  level increased 12-fold in one renal transplant patient receiving multiple medications, including  DRUG2 .",mechanism,ezetimibe,cyclosporine
Patients who take both  DRUG1  and  DRUG2  should be carefully monitored.,advise,ezetimibe,cyclosporine
"Carcinogenesis, Mutagenesis, Impairment of Fertility A 104-week dietary carcinogenicity study with  DRUG1  was conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 times the human exposure at 10 mg daily based on AUC0-24hr for total  DRUG2 ).",negative,ezetimibe,ezetimibe
A 104-week dietary carcinogenicity study with  DRUG1  was also conducted in mice at doses up to 500 mg/kg/day (>150 times the human exposure at 10 mg daily based on AUC0-24hr for total  DRUG2 ).,negative,ezetimibe,ezetimibe
"In oral (gavage) fertility studies of  DRUG1  conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats (~7 times the human exposure at 10 mg daily based on AUC0-24hr for total  DRUG2 ).",negative,ezetimibe,ezetimibe
"In rabbits treated with  DRUG1 , an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day (150 times the human exposure at 10 mg daily based on AUC0-24hr for total  DRUG2 ).",negative,ezetimibe,ezetimibe
Multiple dose studies of  DRUG1  given in combination with  DRUG2  ( DRUGOTHER ) in rats and rabbits during organogenesis result in higher  DRUGOTHER  and statin exposures.,negative,ezetimibe,HMG-CoA reductase inhibitors
Multiple dose studies of  DRUG1  given in combination with  DRUGOTHER  ( DRUG2 ) in rats and rabbits during organogenesis result in higher  DRUGOTHER  and statin exposures.,negative,ezetimibe,statins
Multiple dose studies of  DRUG1  given in combination with  DRUGOTHER  ( DRUGOTHER ) in rats and rabbits during organogenesis result in higher  DRUG2  and statin exposures.,negative,ezetimibe,ezetimibe
Multiple dose studies of  DRUGOTHER  given in combination with  DRUG1  ( DRUG2 ) in rats and rabbits during organogenesis result in higher  DRUGOTHER  and statin exposures.,negative,HMG-CoA reductase inhibitors,statins
Multiple dose studies of  DRUGOTHER  given in combination with  DRUG1  ( DRUGOTHER ) in rats and rabbits during organogenesis result in higher  DRUG2  and statin exposures.,negative,HMG-CoA reductase inhibitors,ezetimibe
Multiple dose studies of  DRUGOTHER  given in combination with  DRUGOTHER  ( DRUG1 ) in rats and rabbits during organogenesis result in higher  DRUG2  and statin exposures.,negative,statins,ezetimibe
"When  DRUG1  is administered with an  DRUG2  in a woman of childbearing potential, refer to the pregnancy category and package labeling for the  DRUGOTHER .",negative,ZETIA,HMG-CoA reductase inhibitor
"When  DRUG1  is administered with an  DRUGOTHER  in a woman of childbearing potential, refer to the pregnancy category and package labeling for the  DRUG2 .",negative,ZETIA,HMG-CoA reductase inhibitor
"When  DRUGOTHER  is administered with an  DRUG1  in a woman of childbearing potential, refer to the pregnancy category and package labeling for the  DRUG2 .",negative,HMG-CoA reductase inhibitor,HMG-CoA reductase inhibitor
"While co-administration of  DRUG1     appeared to increase the clearance of  DRUG2  by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of  DRUGOTHER .",mechanism,ZAVESCA,Cerezyme
"While co-administration of  DRUG1     appeared to increase the clearance of  DRUGOTHER  by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of  DRUG2 .",negative,ZAVESCA,Cerezyme
"While co-administration of  DRUGOTHER     appeared to increase the clearance of  DRUG1  by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of  DRUG2 .",negative,Cerezyme,Cerezyme
Combination therapy with  DRUG1     ( DRUG2 ) and  DRUGOTHER     is not indicated.,negative,Cerezyme,imiglucerase
Combination therapy with  DRUG1     ( DRUGOTHER ) and  DRUG2     is not indicated.,advise,Cerezyme,ZAVESCA
Combination therapy with  DRUGOTHER     ( DRUG1 ) and  DRUG2     is not indicated.,advise,imiglucerase,ZAVESCA
"Interaction with  DRUG1 : Although  DRUG2  does not itself cause orthostatic hypotension, its administration to patients already receiving  DRUGOTHER  can result in profound orthostatic effects.",negative,Guanethidine,minoxidil
"Interaction with  DRUG1 : Although  DRUGOTHER  does not itself cause orthostatic hypotension, its administration to patients already receiving  DRUG2  can result in profound orthostatic effects.",negative,Guanethidine,guanethidine
"Interaction with  DRUGOTHER : Although  DRUG1  does not itself cause orthostatic hypotension, its administration to patients already receiving  DRUG2  can result in profound orthostatic effects.",effect,minoxidil,guanethidine
If at all possible  DRUG1  should be discontinued well before  DRUG2  is begun.,advise,guanethidine,minoxidil
"however, in patients with Paget's Disease prior  DRUG1  use appears to reduce the anti-resorptive response to  DRUG2  nasal spray.",effect,diphosphonate,Calcitonin (salmon)
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,theophylline
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,cisapride
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,antipyrine
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,caffeine
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,carbamazepine
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,diazepam
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,desmethyldiazepam
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,diclofenac
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,naproxen
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,piroxicam
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,digoxin
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,ethanol
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,glyburide
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG2  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,contraceptive
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG2 / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,levonorgestrel
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,ethinyl estradiol
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,metoprolol
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,nifedipine
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,phenytoin
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,warfarin
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,midazolam
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,pantoprazole,clarithromycin
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,pantoprazole,metronidazole
"Based on studies evaluating possible interactions of  DRUG1  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,pantoprazole,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,theophylline,cisapride
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,theophylline,antipyrine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,theophylline,caffeine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,theophylline,carbamazepine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,theophylline,diazepam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,theophylline,desmethyldiazepam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,theophylline,diclofenac
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,theophylline,naproxen
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,theophylline,piroxicam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,theophylline,digoxin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,theophylline,ethanol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,theophylline,glyburide
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG2  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,theophylline,contraceptive
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG2 / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,theophylline,levonorgestrel
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,theophylline,ethinyl estradiol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,theophylline,metoprolol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,theophylline,nifedipine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,theophylline,phenytoin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,theophylline,warfarin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,theophylline,midazolam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,theophylline,clarithromycin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,theophylline,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,theophylline,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,cisapride,antipyrine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,cisapride,caffeine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,cisapride,carbamazepine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,cisapride,diazepam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,cisapride,desmethyldiazepam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,cisapride,diclofenac
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,cisapride,naproxen
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,cisapride,piroxicam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,cisapride,digoxin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,cisapride,ethanol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,cisapride,glyburide
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG2  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,cisapride,contraceptive
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG2 / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,cisapride,levonorgestrel
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,cisapride,ethinyl estradiol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,cisapride,metoprolol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,cisapride,nifedipine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,cisapride,phenytoin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,cisapride,warfarin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,cisapride,midazolam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,cisapride,clarithromycin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,cisapride,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,cisapride,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,antipyrine,caffeine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,antipyrine,carbamazepine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,antipyrine,diazepam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,antipyrine,desmethyldiazepam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,antipyrine,diclofenac
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,antipyrine,naproxen
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,antipyrine,piroxicam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,antipyrine,digoxin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,antipyrine,ethanol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,antipyrine,glyburide
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG2  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,antipyrine,contraceptive
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG2 / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,antipyrine,levonorgestrel
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,antipyrine,ethinyl estradiol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,antipyrine,metoprolol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,antipyrine,nifedipine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,antipyrine,phenytoin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,antipyrine,warfarin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,antipyrine,midazolam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,antipyrine,clarithromycin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,antipyrine,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,antipyrine,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,caffeine,carbamazepine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,caffeine,diazepam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,caffeine,desmethyldiazepam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,caffeine,diclofenac
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,caffeine,naproxen
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,caffeine,piroxicam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,caffeine,digoxin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,caffeine,ethanol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,caffeine,glyburide
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG2  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,caffeine,contraceptive
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG2 / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,caffeine,levonorgestrel
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,caffeine,ethinyl estradiol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,caffeine,metoprolol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,caffeine,nifedipine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,caffeine,phenytoin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,caffeine,warfarin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,caffeine,midazolam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,caffeine,clarithromycin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,caffeine,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,caffeine,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,carbamazepine,diazepam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (and its active metabolite,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,carbamazepine,desmethyldiazepam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,carbamazepine,diclofenac
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,carbamazepine,naproxen
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,carbamazepine,piroxicam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,carbamazepine,digoxin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,carbamazepine,ethanol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,carbamazepine,glyburide
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG2  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,carbamazepine,contraceptive
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG2 / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,carbamazepine,levonorgestrel
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,carbamazepine,ethinyl estradiol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,carbamazepine,metoprolol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,carbamazepine,nifedipine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,carbamazepine,phenytoin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,carbamazepine,warfarin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,carbamazepine,midazolam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,carbamazepine,clarithromycin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,carbamazepine,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,carbamazepine,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (and its active metabolite,  DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diazepam,desmethyldiazepam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (and its active metabolite,  DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diazepam,diclofenac
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diazepam,naproxen
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diazepam,piroxicam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diazepam,digoxin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diazepam,ethanol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diazepam,glyburide
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG2  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diazepam,contraceptive
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG2 / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diazepam,levonorgestrel
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diazepam,ethinyl estradiol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diazepam,metoprolol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diazepam,nifedipine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diazepam,phenytoin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diazepam,warfarin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diazepam,midazolam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,diazepam,clarithromycin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,diazepam,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,diazepam,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG1 ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,desmethyldiazepam,diclofenac
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG1 ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,desmethyldiazepam,naproxen
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,desmethyldiazepam,piroxicam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,desmethyldiazepam,digoxin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,desmethyldiazepam,ethanol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,desmethyldiazepam,glyburide
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG2  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,desmethyldiazepam,contraceptive
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG2 / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,desmethyldiazepam,levonorgestrel
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,desmethyldiazepam,ethinyl estradiol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,desmethyldiazepam,metoprolol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,desmethyldiazepam,nifedipine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,desmethyldiazepam,phenytoin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,desmethyldiazepam,warfarin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,desmethyldiazepam,midazolam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,desmethyldiazepam,clarithromycin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,desmethyldiazepam,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,desmethyldiazepam,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diclofenac,naproxen
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diclofenac,piroxicam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diclofenac,digoxin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diclofenac,ethanol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diclofenac,glyburide
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG2  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diclofenac,contraceptive
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG2 / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diclofenac,levonorgestrel
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diclofenac,ethinyl estradiol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diclofenac,metoprolol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diclofenac,nifedipine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diclofenac,phenytoin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diclofenac,warfarin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,diclofenac,midazolam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,diclofenac,clarithromycin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,diclofenac,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,diclofenac,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,naproxen,piroxicam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,naproxen,digoxin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,naproxen,ethanol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,naproxen,glyburide
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG2  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,naproxen,contraceptive
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG2 / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,naproxen,levonorgestrel
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,naproxen,ethinyl estradiol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,naproxen,metoprolol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,naproxen,nifedipine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,naproxen,phenytoin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,naproxen,warfarin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,naproxen,midazolam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,naproxen,clarithromycin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,naproxen,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,naproxen,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,piroxicam,digoxin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,piroxicam,ethanol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,piroxicam,glyburide
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG2  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,piroxicam,contraceptive
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG2 / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,piroxicam,levonorgestrel
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,piroxicam,ethinyl estradiol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,piroxicam,metoprolol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,piroxicam,nifedipine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,piroxicam,phenytoin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,piroxicam,warfarin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,piroxicam,midazolam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,piroxicam,clarithromycin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,piroxicam,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,piroxicam,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,digoxin,ethanol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,digoxin,glyburide
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG2  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,digoxin,contraceptive
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG2 / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,digoxin,levonorgestrel
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,digoxin,ethinyl estradiol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,digoxin,metoprolol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,digoxin,nifedipine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,digoxin,phenytoin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,digoxin,warfarin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,digoxin,midazolam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,digoxin,clarithromycin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,digoxin,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,digoxin,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,ethanol,glyburide
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , an oral  DRUG2  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,ethanol,contraceptive
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG2 / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,ethanol,levonorgestrel
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,ethanol,ethinyl estradiol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,ethanol,metoprolol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,ethanol,nifedipine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,ethanol,phenytoin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,ethanol,warfarin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,ethanol,midazolam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,ethanol,clarithromycin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,ethanol,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,ethanol,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , an oral  DRUG2  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,glyburide,contraceptive
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , an oral  DRUGOTHER  ( DRUG2 / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,glyburide,levonorgestrel
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , an oral  DRUGOTHER  ( DRUGOTHER / DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,glyburide,ethinyl estradiol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,glyburide,metoprolol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,glyburide,nifedipine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,glyburide,phenytoin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,glyburide,warfarin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,glyburide,midazolam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,glyburide,clarithromycin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,glyburide,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,glyburide,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG1  ( DRUG2 / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,contraceptive,levonorgestrel
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG1  ( DRUGOTHER / DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,contraceptive,ethinyl estradiol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG1  ( DRUGOTHER / DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,contraceptive,metoprolol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG1  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,contraceptive,nifedipine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG1  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,contraceptive,phenytoin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG1  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,contraceptive,warfarin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG1  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,contraceptive,midazolam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG1  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,contraceptive,clarithromycin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG1  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,contraceptive,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUG1  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,contraceptive,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG1 / DRUG2 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,levonorgestrel,ethinyl estradiol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG1 / DRUGOTHER ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,levonorgestrel,metoprolol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG1 / DRUGOTHER ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,levonorgestrel,nifedipine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG1 / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,levonorgestrel,phenytoin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG1 / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,levonorgestrel,warfarin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG1 / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,levonorgestrel,midazolam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG1 / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,levonorgestrel,clarithromycin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG1 / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,levonorgestrel,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUG1 / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,levonorgestrel,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUG1 ),  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,ethinyl estradiol,metoprolol
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUG1 ),  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,ethinyl estradiol,nifedipine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,ethinyl estradiol,phenytoin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,ethinyl estradiol,warfarin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,ethinyl estradiol,midazolam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,ethinyl estradiol,clarithromycin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,ethinyl estradiol,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUG1 ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,ethinyl estradiol,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,metoprolol,nifedipine
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,metoprolol,phenytoin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,metoprolol,warfarin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,metoprolol,midazolam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,metoprolol,clarithromycin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,metoprolol,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,metoprolol,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,nifedipine,phenytoin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,nifedipine,warfarin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,nifedipine,midazolam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,nifedipine,clarithromycin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,nifedipine,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,nifedipine,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,phenytoin,warfarin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,phenytoin,midazolam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,phenytoin,clarithromycin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,phenytoin,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,phenytoin,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,warfarin,midazolam
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,warfarin,clarithromycin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,warfarin,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,warfarin,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,midazolam,clarithromycin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,midazolam,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,midazolam,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , or  DRUGOTHER .",negative,clarithromycin,metronidazole
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , or  DRUG2 .",negative,clarithromycin,amoxicillin
"Based on studies evaluating possible interactions of  DRUGOTHER  with other drugs, no dosage adjustment is needed with concomitant use of the following:  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  (and its active metabolite,  DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , an oral  DRUGOTHER  ( DRUGOTHER / DRUGOTHER ),  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , or  DRUG2 .",negative,metronidazole,amoxicillin
"Therefore, when coadministered with  DRUG1 , adjustment of the dosage of  DRUG2  or of such drugs may not be necessary.",negative,pantoprazole,pantoprazole
"There have been postmarketing reports of increased INR and prothrombin time in patients receiving  DRUG1 , including  DRUG2 , and  DRUGOTHER  concomitantly.",negative,proton pump inhibitors,pantoprazole
"There have been postmarketing reports of increased INR and prothrombin time in patients receiving  DRUG1 , including  DRUGOTHER , and  DRUG2  concomitantly.",effect,proton pump inhibitors,warfarin
"There have been postmarketing reports of increased INR and prothrombin time in patients receiving  DRUGOTHER , including  DRUG1 , and  DRUG2  concomitantly.",effect,pantoprazole,warfarin
Patients treated with  DRUG1  and  DRUG2  concomitantly should be monitored for increases in INR and prothrombin time.,advise,proton pump inhibitors,warfarin
"Because of profound and long lasting inhibition of gastric acid secretion,  DRUG1  may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg,  DRUG2 ,  DRUGOTHER  esters, and  DRUGOTHER  salts).",mechanism,pantoprazole,ketoconazole
"Because of profound and long lasting inhibition of gastric acid secretion,  DRUG1  may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg,  DRUGOTHER ,  DRUG2  esters, and  DRUGOTHER  salts).",mechanism,pantoprazole,ampicillin
"Because of profound and long lasting inhibition of gastric acid secretion,  DRUG1  may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg,  DRUGOTHER ,  DRUGOTHER  esters, and  DRUG2  salts).",mechanism,pantoprazole,iron
"Because of profound and long lasting inhibition of gastric acid secretion,  DRUGOTHER  may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg,  DRUG1 ,  DRUG2  esters, and  DRUGOTHER  salts).",negative,ketoconazole,ampicillin
"Because of profound and long lasting inhibition of gastric acid secretion,  DRUGOTHER  may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg,  DRUG1 ,  DRUGOTHER  esters, and  DRUG2  salts).",negative,ketoconazole,iron
"Because of profound and long lasting inhibition of gastric acid secretion,  DRUGOTHER  may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg,  DRUGOTHER ,  DRUG1  esters, and  DRUG2  salts).",negative,ampicillin,iron
"Laboratory Tests There have been reports of false-positive urine screening tests for  DRUG1  ( DRUG2 ) in patients receiving most  DRUGOTHER , including  DRUGOTHER .",negative,tetrahydrocannabinol,THC
"Laboratory Tests There have been reports of false-positive urine screening tests for  DRUG1  ( DRUGOTHER ) in patients receiving most  DRUG2 , including  DRUGOTHER .",negative,tetrahydrocannabinol,proton pump inhibitors
"Laboratory Tests There have been reports of false-positive urine screening tests for  DRUG1  ( DRUGOTHER ) in patients receiving most  DRUGOTHER , including  DRUG2 .",negative,tetrahydrocannabinol,pantoprazole
"Laboratory Tests There have been reports of false-positive urine screening tests for  DRUGOTHER  ( DRUG1 ) in patients receiving most  DRUG2 , including  DRUGOTHER .",negative,THC,proton pump inhibitors
"Laboratory Tests There have been reports of false-positive urine screening tests for  DRUGOTHER  ( DRUG1 ) in patients receiving most  DRUGOTHER , including  DRUG2 .",negative,THC,pantoprazole
"Laboratory Tests There have been reports of false-positive urine screening tests for  DRUGOTHER  ( DRUGOTHER ) in patients receiving most  DRUG1 , including  DRUG2 .",negative,proton pump inhibitors,pantoprazole
"The aim of the present study was to investigate whether HB-EGF is a therapeutic target for T-ALL, and to further elucidate the antitumor effects of a specific inhibitor of HB-EGF,  DRUG1  ( DRUG2 ).",negative,cross-reacting material 197,CRM197
"We elucidated the expression of HB-EGF in T-ALL cell lines, and evaluated the effect of  DRUG1  on these cells alone or in combination with  DRUG2 .",negative,CRM197,anticancer agent
" DRUG1  induced apoptosis, and furthermore, the combination of  DRUG2  plus  DRUGOTHER  enhanced cytotoxicity in a T-ALL cell line.",negative,CRM197,CRM197
" DRUG1  induced apoptosis, and furthermore, the combination of  DRUGOTHER  plus  DRUG2  enhanced cytotoxicity in a T-ALL cell line.",negative,CRM197,doxorubicin
" DRUGOTHER  induced apoptosis, and furthermore, the combination of  DRUG1  plus  DRUG2  enhanced cytotoxicity in a T-ALL cell line.",effect,CRM197,doxorubicin
" DRUG1  has been reported to accelerate the metabolism of  DRUG2  by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for  DRUGOTHER .",mechanism,Mitotane,warfarin
" DRUG1  has been reported to accelerate the metabolism of  DRUGOTHER  by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for  DRUG2 .",negative,Mitotane,warfarin
" DRUGOTHER  has been reported to accelerate the metabolism of  DRUG1  by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for  DRUG2 .",negative,warfarin,warfarin
"Therefore, physicians should closely monitor patients for a change in  DRUG1  dosage requirements when administering  DRUG2  to patients on  DRUGOTHER .",negative,anticoagulant,Mitotane
"Therefore, physicians should closely monitor patients for a change in  DRUG1  dosage requirements when administering  DRUGOTHER  to patients on  DRUG2 .",negative,anticoagulant,coumarin-type anticoagulants
"Therefore, physicians should closely monitor patients for a change in  DRUGOTHER  dosage requirements when administering  DRUG1  to patients on  DRUG2 .",advise,Mitotane,coumarin-type anticoagulants
"The bioavailability of  DRUG1  is decreased 80% by  DRUG2 , when  DRUGOTHER  and  DRUGOTHER  are administered at the same time, and 60% by some  DRUGOTHER - or  DRUGOTHER -containing  DRUGOTHER , when administered 1 hour before  DRUGOTHER .",mechanism,SKELID,calcium
"The bioavailability of  DRUG1  is decreased 80% by  DRUGOTHER , when  DRUG2  and  DRUGOTHER  are administered at the same time, and 60% by some  DRUGOTHER - or  DRUGOTHER -containing  DRUGOTHER , when administered 1 hour before  DRUGOTHER .",negative,SKELID,calcium
"The bioavailability of  DRUG1  is decreased 80% by  DRUGOTHER , when  DRUGOTHER  and  DRUG2  are administered at the same time, and 60% by some  DRUGOTHER - or  DRUGOTHER -containing  DRUGOTHER , when administered 1 hour before  DRUGOTHER .",negative,SKELID,SKELID
"The bioavailability of  DRUG1  is decreased 80% by  DRUGOTHER , when  DRUGOTHER  and  DRUGOTHER  are administered at the same time, and 60% by some  DRUG2 - or  DRUGOTHER -containing  DRUGOTHER , when administered 1 hour before  DRUGOTHER .",negative,SKELID,aluminum
"The bioavailability of  DRUG1  is decreased 80% by  DRUGOTHER , when  DRUGOTHER  and  DRUGOTHER  are administered at the same time, and 60% by some  DRUGOTHER - or  DRUG2 -containing  DRUGOTHER , when administered 1 hour before  DRUGOTHER .",negative,SKELID,magnesium
"The bioavailability of  DRUG1  is decreased 80% by  DRUGOTHER , when  DRUGOTHER  and  DRUGOTHER  are administered at the same time, and 60% by some  DRUGOTHER - or  DRUGOTHER -containing  DRUG2 , when administered 1 hour before  DRUGOTHER .",negative,SKELID,antacids
"The bioavailability of  DRUG1  is decreased 80% by  DRUGOTHER , when  DRUGOTHER  and  DRUGOTHER  are administered at the same time, and 60% by some  DRUGOTHER - or  DRUGOTHER -containing  DRUGOTHER , when administered 1 hour before  DRUG2 .",negative,SKELID,SKELID
"The bioavailability of  DRUGOTHER  is decreased 80% by  DRUG1 , when  DRUG2  and  DRUGOTHER  are administered at the same time, and 60% by some  DRUGOTHER - or  DRUGOTHER -containing  DRUGOTHER , when administered 1 hour before  DRUGOTHER .",negative,calcium,calcium
"The bioavailability of  DRUGOTHER  is decreased 80% by  DRUG1 , when  DRUGOTHER  and  DRUG2  are administered at the same time, and 60% by some  DRUGOTHER - or  DRUGOTHER -containing  DRUGOTHER , when administered 1 hour before  DRUGOTHER .",negative,calcium,SKELID
"The bioavailability of  DRUGOTHER  is decreased 80% by  DRUG1 , when  DRUGOTHER  and  DRUGOTHER  are administered at the same time, and 60% by some  DRUG2 - or  DRUGOTHER -containing  DRUGOTHER , when administered 1 hour before  DRUGOTHER .",negative,calcium,aluminum
"The bioavailability of  DRUGOTHER  is decreased 80% by  DRUG1 , when  DRUGOTHER  and  DRUGOTHER  are administered at the same time, and 60% by some  DRUGOTHER - or  DRUG2 -containing  DRUGOTHER , when administered 1 hour before  DRUGOTHER .",negative,calcium,magnesium
"The bioavailability of  DRUGOTHER  is decreased 80% by  DRUG1 , when  DRUGOTHER  and  DRUGOTHER  are administered at the same time, and 60% by some  DRUGOTHER - or  DRUGOTHER -containing  DRUG2 , when administered 1 hour before  DRUGOTHER .",negative,calcium,antacids
"The bioavailability of  DRUGOTHER  is decreased 80% by  DRUG1 , when  DRUGOTHER  and  DRUGOTHER  are administered at the same time, and 60% by some  DRUGOTHER - or  DRUGOTHER -containing  DRUGOTHER , when administered 1 hour before  DRUG2 .",negative,calcium,SKELID
"The bioavailability of  DRUGOTHER  is decreased 80% by  DRUGOTHER , when  DRUG1  and  DRUG2  are administered at the same time, and 60% by some  DRUGOTHER - or  DRUGOTHER -containing  DRUGOTHER , when administered 1 hour before  DRUGOTHER .",negative,calcium,SKELID
"The bioavailability of  DRUGOTHER  is decreased 80% by  DRUGOTHER , when  DRUG1  and  DRUGOTHER  are administered at the same time, and 60% by some  DRUG2 - or  DRUGOTHER -containing  DRUGOTHER , when administered 1 hour before  DRUGOTHER .",negative,calcium,aluminum
"The bioavailability of  DRUGOTHER  is decreased 80% by  DRUGOTHER , when  DRUG1  and  DRUGOTHER  are administered at the same time, and 60% by some  DRUGOTHER - or  DRUG2 -containing  DRUGOTHER , when administered 1 hour before  DRUGOTHER .",negative,calcium,magnesium
"The bioavailability of  DRUGOTHER  is decreased 80% by  DRUGOTHER , when  DRUG1  and  DRUGOTHER  are administered at the same time, and 60% by some  DRUGOTHER - or  DRUGOTHER -containing  DRUG2 , when administered 1 hour before  DRUGOTHER .",negative,calcium,antacids
"The bioavailability of  DRUGOTHER  is decreased 80% by  DRUGOTHER , when  DRUG1  and  DRUGOTHER  are administered at the same time, and 60% by some  DRUGOTHER - or  DRUGOTHER -containing  DRUGOTHER , when administered 1 hour before  DRUG2 .",negative,calcium,SKELID
"The bioavailability of  DRUGOTHER  is decreased 80% by  DRUGOTHER , when  DRUGOTHER  and  DRUG1  are administered at the same time, and 60% by some  DRUG2 - or  DRUGOTHER -containing  DRUGOTHER , when administered 1 hour before  DRUGOTHER .",negative,SKELID,aluminum
"The bioavailability of  DRUGOTHER  is decreased 80% by  DRUGOTHER , when  DRUGOTHER  and  DRUG1  are administered at the same time, and 60% by some  DRUGOTHER - or  DRUG2 -containing  DRUGOTHER , when administered 1 hour before  DRUGOTHER .",negative,SKELID,magnesium
"The bioavailability of  DRUGOTHER  is decreased 80% by  DRUGOTHER , when  DRUGOTHER  and  DRUG1  are administered at the same time, and 60% by some  DRUGOTHER - or  DRUGOTHER -containing  DRUG2 , when administered 1 hour before  DRUGOTHER .",negative,SKELID,antacids
"The bioavailability of  DRUGOTHER  is decreased 80% by  DRUGOTHER , when  DRUGOTHER  and  DRUG1  are administered at the same time, and 60% by some  DRUGOTHER - or  DRUGOTHER -containing  DRUGOTHER , when administered 1 hour before  DRUG2 .",negative,SKELID,SKELID
"The bioavailability of  DRUGOTHER  is decreased 80% by  DRUGOTHER , when  DRUGOTHER  and  DRUGOTHER  are administered at the same time, and 60% by some  DRUG1 - or  DRUG2 -containing  DRUGOTHER , when administered 1 hour before  DRUGOTHER .",negative,aluminum,magnesium
"The bioavailability of  DRUGOTHER  is decreased 80% by  DRUGOTHER , when  DRUGOTHER  and  DRUGOTHER  are administered at the same time, and 60% by some  DRUG1 - or  DRUGOTHER -containing  DRUG2 , when administered 1 hour before  DRUGOTHER .",negative,aluminum,antacids
"The bioavailability of  DRUGOTHER  is decreased 80% by  DRUGOTHER , when  DRUGOTHER  and  DRUGOTHER  are administered at the same time, and 60% by some  DRUG1 - or  DRUGOTHER -containing  DRUGOTHER , when administered 1 hour before  DRUG2 .",mechanism,aluminum,SKELID
"The bioavailability of  DRUGOTHER  is decreased 80% by  DRUGOTHER , when  DRUGOTHER  and  DRUGOTHER  are administered at the same time, and 60% by some  DRUGOTHER - or  DRUG1 -containing  DRUG2 , when administered 1 hour before  DRUGOTHER .",negative,magnesium,antacids
"The bioavailability of  DRUGOTHER  is decreased 80% by  DRUGOTHER , when  DRUGOTHER  and  DRUGOTHER  are administered at the same time, and 60% by some  DRUGOTHER - or  DRUG1 -containing  DRUGOTHER , when administered 1 hour before  DRUG2 .",mechanism,magnesium,SKELID
"The bioavailability of  DRUGOTHER  is decreased 80% by  DRUGOTHER , when  DRUGOTHER  and  DRUGOTHER  are administered at the same time, and 60% by some  DRUGOTHER - or  DRUGOTHER -containing  DRUG1 , when administered 1 hour before  DRUG2 .",negative,antacids,SKELID
 DRUG1  may decrease bioavailability of  DRUG2  by up to 50% when taken 2 hours after  DRUGOTHER .,mechanism,Aspirin,SKELID
 DRUG1  may decrease bioavailability of  DRUGOTHER  by up to 50% when taken 2 hours after  DRUG2 .,negative,Aspirin,SKELID
 DRUGOTHER  may decrease bioavailability of  DRUG1  by up to 50% when taken 2 hours after  DRUG2 .,negative,SKELID,SKELID
The bioavailability of  DRUG1  is increased 2-4 fold by  DRUG2  but is not significantly altered by coadministration of  DRUGOTHER .,mechanism,SKELID,indomethacin
The bioavailability of  DRUG1  is increased 2-4 fold by  DRUGOTHER  but is not significantly altered by coadministration of  DRUG2 .,negative,SKELID,diclofenac
The bioavailability of  DRUGOTHER  is increased 2-4 fold by  DRUG1  but is not significantly altered by coadministration of  DRUG2 .,negative,indomethacin,diclofenac
The pharmacokinetic parameters of  DRUG1  are not significantly modified by  DRUG2  coadministration.,negative,digoxin,SKELID
In vitro studies show that  DRUG1  does not displace  DRUG2  from its binding site on protein.,negative,tiludronate,warfarin
"CYP 3A4 Inhibitors (e.g.  DRUG1  and  DRUG2 ) There have been rare reports of serious adverse events in connection with the coadministration of certain  DRUGOTHER  (e.g.  DRUGOTHER  and  DRUGOTHER ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.",negative,Macrolide Antibiotics,Protease Inhibitors
"CYP 3A4 Inhibitors (e.g.  DRUG1  and  DRUGOTHER ) There have been rare reports of serious adverse events in connection with the coadministration of certain  DRUG2  (e.g.  DRUGOTHER  and  DRUGOTHER ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.",negative,Macrolide Antibiotics,ergot alkaloid drugs
"CYP 3A4 Inhibitors (e.g.  DRUG1  and  DRUGOTHER ) There have been rare reports of serious adverse events in connection with the coadministration of certain  DRUGOTHER  (e.g.  DRUG2  and  DRUGOTHER ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.",negative,Macrolide Antibiotics,dihydroergotamine
"CYP 3A4 Inhibitors (e.g.  DRUG1  and  DRUGOTHER ) There have been rare reports of serious adverse events in connection with the coadministration of certain  DRUGOTHER  (e.g.  DRUGOTHER  and  DRUG2 ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.",negative,Macrolide Antibiotics,ergotamine
"CYP 3A4 Inhibitors (e.g.  DRUGOTHER  and  DRUG1 ) There have been rare reports of serious adverse events in connection with the coadministration of certain  DRUG2  (e.g.  DRUGOTHER  and  DRUGOTHER ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.",negative,Protease Inhibitors,ergot alkaloid drugs
"CYP 3A4 Inhibitors (e.g.  DRUGOTHER  and  DRUG1 ) There have been rare reports of serious adverse events in connection with the coadministration of certain  DRUGOTHER  (e.g.  DRUG2  and  DRUGOTHER ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.",negative,Protease Inhibitors,dihydroergotamine
"CYP 3A4 Inhibitors (e.g.  DRUGOTHER  and  DRUG1 ) There have been rare reports of serious adverse events in connection with the coadministration of certain  DRUGOTHER  (e.g.  DRUGOTHER  and  DRUG2 ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.",negative,Protease Inhibitors,ergotamine
"CYP 3A4 Inhibitors (e.g.  DRUGOTHER  and  DRUGOTHER ) There have been rare reports of serious adverse events in connection with the coadministration of certain  DRUG1  (e.g.  DRUG2  and  DRUGOTHER ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.",negative,ergot alkaloid drugs,dihydroergotamine
"CYP 3A4 Inhibitors (e.g.  DRUGOTHER  and  DRUGOTHER ) There have been rare reports of serious adverse events in connection with the coadministration of certain  DRUG1  (e.g.  DRUGOTHER  and  DRUG2 ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.",negative,ergot alkaloid drugs,ergotamine
"CYP 3A4 Inhibitors (e.g.  DRUGOTHER  and  DRUGOTHER ) There have been rare reports of serious adverse events in connection with the coadministration of certain  DRUGOTHER  (e.g.  DRUG1  and  DRUG2 ) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.",negative,dihydroergotamine,ergotamine
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUG1  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,macrolide antibiotics,erythromycin
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUG1  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,macrolide antibiotics,troleandomycin
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,macrolide antibiotics,clarithromycin
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,macrolide antibiotics,HIV protease inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,macrolide antibiotics,reverse transcriptase inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,macrolide antibiotics,ritonavir
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,macrolide antibiotics,indinavir
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,macrolide antibiotics,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,macrolide antibiotics,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,macrolide antibiotics,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,macrolide antibiotics,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,macrolide antibiotics,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,macrolide antibiotics,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,erythromycin,troleandomycin
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,erythromycin,clarithromycin
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,erythromycin,HIV protease inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,erythromycin,reverse transcriptase inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,erythromycin,ritonavir
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,erythromycin,indinavir
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,erythromycin,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,erythromycin,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,erythromycin,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,erythromycin,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,erythromycin,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,erythromycin,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,troleandomycin,clarithromycin
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUG2  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,troleandomycin,HIV protease inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  or  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,troleandomycin,reverse transcriptase inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,troleandomycin,ritonavir
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,troleandomycin,indinavir
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,troleandomycin,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,troleandomycin,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,troleandomycin,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,troleandomycin,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,troleandomycin,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,troleandomycin,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUG2  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,clarithromycin,HIV protease inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  or  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,clarithromycin,reverse transcriptase inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,clarithromycin,ritonavir
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,clarithromycin,indinavir
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,clarithromycin,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,clarithromycin,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,clarithromycin,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,clarithromycin,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,clarithromycin,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,clarithromycin,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  or  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,HIV protease inhibitors,reverse transcriptase inhibitors
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  or  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,HIV protease inhibitors,ritonavir
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,HIV protease inhibitors,indinavir
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,HIV protease inhibitors,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,HIV protease inhibitors,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,HIV protease inhibitors,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,HIV protease inhibitors,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,HIV protease inhibitors,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,HIV protease inhibitors,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUG1  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,reverse transcriptase inhibitors,ritonavir
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUG1  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,reverse transcriptase inhibitors,indinavir
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,reverse transcriptase inhibitors,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,reverse transcriptase inhibitors,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,reverse transcriptase inhibitors,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,reverse transcriptase inhibitors,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,reverse transcriptase inhibitors,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,reverse transcriptase inhibitors,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,ritonavir,indinavir
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,ritonavir,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,ritonavir,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,ritonavir,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,ritonavir,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,ritonavir,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,ritonavir,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,indinavir,nelfinavir
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,indinavir,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ) or  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,indinavir,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,indinavir,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,indinavir,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,indinavir,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,nelfinavir,delavirdine
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ) or  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,nelfinavir,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,nelfinavir,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,nelfinavir,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,nelfinavir,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ) or  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,delavirdine,azole antifungals
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ) or  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,delavirdine,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,delavirdine,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,delavirdine,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUG1  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,azole antifungals,ketoconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUG1  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,azole antifungals,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,azole antifungals,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ).",negative,ketoconazole,itraconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ).",negative,ketoconazole,voriconazole
"Examples of some of the more potent CYP 3A4 inhibitors include  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER  or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ).",negative,itraconazole,voriconazole
"Less potent inhibitors include  DRUG1 ,  DRUG2 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,saquinavir,nefazodone
"Less potent inhibitors include  DRUG1 ,  DRUGOTHER ,  DRUG2 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,saquinavir,fluconazole
"Less potent inhibitors include  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,saquinavir,fluoxetine
"Less potent inhibitors include  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,saquinavir,fluvoxamine
"Less potent inhibitors include  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,saquinavir,zileuton
"Less potent inhibitors include  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,saquinavir,clotrimazole
"Less potent inhibitors include  DRUGOTHER ,  DRUG1 ,  DRUG2 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,nefazodone,fluconazole
"Less potent inhibitors include  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , grapefruit juice,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,nefazodone,fluoxetine
"Less potent inhibitors include  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,nefazodone,fluvoxamine
"Less potent inhibitors include  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,nefazodone,zileuton
"Less potent inhibitors include  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,nefazodone,clotrimazole
"Less potent inhibitors include  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , grapefruit juice,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,fluconazole,fluoxetine
"Less potent inhibitors include  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , grapefruit juice,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,fluconazole,fluvoxamine
"Less potent inhibitors include  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,fluconazole,zileuton
"Less potent inhibitors include  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,fluconazole,clotrimazole
"Less potent inhibitors include  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,fluoxetine,fluvoxamine
"Less potent inhibitors include  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,fluoxetine,zileuton
"Less potent inhibitors include  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,fluoxetine,clotrimazole
"Less potent inhibitors include  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER .",negative,fluvoxamine,zileuton
"Less potent inhibitors include  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 .",negative,fluvoxamine,clotrimazole
"Less potent inhibitors include  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , grapefruit juice,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 .",negative,zileuton,clotrimazole
Caution should be exercised when  DRUG1     ( DRUG2 ) is used concurrently with other  DRUGOTHER  or  DRUGOTHER .,negative,Methergine,methylergonovine maleate
Caution should be exercised when  DRUG1     ( DRUGOTHER ) is used concurrently with other  DRUG2  or  DRUGOTHER .,advise,Methergine,vasoconstrictors
Caution should be exercised when  DRUG1     ( DRUGOTHER ) is used concurrently with other  DRUGOTHER  or  DRUG2 .,advise,Methergine,ergot alkaloids
Caution should be exercised when  DRUGOTHER     ( DRUG1 ) is used concurrently with other  DRUG2  or  DRUGOTHER .,advise,methylergonovine maleate,vasoconstrictors
Caution should be exercised when  DRUGOTHER     ( DRUG1 ) is used concurrently with other  DRUGOTHER  or  DRUG2 .,negative,methylergonovine maleate,ergot alkaloids
Caution should be exercised when  DRUGOTHER     ( DRUGOTHER ) is used concurrently with other  DRUG1  or  DRUG2 .,negative,vasoconstrictors,ergot alkaloids
"Use with Other  DRUG1 : The depressant effects of  DRUG2  are potentiated by the presence of other  DRUGOTHER  such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,Central Nervous System Depressants,morphine
"Use with Other  DRUG1 : The depressant effects of  DRUGOTHER  are potentiated by the presence of other  DRUG2  such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,Central Nervous System Depressants,CNS depressants
"Use with Other  DRUG1 : The depressant effects of  DRUGOTHER  are potentiated by the presence of other  DRUGOTHER  such as  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,Central Nervous System Depressants,alcohol
"Use with Other  DRUG1 : The depressant effects of  DRUGOTHER  are potentiated by the presence of other  DRUGOTHER  such as  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,Central Nervous System Depressants,sedatives
"Use with Other  DRUG1 : The depressant effects of  DRUGOTHER  are potentiated by the presence of other  DRUGOTHER  such as  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,Central Nervous System Depressants,antihistaminics
"Use with Other  DRUG1 : The depressant effects of  DRUGOTHER  are potentiated by the presence of other  DRUGOTHER  such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,Central Nervous System Depressants,psychotropic drugs
"Use with Other  DRUGOTHER : The depressant effects of  DRUG1  are potentiated by the presence of other  DRUG2  such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",effect,morphine,CNS depressants
"Use with Other  DRUGOTHER : The depressant effects of  DRUG1  are potentiated by the presence of other  DRUGOTHER  such as  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",effect,morphine,alcohol
"Use with Other  DRUGOTHER : The depressant effects of  DRUG1  are potentiated by the presence of other  DRUGOTHER  such as  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",effect,morphine,sedatives
"Use with Other  DRUGOTHER : The depressant effects of  DRUG1  are potentiated by the presence of other  DRUGOTHER  such as  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",effect,morphine,antihistaminics
"Use with Other  DRUGOTHER : The depressant effects of  DRUG1  are potentiated by the presence of other  DRUGOTHER  such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",effect,morphine,psychotropic drugs
"Use with Other  DRUGOTHER : The depressant effects of  DRUGOTHER  are potentiated by the presence of other  DRUG1  such as  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER .",negative,CNS depressants,alcohol
"Use with Other  DRUGOTHER : The depressant effects of  DRUGOTHER  are potentiated by the presence of other  DRUG1  such as  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,CNS depressants,sedatives
"Use with Other  DRUGOTHER : The depressant effects of  DRUGOTHER  are potentiated by the presence of other  DRUG1  such as  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,CNS depressants,antihistaminics
"Use with Other  DRUGOTHER : The depressant effects of  DRUGOTHER  are potentiated by the presence of other  DRUG1  such as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,CNS depressants,psychotropic drugs
"Use with Other  DRUGOTHER : The depressant effects of  DRUGOTHER  are potentiated by the presence of other  DRUGOTHER  such as  DRUG1 ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,alcohol,sedatives
"Use with Other  DRUGOTHER : The depressant effects of  DRUGOTHER  are potentiated by the presence of other  DRUGOTHER  such as  DRUG1 ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,alcohol,antihistaminics
"Use with Other  DRUGOTHER : The depressant effects of  DRUGOTHER  are potentiated by the presence of other  DRUGOTHER  such as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,alcohol,psychotropic drugs
"Use with Other  DRUGOTHER : The depressant effects of  DRUGOTHER  are potentiated by the presence of other  DRUGOTHER  such as  DRUGOTHER ,  DRUG1 ,  DRUG2 , or  DRUGOTHER .",negative,sedatives,antihistaminics
"Use with Other  DRUGOTHER : The depressant effects of  DRUGOTHER  are potentiated by the presence of other  DRUGOTHER  such as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , or  DRUG2 .",negative,sedatives,psychotropic drugs
"Use with Other  DRUGOTHER : The depressant effects of  DRUGOTHER  are potentiated by the presence of other  DRUGOTHER  such as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , or  DRUG2 .",negative,antihistaminics,psychotropic drugs
"Use of  DRUG1  in conjunction with oral  DRUG2  may increase the risk of respiratory depression, hypotension and profound sedation or coma.",effect,neuroleptics,morphine
"Interaction with  DRUG1 :  DRUG2  (i.e.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  DRUGOTHER .",negative,Mixed Agonist/Antagonist Opioid Analgesics,Agonist/antagonist analgesics
"Interaction with  DRUG1 :  DRUGOTHER  (i.e.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  DRUGOTHER .",negative,Mixed Agonist/Antagonist Opioid Analgesics,pentazocine
"Interaction with  DRUG1 :  DRUGOTHER  (i.e.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  DRUGOTHER .",negative,Mixed Agonist/Antagonist Opioid Analgesics,nalbuphine
"Interaction with  DRUG1 :  DRUGOTHER  (i.e.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  DRUGOTHER .",negative,Mixed Agonist/Antagonist Opioid Analgesics,butorphanol
"Interaction with  DRUG1 :  DRUGOTHER  (i.e.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  DRUGOTHER .",negative,Mixed Agonist/Antagonist Opioid Analgesics,buprenorphine
"Interaction with  DRUG1 :  DRUGOTHER  (i.e.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  DRUG2 .",negative,Mixed Agonist/Antagonist Opioid Analgesics,opioid agonist analgesic
"Interaction with  DRUGOTHER :  DRUG1  (i.e.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  DRUGOTHER .",negative,Agonist/antagonist analgesics,pentazocine
"Interaction with  DRUGOTHER :  DRUG1  (i.e.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  DRUGOTHER .",negative,Agonist/antagonist analgesics,nalbuphine
"Interaction with  DRUGOTHER :  DRUG1  (i.e.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  DRUGOTHER .",negative,Agonist/antagonist analgesics,butorphanol
"Interaction with  DRUGOTHER :  DRUG1  (i.e.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  DRUGOTHER .",negative,Agonist/antagonist analgesics,buprenorphine
"Interaction with  DRUGOTHER :  DRUG1  (i.e.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  DRUG2 .",advise,Agonist/antagonist analgesics,opioid agonist analgesic
"Interaction with  DRUGOTHER :  DRUGOTHER  (i.e.,  DRUG1 ,  DRUG2 ,  DRUGOTHER , or  DRUGOTHER ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  DRUGOTHER .",negative,pentazocine,nalbuphine
"Interaction with  DRUGOTHER :  DRUGOTHER  (i.e.,  DRUG1 ,  DRUGOTHER ,  DRUG2 , or  DRUGOTHER ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  DRUGOTHER .",negative,pentazocine,butorphanol
"Interaction with  DRUGOTHER :  DRUGOTHER  (i.e.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , or  DRUG2 ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  DRUGOTHER .",negative,pentazocine,buprenorphine
"Interaction with  DRUGOTHER :  DRUGOTHER  (i.e.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , or  DRUGOTHER ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  DRUG2 .",advise,pentazocine,opioid agonist analgesic
"Interaction with  DRUGOTHER :  DRUGOTHER  (i.e.,  DRUGOTHER ,  DRUG1 ,  DRUG2 , or  DRUGOTHER ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  DRUGOTHER .",negative,nalbuphine,butorphanol
"Interaction with  DRUGOTHER :  DRUGOTHER  (i.e.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , or  DRUG2 ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  DRUGOTHER .",negative,nalbuphine,buprenorphine
"Interaction with  DRUGOTHER :  DRUGOTHER  (i.e.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , or  DRUGOTHER ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  DRUG2 .",advise,nalbuphine,opioid agonist analgesic
"Interaction with  DRUGOTHER :  DRUGOTHER  (i.e.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , or  DRUG2 ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  DRUGOTHER .",negative,butorphanol,buprenorphine
"Interaction with  DRUGOTHER :  DRUGOTHER  (i.e.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , or  DRUGOTHER ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  DRUG2 .",advise,butorphanol,opioid agonist analgesic
"Interaction with  DRUGOTHER :  DRUGOTHER  (i.e.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or  DRUG1 ) should NOT be administered to patients who have received or are receiving a course of therapy with a proof  DRUG2 .",advise,buprenorphine,opioid agonist analgesic
 DRUG1  administered concomitantly with  DRUG2  may significantly decrease the serum concentrations of  DRUGOTHER .,mechanism,Aminoglutethimide,depo-subQ provera 104
 DRUG1  administered concomitantly with  DRUGOTHER  may significantly decrease the serum concentrations of  DRUG2 .,negative,Aminoglutethimide,MPA
 DRUGOTHER  administered concomitantly with  DRUG1  may significantly decrease the serum concentrations of  DRUG2 .,negative,depo-subQ provera 104,MPA
Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of  DRUG1  or  DRUG2  to warrant dosage adjustment when  DRUGOTHER  is administered with these drugs.,negative,zidovudine,rifabutin
Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of  DRUG1  or  DRUGOTHER  to warrant dosage adjustment when  DRUG2  is administered with these drugs.,negative,zidovudine,megestrol acetate
Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of  DRUGOTHER  or  DRUG1  to warrant dosage adjustment when  DRUG2  is administered with these drugs.,negative,rifabutin,megestrol acetate
A pharmacokinetic study demonstrated that coadministration of  DRUG1  and  DRUG2  results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of  DRUGOTHER .,mechanism,megestrol acetate,indinavir
A pharmacokinetic study demonstrated that coadministration of  DRUG1  and  DRUGOTHER  results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of  DRUG2 .,negative,megestrol acetate,indinavir
A pharmacokinetic study demonstrated that coadministration of  DRUGOTHER  and  DRUG1  results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of  DRUG2 .,negative,indinavir,indinavir
Administration of a higher dose of  DRUG1  should be considered when coadministering with  DRUG2 .,advise,indinavir,megestrol acetate
"The effects of  DRUG1 ,  DRUG2  or  DRUGOTHER  on the pharmacokinetics of  DRUGOTHER  were not studied.",negative,indinavir,zidovudine
"The effects of  DRUG1 ,  DRUGOTHER  or  DRUG2  on the pharmacokinetics of  DRUGOTHER  were not studied.",negative,indinavir,rifabutin
"The effects of  DRUG1 ,  DRUGOTHER  or  DRUGOTHER  on the pharmacokinetics of  DRUG2  were not studied.",negative,indinavir,megestrol acetate
"The effects of  DRUGOTHER ,  DRUG1  or  DRUG2  on the pharmacokinetics of  DRUGOTHER  were not studied.",negative,zidovudine,rifabutin
"The effects of  DRUGOTHER ,  DRUG1  or  DRUGOTHER  on the pharmacokinetics of  DRUG2  were not studied.",negative,zidovudine,megestrol acetate
"The effects of  DRUGOTHER ,  DRUGOTHER  or  DRUG1  on the pharmacokinetics of  DRUG2  were not studied.",negative,rifabutin,megestrol acetate
 DRUG1  and  DRUG2  are incompatible with  DRUGOTHER  solution.,negative,norepinephrine,dobutamine
 DRUG1  and  DRUGOTHER  are incompatible with  DRUG2  solution.,int,norepinephrine,sodium bicarbonate
 DRUGOTHER  and  DRUG1  are incompatible with  DRUG2  solution.,int,dobutamine,sodium bicarbonate
"The addition of  DRUG1  to parenteral solutions containing  DRUG2  should be avoided, except where compatibility has been previously established.",negative,sodium bicarbonate,calcium
 DRUG1 : The effects of chronic  DRUG2  use on the metabolism of  DRUGOTHER  are not known.,negative,Cimetidine,cimetidine
 DRUG1 : The effects of chronic  DRUGOTHER  use on the metabolism of  DRUG2  are not known.,negative,Cimetidine,rimantadine
 DRUGOTHER : The effects of chronic  DRUG1  use on the metabolism of  DRUG2  are not known.,negative,cimetidine,rimantadine
"When a single 100 mg dose of  DRUG1  was administered one hour after the initiation of  DRUG2  (300 mg four times a day), the apparent total  DRUGOTHER  clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total  DRUGOTHER  clearance in the same subjects in the absence of  DRUGOTHER ).",mechanism,rimantadine HCl,Cimetidine
"When a single 100 mg dose of  DRUG1  was administered one hour after the initiation of  DRUGOTHER  (300 mg four times a day), the apparent total  DRUG2  clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total  DRUGOTHER  clearance in the same subjects in the absence of  DRUGOTHER ).",negative,rimantadine HCl,rimantadine
"When a single 100 mg dose of  DRUG1  was administered one hour after the initiation of  DRUGOTHER  (300 mg four times a day), the apparent total  DRUGOTHER  clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total  DRUG2  clearance in the same subjects in the absence of  DRUGOTHER ).",negative,rimantadine HCl,rimantadine
"When a single 100 mg dose of  DRUG1  was administered one hour after the initiation of  DRUGOTHER  (300 mg four times a day), the apparent total  DRUGOTHER  clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total  DRUGOTHER  clearance in the same subjects in the absence of  DRUG2 ).",negative,rimantadine HCl,cimetidine
"When a single 100 mg dose of  DRUGOTHER  was administered one hour after the initiation of  DRUG1  (300 mg four times a day), the apparent total  DRUG2  clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total  DRUGOTHER  clearance in the same subjects in the absence of  DRUGOTHER ).",negative,Cimetidine,rimantadine
"When a single 100 mg dose of  DRUGOTHER  was administered one hour after the initiation of  DRUG1  (300 mg four times a day), the apparent total  DRUGOTHER  clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total  DRUG2  clearance in the same subjects in the absence of  DRUGOTHER ).",negative,Cimetidine,rimantadine
"When a single 100 mg dose of  DRUGOTHER  was administered one hour after the initiation of  DRUG1  (300 mg four times a day), the apparent total  DRUGOTHER  clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total  DRUGOTHER  clearance in the same subjects in the absence of  DRUG2 ).",negative,Cimetidine,cimetidine
"When a single 100 mg dose of  DRUGOTHER  was administered one hour after the initiation of  DRUGOTHER  (300 mg four times a day), the apparent total  DRUG1  clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total  DRUG2  clearance in the same subjects in the absence of  DRUGOTHER ).",negative,rimantadine,rimantadine
"When a single 100 mg dose of  DRUGOTHER  was administered one hour after the initiation of  DRUGOTHER  (300 mg four times a day), the apparent total  DRUG1  clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total  DRUGOTHER  clearance in the same subjects in the absence of  DRUG2 ).",negative,rimantadine,cimetidine
"When a single 100 mg dose of  DRUGOTHER  was administered one hour after the initiation of  DRUGOTHER  (300 mg four times a day), the apparent total  DRUGOTHER  clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total  DRUG1  clearance in the same subjects in the absence of  DRUG2 ).",negative,rimantadine,cimetidine
" DRUG1 :  DRUG2 , 100 mg, was given twice daily for 13 days to 12 healthy volunteers.",negative,Acetaminophen,Rimantadine HCl
Coadministration with  DRUG1  reduced the peak concentration and AUC values for  DRUG2  by approximately 11%.,mechanism,acetaminophen,rimantadine
" DRUG1 :  DRUG2 , 100 mg, was given twice daily fro 13 days to 12 healthy volunteers.",negative,Aspirin,Rimantadine HCl
Peak plasma concentrations and AUC of  DRUG1  were reduced approximately 10% in the presence of  DRUG2 .,mechanism,rimantadine,aspirin
Other  DRUG1  should not be used concomitantly with  DRUG2     ( DRUGOTHER  USP) because they may have additive effects.,advise,beta adrenergic aerosol bronchodilators,Alupent
Other  DRUG1  should not be used concomitantly with  DRUGOTHER     ( DRUG2  USP) because they may have additive effects.,advise,beta adrenergic aerosol bronchodilators,metaproterenol sulfate
Other  DRUGOTHER  should not be used concomitantly with  DRUG1     ( DRUG2  USP) because they may have additive effects.,negative,Alupent,metaproterenol sulfate
" DRUG1  should be administered with caution to patients being treated with  DRUG2  or  DRUGOTHER , since the action of  DRUGOTHER  on the vascular system may be potentiated.",advise,Beta adrenergic agonists,monoamine oxidase inhibitors
" DRUG1  should be administered with caution to patients being treated with  DRUGOTHER  or  DRUG2 , since the action of  DRUGOTHER  on the vascular system may be potentiated.",advise,Beta adrenergic agonists,tricyclic antidepressants
" DRUG1  should be administered with caution to patients being treated with  DRUGOTHER  or  DRUGOTHER , since the action of  DRUG2  on the vascular system may be potentiated.",negative,Beta adrenergic agonists,beta adrenergic agonists
" DRUGOTHER  should be administered with caution to patients being treated with  DRUG1  or  DRUG2 , since the action of  DRUGOTHER  on the vascular system may be potentiated.",negative,monoamine oxidase inhibitors,tricyclic antidepressants
" DRUGOTHER  should be administered with caution to patients being treated with  DRUG1  or  DRUGOTHER , since the action of  DRUG2  on the vascular system may be potentiated.",negative,monoamine oxidase inhibitors,beta adrenergic agonists
" DRUGOTHER  should be administered with caution to patients being treated with  DRUGOTHER  or  DRUG1 , since the action of  DRUG2  on the vascular system may be potentiated.",negative,tricyclic antidepressants,beta adrenergic agonists
"Although  DRUG1  (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between  DRUG2  and  DRUGOTHER  has not been systematically studied.",negative,MIVACRON,MIVACRON
"Although  DRUG1  (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between  DRUGOTHER  and  DRUG2  has not been systematically studied.",negative,MIVACRON,succinylcholine
"Although  DRUGOTHER  (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between  DRUG1  and  DRUG2  has not been systematically studied.",negative,MIVACRON,succinylcholine
Prior administration of  DRUG1  can potentiate the neuromuscular blocking effects of  DRUG2 .,effect,succinylcholine,nondepolarizing agents
Evidence of spontaneous recovery from  DRUG1  should be observed before the administration of  DRUG2 .,advise,succinylcholine,MIVACRON
The use of  DRUG1  before  DRUG2  to attenuate some of the side effects of  DRUGOTHER  has not been studied.,negative,MIVACRON,succinylcholine
The use of  DRUG1  before  DRUGOTHER  to attenuate some of the side effects of  DRUG2  has not been studied.,negative,MIVACRON,succinylcholine
The use of  DRUGOTHER  before  DRUG1  to attenuate some of the side effects of  DRUG2  has not been studied.,negative,succinylcholine,succinylcholine
There are no clinical data on the use of  DRUG1  with other  DRUG2 .,negative,MIVACRON,nondepolarizing neuromuscular blocking agents
 DRUG1  and  DRUG2  (administered with  DRUGOTHER / DRUGOTHER  to achieve 1.25 M.C.,negative,Isoflurane,enflurane
 DRUG1  and  DRUGOTHER  (administered with  DRUG2 / DRUGOTHER  to achieve 1.25 M.C.,negative,Isoflurane,nitrous oxide
 DRUG1  and  DRUGOTHER  (administered with  DRUGOTHER / DRUG2  to achieve 1.25 M.C.,negative,Isoflurane,oxygen
 DRUGOTHER  and  DRUG1  (administered with  DRUG2 / DRUGOTHER  to achieve 1.25 M.C.,negative,enflurane,nitrous oxide
 DRUGOTHER  and  DRUG1  (administered with  DRUGOTHER / DRUG2  to achieve 1.25 M.C.,negative,enflurane,oxygen
 DRUGOTHER  and  DRUGOTHER  (administered with  DRUG1 / DRUG2  to achieve 1.25 M.C.,negative,nitrous oxide,oxygen
A greater potentiation of the neuromuscular blocking effects of  DRUG1  may be expected with higher concentrations of  DRUG2  or  DRUGOTHER .,negative,MIVACRON,enflurane
A greater potentiation of the neuromuscular blocking effects of  DRUG1  may be expected with higher concentrations of  DRUGOTHER  or  DRUG2 .,negative,MIVACRON,isoflurane
A greater potentiation of the neuromuscular blocking effects of  DRUGOTHER  may be expected with higher concentrations of  DRUG1  or  DRUG2 .,negative,enflurane,isoflurane
"Other drugs which may enhance the neuromuscular blocking action of  DRUG1  such as  DRUG2  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,nondepolarizing agents,MIVACRON
"Other drugs which may enhance the neuromuscular blocking action of  DRUG1  such as  DRUGOTHER  include certain  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,nondepolarizing agents,antibiotics
"Other drugs which may enhance the neuromuscular blocking action of  DRUG1  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,nondepolarizing agents,aminoglycosides
"Other drugs which may enhance the neuromuscular blocking action of  DRUG1  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,nondepolarizing agents,tetracyclines
"Other drugs which may enhance the neuromuscular blocking action of  DRUG1  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,nondepolarizing agents,bacitracin
"Other drugs which may enhance the neuromuscular blocking action of  DRUG1  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,nondepolarizing agents,polymyxins
"Other drugs which may enhance the neuromuscular blocking action of  DRUG1  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,nondepolarizing agents,lincomycin
"Other drugs which may enhance the neuromuscular blocking action of  DRUG1  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,nondepolarizing agents,clindamycin
"Other drugs which may enhance the neuromuscular blocking action of  DRUG1  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,nondepolarizing agents,colistin
"Other drugs which may enhance the neuromuscular blocking action of  DRUG1  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,nondepolarizing agents,sodium colistimethate
"Other drugs which may enhance the neuromuscular blocking action of  DRUG1  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUG2  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,nondepolarizing agents,magnesium
"Other drugs which may enhance the neuromuscular blocking action of  DRUG1  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUG2 , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,nondepolarizing agents,lithium
"Other drugs which may enhance the neuromuscular blocking action of  DRUG1  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",int,nondepolarizing agents,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of  DRUG1  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",int,nondepolarizing agents,procainamide
"Other drugs which may enhance the neuromuscular blocking action of  DRUG1  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",int,nondepolarizing agents,quinidine
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUG1  include certain  DRUG2  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,MIVACRON,antibiotics
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUG1  include certain  DRUGOTHER  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,MIVACRON,aminoglycosides
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUG1  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,MIVACRON,tetracyclines
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUG1  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,MIVACRON,bacitracin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUG1  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,MIVACRON,polymyxins
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUG1  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,MIVACRON,lincomycin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUG1  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,MIVACRON,clindamycin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUG1  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,MIVACRON,colistin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUG1  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,MIVACRON,sodium colistimethate
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUG1  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUG2  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,MIVACRON,magnesium
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUG1  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUG2 , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",int,MIVACRON,lithium
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUG1  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",int,MIVACRON,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUG1  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",int,MIVACRON,procainamide
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUG1  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",int,MIVACRON,quinidine
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUG1  (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,antibiotics,aminoglycosides
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUG1  (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,antibiotics,tetracyclines
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,antibiotics,bacitracin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,antibiotics,polymyxins
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,antibiotics,lincomycin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,antibiotics,clindamycin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,antibiotics,colistin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,antibiotics,sodium colistimethate
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUG2  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,antibiotics,magnesium
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUG2 , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,antibiotics,lithium
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,antibiotics,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,antibiotics,procainamide
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUG1  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,antibiotics,quinidine
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,aminoglycosides,tetracyclines
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,aminoglycosides,bacitracin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,aminoglycosides,polymyxins
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,aminoglycosides,lincomycin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,aminoglycosides,clindamycin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,aminoglycosides,colistin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,aminoglycosides,sodium colistimethate
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUG2  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,aminoglycosides,magnesium
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUG2 , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,aminoglycosides,lithium
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,aminoglycosides,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,aminoglycosides,procainamide
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,aminoglycosides,quinidine
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,tetracyclines,bacitracin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,tetracyclines,polymyxins
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,tetracyclines,lincomycin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,tetracyclines,clindamycin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,tetracyclines,colistin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,tetracyclines,sodium colistimethate
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUG2  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,tetracyclines,magnesium
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUG2 , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,tetracyclines,lithium
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,tetracyclines,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,tetracyclines,procainamide
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,tetracyclines,quinidine
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,bacitracin,polymyxins
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,bacitracin,lincomycin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,bacitracin,clindamycin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,bacitracin,colistin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,bacitracin,sodium colistimethate
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUG2  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,bacitracin,magnesium
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUG2 , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,bacitracin,lithium
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,bacitracin,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,bacitracin,procainamide
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,bacitracin,quinidine
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,polymyxins,lincomycin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,polymyxins,clindamycin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,polymyxins,colistin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,polymyxins,sodium colistimethate
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUG2  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,polymyxins,magnesium
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUG2 , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,polymyxins,lithium
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,polymyxins,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,polymyxins,procainamide
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,polymyxins,quinidine
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,lincomycin,clindamycin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,lincomycin,colistin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,lincomycin,sodium colistimethate
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUG2  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,lincomycin,magnesium
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUG2 , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,lincomycin,lithium
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,lincomycin,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,lincomycin,procainamide
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,lincomycin,quinidine
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,clindamycin,colistin
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,clindamycin,sodium colistimethate
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ),  DRUG2  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,clindamycin,magnesium
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUG2 , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,clindamycin,lithium
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,clindamycin,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,clindamycin,procainamide
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,clindamycin,quinidine
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,colistin,sodium colistimethate
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ),  DRUG2  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,colistin,magnesium
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUG2 , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,colistin,lithium
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,colistin,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,colistin,procainamide
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,colistin,quinidine
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ),  DRUG2  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,sodium colistimethate,magnesium
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ),  DRUGOTHER  salts,  DRUG2 , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,sodium colistimethate,lithium
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,sodium colistimethate,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,sodium colistimethate,procainamide
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,sodium colistimethate,quinidine
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUG1  salts,  DRUG2 , local  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,magnesium,lithium
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUG1  salts,  DRUGOTHER , local  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,magnesium,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUG1  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,magnesium,procainamide
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUG1  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,magnesium,quinidine
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUG1 , local  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,lithium,anesthetics
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUG1 , local  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,lithium,procainamide
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUG1 , local  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,lithium,quinidine
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUG1 ,  DRUG2 , and  DRUGOTHER .",negative,anesthetics,procainamide
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUG1 ,  DRUGOTHER , and  DRUG2 .",negative,anesthetics,quinidine
"Other drugs which may enhance the neuromuscular blocking action of  DRUGOTHER  such as  DRUGOTHER  include certain  DRUGOTHER  (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ),  DRUGOTHER  salts,  DRUGOTHER , local  DRUGOTHER ,  DRUG1 , and  DRUG2 .",negative,procainamide,quinidine
"The neuromuscular blocking effect of  DRUG1  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  DRUG2 ,  DRUGOTHER , or certain  DRUGOTHER ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  DRUGOTHER  has been demonstrated in patients chronically administered  DRUGOTHER  or  DRUGOTHER .",effect,MIVACRON,contraceptives
"The neuromuscular blocking effect of  DRUG1  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  DRUGOTHER ,  DRUG2 , or certain  DRUGOTHER ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  DRUGOTHER  has been demonstrated in patients chronically administered  DRUGOTHER  or  DRUGOTHER .",effect,MIVACRON,glucocorticoids
"The neuromuscular blocking effect of  DRUG1  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  DRUGOTHER ,  DRUGOTHER , or certain  DRUG2 ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  DRUGOTHER  has been demonstrated in patients chronically administered  DRUGOTHER  or  DRUGOTHER .",effect,MIVACRON,monoamine oxidase inhibitors
"The neuromuscular blocking effect of  DRUG1  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  DRUGOTHER ,  DRUGOTHER , or certain  DRUGOTHER ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  DRUG2  has been demonstrated in patients chronically administered  DRUGOTHER  or  DRUGOTHER .",negative,MIVACRON,neuromuscular blocking agents
"The neuromuscular blocking effect of  DRUG1  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  DRUGOTHER ,  DRUGOTHER , or certain  DRUGOTHER ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  DRUGOTHER  has been demonstrated in patients chronically administered  DRUG2  or  DRUGOTHER .",negative,MIVACRON,phenytoin
"The neuromuscular blocking effect of  DRUG1  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  DRUGOTHER ,  DRUGOTHER , or certain  DRUGOTHER ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  DRUGOTHER  has been demonstrated in patients chronically administered  DRUGOTHER  or  DRUG2 .",negative,MIVACRON,carbamazepine
"The neuromuscular blocking effect of  DRUGOTHER  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  DRUG1 ,  DRUG2 , or certain  DRUGOTHER ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  DRUGOTHER  has been demonstrated in patients chronically administered  DRUGOTHER  or  DRUGOTHER .",negative,contraceptives,glucocorticoids
"The neuromuscular blocking effect of  DRUGOTHER  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  DRUG1 ,  DRUGOTHER , or certain  DRUG2 ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  DRUGOTHER  has been demonstrated in patients chronically administered  DRUGOTHER  or  DRUGOTHER .",negative,contraceptives,monoamine oxidase inhibitors
"The neuromuscular blocking effect of  DRUGOTHER  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  DRUG1 ,  DRUGOTHER , or certain  DRUGOTHER ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  DRUG2  has been demonstrated in patients chronically administered  DRUGOTHER  or  DRUGOTHER .",negative,contraceptives,neuromuscular blocking agents
"The neuromuscular blocking effect of  DRUGOTHER  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  DRUG1 ,  DRUGOTHER , or certain  DRUGOTHER ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  DRUGOTHER  has been demonstrated in patients chronically administered  DRUG2  or  DRUGOTHER .",negative,contraceptives,phenytoin
"The neuromuscular blocking effect of  DRUGOTHER  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  DRUG1 ,  DRUGOTHER , or certain  DRUGOTHER ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  DRUGOTHER  has been demonstrated in patients chronically administered  DRUGOTHER  or  DRUG2 .",negative,contraceptives,carbamazepine
"The neuromuscular blocking effect of  DRUGOTHER  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  DRUGOTHER ,  DRUG1 , or certain  DRUG2 ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  DRUGOTHER  has been demonstrated in patients chronically administered  DRUGOTHER  or  DRUGOTHER .",negative,glucocorticoids,monoamine oxidase inhibitors
"The neuromuscular blocking effect of  DRUGOTHER  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  DRUGOTHER ,  DRUG1 , or certain  DRUGOTHER ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  DRUG2  has been demonstrated in patients chronically administered  DRUGOTHER  or  DRUGOTHER .",negative,glucocorticoids,neuromuscular blocking agents
"The neuromuscular blocking effect of  DRUGOTHER  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  DRUGOTHER ,  DRUG1 , or certain  DRUGOTHER ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  DRUGOTHER  has been demonstrated in patients chronically administered  DRUG2  or  DRUGOTHER .",negative,glucocorticoids,phenytoin
"The neuromuscular blocking effect of  DRUGOTHER  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  DRUGOTHER ,  DRUG1 , or certain  DRUGOTHER ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  DRUGOTHER  has been demonstrated in patients chronically administered  DRUGOTHER  or  DRUG2 .",negative,glucocorticoids,carbamazepine
"The neuromuscular blocking effect of  DRUGOTHER  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  DRUGOTHER ,  DRUGOTHER , or certain  DRUG1 ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  DRUG2  has been demonstrated in patients chronically administered  DRUGOTHER  or  DRUGOTHER .",negative,monoamine oxidase inhibitors,neuromuscular blocking agents
"The neuromuscular blocking effect of  DRUGOTHER  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  DRUGOTHER ,  DRUGOTHER , or certain  DRUG1 ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  DRUGOTHER  has been demonstrated in patients chronically administered  DRUG2  or  DRUGOTHER .",negative,monoamine oxidase inhibitors,phenytoin
"The neuromuscular blocking effect of  DRUGOTHER  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  DRUGOTHER ,  DRUGOTHER , or certain  DRUG1 ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  DRUGOTHER  has been demonstrated in patients chronically administered  DRUGOTHER  or  DRUG2 .",negative,monoamine oxidase inhibitors,carbamazepine
"The neuromuscular blocking effect of  DRUGOTHER  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  DRUGOTHER ,  DRUGOTHER , or certain  DRUGOTHER ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  DRUG1  has been demonstrated in patients chronically administered  DRUG2  or  DRUGOTHER .",effect,neuromuscular blocking agents,phenytoin
"The neuromuscular blocking effect of  DRUGOTHER  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  DRUGOTHER ,  DRUGOTHER , or certain  DRUGOTHER ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  DRUG1  has been demonstrated in patients chronically administered  DRUGOTHER  or  DRUG2 .",effect,neuromuscular blocking agents,carbamazepine
"The neuromuscular blocking effect of  DRUGOTHER  may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral  DRUGOTHER ,  DRUGOTHER , or certain  DRUGOTHER ) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing  DRUGOTHER  has been demonstrated in patients chronically administered  DRUG1  or  DRUG2 .",negative,phenytoin,carbamazepine
"While the effects of chronic  DRUG1  or  DRUG2  therapy on the action of  DRUGOTHER  are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.",negative,phenytoin,carbamazepine
"While the effects of chronic  DRUG1  or  DRUGOTHER  therapy on the action of  DRUG2  are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.",effect,phenytoin,MIVACRON
"While the effects of chronic  DRUGOTHER  or  DRUG1  therapy on the action of  DRUG2  are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.",effect,carbamazepine,MIVACRON
Some drug interactions are:  - birth control pills -  DRUG1  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUG2  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,corticosteroids,phenytoin
Some drug interactions are:  - birth control pills -  DRUG1  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUG2  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,corticosteroids,carbamazepine
Some drug interactions are:  - birth control pills -  DRUG1  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUG2  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,corticosteroids,antibiotics
Some drug interactions are:  - birth control pills -  DRUG1  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUG2  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,corticosteroids,cisplatin
Some drug interactions are:  - birth control pills -  DRUG1  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUG2  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,corticosteroids,edrophonium
Some drug interactions are:  - birth control pills -  DRUG1  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUG2  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,corticosteroids,neostigmine
Some drug interactions are:  - birth control pills -  DRUG1  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUG2  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,corticosteroids,polymyxin B
Some drug interactions are:  - birth control pills -  DRUG1  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUG2  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,corticosteroids,bacitracin
Some drug interactions are:  - birth control pills -  DRUG1  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUG2  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,corticosteroids,anesthetics
Some drug interactions are:  - birth control pills -  DRUG1  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUG2  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,corticosteroids,procaine
Some drug interactions are:  - birth control pills -  DRUG1  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUG2  -  DRUGOTHER  or other  DRUGOTHER ,negative,corticosteroids,anesthetics
Some drug interactions are:  - birth control pills -  DRUG1  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUG2  or other  DRUGOTHER ,negative,corticosteroids,succinylcholine
Some drug interactions are:  - birth control pills -  DRUG1  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUG2 ,negative,corticosteroids,muscle relaxants
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUG1  or  DRUG2  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,phenytoin,carbamazepine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUG1  or  DRUGOTHER  - certain  DRUG2  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,phenytoin,antibiotics
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUG1  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUG2  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,phenytoin,cisplatin
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUG1  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUG2  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,phenytoin,edrophonium
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUG1  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUG2  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,phenytoin,neostigmine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUG1  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUG2  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,phenytoin,polymyxin B
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUG1  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUG2  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,phenytoin,bacitracin
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUG1  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUG2  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,phenytoin,anesthetics
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUG1  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUG2  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,phenytoin,procaine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUG1  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUG2  -  DRUGOTHER  or other  DRUGOTHER ,negative,phenytoin,anesthetics
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUG1  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUG2  or other  DRUGOTHER ,negative,phenytoin,succinylcholine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUG1  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUG2 ,negative,phenytoin,muscle relaxants
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUG1  - certain  DRUG2  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,carbamazepine,antibiotics
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUG1  - certain  DRUGOTHER  given by injection -  DRUG2  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,carbamazepine,cisplatin
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUG1  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUG2  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,carbamazepine,edrophonium
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUG1  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUG2  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,carbamazepine,neostigmine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUG1  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUG2  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,carbamazepine,polymyxin B
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUG1  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUG2  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,carbamazepine,bacitracin
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUG1  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUG2  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,carbamazepine,anesthetics
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUG1  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUG2  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,carbamazepine,procaine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUG1  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUG2  -  DRUGOTHER  or other  DRUGOTHER ,negative,carbamazepine,anesthetics
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUG1  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUG2  or other  DRUGOTHER ,negative,carbamazepine,succinylcholine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUG1  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUG2 ,negative,carbamazepine,muscle relaxants
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUG1  given by injection -  DRUG2  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,antibiotics,cisplatin
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUG1  given by injection -  DRUGOTHER  -  DRUG2  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,antibiotics,edrophonium
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUG1  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUG2  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,antibiotics,neostigmine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUG1  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUG2  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,antibiotics,polymyxin B
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUG1  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUG2  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,antibiotics,bacitracin
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUG1  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUG2  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,antibiotics,anesthetics
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUG1  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUG2  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,antibiotics,procaine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUG1  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUG2  -  DRUGOTHER  or other  DRUGOTHER ,negative,antibiotics,anesthetics
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUG1  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUG2  or other  DRUGOTHER ,negative,antibiotics,succinylcholine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUG1  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUG2 ,negative,antibiotics,muscle relaxants
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUG1  -  DRUG2  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,cisplatin,edrophonium
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUG1  -  DRUGOTHER  -  DRUG2  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,cisplatin,neostigmine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUG1  -  DRUGOTHER  -  DRUGOTHER  -  DRUG2  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,cisplatin,polymyxin B
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUG1  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUG2  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,cisplatin,bacitracin
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUG1  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUG2  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,cisplatin,anesthetics
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUG1  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUG2  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,cisplatin,procaine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUG1  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUG2  -  DRUGOTHER  or other  DRUGOTHER ,negative,cisplatin,anesthetics
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUG1  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUG2  or other  DRUGOTHER ,negative,cisplatin,succinylcholine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUG1  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUG2 ,negative,cisplatin,muscle relaxants
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUG1  -  DRUG2  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,edrophonium,neostigmine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUG1  -  DRUGOTHER  -  DRUG2  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,edrophonium,polymyxin B
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUG1  -  DRUGOTHER  -  DRUGOTHER  or  DRUG2  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,edrophonium,bacitracin
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUG1  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUG2  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,edrophonium,anesthetics
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUG1  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUG2  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,edrophonium,procaine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUG1  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUG2  -  DRUGOTHER  or other  DRUGOTHER ,negative,edrophonium,anesthetics
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUG1  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUG2  or other  DRUGOTHER ,negative,edrophonium,succinylcholine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUG1  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUG2 ,negative,edrophonium,muscle relaxants
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUG1  -  DRUG2  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,neostigmine,polymyxin B
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUG1  -  DRUGOTHER  or  DRUG2  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,neostigmine,bacitracin
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUG1  -  DRUGOTHER  or  DRUGOTHER  - local  DRUG2  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,neostigmine,anesthetics
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUG1  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUG2  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,neostigmine,procaine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUG1  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUG2  -  DRUGOTHER  or other  DRUGOTHER ,negative,neostigmine,anesthetics
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUG1  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUG2  or other  DRUGOTHER ,negative,neostigmine,succinylcholine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUG1  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUG2 ,negative,neostigmine,muscle relaxants
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUG1  or  DRUG2  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,polymyxin B,bacitracin
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUG1  or  DRUGOTHER  - local  DRUG2  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,polymyxin B,anesthetics
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUG1  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUG2  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,polymyxin B,procaine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUG1  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUG2  -  DRUGOTHER  or other  DRUGOTHER ,negative,polymyxin B,anesthetics
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUG1  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUG2  or other  DRUGOTHER ,negative,polymyxin B,succinylcholine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUG1  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUG2 ,negative,polymyxin B,muscle relaxants
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUG1  - local  DRUG2  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,bacitracin,anesthetics
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUG1  - local  DRUGOTHER  such as  DRUG2  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,bacitracin,procaine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUG1  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUG2  -  DRUGOTHER  or other  DRUGOTHER ,negative,bacitracin,anesthetics
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUG1  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUG2  or other  DRUGOTHER ,negative,bacitracin,succinylcholine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUG1  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUG2 ,negative,bacitracin,muscle relaxants
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUG1  such as  DRUG2  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUGOTHER ,negative,anesthetics,procaine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUG1  such as  DRUGOTHER  - general  DRUG2  -  DRUGOTHER  or other  DRUGOTHER ,negative,anesthetics,anesthetics
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUG1  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUG2  or other  DRUGOTHER ,negative,anesthetics,succinylcholine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUG1  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUG2 ,negative,anesthetics,muscle relaxants
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUG1  - general  DRUG2  -  DRUGOTHER  or other  DRUGOTHER ,negative,procaine,anesthetics
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUG1  - general  DRUGOTHER  -  DRUG2  or other  DRUGOTHER ,negative,procaine,succinylcholine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUG1  - general  DRUGOTHER  -  DRUGOTHER  or other  DRUG2 ,negative,procaine,muscle relaxants
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUG1  -  DRUG2  or other  DRUGOTHER ,negative,anesthetics,succinylcholine
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUG1  -  DRUGOTHER  or other  DRUG2 ,negative,anesthetics,muscle relaxants
Some drug interactions are:  - birth control pills -  DRUGOTHER  - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as  DRUGOTHER  or  DRUGOTHER  - certain  DRUGOTHER  given by injection -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  -  DRUGOTHER  or  DRUGOTHER  - local  DRUGOTHER  such as  DRUGOTHER  - general  DRUGOTHER  -  DRUG1  or other  DRUG2 ,negative,succinylcholine,muscle relaxants
"Co-administration of  DRUG1  with strong inhibitors of the CYP3A4 family (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",mechanism,SUTENT,ketoconazole
"Co-administration of  DRUG1  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",mechanism,SUTENT,itraconazole
"Co-administration of  DRUG1  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",mechanism,SUTENT,clarithromycin
"Co-administration of  DRUG1  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",mechanism,SUTENT,atazanavir
"Co-administration of  DRUG1  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",mechanism,SUTENT,indinavir
"Co-administration of  DRUG1  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",mechanism,SUTENT,nefazodone
"Co-administration of  DRUG1  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",mechanism,SUTENT,nelfinavir
"Co-administration of  DRUG1  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",mechanism,SUTENT,ritonavir
"Co-administration of  DRUG1  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",mechanism,SUTENT,saquinavir
"Co-administration of  DRUG1  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",mechanism,SUTENT,telithromycin
"Co-administration of  DRUG1  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) may increases  DRUGOTHER  concentrations.",mechanism,SUTENT,voriconizole
"Co-administration of  DRUG1  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUG2  concentrations.",negative,SUTENT,sunitinib
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,ketoconazole,itraconazole
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,ketoconazole,clarithromycin
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,ketoconazole,atazanavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,ketoconazole,indinavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,ketoconazole,nefazodone
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,ketoconazole,nelfinavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,ketoconazole,ritonavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,ketoconazole,saquinavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,ketoconazole,telithromycin
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) may increases  DRUGOTHER  concentrations.",negative,ketoconazole,voriconizole
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUG2  concentrations.",negative,ketoconazole,sunitinib
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,itraconazole,clarithromycin
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,itraconazole,atazanavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,itraconazole,indinavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,itraconazole,nefazodone
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,itraconazole,nelfinavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,itraconazole,ritonavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,itraconazole,saquinavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,itraconazole,telithromycin
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) may increases  DRUGOTHER  concentrations.",negative,itraconazole,voriconizole
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUG2  concentrations.",negative,itraconazole,sunitinib
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,clarithromycin,atazanavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,clarithromycin,indinavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,clarithromycin,nefazodone
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,clarithromycin,nelfinavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,clarithromycin,ritonavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,clarithromycin,saquinavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,clarithromycin,telithromycin
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) may increases  DRUGOTHER  concentrations.",negative,clarithromycin,voriconizole
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUG2  concentrations.",negative,clarithromycin,sunitinib
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,atazanavir,indinavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,atazanavir,nefazodone
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,atazanavir,nelfinavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,atazanavir,ritonavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,atazanavir,saquinavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,atazanavir,telithromycin
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) may increases  DRUGOTHER  concentrations.",negative,atazanavir,voriconizole
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUG2  concentrations.",negative,atazanavir,sunitinib
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,indinavir,nefazodone
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,indinavir,nelfinavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,indinavir,ritonavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,indinavir,saquinavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,indinavir,telithromycin
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) may increases  DRUGOTHER  concentrations.",negative,indinavir,voriconizole
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUG2  concentrations.",negative,indinavir,sunitinib
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,nefazodone,nelfinavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,nefazodone,ritonavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,nefazodone,saquinavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,nefazodone,telithromycin
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) may increases  DRUGOTHER  concentrations.",negative,nefazodone,voriconizole
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUG2  concentrations.",negative,nefazodone,sunitinib
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,nelfinavir,ritonavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,nelfinavir,saquinavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,nelfinavir,telithromycin
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) may increases  DRUGOTHER  concentrations.",negative,nelfinavir,voriconizole
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUG2  concentrations.",negative,nelfinavir,sunitinib
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,ritonavir,saquinavir
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,ritonavir,telithromycin
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) may increases  DRUGOTHER  concentrations.",negative,ritonavir,voriconizole
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUG2  concentrations.",negative,ritonavir,sunitinib
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ) may increases  DRUGOTHER  concentrations.",negative,saquinavir,telithromycin
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ) may increases  DRUGOTHER  concentrations.",negative,saquinavir,voriconizole
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ) may increases  DRUG2  concentrations.",negative,saquinavir,sunitinib
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ) may increases  DRUGOTHER  concentrations.",negative,telithromycin,voriconizole
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ) may increases  DRUG2  concentrations.",negative,telithromycin,sunitinib
"Co-administration of  DRUGOTHER  with strong inhibitors of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ) may increases  DRUG2  concentrations.",negative,voriconizole,sunitinib
"Co-administration of  DRUG1  with inducers of the CYP3A4 family (e.g.,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",mechanism,SUTENT,dexamethasone
"Co-administration of  DRUG1  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",mechanism,SUTENT,phenytoin
"Co-administration of  DRUG1  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",mechanism,SUTENT,carbamazepine
"Co-administration of  DRUG1  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",mechanism,SUTENT,rifampin
"Co-administration of  DRUG1  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",mechanism,SUTENT,rifabutin
"Co-administration of  DRUG1  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",mechanism,SUTENT,rifapentin
"Co-administration of  DRUG1  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",mechanism,SUTENT,phenobarbital
"Co-administration of  DRUG1  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , St. Johns Wort) may decrease  DRUG2  concentrations.",negative,SUTENT,sunitinib
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",negative,dexamethasone,phenytoin
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",negative,dexamethasone,carbamazepine
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",negative,dexamethasone,rifampin
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",negative,dexamethasone,rifabutin
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",negative,dexamethasone,rifapentin
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",negative,dexamethasone,phenobarbital
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , St. Johns Wort) may decrease  DRUG2  concentrations.",negative,dexamethasone,sunitinib
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",negative,phenytoin,carbamazepine
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",negative,phenytoin,rifampin
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",negative,phenytoin,rifabutin
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",negative,phenytoin,rifapentin
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",negative,phenytoin,phenobarbital
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , St. Johns Wort) may decrease  DRUG2  concentrations.",negative,phenytoin,sunitinib
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",negative,carbamazepine,rifampin
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",negative,carbamazepine,rifabutin
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",negative,carbamazepine,rifapentin
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",negative,carbamazepine,phenobarbital
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , St. Johns Wort) may decrease  DRUG2  concentrations.",negative,carbamazepine,sunitinib
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",negative,rifampin,rifabutin
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",negative,rifampin,rifapentin
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",negative,rifampin,phenobarbital
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , St. Johns Wort) may decrease  DRUG2  concentrations.",negative,rifampin,sunitinib
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",negative,rifabutin,rifapentin
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",negative,rifabutin,phenobarbital
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , St. Johns Wort) may decrease  DRUG2  concentrations.",negative,rifabutin,sunitinib
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , St. Johns Wort) may decrease  DRUGOTHER  concentrations.",negative,rifapentin,phenobarbital
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , St. Johns Wort) may decrease  DRUG2  concentrations.",negative,rifapentin,sunitinib
"Co-administration of  DRUGOTHER  with inducers of the CYP3A4 family (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , St. Johns Wort) may decrease  DRUG2  concentrations.",negative,phenobarbital,sunitinib
[Efficacy of fixed combination  DRUG1 / DRUG2  in hospitalized patients with hypertensive disease],negative,amlodipine,valsartan
Efficacy and tolerability of fixed  DRUG1 / DRUG2  combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology.,negative,amlodipine,valsartan
All patients had indications for antihypertensive therapy and were randomized either to fixed combination  DRUG1 / DRUG2  (n=43) or to therapy which corresponded to the hospital formulary (n=43).,negative,amlodipine,valsartan
Rate of achievement of target BP with fixed combination  DRUG1 / DRUG2  (93%) was comparable with that on traditional therapy (90%).,negative,amlodipine,valsartan
"But the use of fixed combination  DRUG1 / DRUG2  compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of  DRUGOTHER  (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05).",effect,amlodipine,valsartan
"But the use of fixed combination  DRUG1 / DRUGOTHER  compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of  DRUG2  (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05).",negative,amlodipine,antihypertensive drugs
"But the use of fixed combination  DRUGOTHER / DRUG1  compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of  DRUG2  (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05).",negative,valsartan,antihypertensive drugs
"We have demonstrated appropriateness of inhospital administration of fixed  DRUG1 / DRUG2  combination as an approach allowing to achieve target BP in shorter time, with the use of fewer  DRUGOTHER , and diminishing concealed inefficacy of treatment.",effect,amlodipine,valsartan
"We have demonstrated appropriateness of inhospital administration of fixed  DRUG1 / DRUGOTHER  combination as an approach allowing to achieve target BP in shorter time, with the use of fewer  DRUG2 , and diminishing concealed inefficacy of treatment.",negative,amlodipine,antihypertensive drugs
"We have demonstrated appropriateness of inhospital administration of fixed  DRUGOTHER / DRUG1  combination as an approach allowing to achieve target BP in shorter time, with the use of fewer  DRUG2 , and diminishing concealed inefficacy of treatment.",negative,valsartan,antihypertensive drugs
Phase I trial of  DRUG1  and  DRUG2  in patients with relapsed multiple myeloma: evidence for  DRUGOTHER - DRUGOTHER  interaction via P-glycoprotein.,negative,lenalidomide,CCI-779
Phase I trial of  DRUG1  and  DRUGOTHER  in patients with relapsed multiple myeloma: evidence for  DRUG2 - DRUGOTHER  interaction via P-glycoprotein.,negative,lenalidomide,lenalidomide
Phase I trial of  DRUG1  and  DRUGOTHER  in patients with relapsed multiple myeloma: evidence for  DRUGOTHER - DRUG2  interaction via P-glycoprotein.,negative,lenalidomide,CCI-779
Phase I trial of  DRUGOTHER  and  DRUG1  in patients with relapsed multiple myeloma: evidence for  DRUG2 - DRUGOTHER  interaction via P-glycoprotein.,negative,CCI-779,lenalidomide
Phase I trial of  DRUGOTHER  and  DRUG1  in patients with relapsed multiple myeloma: evidence for  DRUGOTHER - DRUG2  interaction via P-glycoprotein.,negative,CCI-779,CCI-779
Phase I trial of  DRUGOTHER  and  DRUGOTHER  in patients with relapsed multiple myeloma: evidence for  DRUG1 - DRUG2  interaction via P-glycoprotein.,negative,lenalidomide,CCI-779
The preclinical combination of  DRUG1  with the mTOR inhibitor  DRUG2  has displayed synergy in vitro and represents a novel combination in MM.,effect,lenalidomide,CCI-779
The authors report the case of an infant with confirmed congenital hypothyroidism on  DRUG1  who experienced a possible drug interaction with  DRUG2 .,int,levothyroxine,simeticone
Questioning revealed the child was taking  DRUG1  drops before feeds while on  DRUG2 .,negative,Infacol,levothyroxine
Drug interaction of  DRUG1  with  DRUG2  has not been reported previously and is not listed in the British National Formulary for Children.,negative,thyroxine,simeticone
"These are described in greater detail below:  Oral  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,hypoglycemics,Coumarin-type anticoagulants
"These are described in greater detail below:  Oral  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,hypoglycemics,Phenytoin
"These are described in greater detail below:  Oral  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,hypoglycemics,Cyclosporine
"These are described in greater detail below:  Oral  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,hypoglycemics,Rifampin
"These are described in greater detail below:  Oral  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,hypoglycemics,Theophylline
"These are described in greater detail below:  Oral  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,hypoglycemics,Terfenadine
"These are described in greater detail below:  Oral  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,hypoglycemics,Cisapride
"These are described in greater detail below:  Oral  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,hypoglycemics,Astemizole
"These are described in greater detail below:  Oral  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,hypoglycemics,Rifabutin
"These are described in greater detail below:  Oral  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,hypoglycemics,Tacrolimus
"These are described in greater detail below:  Oral  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,hypoglycemics,Short-acting benzodiazepines
"These are described in greater detail below:  Oral  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUG2 : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,hypoglycemics,hypoglycemics
"These are described in greater detail below:  Oral  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUG2  with oral  DRUGOTHER ;",negative,hypoglycemics,DIFLUCAN
"These are described in greater detail below:  Oral  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUG2 ;",negative,hypoglycemics,hypoglycemic agents
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Coumarin-type anticoagulants,Phenytoin
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Coumarin-type anticoagulants,Cyclosporine
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Coumarin-type anticoagulants,Rifampin
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Coumarin-type anticoagulants,Theophylline
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Coumarin-type anticoagulants,Terfenadine
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Coumarin-type anticoagulants,Cisapride
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Coumarin-type anticoagulants,Astemizole
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Coumarin-type anticoagulants,Rifabutin
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Coumarin-type anticoagulants,Tacrolimus
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Coumarin-type anticoagulants,Short-acting benzodiazepines
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUG2 : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Coumarin-type anticoagulants,hypoglycemics
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUG2  with oral  DRUGOTHER ;",negative,Coumarin-type anticoagulants,DIFLUCAN
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUG2 ;",negative,Coumarin-type anticoagulants,hypoglycemic agents
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Phenytoin,Cyclosporine
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Phenytoin,Rifampin
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Phenytoin,Theophylline
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Phenytoin,Terfenadine
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Phenytoin,Cisapride
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Phenytoin,Astemizole
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Phenytoin,Rifabutin
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Phenytoin,Tacrolimus
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Phenytoin,Short-acting benzodiazepines
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUG2 : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Phenytoin,hypoglycemics
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUG2  with oral  DRUGOTHER ;",negative,Phenytoin,DIFLUCAN
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUG2 ;",negative,Phenytoin,hypoglycemic agents
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Cyclosporine,Rifampin
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Cyclosporine,Theophylline
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Cyclosporine,Terfenadine
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Cyclosporine,Cisapride
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Cyclosporine,Astemizole
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Cyclosporine,Rifabutin
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Cyclosporine,Tacrolimus
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Cyclosporine,Short-acting benzodiazepines
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUG2 : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Cyclosporine,hypoglycemics
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUG2  with oral  DRUGOTHER ;",negative,Cyclosporine,DIFLUCAN
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUG2 ;",negative,Cyclosporine,hypoglycemic agents
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Rifampin,Theophylline
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Rifampin,Terfenadine
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Rifampin,Cisapride
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Rifampin,Astemizole
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Rifampin,Rifabutin
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Rifampin,Tacrolimus
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Rifampin,Short-acting benzodiazepines
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUG2 : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Rifampin,hypoglycemics
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUG2  with oral  DRUGOTHER ;",negative,Rifampin,DIFLUCAN
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUG2 ;",negative,Rifampin,hypoglycemic agents
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Theophylline,Terfenadine
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Theophylline,Cisapride
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Theophylline,Astemizole
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Theophylline,Rifabutin
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Theophylline,Tacrolimus
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Theophylline,Short-acting benzodiazepines
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUG2 : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Theophylline,hypoglycemics
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUG2  with oral  DRUGOTHER ;",negative,Theophylline,DIFLUCAN
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUG2 ;",negative,Theophylline,hypoglycemic agents
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Terfenadine,Cisapride
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Terfenadine,Astemizole
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Terfenadine,Rifabutin
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Terfenadine,Tacrolimus
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Terfenadine,Short-acting benzodiazepines
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUG2 : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Terfenadine,hypoglycemics
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUG2  with oral  DRUGOTHER ;",negative,Terfenadine,DIFLUCAN
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUG2 ;",negative,Terfenadine,hypoglycemic agents
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Cisapride,Astemizole
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Cisapride,Rifabutin
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Cisapride,Tacrolimus
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Cisapride,Short-acting benzodiazepines
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUG2 : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Cisapride,hypoglycemics
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUG2  with oral  DRUGOTHER ;",negative,Cisapride,DIFLUCAN
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUG2 ;",negative,Cisapride,hypoglycemic agents
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Astemizole,Rifabutin
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Astemizole,Tacrolimus
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Astemizole,Short-acting benzodiazepines
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUG2 : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Astemizole,hypoglycemics
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUG2  with oral  DRUGOTHER ;",negative,Astemizole,DIFLUCAN
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUG2 ;",negative,Astemizole,hypoglycemic agents
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Rifabutin,Tacrolimus
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Rifabutin,Short-acting benzodiazepines
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUG2 : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Rifabutin,hypoglycemics
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUG2  with oral  DRUGOTHER ;",negative,Rifabutin,DIFLUCAN
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUG2 ;",negative,Rifabutin,hypoglycemic agents
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Tacrolimus,Short-acting benzodiazepines
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  Oral  DRUG2 : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Tacrolimus,hypoglycemics
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUG2  with oral  DRUGOTHER ;",negative,Tacrolimus,DIFLUCAN
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUG2 ;",negative,Tacrolimus,hypoglycemic agents
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  Oral  DRUG2 : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUGOTHER ;",negative,Short-acting benzodiazepines,hypoglycemics
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUG2  with oral  DRUGOTHER ;",negative,Short-acting benzodiazepines,DIFLUCAN
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUG2 ;",negative,Short-acting benzodiazepines,hypoglycemic agents
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUG1 : Clinically significant hypoglycemia may be precipitated by the use of  DRUG2  with oral  DRUGOTHER ;",negative,hypoglycemics,DIFLUCAN
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUG1 : Clinically significant hypoglycemia may be precipitated by the use of  DRUGOTHER  with oral  DRUG2 ;",negative,hypoglycemics,hypoglycemic agents
"These are described in greater detail below:  Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  Oral  DRUGOTHER : Clinically significant hypoglycemia may be precipitated by the use of  DRUG1  with oral  DRUG2 ;",effect,DIFLUCAN,hypoglycemic agents
one fatality has been reported from hypoglycemia in association with combined  DRUG1  and  DRUG2  use.,effect,DIFLUCAN,glyburide
" DRUG1  reduces the metabolism of  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  and increases the plasma concentration of these agents.",mechanism,DIFLUCAN,tolbutamide
" DRUG1  reduces the metabolism of  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  and increases the plasma concentration of these agents.",mechanism,DIFLUCAN,glyburide
" DRUG1  reduces the metabolism of  DRUGOTHER ,  DRUGOTHER , and  DRUG2  and increases the plasma concentration of these agents.",mechanism,DIFLUCAN,glipizide
" DRUGOTHER  reduces the metabolism of  DRUG1 ,  DRUG2 , and  DRUGOTHER  and increases the plasma concentration of these agents.",negative,tolbutamide,glyburide
" DRUGOTHER  reduces the metabolism of  DRUG1 ,  DRUGOTHER , and  DRUG2  and increases the plasma concentration of these agents.",negative,tolbutamide,glipizide
" DRUGOTHER  reduces the metabolism of  DRUGOTHER ,  DRUG1 , and  DRUG2  and increases the plasma concentration of these agents.",negative,glyburide,glipizide
"When  DRUG1  is used concomitantly with these or other  DRUG2 , blood glucose concentrations should be carefully monitored and the dose of the  DRUGOTHER  should be adjusted as necessary.",advise,DIFLUCAN,sulfonylurea oral hypoglycemic agents
"When  DRUG1  is used concomitantly with these or other  DRUGOTHER , blood glucose concentrations should be carefully monitored and the dose of the  DRUG2  should be adjusted as necessary.",negative,DIFLUCAN,sulfonylurea
"When  DRUGOTHER  is used concomitantly with these or other  DRUG1 , blood glucose concentrations should be carefully monitored and the dose of the  DRUG2  should be adjusted as necessary.",negative,sulfonylurea oral hypoglycemic agents,sulfonylurea
 DRUG1 : Prothrombin time may be increased in patients receiving concomitant  DRUG2  and  DRUGOTHER .,negative,Coumarin-type anticoagulants,DIFLUCAN
 DRUG1 : Prothrombin time may be increased in patients receiving concomitant  DRUGOTHER  and  DRUG2 .,negative,Coumarin-type anticoagulants,coumarin-type anticoagulants
 DRUGOTHER : Prothrombin time may be increased in patients receiving concomitant  DRUG1  and  DRUG2 .,effect,DIFLUCAN,coumarin-type anticoagulants
"In post-marketing experience, as with other  DRUG1 , bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving  DRUG2  concurrently with  DRUGOTHER .",negative,azole antifungals,fluconazole
"In post-marketing experience, as with other  DRUG1 , bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving  DRUGOTHER  concurrently with  DRUG2 .",negative,azole antifungals,warfarin
"In post-marketing experience, as with other  DRUGOTHER , bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving  DRUG1  concurrently with  DRUG2 .",effect,fluconazole,warfarin
Careful monitoring of prothrombin time in patients receiving  DRUG1  and  DRUG2  is recommended.,advise,DIFLUCAN,coumarin-type anticoagulants
 DRUG1 :  DRUG2  increases the plasma concentrations of  DRUGOTHER .,negative,Phenytoin,DIFLUCAN
 DRUG1 :  DRUGOTHER  increases the plasma concentrations of  DRUG2 .,negative,Phenytoin,phenytoin
 DRUGOTHER :  DRUG1  increases the plasma concentrations of  DRUG2 .,mechanism,DIFLUCAN,phenytoin
Careful monitoring of  DRUG1  concentrations in patients receiving  DRUG2  and  DRUGOTHER  is recommended.,negative,phenytoin,DIFLUCAN
Careful monitoring of  DRUG1  concentrations in patients receiving  DRUGOTHER  and  DRUG2  is recommended.,negative,phenytoin,phenytoin
Careful monitoring of  DRUGOTHER  concentrations in patients receiving  DRUG1  and  DRUG2  is recommended.,advise,DIFLUCAN,phenytoin
 DRUG1 :  DRUG2  may significantly increase  DRUGOTHER  levels in renal transplant patients with or without renal impairment.,negative,Cyclosporine,DIFLUCAN
 DRUG1 :  DRUGOTHER  may significantly increase  DRUG2  levels in renal transplant patients with or without renal impairment.,negative,Cyclosporine,cyclosporine
 DRUGOTHER :  DRUG1  may significantly increase  DRUG2  levels in renal transplant patients with or without renal impairment.,mechanism,DIFLUCAN,cyclosporine
Careful monitoring of  DRUG1  concentrations and serum creatinine is recommended in patients receiving  DRUG2  and  DRUGOTHER .,negative,cyclosporine,DIFLUCAN
Careful monitoring of  DRUG1  concentrations and serum creatinine is recommended in patients receiving  DRUGOTHER  and  DRUG2 .,negative,cyclosporine,cyclosporine
Careful monitoring of  DRUGOTHER  concentrations and serum creatinine is recommended in patients receiving  DRUG1  and  DRUG2 .,advise,DIFLUCAN,cyclosporine
 DRUG1 :  DRUG2  enhances the metabolism of concurrently administered  DRUGOTHER .,negative,Rifampin,Rifampin
 DRUG1 :  DRUGOTHER  enhances the metabolism of concurrently administered  DRUG2 .,negative,Rifampin,DIFLUCAN
 DRUGOTHER :  DRUG1  enhances the metabolism of concurrently administered  DRUG2 .,mechanism,Rifampin,DIFLUCAN
"Depending on clinical circumstances, consideration should be given to increasing the dose of  DRUG1  when it is administered with  DRUG2 .",advise,DIFLUCAN,rifampin
 DRUG1 :  DRUG2  increases the serum concentrations of  DRUGOTHER .,negative,Theophylline,DIFLUCAN
 DRUG1 :  DRUGOTHER  increases the serum concentrations of  DRUG2 .,negative,Theophylline,theophylline
 DRUGOTHER :  DRUG1  increases the serum concentrations of  DRUG2 .,mechanism,DIFLUCAN,theophylline
Careful monitoring of serum  DRUG1  concentrations in patients receiving  DRUG2  and  DRUGOTHER  is recommended.,negative,theophylline,DIFLUCAN
Careful monitoring of serum  DRUG1  concentrations in patients receiving  DRUGOTHER  and  DRUG2  is recommended.,negative,theophylline,theophylline
Careful monitoring of serum  DRUGOTHER  concentrations in patients receiving  DRUG1  and  DRUG2  is recommended.,advise,DIFLUCAN,theophylline
" DRUG1 : Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving  DRUG2  in conjunction with  DRUGOTHER , interaction studies have been performed.",negative,Terfenadine,azole antifungals
" DRUG1 : Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving  DRUGOTHER  in conjunction with  DRUG2 , interaction studies have been performed.",negative,Terfenadine,terfenadine
" DRUGOTHER : Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving  DRUG1  in conjunction with  DRUG2 , interaction studies have been performed.",effect,azole antifungals,terfenadine
Another study at a 400-mg and 800-mg daily dose of  DRUG1  demonstrated that  DRUG2  taken in doses of 400 mg per day or greater significantly increases plasma levels of  DRUGOTHER  when taken concomitantly.,negative,fluconazole,DIFLUCAN
Another study at a 400-mg and 800-mg daily dose of  DRUG1  demonstrated that  DRUGOTHER  taken in doses of 400 mg per day or greater significantly increases plasma levels of  DRUG2  when taken concomitantly.,negative,fluconazole,terfenadine
Another study at a 400-mg and 800-mg daily dose of  DRUGOTHER  demonstrated that  DRUG1  taken in doses of 400 mg per day or greater significantly increases plasma levels of  DRUG2  when taken concomitantly.,mechanism,DIFLUCAN,terfenadine
The combined use of  DRUG1  at doses of 400 mg or greater with  DRUG2  is contraindicated.,advise,fluconazole,terfenadine
The coadministration of  DRUG1  at doses lower than 400 mg/day with  DRUG2  should be carefully monitored.,advise,fluconazole,terfenadine
" DRUG1 : There have been reports of cardiac events, including torsade de pointes in patients to whom  DRUG2  and  DRUGOTHER  were coadministered.",negative,Cisapride,fluconazole
" DRUG1 : There have been reports of cardiac events, including torsade de pointes in patients to whom  DRUGOTHER  and  DRUG2  were coadministered.",negative,Cisapride,cisapride
" DRUGOTHER : There have been reports of cardiac events, including torsade de pointes in patients to whom  DRUG1  and  DRUG2  were coadministered.",effect,fluconazole,cisapride
A controlled study found that concomitant  DRUG1  200 mg once daily and  DRUG2  20 mg four times a day yielded a significant increase in  DRUGOTHER  plasma levels and prolongation of QTc interval.,mechanism,fluconazole,cisapride
A controlled study found that concomitant  DRUG1  200 mg once daily and  DRUGOTHER  20 mg four times a day yielded a significant increase in  DRUG2  plasma levels and prolongation of QTc interval.,negative,fluconazole,cisapride
A controlled study found that concomitant  DRUGOTHER  200 mg once daily and  DRUG1  20 mg four times a day yielded a significant increase in  DRUG2  plasma levels and prolongation of QTc interval.,negative,cisapride,cisapride
The combined use of  DRUG1  with  DRUG2  is contraindicated.,advise,fluconazole,cisapride
 DRUG1 : The use of  DRUG2  in patients concurrently taking  DRUGOTHER  or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs.,negative,Astemizole,fluconazole
 DRUG1 : The use of  DRUGOTHER  in patients concurrently taking  DRUG2  or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs.,negative,Astemizole,astemizole
 DRUGOTHER : The use of  DRUG1  in patients concurrently taking  DRUG2  or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs.,mechanism,fluconazole,astemizole
 DRUG1 : There have been reports of uveitis in patients to whom  DRUG2  and  DRUGOTHER  were coadministered.,negative,Rifabutin,fluconazole
 DRUG1 : There have been reports of uveitis in patients to whom  DRUGOTHER  and  DRUG2  were coadministered.,negative,Rifabutin,rifabutin
 DRUGOTHER : There have been reports of uveitis in patients to whom  DRUG1  and  DRUG2  were coadministered.,effect,fluconazole,rifabutin
Patients receiving  DRUG1  and  DRUG2  concomitantly should be carefully monitored.,advise,rifabutin,fluconazole
 DRUG1 : There have been reports of nephrotoxicity in patients to whom  DRUG2  and  DRUGOTHER  were coadministered.,negative,Tacrolimus,fluconazole
 DRUG1 : There have been reports of nephrotoxicity in patients to whom  DRUGOTHER  and  DRUG2  were coadministered.,negative,Tacrolimus,tacrolimus
 DRUGOTHER : There have been reports of nephrotoxicity in patients to whom  DRUG1  and  DRUG2  were coadministered.,effect,fluconazole,tacrolimus
Patients receiving  DRUG1  and  DRUG2  concomitantly should be carefully monitored.,advise,tacrolimus,fluconazole
" DRUG1 : Following oral administration of  DRUG2 ,  DRUGOTHER  resulted in substantial increases in  DRUGOTHER  concentrations and psychomotor effects.",negative,Short-acting Benzodiazepines,midazolam
" DRUG1 : Following oral administration of  DRUGOTHER ,  DRUG2  resulted in substantial increases in  DRUGOTHER  concentrations and psychomotor effects.",negative,Short-acting Benzodiazepines,fluconazole
" DRUG1 : Following oral administration of  DRUGOTHER ,  DRUGOTHER  resulted in substantial increases in  DRUG2  concentrations and psychomotor effects.",negative,Short-acting Benzodiazepines,midazolam
" DRUGOTHER : Following oral administration of  DRUG1 ,  DRUG2  resulted in substantial increases in  DRUGOTHER  concentrations and psychomotor effects.",mechanism,midazolam,fluconazole
" DRUGOTHER : Following oral administration of  DRUG1 ,  DRUGOTHER  resulted in substantial increases in  DRUG2  concentrations and psychomotor effects.",negative,midazolam,midazolam
" DRUGOTHER : Following oral administration of  DRUGOTHER ,  DRUG1  resulted in substantial increases in  DRUG2  concentrations and psychomotor effects.",negative,fluconazole,midazolam
This effect on  DRUG1  appears to be more pronounced following oral administration of  DRUG2  than with  DRUGOTHER  administered intravenously.,effect,midazolam,fluconazole
This effect on  DRUG1  appears to be more pronounced following oral administration of  DRUGOTHER  than with  DRUG2  administered intravenously.,negative,midazolam,fluconazole
This effect on  DRUGOTHER  appears to be more pronounced following oral administration of  DRUG1  than with  DRUG2  administered intravenously.,negative,fluconazole,fluconazole
"If  DRUG1 , which are metabolized by the cytochrome P450 system, are concomitantly administered with  DRUG2 , consideration should be given to decreasing the  DRUGOTHER  dosage, and the patients should be appropriately monitored.",advise,short-acting benzodiazepines,fluconazole
"If  DRUG1 , which are metabolized by the cytochrome P450 system, are concomitantly administered with  DRUGOTHER , consideration should be given to decreasing the  DRUG2  dosage, and the patients should be appropriately monitored.",negative,short-acting benzodiazepines,benzodiazepine
"If  DRUGOTHER , which are metabolized by the cytochrome P450 system, are concomitantly administered with  DRUG1 , consideration should be given to decreasing the  DRUG2  dosage, and the patients should be appropriately monitored.",negative,fluconazole,benzodiazepine
 DRUG1  tablets coadministered with  DRUG2 - and  DRUGOTHER -containing oral  DRUGOTHER  produced an overall mean increase in  DRUGOTHER  and  DRUGOTHER  levels;,mechanism,Fluconazole,ethinyl estradiol
 DRUG1  tablets coadministered with  DRUGOTHER - and  DRUG2 -containing oral  DRUGOTHER  produced an overall mean increase in  DRUGOTHER  and  DRUGOTHER  levels;,mechanism,Fluconazole,levonorgestrel
 DRUG1  tablets coadministered with  DRUGOTHER - and  DRUGOTHER -containing oral  DRUG2  produced an overall mean increase in  DRUGOTHER  and  DRUGOTHER  levels;,negative,Fluconazole,contraceptives
 DRUG1  tablets coadministered with  DRUGOTHER - and  DRUGOTHER -containing oral  DRUGOTHER  produced an overall mean increase in  DRUG2  and  DRUGOTHER  levels;,negative,Fluconazole,ethinyl estradiol
 DRUG1  tablets coadministered with  DRUGOTHER - and  DRUGOTHER -containing oral  DRUGOTHER  produced an overall mean increase in  DRUGOTHER  and  DRUG2  levels;,negative,Fluconazole,levonorgestrel
 DRUGOTHER  tablets coadministered with  DRUG1 - and  DRUG2 -containing oral  DRUGOTHER  produced an overall mean increase in  DRUGOTHER  and  DRUGOTHER  levels;,negative,ethinyl estradiol,levonorgestrel
 DRUGOTHER  tablets coadministered with  DRUG1 - and  DRUGOTHER -containing oral  DRUG2  produced an overall mean increase in  DRUGOTHER  and  DRUGOTHER  levels;,negative,ethinyl estradiol,contraceptives
 DRUGOTHER  tablets coadministered with  DRUG1 - and  DRUGOTHER -containing oral  DRUGOTHER  produced an overall mean increase in  DRUG2  and  DRUGOTHER  levels;,negative,ethinyl estradiol,ethinyl estradiol
 DRUGOTHER  tablets coadministered with  DRUG1 - and  DRUGOTHER -containing oral  DRUGOTHER  produced an overall mean increase in  DRUGOTHER  and  DRUG2  levels;,negative,ethinyl estradiol,levonorgestrel
 DRUGOTHER  tablets coadministered with  DRUGOTHER - and  DRUG1 -containing oral  DRUG2  produced an overall mean increase in  DRUGOTHER  and  DRUGOTHER  levels;,negative,levonorgestrel,contraceptives
 DRUGOTHER  tablets coadministered with  DRUGOTHER - and  DRUG1 -containing oral  DRUGOTHER  produced an overall mean increase in  DRUG2  and  DRUGOTHER  levels;,negative,levonorgestrel,ethinyl estradiol
 DRUGOTHER  tablets coadministered with  DRUGOTHER - and  DRUG1 -containing oral  DRUGOTHER  produced an overall mean increase in  DRUGOTHER  and  DRUG2  levels;,negative,levonorgestrel,levonorgestrel
 DRUGOTHER  tablets coadministered with  DRUGOTHER - and  DRUGOTHER -containing oral  DRUG1  produced an overall mean increase in  DRUG2  and  DRUGOTHER  levels;,negative,contraceptives,ethinyl estradiol
 DRUGOTHER  tablets coadministered with  DRUGOTHER - and  DRUGOTHER -containing oral  DRUG1  produced an overall mean increase in  DRUGOTHER  and  DRUG2  levels;,negative,contraceptives,levonorgestrel
 DRUGOTHER  tablets coadministered with  DRUGOTHER - and  DRUGOTHER -containing oral  DRUGOTHER  produced an overall mean increase in  DRUG1  and  DRUG2  levels;,negative,ethinyl estradiol,levonorgestrel
"however, in some patients there were decreases up to 47% and 33% of  DRUG1  and  DRUG2  levels.",negative,ethinyl estradiol,levonorgestrel
The data presently available indicate that the decreases in some individual  DRUG1  and  DRUG2  AUC values with  DRUGOTHER  treatment are likely the result of random variation.,negative,ethinyl estradiol,levonorgestrel
The data presently available indicate that the decreases in some individual  DRUG1  and  DRUGOTHER  AUC values with  DRUG2  treatment are likely the result of random variation.,negative,ethinyl estradiol,fluconazole
The data presently available indicate that the decreases in some individual  DRUGOTHER  and  DRUG1  AUC values with  DRUG2  treatment are likely the result of random variation.,negative,levonorgestrel,fluconazole
"While there is evidence that  DRUG1  can inhibit the metabolism of  DRUG2  and  DRUGOTHER , there is no evidence that  DRUGOTHER  is a net inducer of  DRUGOTHER  or  DRUGOTHER  metabolism.",mechanism,fluconazole,ethinyl estradiol
"While there is evidence that  DRUG1  can inhibit the metabolism of  DRUGOTHER  and  DRUG2 , there is no evidence that  DRUGOTHER  is a net inducer of  DRUGOTHER  or  DRUGOTHER  metabolism.",mechanism,fluconazole,levonorgestrel
"While there is evidence that  DRUG1  can inhibit the metabolism of  DRUGOTHER  and  DRUGOTHER , there is no evidence that  DRUG2  is a net inducer of  DRUGOTHER  or  DRUGOTHER  metabolism.",negative,fluconazole,fluconazole
"While there is evidence that  DRUG1  can inhibit the metabolism of  DRUGOTHER  and  DRUGOTHER , there is no evidence that  DRUGOTHER  is a net inducer of  DRUG2  or  DRUGOTHER  metabolism.",negative,fluconazole,ethinyl estradiol
"While there is evidence that  DRUG1  can inhibit the metabolism of  DRUGOTHER  and  DRUGOTHER , there is no evidence that  DRUGOTHER  is a net inducer of  DRUGOTHER  or  DRUG2  metabolism.",negative,fluconazole,levonorgestrel
"While there is evidence that  DRUGOTHER  can inhibit the metabolism of  DRUG1  and  DRUG2 , there is no evidence that  DRUGOTHER  is a net inducer of  DRUGOTHER  or  DRUGOTHER  metabolism.",negative,ethinyl estradiol,levonorgestrel
"While there is evidence that  DRUGOTHER  can inhibit the metabolism of  DRUG1  and  DRUGOTHER , there is no evidence that  DRUG2  is a net inducer of  DRUGOTHER  or  DRUGOTHER  metabolism.",negative,ethinyl estradiol,fluconazole
"While there is evidence that  DRUGOTHER  can inhibit the metabolism of  DRUG1  and  DRUGOTHER , there is no evidence that  DRUGOTHER  is a net inducer of  DRUG2  or  DRUGOTHER  metabolism.",negative,ethinyl estradiol,ethinyl estradiol
"While there is evidence that  DRUGOTHER  can inhibit the metabolism of  DRUG1  and  DRUGOTHER , there is no evidence that  DRUGOTHER  is a net inducer of  DRUGOTHER  or  DRUG2  metabolism.",negative,ethinyl estradiol,levonorgestrel
"While there is evidence that  DRUGOTHER  can inhibit the metabolism of  DRUGOTHER  and  DRUG1 , there is no evidence that  DRUG2  is a net inducer of  DRUGOTHER  or  DRUGOTHER  metabolism.",negative,levonorgestrel,fluconazole
"While there is evidence that  DRUGOTHER  can inhibit the metabolism of  DRUGOTHER  and  DRUG1 , there is no evidence that  DRUGOTHER  is a net inducer of  DRUG2  or  DRUGOTHER  metabolism.",negative,levonorgestrel,ethinyl estradiol
"While there is evidence that  DRUGOTHER  can inhibit the metabolism of  DRUGOTHER  and  DRUG1 , there is no evidence that  DRUGOTHER  is a net inducer of  DRUGOTHER  or  DRUG2  metabolism.",negative,levonorgestrel,levonorgestrel
"While there is evidence that  DRUGOTHER  can inhibit the metabolism of  DRUGOTHER  and  DRUGOTHER , there is no evidence that  DRUG1  is a net inducer of  DRUG2  or  DRUGOTHER  metabolism.",negative,fluconazole,ethinyl estradiol
"While there is evidence that  DRUGOTHER  can inhibit the metabolism of  DRUGOTHER  and  DRUGOTHER , there is no evidence that  DRUG1  is a net inducer of  DRUGOTHER  or  DRUG2  metabolism.",negative,fluconazole,levonorgestrel
"While there is evidence that  DRUGOTHER  can inhibit the metabolism of  DRUGOTHER  and  DRUGOTHER , there is no evidence that  DRUGOTHER  is a net inducer of  DRUG1  or  DRUG2  metabolism.",negative,ethinyl estradiol,levonorgestrel
"Interaction of  DRUG1  and  DRUG2 , in vitro and in vivo, in human A375 melanoma cells.",negative,dacarbazine,imexon
"We evaluated mechanisms of interaction between the alkyating agent  DRUG1  ( DRUG2 ) and the pro-oxidant,  DRUGOTHER , in the human A375 melanoma cell line.",negative,dacarbazine,DTIC
"We evaluated mechanisms of interaction between the alkyating agent  DRUG1  ( DRUGOTHER ) and the pro-oxidant,  DRUG2 , in the human A375 melanoma cell line.",negative,dacarbazine,imexon
"We evaluated mechanisms of interaction between the alkyating agent  DRUGOTHER  ( DRUG1 ) and the pro-oxidant,  DRUG2 , in the human A375 melanoma cell line.",negative,DTIC,imexon
"The effect of  DRUG1  and  DRUG2 , alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay).",negative,DTIC,imexon
There was a >75% reduction in cellular glutathione and cysteine with  DRUG1  but not  DRUG2 .,negative,imexon,DTIC
 DRUG1  and  DRUG2  show additive effects in vitro but not in vivo in human A375 melanoma cells.,effect,Imexon,dacarbazine
 DRUG1 : Concurrent use of  DRUG2  and  DRUGOTHER  may result in increased systemic toxicity since  DRUGOTHER  inhibit the breakdown of  DRUGOTHER .,negative,Anticholinesterases,procaine hydrochloride
 DRUG1 : Concurrent use of  DRUGOTHER  and  DRUG2  may result in increased systemic toxicity since  DRUGOTHER  inhibit the breakdown of  DRUGOTHER .,negative,Anticholinesterases,anticholinesterase agents
 DRUG1 : Concurrent use of  DRUGOTHER  and  DRUGOTHER  may result in increased systemic toxicity since  DRUG2  inhibit the breakdown of  DRUGOTHER .,negative,Anticholinesterases,anticholinesterases
 DRUG1 : Concurrent use of  DRUGOTHER  and  DRUGOTHER  may result in increased systemic toxicity since  DRUGOTHER  inhibit the breakdown of  DRUG2 .,negative,Anticholinesterases,procaine hydrochloride
 DRUGOTHER : Concurrent use of  DRUG1  and  DRUG2  may result in increased systemic toxicity since  DRUGOTHER  inhibit the breakdown of  DRUGOTHER .,effect,procaine hydrochloride,anticholinesterase agents
 DRUGOTHER : Concurrent use of  DRUG1  and  DRUGOTHER  may result in increased systemic toxicity since  DRUG2  inhibit the breakdown of  DRUGOTHER .,negative,procaine hydrochloride,anticholinesterases
 DRUGOTHER : Concurrent use of  DRUG1  and  DRUGOTHER  may result in increased systemic toxicity since  DRUGOTHER  inhibit the breakdown of  DRUG2 .,negative,procaine hydrochloride,procaine hydrochloride
 DRUGOTHER : Concurrent use of  DRUGOTHER  and  DRUG1  may result in increased systemic toxicity since  DRUG2  inhibit the breakdown of  DRUGOTHER .,negative,anticholinesterase agents,anticholinesterases
 DRUGOTHER : Concurrent use of  DRUGOTHER  and  DRUG1  may result in increased systemic toxicity since  DRUGOTHER  inhibit the breakdown of  DRUG2 .,negative,anticholinesterase agents,procaine hydrochloride
 DRUGOTHER : Concurrent use of  DRUGOTHER  and  DRUGOTHER  may result in increased systemic toxicity since  DRUG1  inhibit the breakdown of  DRUG2 .,mechanism,anticholinesterases,procaine hydrochloride
 DRUG1  medications: Concurrent use of  DRUG2  and  DRUGOTHER  may result in additive depressant effects.,negative,CNS depressant,procaine hydrochloride
 DRUG1  medications: Concurrent use of  DRUGOTHER  and  DRUG2  may result in additive depressant effects.,negative,CNS depressant,CNS depressant medications
 DRUGOTHER  medications: Concurrent use of  DRUG1  and  DRUG2  may result in additive depressant effects.,effect,procaine hydrochloride,CNS depressant medications
" DRUG1 :  DRUG2  may increase the diffusion rate of  DRUGOTHER , resulting in a decreased time of onset, but an increase in systemic toxicity.",negative,Hyaluronidase,Hyaluronidase
" DRUG1 :  DRUGOTHER  may increase the diffusion rate of  DRUG2 , resulting in a decreased time of onset, but an increase in systemic toxicity.",negative,Hyaluronidase,procaine hydrochloride
" DRUGOTHER :  DRUG1  may increase the diffusion rate of  DRUG2 , resulting in a decreased time of onset, but an increase in systemic toxicity.",mechanism,Hyaluronidase,procaine hydrochloride
 DRUG1  (such as  DRUG2 ): Concurrent use of  DRUGOTHER  and  DRUGOTHER  may result in prolongation or enhancement of the neuromuscular blockade.,negative,Neuromuscular blocking agents,suxamethonium chloride
 DRUG1  (such as  DRUGOTHER ): Concurrent use of  DRUG2  and  DRUGOTHER  may result in prolongation or enhancement of the neuromuscular blockade.,negative,Neuromuscular blocking agents,procaine hydrochloride
 DRUG1  (such as  DRUGOTHER ): Concurrent use of  DRUGOTHER  and  DRUG2  may result in prolongation or enhancement of the neuromuscular blockade.,negative,Neuromuscular blocking agents,neuromuscular blocking agents
 DRUGOTHER  (such as  DRUG1 ): Concurrent use of  DRUG2  and  DRUGOTHER  may result in prolongation or enhancement of the neuromuscular blockade.,negative,suxamethonium chloride,procaine hydrochloride
 DRUGOTHER  (such as  DRUG1 ): Concurrent use of  DRUGOTHER  and  DRUG2  may result in prolongation or enhancement of the neuromuscular blockade.,negative,suxamethonium chloride,neuromuscular blocking agents
 DRUGOTHER  (such as  DRUGOTHER ): Concurrent use of  DRUG1  and  DRUG2  may result in prolongation or enhancement of the neuromuscular blockade.,effect,procaine hydrochloride,neuromuscular blocking agents
 DRUG1 : Concurrent use of  DRUG2  and  DRUGOTHER  may result in a reduction of the antibacterial action of the  DRUGOTHER .,negative,Sulfonamides,procaine hydrochloride
 DRUG1 : Concurrent use of  DRUGOTHER  and  DRUG2  may result in a reduction of the antibacterial action of the  DRUGOTHER .,negative,Sulfonamides,sulfonamides
 DRUG1 : Concurrent use of  DRUGOTHER  and  DRUGOTHER  may result in a reduction of the antibacterial action of the  DRUG2 .,negative,Sulfonamides,sulfonamide
 DRUGOTHER : Concurrent use of  DRUG1  and  DRUG2  may result in a reduction of the antibacterial action of the  DRUGOTHER .,effect,procaine hydrochloride,sulfonamides
 DRUGOTHER : Concurrent use of  DRUG1  and  DRUGOTHER  may result in a reduction of the antibacterial action of the  DRUG2 .,negative,procaine hydrochloride,sulfonamide
 DRUGOTHER : Concurrent use of  DRUGOTHER  and  DRUG1  may result in a reduction of the antibacterial action of the  DRUG2 .,negative,sulfonamides,sulfonamide
 DRUG1 : Concurrent use of  DRUG2  and  DRUGOTHER  may extend the plasma half-life of  DRUGOTHER .,negative,Acetazolamide,acetazolamide
 DRUG1 : Concurrent use of  DRUGOTHER  and  DRUG2  may extend the plasma half-life of  DRUGOTHER .,negative,Acetazolamide,procaine hydrochloride
 DRUG1 : Concurrent use of  DRUGOTHER  and  DRUGOTHER  may extend the plasma half-life of  DRUG2 .,negative,Acetazolamide,procaine
 DRUGOTHER : Concurrent use of  DRUG1  and  DRUG2  may extend the plasma half-life of  DRUGOTHER .,mechanism,acetazolamide,procaine hydrochloride
 DRUGOTHER : Concurrent use of  DRUG1  and  DRUGOTHER  may extend the plasma half-life of  DRUG2 .,negative,acetazolamide,procaine
 DRUGOTHER : Concurrent use of  DRUGOTHER  and  DRUG1  may extend the plasma half-life of  DRUG2 .,negative,procaine hydrochloride,procaine
" DRUG1  may enhance the effects of  DRUG2 ,  DRUGOTHER  and other  DRUGOTHER .",effect,SKELAXIN,alcohol
" DRUG1  may enhance the effects of  DRUGOTHER ,  DRUG2  and other  DRUGOTHER .",effect,SKELAXIN,barbiturates
" DRUG1  may enhance the effects of  DRUGOTHER ,  DRUGOTHER  and other  DRUG2 .",effect,SKELAXIN,CNS depressants
" DRUGOTHER  may enhance the effects of  DRUG1 ,  DRUG2  and other  DRUGOTHER .",negative,alcohol,barbiturates
" DRUGOTHER  may enhance the effects of  DRUG1 ,  DRUGOTHER  and other  DRUG2 .",negative,alcohol,CNS depressants
" DRUGOTHER  may enhance the effects of  DRUGOTHER ,  DRUG1  and other  DRUG2 .",negative,barbiturates,CNS depressants
"Although this has not occurred in in vitro studies with  DRUG1 , interactions with  DRUG2  have been reported with  DRUGOTHER  since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering  DRUGOTHER  to patients on  DRUGOTHER  and other highly protein-bound drugs.",negative,coumarin-type anticoagulants,coumarin-type anticoagulants
"Although this has not occurred in in vitro studies with  DRUG1 , interactions with  DRUGOTHER  have been reported with  DRUG2  since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering  DRUGOTHER  to patients on  DRUGOTHER  and other highly protein-bound drugs.",negative,coumarin-type anticoagulants,FELDENE
"Although this has not occurred in in vitro studies with  DRUG1 , interactions with  DRUGOTHER  have been reported with  DRUGOTHER  since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering  DRUG2  to patients on  DRUGOTHER  and other highly protein-bound drugs.",negative,coumarin-type anticoagulants,FELDENE
"Although this has not occurred in in vitro studies with  DRUG1 , interactions with  DRUGOTHER  have been reported with  DRUGOTHER  since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering  DRUGOTHER  to patients on  DRUG2  and other highly protein-bound drugs.",negative,coumarin-type anticoagulants,coumarin-type anticoagulants
"Although this has not occurred in in vitro studies with  DRUGOTHER , interactions with  DRUG1  have been reported with  DRUG2  since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering  DRUGOTHER  to patients on  DRUGOTHER  and other highly protein-bound drugs.",int,coumarin-type anticoagulants,FELDENE
"Although this has not occurred in in vitro studies with  DRUGOTHER , interactions with  DRUG1  have been reported with  DRUGOTHER  since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering  DRUG2  to patients on  DRUGOTHER  and other highly protein-bound drugs.",negative,coumarin-type anticoagulants,FELDENE
"Although this has not occurred in in vitro studies with  DRUGOTHER , interactions with  DRUG1  have been reported with  DRUGOTHER  since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering  DRUGOTHER  to patients on  DRUG2  and other highly protein-bound drugs.",negative,coumarin-type anticoagulants,coumarin-type anticoagulants
"Although this has not occurred in in vitro studies with  DRUGOTHER , interactions with  DRUGOTHER  have been reported with  DRUG1  since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering  DRUG2  to patients on  DRUGOTHER  and other highly protein-bound drugs.",negative,FELDENE,FELDENE
"Although this has not occurred in in vitro studies with  DRUGOTHER , interactions with  DRUGOTHER  have been reported with  DRUG1  since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering  DRUGOTHER  to patients on  DRUG2  and other highly protein-bound drugs.",negative,FELDENE,coumarin-type anticoagulants
"Although this has not occurred in in vitro studies with  DRUGOTHER , interactions with  DRUGOTHER  have been reported with  DRUGOTHER  since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering  DRUG1  to patients on  DRUG2  and other highly protein-bound drugs.",advise,FELDENE,coumarin-type anticoagulants
"Plasma levels of  DRUG1  are depressed to approximately 80% of their normal values when  DRUG2  is administered in conjunction with  DRUGOTHER  (3900 mg/day), but concomitant administration of  DRUGOTHER  has no effect on  DRUGOTHER  plasma levels .  DRUGOTHER , including  DRUGOTHER , have been reported to increase steady state plasma  DRUGOTHER  levels.",negative,piroxicam,FELDENE
"Plasma levels of  DRUG1  are depressed to approximately 80% of their normal values when  DRUGOTHER  is administered in conjunction with  DRUG2  (3900 mg/day), but concomitant administration of  DRUGOTHER  has no effect on  DRUGOTHER  plasma levels .  DRUGOTHER , including  DRUGOTHER , have been reported to increase steady state plasma  DRUGOTHER  levels.",negative,piroxicam,aspirin
"Plasma levels of  DRUG1  are depressed to approximately 80% of their normal values when  DRUGOTHER  is administered in conjunction with  DRUGOTHER  (3900 mg/day), but concomitant administration of  DRUG2  has no effect on  DRUGOTHER  plasma levels .  DRUGOTHER , including  DRUGOTHER , have been reported to increase steady state plasma  DRUGOTHER  levels.",negative,piroxicam,antacids
"Plasma levels of  DRUG1  are depressed to approximately 80% of their normal values when  DRUGOTHER  is administered in conjunction with  DRUGOTHER  (3900 mg/day), but concomitant administration of  DRUGOTHER  has no effect on  DRUG2  plasma levels .  DRUGOTHER , including  DRUGOTHER , have been reported to increase steady state plasma  DRUGOTHER  levels.",negative,piroxicam,piroxicam
"Plasma levels of  DRUG1  are depressed to approximately 80% of their normal values when  DRUGOTHER  is administered in conjunction with  DRUGOTHER  (3900 mg/day), but concomitant administration of  DRUGOTHER  has no effect on  DRUGOTHER  plasma levels .  DRUG2 , including  DRUGOTHER , have been reported to increase steady state plasma  DRUGOTHER  levels.",negative,piroxicam,Nonsteroidal anti-inflammatory agents
"Plasma levels of  DRUG1  are depressed to approximately 80% of their normal values when  DRUGOTHER  is administered in conjunction with  DRUGOTHER  (3900 mg/day), but concomitant administration of  DRUGOTHER  has no effect on  DRUGOTHER  plasma levels .  DRUGOTHER , including  DRUG2 , have been reported to increase steady state plasma  DRUGOTHER  levels.",negative,piroxicam,FELDENE
"Plasma levels of  DRUG1  are depressed to approximately 80% of their normal values when  DRUGOTHER  is administered in conjunction with  DRUGOTHER  (3900 mg/day), but concomitant administration of  DRUGOTHER  has no effect on  DRUGOTHER  plasma levels .  DRUGOTHER , including  DRUGOTHER , have been reported to increase steady state plasma  DRUG2  levels.",negative,piroxicam,lithium
"Plasma levels of  DRUGOTHER  are depressed to approximately 80% of their normal values when  DRUG1  is administered in conjunction with  DRUG2  (3900 mg/day), but concomitant administration of  DRUGOTHER  has no effect on  DRUGOTHER  plasma levels .  DRUGOTHER , including  DRUGOTHER , have been reported to increase steady state plasma  DRUGOTHER  levels.",mechanism,FELDENE,aspirin
"Plasma levels of  DRUGOTHER  are depressed to approximately 80% of their normal values when  DRUG1  is administered in conjunction with  DRUGOTHER  (3900 mg/day), but concomitant administration of  DRUG2  has no effect on  DRUGOTHER  plasma levels .  DRUGOTHER , including  DRUGOTHER , have been reported to increase steady state plasma  DRUGOTHER  levels.",negative,FELDENE,antacids
"Plasma levels of  DRUGOTHER  are depressed to approximately 80% of their normal values when  DRUG1  is administered in conjunction with  DRUGOTHER  (3900 mg/day), but concomitant administration of  DRUGOTHER  has no effect on  DRUG2  plasma levels .  DRUGOTHER , including  DRUGOTHER , have been reported to increase steady state plasma  DRUGOTHER  levels.",negative,FELDENE,piroxicam
"Plasma levels of  DRUGOTHER  are depressed to approximately 80% of their normal values when  DRUG1  is administered in conjunction with  DRUGOTHER  (3900 mg/day), but concomitant administration of  DRUGOTHER  has no effect on  DRUGOTHER  plasma levels .  DRUG2 , including  DRUGOTHER , have been reported to increase steady state plasma  DRUGOTHER  levels.",negative,FELDENE,Nonsteroidal anti-inflammatory agents
"Plasma levels of  DRUGOTHER  are depressed to approximately 80% of their normal values when  DRUG1  is administered in conjunction with  DRUGOTHER  (3900 mg/day), but concomitant administration of  DRUGOTHER  has no effect on  DRUGOTHER  plasma levels .  DRUGOTHER , including  DRUG2 , have been reported to increase steady state plasma  DRUGOTHER  levels.",negative,FELDENE,FELDENE
"Plasma levels of  DRUGOTHER  are depressed to approximately 80% of their normal values when  DRUG1  is administered in conjunction with  DRUGOTHER  (3900 mg/day), but concomitant administration of  DRUGOTHER  has no effect on  DRUGOTHER  plasma levels .  DRUGOTHER , including  DRUGOTHER , have been reported to increase steady state plasma  DRUG2  levels.",negative,FELDENE,lithium
"Plasma levels of  DRUGOTHER  are depressed to approximately 80% of their normal values when  DRUGOTHER  is administered in conjunction with  DRUG1  (3900 mg/day), but concomitant administration of  DRUG2  has no effect on  DRUGOTHER  plasma levels .  DRUGOTHER , including  DRUGOTHER , have been reported to increase steady state plasma  DRUGOTHER  levels.",negative,aspirin,antacids
"Plasma levels of  DRUGOTHER  are depressed to approximately 80% of their normal values when  DRUGOTHER  is administered in conjunction with  DRUG1  (3900 mg/day), but concomitant administration of  DRUGOTHER  has no effect on  DRUG2  plasma levels .  DRUGOTHER , including  DRUGOTHER , have been reported to increase steady state plasma  DRUGOTHER  levels.",negative,aspirin,piroxicam
"Plasma levels of  DRUGOTHER  are depressed to approximately 80% of their normal values when  DRUGOTHER  is administered in conjunction with  DRUG1  (3900 mg/day), but concomitant administration of  DRUGOTHER  has no effect on  DRUGOTHER  plasma levels .  DRUG2 , including  DRUGOTHER , have been reported to increase steady state plasma  DRUGOTHER  levels.",negative,aspirin,Nonsteroidal anti-inflammatory agents
"Plasma levels of  DRUGOTHER  are depressed to approximately 80% of their normal values when  DRUGOTHER  is administered in conjunction with  DRUG1  (3900 mg/day), but concomitant administration of  DRUGOTHER  has no effect on  DRUGOTHER  plasma levels .  DRUGOTHER , including  DRUG2 , have been reported to increase steady state plasma  DRUGOTHER  levels.",negative,aspirin,FELDENE
"Plasma levels of  DRUGOTHER  are depressed to approximately 80% of their normal values when  DRUGOTHER  is administered in conjunction with  DRUG1  (3900 mg/day), but concomitant administration of  DRUGOTHER  has no effect on  DRUGOTHER  plasma levels .  DRUGOTHER , including  DRUGOTHER , have been reported to increase steady state plasma  DRUG2  levels.",negative,aspirin,lithium
"Plasma levels of  DRUGOTHER  are depressed to approximately 80% of their normal values when  DRUGOTHER  is administered in conjunction with  DRUGOTHER  (3900 mg/day), but concomitant administration of  DRUG1  has no effect on  DRUG2  plasma levels .  DRUGOTHER , including  DRUGOTHER , have been reported to increase steady state plasma  DRUGOTHER  levels.",negative,antacids,piroxicam
"Plasma levels of  DRUGOTHER  are depressed to approximately 80% of their normal values when  DRUGOTHER  is administered in conjunction with  DRUGOTHER  (3900 mg/day), but concomitant administration of  DRUG1  has no effect on  DRUGOTHER  plasma levels .  DRUG2 , including  DRUGOTHER , have been reported to increase steady state plasma  DRUGOTHER  levels.",negative,antacids,Nonsteroidal anti-inflammatory agents
"Plasma levels of  DRUGOTHER  are depressed to approximately 80% of their normal values when  DRUGOTHER  is administered in conjunction with  DRUGOTHER  (3900 mg/day), but concomitant administration of  DRUG1  has no effect on  DRUGOTHER  plasma levels .  DRUGOTHER , including  DRUG2 , have been reported to increase steady state plasma  DRUGOTHER  levels.",negative,antacids,FELDENE
"Plasma levels of  DRUGOTHER  are depressed to approximately 80% of their normal values when  DRUGOTHER  is administered in conjunction with  DRUGOTHER  (3900 mg/day), but concomitant administration of  DRUG1  has no effect on  DRUGOTHER  plasma levels .  DRUGOTHER , including  DRUGOTHER , have been reported to increase steady state plasma  DRUG2  levels.",negative,antacids,lithium
"Plasma levels of  DRUGOTHER  are depressed to approximately 80% of their normal values when  DRUGOTHER  is administered in conjunction with  DRUGOTHER  (3900 mg/day), but concomitant administration of  DRUGOTHER  has no effect on  DRUG1  plasma levels .  DRUG2 , including  DRUGOTHER , have been reported to increase steady state plasma  DRUGOTHER  levels.",negative,piroxicam,Nonsteroidal anti-inflammatory agents
"Plasma levels of  DRUGOTHER  are depressed to approximately 80% of their normal values when  DRUGOTHER  is administered in conjunction with  DRUGOTHER  (3900 mg/day), but concomitant administration of  DRUGOTHER  has no effect on  DRUG1  plasma levels .  DRUGOTHER , including  DRUG2 , have been reported to increase steady state plasma  DRUGOTHER  levels.",negative,piroxicam,FELDENE
"Plasma levels of  DRUGOTHER  are depressed to approximately 80% of their normal values when  DRUGOTHER  is administered in conjunction with  DRUGOTHER  (3900 mg/day), but concomitant administration of  DRUGOTHER  has no effect on  DRUG1  plasma levels .  DRUGOTHER , including  DRUGOTHER , have been reported to increase steady state plasma  DRUG2  levels.",negative,piroxicam,lithium
"Plasma levels of  DRUGOTHER  are depressed to approximately 80% of their normal values when  DRUGOTHER  is administered in conjunction with  DRUGOTHER  (3900 mg/day), but concomitant administration of  DRUGOTHER  has no effect on  DRUGOTHER  plasma levels .  DRUG1 , including  DRUG2 , have been reported to increase steady state plasma  DRUGOTHER  levels.",negative,Nonsteroidal anti-inflammatory agents,FELDENE
"Plasma levels of  DRUGOTHER  are depressed to approximately 80% of their normal values when  DRUGOTHER  is administered in conjunction with  DRUGOTHER  (3900 mg/day), but concomitant administration of  DRUGOTHER  has no effect on  DRUGOTHER  plasma levels .  DRUG1 , including  DRUGOTHER , have been reported to increase steady state plasma  DRUG2  levels.",mechanism,Nonsteroidal anti-inflammatory agents,lithium
"Plasma levels of  DRUGOTHER  are depressed to approximately 80% of their normal values when  DRUGOTHER  is administered in conjunction with  DRUGOTHER  (3900 mg/day), but concomitant administration of  DRUGOTHER  has no effect on  DRUGOTHER  plasma levels .  DRUGOTHER , including  DRUG1 , have been reported to increase steady state plasma  DRUG2  levels.",mechanism,FELDENE,lithium
"It is recommended that plasma  DRUG1  levels be monitored when initiating, adjusting and discontinuing  DRUG2 .",advise,lithium,FELDENE
 DRUG1  may decrease the hypotensive effect of  DRUG2 .,effect,Ritalin,guanethidine
"Human pharmacologic studies have shown that  DRUG1  may inhibit the metabolism of  DRUG2 ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",mechanism,Ritalin,coumarin anticoagulants
"Human pharmacologic studies have shown that  DRUG1  may inhibit the metabolism of  DRUGOTHER ,  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",mechanism,Ritalin,anticonvulsants
"Human pharmacologic studies have shown that  DRUG1  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",mechanism,Ritalin,phenobarbital
"Human pharmacologic studies have shown that  DRUG1  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",mechanism,Ritalin,diphenylhydantoin
"Human pharmacologic studies have shown that  DRUG1  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",mechanism,Ritalin,primidone
"Human pharmacologic studies have shown that  DRUG1  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2 , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",mechanism,Ritalin,phenylbutazone
"Human pharmacologic studies have shown that  DRUG1  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",mechanism,Ritalin,tricyclic drugs
"Human pharmacologic studies have shown that  DRUG1  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",mechanism,Ritalin,imipramine
"Human pharmacologic studies have shown that  DRUG1  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",mechanism,Ritalin,clomipramine
"Human pharmacologic studies have shown that  DRUG1  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",mechanism,Ritalin,desipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUG1 ,  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,coumarin anticoagulants,anticonvulsants
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUG1 ,  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,coumarin anticoagulants,phenobarbital
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUG1 ,  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,coumarin anticoagulants,diphenylhydantoin
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUG1 ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,coumarin anticoagulants,primidone
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUG1 ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2 , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,coumarin anticoagulants,phenylbutazone
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUG1 ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,coumarin anticoagulants,tricyclic drugs
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUG1 ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,coumarin anticoagulants,imipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUG1 ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,coumarin anticoagulants,clomipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUG1 ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,coumarin anticoagulants,desipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUG1  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,anticonvulsants,phenobarbital
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUG1  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,anticonvulsants,diphenylhydantoin
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,anticonvulsants,primidone
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2 , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,anticonvulsants,phenylbutazone
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,anticonvulsants,tricyclic drugs
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,anticonvulsants,imipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,anticonvulsants,clomipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,anticonvulsants,desipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUG1 ,  DRUG2 ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,phenobarbital,diphenylhydantoin
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUG2 ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,phenobarbital,primidone
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUG2 , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,phenobarbital,phenylbutazone
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,phenobarbital,tricyclic drugs
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,phenobarbital,imipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,phenobarbital,clomipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,phenobarbital,desipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUG2 ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,diphenylhydantoin,primidone
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUG2 , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,diphenylhydantoin,phenylbutazone
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER , and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,diphenylhydantoin,tricyclic drugs
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,diphenylhydantoin,imipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,diphenylhydantoin,clomipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,diphenylhydantoin,desipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUG2 , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,primidone,phenylbutazone
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER , and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,primidone,tricyclic drugs
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER , and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,primidone,imipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,primidone,clomipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,primidone,desipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 , and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ).",negative,phenylbutazone,tricyclic drugs
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 , and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,phenylbutazone,imipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 , and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,phenylbutazone,clomipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUG1 , and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,phenylbutazone,desipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUG1  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ).",negative,tricyclic drugs,imipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUG1  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ).",negative,tricyclic drugs,clomipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ).",negative,tricyclic drugs,desipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUG1 ,  DRUG2 ,  DRUGOTHER ).",negative,imipramine,clomipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUG2 ).",negative,imipramine,desipramine
"Human pharmacologic studies have shown that  DRUGOTHER  may inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ),  DRUGOTHER , and  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUG2 ).",negative,clomipramine,desipramine
The safety of using  DRUG1  in combination with  DRUG2  or other centrally acting  DRUGOTHER  has not been systemically evaluated.,negative,methylphenidate,clonidine
The safety of using  DRUG1  in combination with  DRUGOTHER  or other centrally acting  DRUG2  has not been systemically evaluated.,negative,methylphenidate,alpha-2 agonists
The safety of using  DRUGOTHER  in combination with  DRUG1  or other centrally acting  DRUG2  has not been systemically evaluated.,negative,clonidine,alpha-2 agonists
 DRUG1  may inhibit the hepatic metabolism of  DRUG2 .,mechanism,Trimethoprim,phenytoin
" DRUG1 , given at a common clinical dosage, increased the  DRUG2  half-life by 51% and decreased the  DRUGOTHER  metabolic clearance rate by 30%.",mechanism,Trimethoprim,phenytoin
" DRUG1 , given at a common clinical dosage, increased the  DRUGOTHER  half-life by 51% and decreased the  DRUG2  metabolic clearance rate by 30%.",mechanism,Trimethoprim,phenytoin
" DRUGOTHER , given at a common clinical dosage, increased the  DRUG1  half-life by 51% and decreased the  DRUG2  metabolic clearance rate by 30%.",negative,phenytoin,phenytoin
Concomitant use of  DRUG1  with  DRUG2  may result in an adverse drug interaction.,int,alcohol,phentermine hydrochloride
" DRUG1 , a bacteriostatic  DRUG2 , may antagonize the bactericidal effect of  DRUGOTHER  and concurrent use of these drugs should be avoided.",negative,Tetracycline,antibiotic
" DRUG1 , a bacteriostatic  DRUGOTHER , may antagonize the bactericidal effect of  DRUG2  and concurrent use of these drugs should be avoided.",effect,Tetracycline,penicillin
" DRUGOTHER , a bacteriostatic  DRUG1 , may antagonize the bactericidal effect of  DRUG2  and concurrent use of these drugs should be avoided.",negative,antibiotic,penicillin
" DRUG1  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  DRUG2 : can increase seizure activity -  DRUGOTHER : may potentiate the replication of the  DRUGOTHER  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  DRUGOTHER : may cause shortness of breath and bronchospasm -  DRUGOTHER : may decrease patient's response to the  DRUGOTHER ",int,Vindesine,Phenytoin
" DRUG1  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  DRUGOTHER : can increase seizure activity -  DRUG2 : may potentiate the replication of the  DRUGOTHER  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  DRUGOTHER : may cause shortness of breath and bronchospasm -  DRUGOTHER : may decrease patient's response to the  DRUGOTHER ",int,Vindesine,Live virus vaccines
" DRUG1  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  DRUGOTHER : can increase seizure activity -  DRUGOTHER : may potentiate the replication of the  DRUG2  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  DRUGOTHER : may cause shortness of breath and bronchospasm -  DRUGOTHER : may decrease patient's response to the  DRUGOTHER ",negative,Vindesine,vaccine
" DRUG1  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  DRUGOTHER : can increase seizure activity -  DRUGOTHER : may potentiate the replication of the  DRUGOTHER  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  DRUG2 : may cause shortness of breath and bronchospasm -  DRUGOTHER : may decrease patient's response to the  DRUGOTHER ",int,Vindesine,Mitomycin-C
" DRUG1  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  DRUGOTHER : can increase seizure activity -  DRUGOTHER : may potentiate the replication of the  DRUGOTHER  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  DRUGOTHER : may cause shortness of breath and bronchospasm -  DRUG2 : may decrease patient's response to the  DRUGOTHER ",int,Vindesine,Killed virus vaccines
" DRUG1  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  DRUGOTHER : can increase seizure activity -  DRUGOTHER : may potentiate the replication of the  DRUGOTHER  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  DRUGOTHER : may cause shortness of breath and bronchospasm -  DRUGOTHER : may decrease patient's response to the  DRUG2 ",negative,Vindesine,vaccine
" DRUGOTHER  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  DRUG1 : can increase seizure activity -  DRUG2 : may potentiate the replication of the  DRUGOTHER  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  DRUGOTHER : may cause shortness of breath and bronchospasm -  DRUGOTHER : may decrease patient's response to the  DRUGOTHER ",negative,Phenytoin,Live virus vaccines
" DRUGOTHER  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  DRUG1 : can increase seizure activity -  DRUGOTHER : may potentiate the replication of the  DRUG2  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  DRUGOTHER : may cause shortness of breath and bronchospasm -  DRUGOTHER : may decrease patient's response to the  DRUGOTHER ",negative,Phenytoin,vaccine
" DRUGOTHER  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  DRUG1 : can increase seizure activity -  DRUGOTHER : may potentiate the replication of the  DRUGOTHER  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  DRUG2 : may cause shortness of breath and bronchospasm -  DRUGOTHER : may decrease patient's response to the  DRUGOTHER ",negative,Phenytoin,Mitomycin-C
" DRUGOTHER  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  DRUG1 : can increase seizure activity -  DRUGOTHER : may potentiate the replication of the  DRUGOTHER  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  DRUGOTHER : may cause shortness of breath and bronchospasm -  DRUG2 : may decrease patient's response to the  DRUGOTHER ",negative,Phenytoin,Killed virus vaccines
" DRUGOTHER  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  DRUG1 : can increase seizure activity -  DRUGOTHER : may potentiate the replication of the  DRUGOTHER  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  DRUGOTHER : may cause shortness of breath and bronchospasm -  DRUGOTHER : may decrease patient's response to the  DRUG2 ",negative,Phenytoin,vaccine
" DRUGOTHER  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  DRUGOTHER : can increase seizure activity -  DRUG1 : may potentiate the replication of the  DRUG2  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  DRUGOTHER : may cause shortness of breath and bronchospasm -  DRUGOTHER : may decrease patient's response to the  DRUGOTHER ",negative,Live virus vaccines,vaccine
" DRUGOTHER  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  DRUGOTHER : can increase seizure activity -  DRUG1 : may potentiate the replication of the  DRUGOTHER  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  DRUG2 : may cause shortness of breath and bronchospasm -  DRUGOTHER : may decrease patient's response to the  DRUGOTHER ",negative,Live virus vaccines,Mitomycin-C
" DRUGOTHER  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  DRUGOTHER : can increase seizure activity -  DRUG1 : may potentiate the replication of the  DRUGOTHER  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  DRUGOTHER : may cause shortness of breath and bronchospasm -  DRUG2 : may decrease patient's response to the  DRUGOTHER ",negative,Live virus vaccines,Killed virus vaccines
" DRUGOTHER  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  DRUGOTHER : can increase seizure activity -  DRUG1 : may potentiate the replication of the  DRUGOTHER  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  DRUGOTHER : may cause shortness of breath and bronchospasm -  DRUGOTHER : may decrease patient's response to the  DRUG2 ",negative,Live virus vaccines,vaccine
" DRUGOTHER  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  DRUGOTHER : can increase seizure activity -  DRUGOTHER : may potentiate the replication of the  DRUG1  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  DRUG2 : may cause shortness of breath and bronchospasm -  DRUGOTHER : may decrease patient's response to the  DRUGOTHER ",negative,vaccine,Mitomycin-C
" DRUGOTHER  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  DRUGOTHER : can increase seizure activity -  DRUGOTHER : may potentiate the replication of the  DRUG1  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  DRUGOTHER : may cause shortness of breath and bronchospasm -  DRUG2 : may decrease patient's response to the  DRUGOTHER ",negative,vaccine,Killed virus vaccines
" DRUGOTHER  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  DRUGOTHER : can increase seizure activity -  DRUGOTHER : may potentiate the replication of the  DRUG1  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  DRUGOTHER : may cause shortness of breath and bronchospasm -  DRUGOTHER : may decrease patient's response to the  DRUG2 ",negative,vaccine,vaccine
" DRUGOTHER  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  DRUGOTHER : can increase seizure activity -  DRUGOTHER : may potentiate the replication of the  DRUGOTHER  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  DRUG1 : may cause shortness of breath and bronchospasm -  DRUG2 : may decrease patient's response to the  DRUGOTHER ",negative,Mitomycin-C,Killed virus vaccines
" DRUGOTHER  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  DRUGOTHER : can increase seizure activity -  DRUGOTHER : may potentiate the replication of the  DRUGOTHER  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  DRUG1 : may cause shortness of breath and bronchospasm -  DRUGOTHER : may decrease patient's response to the  DRUG2 ",negative,Mitomycin-C,vaccine
" DRUGOTHER  can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity -  DRUGOTHER : can increase seizure activity -  DRUGOTHER : may potentiate the replication of the  DRUGOTHER  virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine -  DRUGOTHER : may cause shortness of breath and bronchospasm -  DRUG1 : may decrease patient's response to the  DRUG2 ",negative,Killed virus vaccines,vaccine
Potential for  DRUG1     to Affect Other Drugs  DRUG2  is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes.,negative,INVEGA,Paliperidone
"Given the primary CNS effects of  DRUG1 ,  DRUG2     should be used with caution in combination with other  DRUGOTHER  and  DRUGOTHER .",negative,paliperidone,INVEGA
"Given the primary CNS effects of  DRUG1 ,  DRUGOTHER     should be used with caution in combination with other  DRUG2  and  DRUGOTHER .",advise,paliperidone,centrally acting drugs
"Given the primary CNS effects of  DRUG1 ,  DRUGOTHER     should be used with caution in combination with other  DRUGOTHER  and  DRUG2 .",advise,paliperidone,alcohol
"Given the primary CNS effects of  DRUGOTHER ,  DRUG1     should be used with caution in combination with other  DRUG2  and  DRUGOTHER .",advise,INVEGA,centrally acting drugs
"Given the primary CNS effects of  DRUGOTHER ,  DRUG1     should be used with caution in combination with other  DRUGOTHER  and  DRUG2 .",advise,INVEGA,alcohol
"Given the primary CNS effects of  DRUGOTHER ,  DRUGOTHER     should be used with caution in combination with other  DRUG1  and  DRUG2 .",negative,centrally acting drugs,alcohol
 DRUG1  may antagonize the effect of  DRUG2  and other  DRUGOTHER .,effect,Paliperidone,levodopa
 DRUG1  may antagonize the effect of  DRUGOTHER  and other  DRUG2 .,effect,Paliperidone,dopamine agonists
 DRUGOTHER  may antagonize the effect of  DRUG1  and other  DRUG2 .,negative,levodopa,dopamine agonists
"Potential for Other Drugs to Affect  DRUG1      DRUG2  is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely.",negative,INVEGA,Paliperidone
Do not exceed a 5 mg daily dose of  DRUG1  when administered with therapeutic doses of  DRUG2  or other potent CYP3A4 inhibitors.,advise,VESIcare,ketoconazole
"Patients with Congenital or Acquired QT Prolongation In a study of the effect of  DRUG1  on the QT interval in 76 healthy women, the QT prolonging effect appeared less with  DRUG2  10 mg than with 30 mg (three times the maximum recommended dose), and the effect of  DRUGOTHER  30 mg did not appear as large as that of the positive control  DRUGOTHER  at its therapeutic dose.",negative,solifenacin,solifenacin
"Patients with Congenital or Acquired QT Prolongation In a study of the effect of  DRUG1  on the QT interval in 76 healthy women, the QT prolonging effect appeared less with  DRUGOTHER  10 mg than with 30 mg (three times the maximum recommended dose), and the effect of  DRUG2  30 mg did not appear as large as that of the positive control  DRUGOTHER  at its therapeutic dose.",negative,solifenacin,solifenacin
"Patients with Congenital or Acquired QT Prolongation In a study of the effect of  DRUG1  on the QT interval in 76 healthy women, the QT prolonging effect appeared less with  DRUGOTHER  10 mg than with 30 mg (three times the maximum recommended dose), and the effect of  DRUGOTHER  30 mg did not appear as large as that of the positive control  DRUG2  at its therapeutic dose.",negative,solifenacin,moxifloxacin
"Patients with Congenital or Acquired QT Prolongation In a study of the effect of  DRUGOTHER  on the QT interval in 76 healthy women, the QT prolonging effect appeared less with  DRUG1  10 mg than with 30 mg (three times the maximum recommended dose), and the effect of  DRUG2  30 mg did not appear as large as that of the positive control  DRUGOTHER  at its therapeutic dose.",negative,solifenacin,solifenacin
"Patients with Congenital or Acquired QT Prolongation In a study of the effect of  DRUGOTHER  on the QT interval in 76 healthy women, the QT prolonging effect appeared less with  DRUG1  10 mg than with 30 mg (three times the maximum recommended dose), and the effect of  DRUGOTHER  30 mg did not appear as large as that of the positive control  DRUG2  at its therapeutic dose.",negative,solifenacin,moxifloxacin
"Patients with Congenital or Acquired QT Prolongation In a study of the effect of  DRUGOTHER  on the QT interval in 76 healthy women, the QT prolonging effect appeared less with  DRUGOTHER  10 mg than with 30 mg (three times the maximum recommended dose), and the effect of  DRUG1  30 mg did not appear as large as that of the positive control  DRUG2  at its therapeutic dose.",negative,solifenacin,moxifloxacin
Some  DRUG1  may interact with  DRUG2 .,int,anticonvulsants,Mephenytoin
"Those  DRUG1  include  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,anticonvulsants,divalproex sodium
"Those  DRUG1  include  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,anticonvulsants,valproic acid
"Those  DRUG1  include  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,anticonvulsants,phenobarbital
"Those  DRUGOTHER  include  DRUG1 ,  DRUG2 , and  DRUGOTHER .",negative,divalproex sodium,valproic acid
"Those  DRUGOTHER  include  DRUG1 ,  DRUGOTHER , and  DRUG2 .",negative,divalproex sodium,phenobarbital
"Those  DRUGOTHER  include  DRUGOTHER ,  DRUG1 , and  DRUG2 .",negative,valproic acid,phenobarbital
" DRUG1  may also affect the effects of other drugs, which include some  DRUG2 ,  DRUGOTHER , certain heart medicines, birth control pills,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  Please note that  DRUGOTHER  may interact with other drugs that are not listed here.",effect,Mephenytoin,steroid medications
" DRUG1  may also affect the effects of other drugs, which include some  DRUGOTHER ,  DRUG2 , certain heart medicines, birth control pills,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  Please note that  DRUGOTHER  may interact with other drugs that are not listed here.",effect,Mephenytoin,warfarin
" DRUG1  may also affect the effects of other drugs, which include some  DRUGOTHER ,  DRUGOTHER , certain heart medicines, birth control pills,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  Please note that  DRUGOTHER  may interact with other drugs that are not listed here.",effect,Mephenytoin,anti-infective medicines
" DRUG1  may also affect the effects of other drugs, which include some  DRUGOTHER ,  DRUGOTHER , certain heart medicines, birth control pills,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  Please note that  DRUGOTHER  may interact with other drugs that are not listed here.",effect,Mephenytoin,furosemide
" DRUG1  may also affect the effects of other drugs, which include some  DRUGOTHER ,  DRUGOTHER , certain heart medicines, birth control pills,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  Please note that  DRUGOTHER  may interact with other drugs that are not listed here.",effect,Mephenytoin,theophylline
" DRUG1  may also affect the effects of other drugs, which include some  DRUGOTHER ,  DRUGOTHER , certain heart medicines, birth control pills,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  Please note that  DRUG2  may interact with other drugs that are not listed here.",negative,Mephenytoin,Mephenytoin
" DRUGOTHER  may also affect the effects of other drugs, which include some  DRUG1 ,  DRUG2 , certain heart medicines, birth control pills,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  Please note that  DRUGOTHER  may interact with other drugs that are not listed here.",negative,steroid medications,warfarin
" DRUGOTHER  may also affect the effects of other drugs, which include some  DRUG1 ,  DRUGOTHER , certain heart medicines, birth control pills,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  Please note that  DRUGOTHER  may interact with other drugs that are not listed here.",negative,steroid medications,anti-infective medicines
" DRUGOTHER  may also affect the effects of other drugs, which include some  DRUG1 ,  DRUGOTHER , certain heart medicines, birth control pills,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  Please note that  DRUGOTHER  may interact with other drugs that are not listed here.",negative,steroid medications,furosemide
" DRUGOTHER  may also affect the effects of other drugs, which include some  DRUG1 ,  DRUGOTHER , certain heart medicines, birth control pills,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  Please note that  DRUGOTHER  may interact with other drugs that are not listed here.",negative,steroid medications,theophylline
" DRUGOTHER  may also affect the effects of other drugs, which include some  DRUG1 ,  DRUGOTHER , certain heart medicines, birth control pills,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  Please note that  DRUG2  may interact with other drugs that are not listed here.",negative,steroid medications,Mephenytoin
" DRUGOTHER  may also affect the effects of other drugs, which include some  DRUGOTHER ,  DRUG1 , certain heart medicines, birth control pills,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER  Please note that  DRUGOTHER  may interact with other drugs that are not listed here.",negative,warfarin,anti-infective medicines
" DRUGOTHER  may also affect the effects of other drugs, which include some  DRUGOTHER ,  DRUG1 , certain heart medicines, birth control pills,  DRUGOTHER ,  DRUG2  and  DRUGOTHER  Please note that  DRUGOTHER  may interact with other drugs that are not listed here.",negative,warfarin,furosemide
" DRUGOTHER  may also affect the effects of other drugs, which include some  DRUGOTHER ,  DRUG1 , certain heart medicines, birth control pills,  DRUGOTHER ,  DRUGOTHER  and  DRUG2  Please note that  DRUGOTHER  may interact with other drugs that are not listed here.",negative,warfarin,theophylline
" DRUGOTHER  may also affect the effects of other drugs, which include some  DRUGOTHER ,  DRUG1 , certain heart medicines, birth control pills,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER  Please note that  DRUG2  may interact with other drugs that are not listed here.",negative,warfarin,Mephenytoin
" DRUGOTHER  may also affect the effects of other drugs, which include some  DRUGOTHER ,  DRUGOTHER , certain heart medicines, birth control pills,  DRUG1 ,  DRUG2  and  DRUGOTHER  Please note that  DRUGOTHER  may interact with other drugs that are not listed here.",negative,anti-infective medicines,furosemide
" DRUGOTHER  may also affect the effects of other drugs, which include some  DRUGOTHER ,  DRUGOTHER , certain heart medicines, birth control pills,  DRUG1 ,  DRUGOTHER  and  DRUG2  Please note that  DRUGOTHER  may interact with other drugs that are not listed here.",negative,anti-infective medicines,theophylline
" DRUGOTHER  may also affect the effects of other drugs, which include some  DRUGOTHER ,  DRUGOTHER , certain heart medicines, birth control pills,  DRUG1 ,  DRUGOTHER  and  DRUGOTHER  Please note that  DRUG2  may interact with other drugs that are not listed here.",negative,anti-infective medicines,Mephenytoin
" DRUGOTHER  may also affect the effects of other drugs, which include some  DRUGOTHER ,  DRUGOTHER , certain heart medicines, birth control pills,  DRUGOTHER ,  DRUG1  and  DRUG2  Please note that  DRUGOTHER  may interact with other drugs that are not listed here.",negative,furosemide,theophylline
" DRUGOTHER  may also affect the effects of other drugs, which include some  DRUGOTHER ,  DRUGOTHER , certain heart medicines, birth control pills,  DRUGOTHER ,  DRUG1  and  DRUGOTHER  Please note that  DRUG2  may interact with other drugs that are not listed here.",negative,furosemide,Mephenytoin
" DRUGOTHER  may also affect the effects of other drugs, which include some  DRUGOTHER ,  DRUGOTHER , certain heart medicines, birth control pills,  DRUGOTHER ,  DRUGOTHER  and  DRUG1  Please note that  DRUG2  may interact with other drugs that are not listed here.",negative,theophylline,Mephenytoin
"Although specific drug or food interactions with  DRUG1  have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and grapefruit juice may inhibit its metabolism (increasing serum levels of  DRUGOTHER ).",negative,mifepristone,ketoconazole
"Although specific drug or food interactions with  DRUG1  have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and grapefruit juice may inhibit its metabolism (increasing serum levels of  DRUGOTHER ).",negative,mifepristone,itraconazole
"Although specific drug or food interactions with  DRUG1  have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and grapefruit juice may inhibit its metabolism (increasing serum levels of  DRUGOTHER ).",negative,mifepristone,erythromycin
"Although specific drug or food interactions with  DRUG1  have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and grapefruit juice may inhibit its metabolism (increasing serum levels of  DRUG2 ).",negative,mifepristone,mifepristone
"Although specific drug or food interactions with  DRUGOTHER  have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that  DRUG1 ,  DRUG2 ,  DRUGOTHER , and grapefruit juice may inhibit its metabolism (increasing serum levels of  DRUGOTHER ).",negative,ketoconazole,itraconazole
"Although specific drug or food interactions with  DRUGOTHER  have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that  DRUG1 ,  DRUGOTHER ,  DRUG2 , and grapefruit juice may inhibit its metabolism (increasing serum levels of  DRUGOTHER ).",negative,ketoconazole,erythromycin
"Although specific drug or food interactions with  DRUGOTHER  have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and grapefruit juice may inhibit its metabolism (increasing serum levels of  DRUG2 ).",mechanism,ketoconazole,mifepristone
"Although specific drug or food interactions with  DRUGOTHER  have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that  DRUGOTHER ,  DRUG1 ,  DRUG2 , and grapefruit juice may inhibit its metabolism (increasing serum levels of  DRUGOTHER ).",negative,itraconazole,erythromycin
"Although specific drug or food interactions with  DRUGOTHER  have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and grapefruit juice may inhibit its metabolism (increasing serum levels of  DRUG2 ).",mechanism,itraconazole,mifepristone
"Although specific drug or food interactions with  DRUGOTHER  have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and grapefruit juice may inhibit its metabolism (increasing serum levels of  DRUG2 ).",mechanism,erythromycin,mifepristone
"Furthermore,  DRUG1 ,  DRUG2 , St.",negative,rifampin,dexamethasone
"John   s Wort, and certain  DRUG1  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER ) may induce  DRUGOTHER  metabolism (lowering serum levels of  DRUGOTHER ).",negative,anticonvulsants,phenytoin
"John   s Wort, and certain  DRUG1  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER ) may induce  DRUGOTHER  metabolism (lowering serum levels of  DRUGOTHER ).",negative,anticonvulsants,phenobarbital
"John   s Wort, and certain  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2 ) may induce  DRUGOTHER  metabolism (lowering serum levels of  DRUGOTHER ).",negative,anticonvulsants,carbamazepine
"John   s Wort, and certain  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may induce  DRUG2  metabolism (lowering serum levels of  DRUGOTHER ).",mechanism,anticonvulsants,mifepristone
"John   s Wort, and certain  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may induce  DRUGOTHER  metabolism (lowering serum levels of  DRUG2 ).",negative,anticonvulsants,mifepristone
"John   s Wort, and certain  DRUGOTHER  ( DRUG1 ,  DRUG2 ,  DRUGOTHER ) may induce  DRUGOTHER  metabolism (lowering serum levels of  DRUGOTHER ).",negative,phenytoin,phenobarbital
"John   s Wort, and certain  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUG2 ) may induce  DRUGOTHER  metabolism (lowering serum levels of  DRUGOTHER ).",negative,phenytoin,carbamazepine
"John   s Wort, and certain  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ) may induce  DRUG2  metabolism (lowering serum levels of  DRUGOTHER ).",mechanism,phenytoin,mifepristone
"John   s Wort, and certain  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER ) may induce  DRUGOTHER  metabolism (lowering serum levels of  DRUG2 ).",negative,phenytoin,mifepristone
"John   s Wort, and certain  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUG2 ) may induce  DRUGOTHER  metabolism (lowering serum levels of  DRUGOTHER ).",negative,phenobarbital,carbamazepine
"John   s Wort, and certain  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ) may induce  DRUG2  metabolism (lowering serum levels of  DRUGOTHER ).",mechanism,phenobarbital,mifepristone
"John   s Wort, and certain  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER ) may induce  DRUGOTHER  metabolism (lowering serum levels of  DRUG2 ).",negative,phenobarbital,mifepristone
"John   s Wort, and certain  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ) may induce  DRUG2  metabolism (lowering serum levels of  DRUGOTHER ).",mechanism,carbamazepine,mifepristone
"John   s Wort, and certain  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1 ) may induce  DRUGOTHER  metabolism (lowering serum levels of  DRUG2 ).",negative,carbamazepine,mifepristone
"John   s Wort, and certain  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ) may induce  DRUG1  metabolism (lowering serum levels of  DRUG2 ).",negative,mifepristone,mifepristone
" DRUG1  has been reported to enhance the sedative activity of  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",effect,Thalidomide,barbiturates
" DRUG1  has been reported to enhance the sedative activity of  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,Thalidomide,alcohol
" DRUG1  has been reported to enhance the sedative activity of  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,Thalidomide,chlorpromazine
" DRUG1  has been reported to enhance the sedative activity of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,Thalidomide,reserpine
" DRUGOTHER  has been reported to enhance the sedative activity of  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,barbiturates,alcohol
" DRUGOTHER  has been reported to enhance the sedative activity of  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,barbiturates,chlorpromazine
" DRUGOTHER  has been reported to enhance the sedative activity of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,barbiturates,reserpine
" DRUGOTHER  has been reported to enhance the sedative activity of  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER .",negative,alcohol,chlorpromazine
" DRUGOTHER  has been reported to enhance the sedative activity of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 .",negative,alcohol,reserpine
" DRUGOTHER  has been reported to enhance the sedative activity of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 .",negative,chlorpromazine,reserpine
"Oral  DRUG1 : In 10 healthy women, the pharmacokinetic profiles of  DRUG2  and  DRUGOTHER  following administration of a single dose containing 1.0 mg of  DRUGOTHER  and 75    g of  DRUGOTHER  were studied.",negative,Contraceptives,norethindrone
"Oral  DRUG1 : In 10 healthy women, the pharmacokinetic profiles of  DRUGOTHER  and  DRUG2  following administration of a single dose containing 1.0 mg of  DRUGOTHER  and 75    g of  DRUGOTHER  were studied.",negative,Contraceptives,ethinyl estradiol
"Oral  DRUG1 : In 10 healthy women, the pharmacokinetic profiles of  DRUGOTHER  and  DRUGOTHER  following administration of a single dose containing 1.0 mg of  DRUG2  and 75    g of  DRUGOTHER  were studied.",negative,Contraceptives,norethindrone acetate
"Oral  DRUG1 : In 10 healthy women, the pharmacokinetic profiles of  DRUGOTHER  and  DRUGOTHER  following administration of a single dose containing 1.0 mg of  DRUGOTHER  and 75    g of  DRUG2  were studied.",negative,Contraceptives,ethinyl estradiol
"Oral  DRUGOTHER : In 10 healthy women, the pharmacokinetic profiles of  DRUG1  and  DRUG2  following administration of a single dose containing 1.0 mg of  DRUGOTHER  and 75    g of  DRUGOTHER  were studied.",negative,norethindrone,ethinyl estradiol
"Oral  DRUGOTHER : In 10 healthy women, the pharmacokinetic profiles of  DRUG1  and  DRUGOTHER  following administration of a single dose containing 1.0 mg of  DRUG2  and 75    g of  DRUGOTHER  were studied.",negative,norethindrone,norethindrone acetate
"Oral  DRUGOTHER : In 10 healthy women, the pharmacokinetic profiles of  DRUG1  and  DRUGOTHER  following administration of a single dose containing 1.0 mg of  DRUGOTHER  and 75    g of  DRUG2  were studied.",negative,norethindrone,ethinyl estradiol
"Oral  DRUGOTHER : In 10 healthy women, the pharmacokinetic profiles of  DRUGOTHER  and  DRUG1  following administration of a single dose containing 1.0 mg of  DRUG2  and 75    g of  DRUGOTHER  were studied.",negative,ethinyl estradiol,norethindrone acetate
"Oral  DRUGOTHER : In 10 healthy women, the pharmacokinetic profiles of  DRUGOTHER  and  DRUG1  following administration of a single dose containing 1.0 mg of  DRUGOTHER  and 75    g of  DRUG2  were studied.",negative,ethinyl estradiol,ethinyl estradiol
"Oral  DRUGOTHER : In 10 healthy women, the pharmacokinetic profiles of  DRUGOTHER  and  DRUGOTHER  following administration of a single dose containing 1.0 mg of  DRUG1  and 75    g of  DRUG2  were studied.",negative,norethindrone acetate,ethinyl estradiol
"Important Non- DRUG1  Drug Interactions Drugs That Interfere with  DRUG2 : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,Thalidomide,Hormonal Contraceptives
"Important Non- DRUG1  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,Thalidomide,HIV-protease inhibitors
"Important Non- DRUG1  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,Thalidomide,griseofulvin
"Important Non- DRUG1  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,Thalidomide,modafinil
"Important Non- DRUG1  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,Thalidomide,penicillins
"Important Non- DRUG1  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,Thalidomide,rifampin
"Important Non- DRUG1  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,Thalidomide,rifabutin
"Important Non- DRUG1  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or certain herbal supplements such as St.",negative,Thalidomide,phenytoin
"Important Non- DRUG1  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or certain herbal supplements such as St.",negative,Thalidomide,carbamazepine
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUG1 : Concomitant use of  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,Hormonal Contraceptives,HIV-protease inhibitors
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUG1 : Concomitant use of  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,Hormonal Contraceptives,griseofulvin
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUG1 : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,Hormonal Contraceptives,modafinil
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUG1 : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,Hormonal Contraceptives,penicillins
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUG1 : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,Hormonal Contraceptives,rifampin
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUG1 : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,Hormonal Contraceptives,rifabutin
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUG1 : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or certain herbal supplements such as St.",negative,Hormonal Contraceptives,phenytoin
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUG1 : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or certain herbal supplements such as St.",negative,Hormonal Contraceptives,carbamazepine
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,HIV-protease inhibitors,griseofulvin
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,HIV-protease inhibitors,modafinil
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,HIV-protease inhibitors,penicillins
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,HIV-protease inhibitors,rifampin
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,HIV-protease inhibitors,rifabutin
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or certain herbal supplements such as St.",negative,HIV-protease inhibitors,phenytoin
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or certain herbal supplements such as St.",negative,HIV-protease inhibitors,carbamazepine
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,griseofulvin,modafinil
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,griseofulvin,penicillins
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,griseofulvin,rifampin
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,griseofulvin,rifabutin
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or certain herbal supplements such as St.",negative,griseofulvin,phenytoin
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or certain herbal supplements such as St.",negative,griseofulvin,carbamazepine
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,modafinil,penicillins
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,modafinil,rifampin
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,modafinil,rifabutin
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or certain herbal supplements such as St.",negative,modafinil,phenytoin
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or certain herbal supplements such as St.",negative,modafinil,carbamazepine
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,penicillins,rifampin
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,penicillins,rifabutin
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or certain herbal supplements such as St.",negative,penicillins,phenytoin
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or certain herbal supplements such as St.",negative,penicillins,carbamazepine
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , or certain herbal supplements such as St.",negative,rifampin,rifabutin
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , or certain herbal supplements such as St.",negative,rifampin,phenytoin
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , or certain herbal supplements such as St.",negative,rifampin,carbamazepine
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , or certain herbal supplements such as St.",negative,rifabutin,phenytoin
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , or certain herbal supplements such as St.",negative,rifabutin,carbamazepine
"Important Non- DRUGOTHER  Drug Interactions Drugs That Interfere with  DRUGOTHER : Concomitant use of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , or certain herbal supplements such as St.",negative,phenytoin,carbamazepine
 DRUG1  with  DRUG2  may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies.,effect,John's Wort,hormonal contraceptive agents
"The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of  DRUG1  and  DRUG2 .",effect,selegiline,meperidine
This is typical of the interaction of  DRUG1  and  DRUG2 .,int,meperidine,MAOIs
Severe toxicity has also been reported in patients receiving the combination of  DRUG1  and  DRUG2  and  DRUGOTHER  and  DRUGOTHER .,effect,tricyclic antidepressants,ELDEPRYL
Severe toxicity has also been reported in patients receiving the combination of  DRUG1  and  DRUGOTHER  and  DRUG2  and  DRUGOTHER .,negative,tricyclic antidepressants,selective serotonin reuptake inhibitors
Severe toxicity has also been reported in patients receiving the combination of  DRUG1  and  DRUGOTHER  and  DRUGOTHER  and  DRUG2 .,negative,tricyclic antidepressants,ELDEPRYL
Severe toxicity has also been reported in patients receiving the combination of  DRUGOTHER  and  DRUG1  and  DRUG2  and  DRUGOTHER .,negative,ELDEPRYL,selective serotonin reuptake inhibitors
Severe toxicity has also been reported in patients receiving the combination of  DRUGOTHER  and  DRUG1  and  DRUGOTHER  and  DRUG2 .,negative,ELDEPRYL,ELDEPRYL
Severe toxicity has also been reported in patients receiving the combination of  DRUGOTHER  and  DRUGOTHER  and  DRUG1  and  DRUG2 .,effect,selective serotonin reuptake inhibitors,ELDEPRYL
One case of hypertensive crisis has been reported in a patient taking the recommended doses of  DRUG1  and a  DRUG2  ( DRUGOTHER ).,effect,selegiline,sympathomimetic medication
One case of hypertensive crisis has been reported in a patient taking the recommended doses of  DRUG1  and a  DRUGOTHER  ( DRUG2 ).,effect,selegiline,ephedrine
One case of hypertensive crisis has been reported in a patient taking the recommended doses of  DRUGOTHER  and a  DRUG1  ( DRUG2 ).,negative,sympathomimetic medication,ephedrine
In vitro activity of  DRUG1  combined with  DRUG2  against clinical isolates of  DRUGOTHER -resistant Staphylococcus aureus.,negative,minocycline,fosfomycin
In vitro activity of  DRUG1  combined with  DRUGOTHER  against clinical isolates of  DRUG2 -resistant Staphylococcus aureus.,negative,minocycline,methicillin
In vitro activity of  DRUGOTHER  combined with  DRUG1  against clinical isolates of  DRUG2 -resistant Staphylococcus aureus.,negative,fosfomycin,methicillin
This study aimed to evaluate the in vitro activity of  DRUG1  combined with  DRUG2  against isolates of  DRUGOTHER -resistant Staphylococcus aureus (MRSA).,negative,minocycline,fosfomycin
This study aimed to evaluate the in vitro activity of  DRUG1  combined with  DRUGOTHER  against isolates of  DRUG2 -resistant Staphylococcus aureus (MRSA).,negative,minocycline,methicillin
This study aimed to evaluate the in vitro activity of  DRUGOTHER  combined with  DRUG1  against isolates of  DRUG2 -resistant Staphylococcus aureus (MRSA).,negative,fosfomycin,methicillin
The susceptibility results for  DRUG1  and  DRUG2  were interpreted according to the most relevant criteria.,negative,minocycline,fosfomycin
The combination of  DRUG1  and  DRUG2  can be synergistic against MRSA.,effect,minocycline,fosfomycin
 DRUG1  has been reported to prolong the elimination half-life of  DRUG2  and may lead to severe bone marrow suppression;,mechanism,Streptozocin,doxorubicin
a reduction of the  DRUG1  dosage should be considered in patients receiving  DRUG2  concurrently.,advise,doxorubicin,ZANOSAR
The concurrent use of  DRUG1  and  DRUG2  has been reported in one case to result in reduced  DRUGOTHER  cytotoxicity.,effect,streptozocin,phenytoin
The concurrent use of  DRUG1  and  DRUGOTHER  has been reported in one case to result in reduced  DRUG2  cytotoxicity.,negative,streptozocin,streptozocin
The concurrent use of  DRUGOTHER  and  DRUG1  has been reported in one case to result in reduced  DRUG2  cytotoxicity.,negative,phenytoin,streptozocin
"The concomitant use of other  DRUG1  including  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,CNS depressants,sedatives
"The concomitant use of other  DRUG1  including  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,CNS depressants,hypnotics
"The concomitant use of other  DRUG1  including  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , general  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,CNS depressants,tranquilizers
"The concomitant use of other  DRUG1  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , general  DRUG2 ,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,CNS depressants,anesthetics
"The concomitant use of other  DRUG1  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , general  DRUGOTHER ,  DRUG2 , other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,CNS depressants,phenothiazines
"The concomitant use of other  DRUG1  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER , other  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,CNS depressants,opioids
"The concomitant use of other  DRUG1  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,CNS depressants,tricyclic antidepressants
"The concomitant use of other  DRUG1  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,CNS depressants,monoamine oxidase (MAO) inhibitors
"The concomitant use of other  DRUG1  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  may produce additive CNS depressant effects.",negative,CNS depressants,alcohol
"The concomitant use of other  DRUGOTHER  including  DRUG1 ,  DRUG2 ,  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,sedatives,hypnotics
"The concomitant use of other  DRUGOTHER  including  DRUG1 ,  DRUGOTHER ,  DRUG2 , general  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,sedatives,tranquilizers
"The concomitant use of other  DRUGOTHER  including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , general  DRUG2 ,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,sedatives,anesthetics
"The concomitant use of other  DRUGOTHER  including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , general  DRUGOTHER ,  DRUG2 , other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,sedatives,phenothiazines
"The concomitant use of other  DRUGOTHER  including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER , other  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,sedatives,opioids
"The concomitant use of other  DRUGOTHER  including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,sedatives,tricyclic antidepressants
"The concomitant use of other  DRUGOTHER  including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,sedatives,monoamine oxidase (MAO) inhibitors
"The concomitant use of other  DRUGOTHER  including  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  may produce additive CNS depressant effects.",negative,sedatives,alcohol
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUG1 ,  DRUG2 , general  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,hypnotics,tranquilizers
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , general  DRUG2 ,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,hypnotics,anesthetics
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , general  DRUGOTHER ,  DRUG2 , other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,hypnotics,phenothiazines
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER , other  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,hypnotics,opioids
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,hypnotics,tricyclic antidepressants
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,hypnotics,monoamine oxidase (MAO) inhibitors
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  may produce additive CNS depressant effects.",negative,hypnotics,alcohol
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , general  DRUG2 ,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,tranquilizers,anesthetics
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , general  DRUGOTHER ,  DRUG2 , other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,tranquilizers,phenothiazines
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , general  DRUGOTHER ,  DRUGOTHER , other  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,tranquilizers,opioids
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , general  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,tranquilizers,tricyclic antidepressants
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , general  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,tranquilizers,monoamine oxidase (MAO) inhibitors
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , general  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  may produce additive CNS depressant effects.",negative,tranquilizers,alcohol
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , general  DRUG1 ,  DRUG2 , other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,anesthetics,phenothiazines
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , general  DRUG1 ,  DRUGOTHER , other  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,anesthetics,opioids
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , general  DRUG1 ,  DRUGOTHER , other  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,anesthetics,tricyclic antidepressants
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , general  DRUG1 ,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,anesthetics,monoamine oxidase (MAO) inhibitors
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , general  DRUG1 ,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  may produce additive CNS depressant effects.",negative,anesthetics,alcohol
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , general  DRUGOTHER ,  DRUG1 , other  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,phenothiazines,opioids
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , general  DRUGOTHER ,  DRUG1 , other  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,phenothiazines,tricyclic antidepressants
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , general  DRUGOTHER ,  DRUG1 , other  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,phenothiazines,monoamine oxidase (MAO) inhibitors
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , general  DRUGOTHER ,  DRUG1 , other  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  may produce additive CNS depressant effects.",negative,phenothiazines,alcohol
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER , other  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,opioids,tricyclic antidepressants
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER , other  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,opioids,monoamine oxidase (MAO) inhibitors
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER , other  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2  may produce additive CNS depressant effects.",negative,opioids,alcohol
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER  may produce additive CNS depressant effects.",negative,tricyclic antidepressants,monoamine oxidase (MAO) inhibitors
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2  may produce additive CNS depressant effects.",negative,tricyclic antidepressants,alcohol
"The concomitant use of other  DRUGOTHER  including  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , general  DRUGOTHER ,  DRUGOTHER , other  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2  may produce additive CNS depressant effects.",negative,monoamine oxidase (MAO) inhibitors,alcohol
" DRUG1  or other medications with anticholinergic activity when used concurrently with  DRUG2  may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.",effect,Anticholinergics,opioid analgesics
It has been reported that the incidence of bradycardia was increased when  DRUG1  was combined with  DRUG2  for induction of anesthesia.,effect,oxymorphone,propofol
"In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of  DRUG1  with  DRUG2 ;",effect,cimetidine,opioid analgesics
 DRUG1  competitively inhibits the intracellular phosphorylation of  DRUG2 .,effect,Zidovudine,stavudine
"Therefore, use of  DRUG1  in combination with  DRUG2  should be avoided.",advise,zidovudine,ZERIT
In vitro data indicate that the phosphorylation of  DRUG1  is also inhibited at relevant concentrations by  DRUG2  and  DRUGOTHER .,effect,stavudine,doxorubicin
In vitro data indicate that the phosphorylation of  DRUG1  is also inhibited at relevant concentrations by  DRUGOTHER  and  DRUG2 .,effect,stavudine,ribavirin
In vitro data indicate that the phosphorylation of  DRUGOTHER  is also inhibited at relevant concentrations by  DRUG1  and  DRUG2 .,negative,doxorubicin,ribavirin
"The  DRUG1  ( DRUG2 ), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia.",negative,3-Deazaneplanocin A,DZNep
"We also found that Bcl-2 was overexpressed in  DRUG1  insensitive cells, and cotreatment with  DRUG2  and  DRUGOTHER , a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of  DRUGOTHER  insensitive MM cells.",negative,DZNep,DZNep
"We also found that Bcl-2 was overexpressed in  DRUG1  insensitive cells, and cotreatment with  DRUGOTHER  and  DRUG2 , a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of  DRUGOTHER  insensitive MM cells.",negative,DZNep,ABT-737
"We also found that Bcl-2 was overexpressed in  DRUG1  insensitive cells, and cotreatment with  DRUGOTHER  and  DRUGOTHER , a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of  DRUG2  insensitive MM cells.",negative,DZNep,DZNep
"We also found that Bcl-2 was overexpressed in  DRUGOTHER  insensitive cells, and cotreatment with  DRUG1  and  DRUG2 , a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of  DRUGOTHER  insensitive MM cells.",effect,DZNep,ABT-737
"We also found that Bcl-2 was overexpressed in  DRUGOTHER  insensitive cells, and cotreatment with  DRUG1  and  DRUGOTHER , a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of  DRUG2  insensitive MM cells.",negative,DZNep,DZNep
"We also found that Bcl-2 was overexpressed in  DRUGOTHER  insensitive cells, and cotreatment with  DRUGOTHER  and  DRUG1 , a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of  DRUG2  insensitive MM cells.",negative,ABT-737,DZNep
"In addition,  DRUG1  insensitivity might be associated with overexpression of Bcl-2, and the combination of  DRUG2  and  DRUGOTHER  could synergistically induced apoptosis.",negative,DZNep,ABT-737
"In addition,  DRUG1  insensitivity might be associated with overexpression of Bcl-2, and the combination of  DRUGOTHER  and  DRUG2  could synergistically induced apoptosis.",negative,DZNep,DZNep
"In addition,  DRUGOTHER  insensitivity might be associated with overexpression of Bcl-2, and the combination of  DRUG1  and  DRUG2  could synergistically induced apoptosis.",effect,ABT-737,DZNep
Pharmacokinetic properties of  DRUG1  were not altered by the addition of either  DRUG2  or  DRUGOTHER  or the combination of  DRUGOTHER  and  DRUGOTHER .,negative,abacavir,lamivudine
Pharmacokinetic properties of  DRUG1  were not altered by the addition of either  DRUGOTHER  or  DRUG2  or the combination of  DRUGOTHER  and  DRUGOTHER .,negative,abacavir,zidovudine
Pharmacokinetic properties of  DRUG1  were not altered by the addition of either  DRUGOTHER  or  DRUGOTHER  or the combination of  DRUG2  and  DRUGOTHER .,negative,abacavir,lamivudine
Pharmacokinetic properties of  DRUG1  were not altered by the addition of either  DRUGOTHER  or  DRUGOTHER  or the combination of  DRUGOTHER  and  DRUG2 .,negative,abacavir,zidovudine
Pharmacokinetic properties of  DRUGOTHER  were not altered by the addition of either  DRUG1  or  DRUG2  or the combination of  DRUGOTHER  and  DRUGOTHER .,negative,lamivudine,zidovudine
Pharmacokinetic properties of  DRUGOTHER  were not altered by the addition of either  DRUG1  or  DRUGOTHER  or the combination of  DRUG2  and  DRUGOTHER .,negative,lamivudine,lamivudine
Pharmacokinetic properties of  DRUGOTHER  were not altered by the addition of either  DRUG1  or  DRUGOTHER  or the combination of  DRUGOTHER  and  DRUG2 .,negative,lamivudine,zidovudine
Pharmacokinetic properties of  DRUGOTHER  were not altered by the addition of either  DRUGOTHER  or  DRUG1  or the combination of  DRUG2  and  DRUGOTHER .,negative,zidovudine,lamivudine
Pharmacokinetic properties of  DRUGOTHER  were not altered by the addition of either  DRUGOTHER  or  DRUG1  or the combination of  DRUGOTHER  and  DRUG2 .,negative,zidovudine,zidovudine
Pharmacokinetic properties of  DRUGOTHER  were not altered by the addition of either  DRUGOTHER  or  DRUGOTHER  or the combination of  DRUG1  and  DRUG2 .,negative,lamivudine,zidovudine
No clinically significant changes to  DRUG1  or  DRUG2  pharmacokinetics were observed following concomitant administration of  DRUGOTHER .,negative,lamivudine,zidovudine
No clinically significant changes to  DRUG1  or  DRUGOTHER  pharmacokinetics were observed following concomitant administration of  DRUG2 .,negative,lamivudine,abacavir
No clinically significant changes to  DRUGOTHER  or  DRUG1  pharmacokinetics were observed following concomitant administration of  DRUG2 .,negative,zidovudine,abacavir
 DRUG1  has no effect on the pharmacokinetic properties of  DRUG2 .,negative,Abacavir,ethanol
 DRUG1  decreases the elimination of  DRUG2  causing an increase in overall exposure . The addition of  DRUGOTHER  has no clinically significant effect on the pharmacokinetic properties of  DRUGOTHER .,mechanism,Ethanol,abacavir
 DRUG1  decreases the elimination of  DRUGOTHER  causing an increase in overall exposure . The addition of  DRUG2  has no clinically significant effect on the pharmacokinetic properties of  DRUGOTHER .,negative,Ethanol,methadone
 DRUG1  decreases the elimination of  DRUGOTHER  causing an increase in overall exposure . The addition of  DRUGOTHER  has no clinically significant effect on the pharmacokinetic properties of  DRUG2 .,negative,Ethanol,abacavir
 DRUGOTHER  decreases the elimination of  DRUG1  causing an increase in overall exposure . The addition of  DRUG2  has no clinically significant effect on the pharmacokinetic properties of  DRUGOTHER .,negative,abacavir,methadone
 DRUGOTHER  decreases the elimination of  DRUG1  causing an increase in overall exposure . The addition of  DRUGOTHER  has no clinically significant effect on the pharmacokinetic properties of  DRUG2 .,negative,abacavir,abacavir
 DRUGOTHER  decreases the elimination of  DRUGOTHER  causing an increase in overall exposure . The addition of  DRUG1  has no clinically significant effect on the pharmacokinetic properties of  DRUG2 .,negative,methadone,abacavir
"In a study of 11 HIV-infected patients receiving  DRUG1 -maintenance therapy (40 mg and 90 mg daily) with 600 mg of  DRUG2  twice daily (twice the currently recommended dose), oral  DRUGOTHER  clearance increased 22% (90% CI 6% to 42%).",mechanism,methadone,ZIAGEN
"In a study of 11 HIV-infected patients receiving  DRUG1 -maintenance therapy (40 mg and 90 mg daily) with 600 mg of  DRUGOTHER  twice daily (twice the currently recommended dose), oral  DRUG2  clearance increased 22% (90% CI 6% to 42%).",negative,methadone,methadone
"In a study of 11 HIV-infected patients receiving  DRUGOTHER -maintenance therapy (40 mg and 90 mg daily) with 600 mg of  DRUG1  twice daily (twice the currently recommended dose), oral  DRUG2  clearance increased 22% (90% CI 6% to 42%).",negative,ZIAGEN,methadone
Caution should be exercised when administering  DRUG1  therapy in combination with other  DRUG2 .,advise,ZADAXIN,immunomodulating drugs
"The CNS-depressant effect of  DRUG1  is additive with that of other  DRUG2 , including  DRUGOTHER .",effect,propoxyphene,CNS depressants
"The CNS-depressant effect of  DRUG1  is additive with that of other  DRUGOTHER , including  DRUG2 .",effect,propoxyphene,alcohol
"The CNS-depressant effect of  DRUGOTHER  is additive with that of other  DRUG1 , including  DRUG2 .",negative,CNS depressants,alcohol
"Such occurrences have been reported when  DRUG1  was administered to patients on  DRUG2 ,  DRUGOTHER , or  DRUGOTHER -like drugs.",negative,propoxyphene,antidepressants
"Such occurrences have been reported when  DRUG1  was administered to patients on  DRUGOTHER ,  DRUG2 , or  DRUGOTHER -like drugs.",negative,propoxyphene,anticonvulsants
"Such occurrences have been reported when  DRUG1  was administered to patients on  DRUGOTHER ,  DRUGOTHER , or  DRUG2 -like drugs.",negative,propoxyphene,warfarin
"Such occurrences have been reported when  DRUGOTHER  was administered to patients on  DRUG1 ,  DRUG2 , or  DRUGOTHER -like drugs.",negative,antidepressants,anticonvulsants
"Such occurrences have been reported when  DRUGOTHER  was administered to patients on  DRUG1 ,  DRUGOTHER , or  DRUG2 -like drugs.",negative,antidepressants,warfarin
"Such occurrences have been reported when  DRUGOTHER  was administered to patients on  DRUGOTHER ,  DRUG1 , or  DRUG2 -like drugs.",negative,anticonvulsants,warfarin
"Drug Interactions: The use of  DRUG1     ( DRUG2 ) Injection before  DRUGOTHER , for the purpose of attenuating some of the side effects of  DRUGOTHER , has not been studied.",negative,ZEMURON,rocuronium bromide
"Drug Interactions: The use of  DRUG1     ( DRUGOTHER ) Injection before  DRUG2 , for the purpose of attenuating some of the side effects of  DRUGOTHER , has not been studied.",negative,ZEMURON,succinylcholine
"Drug Interactions: The use of  DRUG1     ( DRUGOTHER ) Injection before  DRUGOTHER , for the purpose of attenuating some of the side effects of  DRUG2 , has not been studied.",negative,ZEMURON,succinylcholine
"Drug Interactions: The use of  DRUGOTHER     ( DRUG1 ) Injection before  DRUG2 , for the purpose of attenuating some of the side effects of  DRUGOTHER , has not been studied.",negative,rocuronium bromide,succinylcholine
"Drug Interactions: The use of  DRUGOTHER     ( DRUG1 ) Injection before  DRUGOTHER , for the purpose of attenuating some of the side effects of  DRUG2 , has not been studied.",negative,rocuronium bromide,succinylcholine
"Drug Interactions: The use of  DRUGOTHER     ( DRUGOTHER ) Injection before  DRUG1 , for the purpose of attenuating some of the side effects of  DRUG2 , has not been studied.",negative,succinylcholine,succinylcholine
"If  DRUG1     is administered following administration of  DRUG2 , it should not be given until recovery from  DRUGOTHER  has been observed.",advise,ZEMURON,succinylcholine
"If  DRUG1     is administered following administration of  DRUGOTHER , it should not be given until recovery from  DRUG2  has been observed.",negative,ZEMURON,succinylcholine
"If  DRUGOTHER     is administered following administration of  DRUG1 , it should not be given until recovery from  DRUG2  has been observed.",negative,succinylcholine,succinylcholine
"The median duration of action of  DRUG1     0.6 mg/kg administered after a 1 mg/kg dose of  DRUG2  when T 1 returned to 75% of control was 36 minutes (range 14-57, n=12) vs.",negative,ZEMURON,succinylcholine
There are no controlled studies documenting the use of  DRUG1     before or after other  DRUG2 .,negative,ZEMURON,nondepolarizing muscle relaxants
The CNS depressant effects of  DRUG1  may be additive with that of other  DRUG2 ..,effect,oxycodone hydrochloride,CNS depressants
"Since  DRUG1  is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter  DRUG2  plasma concentrations.",negative,MEXITIL,mexiletine
"In a formal, single-dose interaction study (n = 6 males) the clearance of  DRUG1  was decreased by 38% following the coadministration of  DRUG2 , an inhibitor of CYP1A2.",mechanism,mexiletine,fluvoxamine
"In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of  DRUG1  did not alter the kinetics of  DRUG2  in the poor CYP2D6 metabolizer group.",negative,propafenone,mexiletine
"In this crossover steady state study, the pharmacokinetics of  DRUG1  were unaffected in either phenotype by the coadministration of  DRUG2 .",negative,propafenone,mexiletine
"Addition of  DRUG1  to  DRUG2  did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than  DRUGOTHER  alone.",negative,mexiletine,propafenone
"Addition of  DRUG1  to  DRUGOTHER  did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than  DRUG2  alone.",negative,mexiletine,propafenone
"Addition of  DRUGOTHER  to  DRUG1  did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than  DRUG2  alone.",negative,propafenone,propafenone
"When concomitant administration of either of these two drugs with  DRUG1  is initiated, the dose of  DRUG2  should be slowly titrated to desired effect.",negative,mexiletine,mexiletine
"In a large compassionate use program  DRUG1     has been used concurrently with commonly employed antianginal,  DRUG2 , and  DRUGOTHER  without observed interactions.",negative,Mexitil,antihypertensive
"In a large compassionate use program  DRUG1     has been used concurrently with commonly employed antianginal,  DRUGOTHER , and  DRUG2  without observed interactions.",negative,Mexitil,anticoagulant drugs
"In a large compassionate use program  DRUGOTHER     has been used concurrently with commonly employed antianginal,  DRUG1 , and  DRUG2  without observed interactions.",negative,antihypertensive,anticoagulant drugs
"A variety of  DRUG1  such as  DRUG2  or  DRUGOTHER  were also added, sometimes with improved control of ventricular ectopy.",negative,antiarrhythmics,quinidine
"A variety of  DRUG1  such as  DRUGOTHER  or  DRUG2  were also added, sometimes with improved control of ventricular ectopy.",negative,antiarrhythmics,propranolol
"A variety of  DRUGOTHER  such as  DRUG1  or  DRUG2  were also added, sometimes with improved control of ventricular ectopy.",negative,quinidine,propranolol
"When  DRUG1  or other hepatic enzyme inducers such as  DRUG2  and  DRUGOTHER  have been taken concurrently with  DRUGOTHER    , lowered  DRUGOTHER     plasma levels have been reported.",negative,phenytoin,rifampin
"When  DRUG1  or other hepatic enzyme inducers such as  DRUGOTHER  and  DRUG2  have been taken concurrently with  DRUGOTHER    , lowered  DRUGOTHER     plasma levels have been reported.",negative,phenytoin,phenobarbital
"When  DRUG1  or other hepatic enzyme inducers such as  DRUGOTHER  and  DRUGOTHER  have been taken concurrently with  DRUG2    , lowered  DRUGOTHER     plasma levels have been reported.",mechanism,phenytoin,Mexitil
"When  DRUG1  or other hepatic enzyme inducers such as  DRUGOTHER  and  DRUGOTHER  have been taken concurrently with  DRUGOTHER    , lowered  DRUG2     plasma levels have been reported.",negative,phenytoin,Mexitil
"When  DRUGOTHER  or other hepatic enzyme inducers such as  DRUG1  and  DRUG2  have been taken concurrently with  DRUGOTHER    , lowered  DRUGOTHER     plasma levels have been reported.",negative,rifampin,phenobarbital
"When  DRUGOTHER  or other hepatic enzyme inducers such as  DRUG1  and  DRUGOTHER  have been taken concurrently with  DRUG2    , lowered  DRUGOTHER     plasma levels have been reported.",mechanism,rifampin,Mexitil
"When  DRUGOTHER  or other hepatic enzyme inducers such as  DRUG1  and  DRUGOTHER  have been taken concurrently with  DRUGOTHER    , lowered  DRUG2     plasma levels have been reported.",negative,rifampin,Mexitil
"When  DRUGOTHER  or other hepatic enzyme inducers such as  DRUGOTHER  and  DRUG1  have been taken concurrently with  DRUG2    , lowered  DRUGOTHER     plasma levels have been reported.",mechanism,phenobarbital,Mexitil
"When  DRUGOTHER  or other hepatic enzyme inducers such as  DRUGOTHER  and  DRUG1  have been taken concurrently with  DRUGOTHER    , lowered  DRUG2     plasma levels have been reported.",negative,phenobarbital,Mexitil
"When  DRUGOTHER  or other hepatic enzyme inducers such as  DRUGOTHER  and  DRUGOTHER  have been taken concurrently with  DRUG1    , lowered  DRUG2     plasma levels have been reported.",negative,Mexitil,Mexitil
"In a formal study,  DRUG1  were shown not to affect  DRUG2     plasma concentrations.",negative,benzodiazepines,Mexitil
"ECG intervals (PR, QRS, and QT) were not affected by concurrent  DRUG1     and  DRUG2 ,  DRUGOTHER , or  DRUGOTHER .",negative,Mexitil,digoxin
"ECG intervals (PR, QRS, and QT) were not affected by concurrent  DRUG1     and  DRUGOTHER ,  DRUG2 , or  DRUGOTHER .",negative,Mexitil,diuretics
"ECG intervals (PR, QRS, and QT) were not affected by concurrent  DRUG1     and  DRUGOTHER ,  DRUGOTHER , or  DRUG2 .",negative,Mexitil,propranolol
"ECG intervals (PR, QRS, and QT) were not affected by concurrent  DRUGOTHER     and  DRUG1 ,  DRUG2 , or  DRUGOTHER .",negative,digoxin,diuretics
"ECG intervals (PR, QRS, and QT) were not affected by concurrent  DRUGOTHER     and  DRUG1 ,  DRUGOTHER , or  DRUG2 .",negative,digoxin,propranolol
"ECG intervals (PR, QRS, and QT) were not affected by concurrent  DRUGOTHER     and  DRUGOTHER ,  DRUG1 , or  DRUG2 .",negative,diuretics,propranolol
"Concurrent administration of  DRUG1  and  DRUG2     has been reported to increase, decrease, or leave unchanged  DRUGOTHER     plasma levels;",mechanism,cimetidine,Mexitil
"Concurrent administration of  DRUG1  and  DRUGOTHER     has been reported to increase, decrease, or leave unchanged  DRUG2     plasma levels;",negative,cimetidine,Mexitil
"Concurrent administration of  DRUGOTHER  and  DRUG1     has been reported to increase, decrease, or leave unchanged  DRUG2     plasma levels;",negative,Mexitil,Mexitil
" DRUG1     does not alter serum  DRUG2  levels but  DRUGOTHER , when used to treat gastrointestinal symptoms due to  DRUGOTHER    , has been reported to lower serum  DRUGOTHER  levels.",negative,Mexitil,digoxin
" DRUG1     does not alter serum  DRUGOTHER  levels but  DRUG2 , when used to treat gastrointestinal symptoms due to  DRUGOTHER    , has been reported to lower serum  DRUGOTHER  levels.",negative,Mexitil,magnesium-aluminum hydroxide
" DRUG1     does not alter serum  DRUGOTHER  levels but  DRUGOTHER , when used to treat gastrointestinal symptoms due to  DRUG2    , has been reported to lower serum  DRUGOTHER  levels.",negative,Mexitil,Mexitil
" DRUG1     does not alter serum  DRUGOTHER  levels but  DRUGOTHER , when used to treat gastrointestinal symptoms due to  DRUGOTHER    , has been reported to lower serum  DRUG2  levels.",negative,Mexitil,digoxin
" DRUGOTHER     does not alter serum  DRUG1  levels but  DRUG2 , when used to treat gastrointestinal symptoms due to  DRUGOTHER    , has been reported to lower serum  DRUGOTHER  levels.",negative,digoxin,magnesium-aluminum hydroxide
" DRUGOTHER     does not alter serum  DRUG1  levels but  DRUGOTHER , when used to treat gastrointestinal symptoms due to  DRUG2    , has been reported to lower serum  DRUGOTHER  levels.",negative,digoxin,Mexitil
" DRUGOTHER     does not alter serum  DRUG1  levels but  DRUGOTHER , when used to treat gastrointestinal symptoms due to  DRUGOTHER    , has been reported to lower serum  DRUG2  levels.",negative,digoxin,digoxin
" DRUGOTHER     does not alter serum  DRUGOTHER  levels but  DRUG1 , when used to treat gastrointestinal symptoms due to  DRUG2    , has been reported to lower serum  DRUGOTHER  levels.",negative,magnesium-aluminum hydroxide,Mexitil
" DRUGOTHER     does not alter serum  DRUGOTHER  levels but  DRUG1 , when used to treat gastrointestinal symptoms due to  DRUGOTHER    , has been reported to lower serum  DRUG2  levels.",mechanism,magnesium-aluminum hydroxide,digoxin
" DRUGOTHER     does not alter serum  DRUGOTHER  levels but  DRUGOTHER , when used to treat gastrointestinal symptoms due to  DRUG1    , has been reported to lower serum  DRUG2  levels.",negative,Mexitil,digoxin
Concurrent use of  DRUG1     and  DRUG2  may lead to increased plasma  DRUGOTHER  levels.,mechanism,Mexitil,theophylline
Concurrent use of  DRUG1     and  DRUGOTHER  may lead to increased plasma  DRUG2  levels.,negative,Mexitil,theophylline
Concurrent use of  DRUGOTHER     and  DRUG1  may lead to increased plasma  DRUG2  levels.,negative,theophylline,theophylline
"This increase was observed at the first test point which was the second day after starting  DRUG1    .  DRUG2  plasma levels returned to pre- DRUGOTHER     values within 48 hours after discontinuing  DRUGOTHER    . If  DRUGOTHER  and  DRUGOTHER  are to be used concurrently,  DRUGOTHER  blood levels should be monitored, particularly when the  DRUGOTHER     dose is changed.",negative,Mexitil,Theophylline
"This increase was observed at the first test point which was the second day after starting  DRUG1    .  DRUGOTHER  plasma levels returned to pre- DRUG2     values within 48 hours after discontinuing  DRUGOTHER    . If  DRUGOTHER  and  DRUGOTHER  are to be used concurrently,  DRUGOTHER  blood levels should be monitored, particularly when the  DRUGOTHER     dose is changed.",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting  DRUG1    .  DRUGOTHER  plasma levels returned to pre- DRUGOTHER     values within 48 hours after discontinuing  DRUG2    . If  DRUGOTHER  and  DRUGOTHER  are to be used concurrently,  DRUGOTHER  blood levels should be monitored, particularly when the  DRUGOTHER     dose is changed.",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting  DRUG1    .  DRUGOTHER  plasma levels returned to pre- DRUGOTHER     values within 48 hours after discontinuing  DRUGOTHER    . If  DRUG2  and  DRUGOTHER  are to be used concurrently,  DRUGOTHER  blood levels should be monitored, particularly when the  DRUGOTHER     dose is changed.",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting  DRUG1    .  DRUGOTHER  plasma levels returned to pre- DRUGOTHER     values within 48 hours after discontinuing  DRUGOTHER    . If  DRUGOTHER  and  DRUG2  are to be used concurrently,  DRUGOTHER  blood levels should be monitored, particularly when the  DRUGOTHER     dose is changed.",negative,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting  DRUG1    .  DRUGOTHER  plasma levels returned to pre- DRUGOTHER     values within 48 hours after discontinuing  DRUGOTHER    . If  DRUGOTHER  and  DRUGOTHER  are to be used concurrently,  DRUG2  blood levels should be monitored, particularly when the  DRUGOTHER     dose is changed.",negative,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting  DRUG1    .  DRUGOTHER  plasma levels returned to pre- DRUGOTHER     values within 48 hours after discontinuing  DRUGOTHER    . If  DRUGOTHER  and  DRUGOTHER  are to be used concurrently,  DRUGOTHER  blood levels should be monitored, particularly when the  DRUG2     dose is changed.",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting  DRUGOTHER    .  DRUG1  plasma levels returned to pre- DRUG2     values within 48 hours after discontinuing  DRUGOTHER    . If  DRUGOTHER  and  DRUGOTHER  are to be used concurrently,  DRUGOTHER  blood levels should be monitored, particularly when the  DRUGOTHER     dose is changed.",negative,Theophylline,Mexitil
"This increase was observed at the first test point which was the second day after starting  DRUGOTHER    .  DRUG1  plasma levels returned to pre- DRUGOTHER     values within 48 hours after discontinuing  DRUG2    . If  DRUGOTHER  and  DRUGOTHER  are to be used concurrently,  DRUGOTHER  blood levels should be monitored, particularly when the  DRUGOTHER     dose is changed.",mechanism,Theophylline,Mexitil
"This increase was observed at the first test point which was the second day after starting  DRUGOTHER    .  DRUG1  plasma levels returned to pre- DRUGOTHER     values within 48 hours after discontinuing  DRUGOTHER    . If  DRUG2  and  DRUGOTHER  are to be used concurrently,  DRUGOTHER  blood levels should be monitored, particularly when the  DRUGOTHER     dose is changed.",negative,Theophylline,Mexitil
"This increase was observed at the first test point which was the second day after starting  DRUGOTHER    .  DRUG1  plasma levels returned to pre- DRUGOTHER     values within 48 hours after discontinuing  DRUGOTHER    . If  DRUGOTHER  and  DRUG2  are to be used concurrently,  DRUGOTHER  blood levels should be monitored, particularly when the  DRUGOTHER     dose is changed.",negative,Theophylline,theophylline
"This increase was observed at the first test point which was the second day after starting  DRUGOTHER    .  DRUG1  plasma levels returned to pre- DRUGOTHER     values within 48 hours after discontinuing  DRUGOTHER    . If  DRUGOTHER  and  DRUGOTHER  are to be used concurrently,  DRUG2  blood levels should be monitored, particularly when the  DRUGOTHER     dose is changed.",negative,Theophylline,theophylline
"This increase was observed at the first test point which was the second day after starting  DRUGOTHER    .  DRUG1  plasma levels returned to pre- DRUGOTHER     values within 48 hours after discontinuing  DRUGOTHER    . If  DRUGOTHER  and  DRUGOTHER  are to be used concurrently,  DRUGOTHER  blood levels should be monitored, particularly when the  DRUG2     dose is changed.",negative,Theophylline,Mexitil
"This increase was observed at the first test point which was the second day after starting  DRUGOTHER    .  DRUGOTHER  plasma levels returned to pre- DRUG1     values within 48 hours after discontinuing  DRUG2    . If  DRUGOTHER  and  DRUGOTHER  are to be used concurrently,  DRUGOTHER  blood levels should be monitored, particularly when the  DRUGOTHER     dose is changed.",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting  DRUGOTHER    .  DRUGOTHER  plasma levels returned to pre- DRUG1     values within 48 hours after discontinuing  DRUGOTHER    . If  DRUG2  and  DRUGOTHER  are to be used concurrently,  DRUGOTHER  blood levels should be monitored, particularly when the  DRUGOTHER     dose is changed.",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting  DRUGOTHER    .  DRUGOTHER  plasma levels returned to pre- DRUG1     values within 48 hours after discontinuing  DRUGOTHER    . If  DRUGOTHER  and  DRUG2  are to be used concurrently,  DRUGOTHER  blood levels should be monitored, particularly when the  DRUGOTHER     dose is changed.",negative,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting  DRUGOTHER    .  DRUGOTHER  plasma levels returned to pre- DRUG1     values within 48 hours after discontinuing  DRUGOTHER    . If  DRUGOTHER  and  DRUGOTHER  are to be used concurrently,  DRUG2  blood levels should be monitored, particularly when the  DRUGOTHER     dose is changed.",negative,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting  DRUGOTHER    .  DRUGOTHER  plasma levels returned to pre- DRUG1     values within 48 hours after discontinuing  DRUGOTHER    . If  DRUGOTHER  and  DRUGOTHER  are to be used concurrently,  DRUGOTHER  blood levels should be monitored, particularly when the  DRUG2     dose is changed.",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting  DRUGOTHER    .  DRUGOTHER  plasma levels returned to pre- DRUGOTHER     values within 48 hours after discontinuing  DRUG1    . If  DRUG2  and  DRUGOTHER  are to be used concurrently,  DRUGOTHER  blood levels should be monitored, particularly when the  DRUGOTHER     dose is changed.",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting  DRUGOTHER    .  DRUGOTHER  plasma levels returned to pre- DRUGOTHER     values within 48 hours after discontinuing  DRUG1    . If  DRUGOTHER  and  DRUG2  are to be used concurrently,  DRUGOTHER  blood levels should be monitored, particularly when the  DRUGOTHER     dose is changed.",negative,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting  DRUGOTHER    .  DRUGOTHER  plasma levels returned to pre- DRUGOTHER     values within 48 hours after discontinuing  DRUG1    . If  DRUGOTHER  and  DRUGOTHER  are to be used concurrently,  DRUG2  blood levels should be monitored, particularly when the  DRUGOTHER     dose is changed.",negative,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting  DRUGOTHER    .  DRUGOTHER  plasma levels returned to pre- DRUGOTHER     values within 48 hours after discontinuing  DRUG1    . If  DRUGOTHER  and  DRUGOTHER  are to be used concurrently,  DRUGOTHER  blood levels should be monitored, particularly when the  DRUG2     dose is changed.",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting  DRUGOTHER    .  DRUGOTHER  plasma levels returned to pre- DRUGOTHER     values within 48 hours after discontinuing  DRUGOTHER    . If  DRUG1  and  DRUG2  are to be used concurrently,  DRUGOTHER  blood levels should be monitored, particularly when the  DRUGOTHER     dose is changed.",advise,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting  DRUGOTHER    .  DRUGOTHER  plasma levels returned to pre- DRUGOTHER     values within 48 hours after discontinuing  DRUGOTHER    . If  DRUG1  and  DRUGOTHER  are to be used concurrently,  DRUG2  blood levels should be monitored, particularly when the  DRUGOTHER     dose is changed.",negative,Mexitil,theophylline
"This increase was observed at the first test point which was the second day after starting  DRUGOTHER    .  DRUGOTHER  plasma levels returned to pre- DRUGOTHER     values within 48 hours after discontinuing  DRUGOTHER    . If  DRUG1  and  DRUGOTHER  are to be used concurrently,  DRUGOTHER  blood levels should be monitored, particularly when the  DRUG2     dose is changed.",negative,Mexitil,Mexitil
"This increase was observed at the first test point which was the second day after starting  DRUGOTHER    .  DRUGOTHER  plasma levels returned to pre- DRUGOTHER     values within 48 hours after discontinuing  DRUGOTHER    . If  DRUGOTHER  and  DRUG1  are to be used concurrently,  DRUG2  blood levels should be monitored, particularly when the  DRUGOTHER     dose is changed.",negative,theophylline,theophylline
"This increase was observed at the first test point which was the second day after starting  DRUGOTHER    .  DRUGOTHER  plasma levels returned to pre- DRUGOTHER     values within 48 hours after discontinuing  DRUGOTHER    . If  DRUGOTHER  and  DRUG1  are to be used concurrently,  DRUGOTHER  blood levels should be monitored, particularly when the  DRUG2     dose is changed.",negative,theophylline,Mexitil
"This increase was observed at the first test point which was the second day after starting  DRUGOTHER    .  DRUGOTHER  plasma levels returned to pre- DRUGOTHER     values within 48 hours after discontinuing  DRUGOTHER    . If  DRUGOTHER  and  DRUGOTHER  are to be used concurrently,  DRUG1  blood levels should be monitored, particularly when the  DRUG2     dose is changed.",negative,theophylline,Mexitil
"Additionally, in one controlled study in five normal subjects and seven patients, the clearance of  DRUG1  was decreased 50% following the administration of  DRUG2    .",mechanism,caffeine,Mexitil
"In vitro studies with human liver microsomes showed that  DRUG1  does not inhibit the metabolism of  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,terbinafine,tolbutamide
"In vitro studies with human liver microsomes showed that  DRUG1  does not inhibit the metabolism of  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,terbinafine,ethinylestradiol
"In vitro studies with human liver microsomes showed that  DRUG1  does not inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,terbinafine,ethoxycoumarin
"In vitro studies with human liver microsomes showed that  DRUG1  does not inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,terbinafine,cyclosporine
"In vitro studies with human liver microsomes showed that  DRUGOTHER  does not inhibit the metabolism of  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,tolbutamide,ethinylestradiol
"In vitro studies with human liver microsomes showed that  DRUGOTHER  does not inhibit the metabolism of  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,tolbutamide,ethoxycoumarin
"In vitro studies with human liver microsomes showed that  DRUGOTHER  does not inhibit the metabolism of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,tolbutamide,cyclosporine
"In vitro studies with human liver microsomes showed that  DRUGOTHER  does not inhibit the metabolism of  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER .",negative,ethinylestradiol,ethoxycoumarin
"In vitro studies with human liver microsomes showed that  DRUGOTHER  does not inhibit the metabolism of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 .",negative,ethinylestradiol,cyclosporine
"In vitro studies with human liver microsomes showed that  DRUGOTHER  does not inhibit the metabolism of  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 .",negative,ethoxycoumarin,cyclosporine
"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as  DRUG1 ,    -blockers,  DRUG2  ( DRUGOTHER ), and  DRUGOTHER , if they have a narrow therapeutic window.",negative,tricyclic antidepressants,selective serotonin reuptake inhibitors
"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as  DRUG1 ,    -blockers,  DRUGOTHER  ( DRUG2 ), and  DRUGOTHER , if they have a narrow therapeutic window.",negative,tricyclic antidepressants,SSRIs
"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as  DRUG1 ,    -blockers,  DRUGOTHER  ( DRUGOTHER ), and  DRUG2 , if they have a narrow therapeutic window.",negative,tricyclic antidepressants,monoamine oxidase inhibitors (MAO-Is) Type B
"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as  DRUGOTHER ,    -blockers,  DRUG1  ( DRUG2 ), and  DRUGOTHER , if they have a narrow therapeutic window.",negative,selective serotonin reuptake inhibitors,SSRIs
"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as  DRUGOTHER ,    -blockers,  DRUG1  ( DRUGOTHER ), and  DRUG2 , if they have a narrow therapeutic window.",negative,selective serotonin reuptake inhibitors,monoamine oxidase inhibitors (MAO-Is) Type B
"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as  DRUGOTHER ,    -blockers,  DRUGOTHER  ( DRUG1 ), and  DRUG2 , if they have a narrow therapeutic window.",negative,SSRIs,monoamine oxidase inhibitors (MAO-Is) Type B
In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that  DRUG1  does not affect the clearance of  DRUG2  or  DRUGOTHER .,negative,terbinafine,antipyrine
In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that  DRUG1  does not affect the clearance of  DRUGOTHER  or  DRUG2 .,negative,terbinafine,digoxin
In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that  DRUGOTHER  does not affect the clearance of  DRUG1  or  DRUG2 .,negative,antipyrine,digoxin
 DRUG1  decreases the clearance of  DRUG2  by 19%.,mechanism,Terbinafine,caffeine
 DRUG1  increases the clearance of  DRUG2  by 15%.,mechanism,Terbinafine,cyclosporine
"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral  DRUG1  and  DRUG2 , however, a causal relationship between  DRUGOTHER     Tablets and these changes has not been established.",effect,terbinafine,warfarin
"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral  DRUG1  and  DRUGOTHER , however, a causal relationship between  DRUG2     Tablets and these changes has not been established.",negative,terbinafine,LAMISIL
"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral  DRUGOTHER  and  DRUG1 , however, a causal relationship between  DRUG2     Tablets and these changes has not been established.",negative,warfarin,LAMISIL
" DRUG1  clearance is increased 100% by  DRUG2 , a CyP450 enzyme inducer, and decreased 33% by  DRUGOTHER , a CyP450 enzyme inhibitor.",mechanism,Terbinafine,rifampin
" DRUG1  clearance is increased 100% by  DRUGOTHER , a CyP450 enzyme inducer, and decreased 33% by  DRUG2 , a CyP450 enzyme inhibitor.",mechanism,Terbinafine,cimetidine
" DRUGOTHER  clearance is increased 100% by  DRUG1 , a CyP450 enzyme inducer, and decreased 33% by  DRUG2 , a CyP450 enzyme inhibitor.",negative,rifampin,cimetidine
 DRUG1  clearance is unaffected by  DRUG2 .,negative,Terbinafine,cyclosporine
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  DRUG1 , hormone replacement therapies,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,contraceptives,hypoglycemics
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  DRUG1 , hormone replacement therapies,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,contraceptives,theophyllines
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  DRUG1 , hormone replacement therapies,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,contraceptives,phenytoins
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  DRUG1 , hormone replacement therapies,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,contraceptives,thiazide diuretics
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  DRUG1 , hormone replacement therapies,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,contraceptives,beta blockers
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  DRUG1 , hormone replacement therapies,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,contraceptives,calcium channel blockers
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  DRUGOTHER , hormone replacement therapies,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,hypoglycemics,theophyllines
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  DRUGOTHER , hormone replacement therapies,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,hypoglycemics,phenytoins
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  DRUGOTHER , hormone replacement therapies,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,hypoglycemics,thiazide diuretics
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  DRUGOTHER , hormone replacement therapies,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,hypoglycemics,beta blockers
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  DRUGOTHER , hormone replacement therapies,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,hypoglycemics,calcium channel blockers
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  DRUGOTHER , hormone replacement therapies,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,theophyllines,phenytoins
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  DRUGOTHER , hormone replacement therapies,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,theophyllines,thiazide diuretics
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  DRUGOTHER , hormone replacement therapies,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,theophyllines,beta blockers
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  DRUGOTHER , hormone replacement therapies,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,theophyllines,calcium channel blockers
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  DRUGOTHER , hormone replacement therapies,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,phenytoins,thiazide diuretics
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  DRUGOTHER , hormone replacement therapies,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,phenytoins,beta blockers
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  DRUGOTHER , hormone replacement therapies,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,phenytoins,calcium channel blockers
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  DRUGOTHER , hormone replacement therapies,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER .",negative,thiazide diuretics,beta blockers
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  DRUGOTHER , hormone replacement therapies,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 .",negative,thiazide diuretics,calcium channel blockers
"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral  DRUGOTHER , hormone replacement therapies,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 .",negative,beta blockers,calcium channel blockers
 DRUG1 :  DRUG2  and probably other  DRUGOTHER  given concomitantly with  DRUGOTHER  can cause unusually large or prolonged losses of fluid and electrolytes.,negative,Diuretics,Furosemide
 DRUG1 :  DRUGOTHER  and probably other  DRUG2  given concomitantly with  DRUGOTHER  can cause unusually large or prolonged losses of fluid and electrolytes.,negative,Diuretics,loop diuretics
 DRUG1 :  DRUGOTHER  and probably other  DRUGOTHER  given concomitantly with  DRUG2  can cause unusually large or prolonged losses of fluid and electrolytes.,negative,Diuretics,metolazone
 DRUGOTHER :  DRUG1  and probably other  DRUG2  given concomitantly with  DRUGOTHER  can cause unusually large or prolonged losses of fluid and electrolytes.,negative,Furosemide,loop diuretics
 DRUGOTHER :  DRUG1  and probably other  DRUGOTHER  given concomitantly with  DRUG2  can cause unusually large or prolonged losses of fluid and electrolytes.,effect,Furosemide,metolazone
 DRUGOTHER :  DRUGOTHER  and probably other  DRUG1  given concomitantly with  DRUG2  can cause unusually large or prolonged losses of fluid and electrolytes.,effect,loop diuretics,metolazone
"Other  DRUG1 : When  DRUG2  Tablets are used with other  DRUGOTHER , care must be taken, especially during initial therapy.",negative,Antihypertensives,MYKROX
"Other  DRUG1 : When  DRUGOTHER  Tablets are used with other  DRUG2 , care must be taken, especially during initial therapy.",negative,Antihypertensives,antihypertensive drugs
"Other  DRUGOTHER : When  DRUG1  Tablets are used with other  DRUG2 , care must be taken, especially during initial therapy.",advise,MYKROX,antihypertensive drugs
" DRUG1 ,  DRUG2 , and  DRUGOTHER : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with  DRUGOTHER  therapy.",negative,Alcohol,Barbiturates
" DRUG1 ,  DRUGOTHER , and  DRUG2 : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with  DRUGOTHER  therapy.",negative,Alcohol,Narcotics
" DRUG1 ,  DRUGOTHER , and  DRUGOTHER : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with  DRUG2  therapy.",negative,Alcohol,metolazone
" DRUGOTHER ,  DRUG1 , and  DRUG2 : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with  DRUGOTHER  therapy.",negative,Barbiturates,Narcotics
" DRUGOTHER ,  DRUG1 , and  DRUGOTHER : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with  DRUG2  therapy.",negative,Barbiturates,metolazone
" DRUGOTHER ,  DRUGOTHER , and  DRUG1 : The hypotensive effects of these drugs may be potentiated by the volume contraction that may be associated with  DRUG2  therapy.",negative,Narcotics,metolazone
 DRUG1 :  DRUG2 -induced hypokalemia can increase the sensitivity of the myocardium to  DRUGOTHER .,negative,Digitalis Glycosides,Diuretic
 DRUG1 :  DRUGOTHER -induced hypokalemia can increase the sensitivity of the myocardium to  DRUG2 .,negative,Digitalis Glycosides,digitalis
 DRUGOTHER :  DRUG1 -induced hypokalemia can increase the sensitivity of the myocardium to  DRUG2 .,effect,Diuretic,digitalis
 DRUG1  or  DRUG2 : May increase the risk of hypokalemia and increase salt and water retention.,negative,Corticosteroids,ACTH
 DRUG1 : Serum  DRUG2  levels may increase.,negative,Lithium,lithium
 DRUG1 :  DRUG2 -induced hypokalemia may enhance neuromuscular blocking effects of  DRUGOTHER  (such as  DRUGOTHER ) the most serious effect would be respiratory depression which could proceed to apnea.,negative,Curariform Drugs,Diuretic
 DRUG1 :  DRUGOTHER -induced hypokalemia may enhance neuromuscular blocking effects of  DRUG2  (such as  DRUGOTHER ) the most serious effect would be respiratory depression which could proceed to apnea.,negative,Curariform Drugs,curariform drugs
 DRUG1 :  DRUGOTHER -induced hypokalemia may enhance neuromuscular blocking effects of  DRUGOTHER  (such as  DRUG2 ) the most serious effect would be respiratory depression which could proceed to apnea.,negative,Curariform Drugs,tubocurarine
 DRUGOTHER :  DRUG1 -induced hypokalemia may enhance neuromuscular blocking effects of  DRUG2  (such as  DRUGOTHER ) the most serious effect would be respiratory depression which could proceed to apnea.,effect,Diuretic,curariform drugs
 DRUGOTHER :  DRUG1 -induced hypokalemia may enhance neuromuscular blocking effects of  DRUGOTHER  (such as  DRUG2 ) the most serious effect would be respiratory depression which could proceed to apnea.,effect,Diuretic,tubocurarine
 DRUGOTHER :  DRUGOTHER -induced hypokalemia may enhance neuromuscular blocking effects of  DRUG1  (such as  DRUG2 ) the most serious effect would be respiratory depression which could proceed to apnea.,negative,curariform drugs,tubocurarine
 DRUG1  and Other  DRUG2 : May decrease the antihypertensive effects of  DRUGOTHER  Tablets.,negative,Salicylates,Non-Steroidal Anti-Inflammatory Drugs
 DRUG1  and Other  DRUGOTHER : May decrease the antihypertensive effects of  DRUG2  Tablets.,effect,Salicylates,MYKROX
 DRUGOTHER  and Other  DRUG1 : May decrease the antihypertensive effects of  DRUG2  Tablets.,effect,Non-Steroidal Anti-Inflammatory Drugs,MYKROX
" DRUG1 :  DRUG2  may decrease arterial responsiveness to  DRUGOTHER , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.",negative,Sympathomimetics,Metolazone
" DRUG1 :  DRUGOTHER  may decrease arterial responsiveness to  DRUG2 , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.",negative,Sympathomimetics,norepinephrine
" DRUGOTHER :  DRUG1  may decrease arterial responsiveness to  DRUG2 , but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use.",effect,Metolazone,norepinephrine
 DRUG1 : Efficacy may be decreased due to urinary alkalizing effect of  DRUG2 .,effect,Methenamine,metolazone
" DRUG1 :  DRUG2 , as well as other  DRUGOTHER , may affect the hypoprothrombinemic response to  DRUGOTHER ;",negative,Anticoagulants,Metolazone
" DRUG1 :  DRUGOTHER , as well as other  DRUG2 , may affect the hypoprothrombinemic response to  DRUGOTHER ;",negative,Anticoagulants,thiazide-like diuretics
" DRUG1 :  DRUGOTHER , as well as other  DRUGOTHER , may affect the hypoprothrombinemic response to  DRUG2 ;",negative,Anticoagulants,anticoagulants
" DRUGOTHER :  DRUG1 , as well as other  DRUG2 , may affect the hypoprothrombinemic response to  DRUGOTHER ;",negative,Metolazone,thiazide-like diuretics
" DRUGOTHER :  DRUG1 , as well as other  DRUGOTHER , may affect the hypoprothrombinemic response to  DRUG2 ;",effect,Metolazone,anticoagulants
" DRUGOTHER :  DRUGOTHER , as well as other  DRUG1 , may affect the hypoprothrombinemic response to  DRUG2 ;",negative,thiazide-like diuretics,anticoagulants
"Interaction with Other  DRUG1 :  DRUG2  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,Central Nervous System Depressants,MEPERIDINE
"Interaction with Other  DRUG1 :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUG2 , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,Central Nervous System Depressants,NARCOTIC ANALGESICS
"Interaction with Other  DRUG1 :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUG2 ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,Central Nervous System Depressants,ANESTHETICS
"Interaction with Other  DRUG1 :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUG2 , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,Central Nervous System Depressants,PHENOTHIAZINES
"Interaction with Other  DRUG1 :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUG2 ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,Central Nervous System Depressants,TRANQUILIZERS
"Interaction with Other  DRUG1 :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUG2  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,Central Nervous System Depressants,SEDATIVE-HYPNOTICS
"Interaction with Other  DRUG1 :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUG2 ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,Central Nervous System Depressants,BARBITURATES
"Interaction with Other  DRUG1 :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUG2  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,Central Nervous System Depressants,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other  DRUG1 :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUG2  (INCLUDING  DRUGOTHER ).",negative,Central Nervous System Depressants,CNS DEPRESSANTS
"Interaction with Other  DRUG1 :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUG2 ).",negative,Central Nervous System Depressants,ALCOHOL
"Interaction with Other  DRUGOTHER :  DRUG1  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUG2 , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",advise,MEPERIDINE,NARCOTIC ANALGESICS
"Interaction with Other  DRUGOTHER :  DRUG1  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUG2 ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",advise,MEPERIDINE,ANESTHETICS
"Interaction with Other  DRUGOTHER :  DRUG1  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUG2 , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",advise,MEPERIDINE,PHENOTHIAZINES
"Interaction with Other  DRUGOTHER :  DRUG1  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUG2 ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",advise,MEPERIDINE,TRANQUILIZERS
"Interaction with Other  DRUGOTHER :  DRUG1  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUG2  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",advise,MEPERIDINE,SEDATIVE-HYPNOTICS
"Interaction with Other  DRUGOTHER :  DRUG1  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUG2 ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",advise,MEPERIDINE,BARBITURATES
"Interaction with Other  DRUGOTHER :  DRUG1  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUG2  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",advise,MEPERIDINE,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other  DRUGOTHER :  DRUG1  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUG2  (INCLUDING  DRUGOTHER ).",advise,MEPERIDINE,CNS DEPRESSANTS
"Interaction with Other  DRUGOTHER :  DRUG1  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUG2 ).",advise,MEPERIDINE,ALCOHOL
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUG1 , GENERAL  DRUG2 ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,NARCOTIC ANALGESICS,ANESTHETICS
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUG1 , GENERAL  DRUGOTHER ,  DRUG2 , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,NARCOTIC ANALGESICS,PHENOTHIAZINES
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUG1 , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUG2 ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,NARCOTIC ANALGESICS,TRANQUILIZERS
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUG1 , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUG2  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,NARCOTIC ANALGESICS,SEDATIVE-HYPNOTICS
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUG1 , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUG2 ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,NARCOTIC ANALGESICS,BARBITURATES
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUG1 , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUG2  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,NARCOTIC ANALGESICS,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUG1 , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUG2  (INCLUDING  DRUGOTHER ).",negative,NARCOTIC ANALGESICS,CNS DEPRESSANTS
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUG1 , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUG2 ).",negative,NARCOTIC ANALGESICS,ALCOHOL
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUG1 ,  DRUG2 , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,ANESTHETICS,PHENOTHIAZINES
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUG1 ,  DRUGOTHER , OTHER  DRUG2 ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,ANESTHETICS,TRANQUILIZERS
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUG1 ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUG2  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,ANESTHETICS,SEDATIVE-HYPNOTICS
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUG1 ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUG2 ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,ANESTHETICS,BARBITURATES
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUG1 ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUG2  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,ANESTHETICS,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUG1 ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUG2  (INCLUDING  DRUGOTHER ).",negative,ANESTHETICS,CNS DEPRESSANTS
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUG1 ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUG2 ).",negative,ANESTHETICS,ALCOHOL
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUG1 , OTHER  DRUG2 ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,PHENOTHIAZINES,TRANQUILIZERS
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUG1 , OTHER  DRUGOTHER ,  DRUG2  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,PHENOTHIAZINES,SEDATIVE-HYPNOTICS
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUG1 , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUG2 ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,PHENOTHIAZINES,BARBITURATES
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUG1 , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUG2  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,PHENOTHIAZINES,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUG1 , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUG2  (INCLUDING  DRUGOTHER ).",negative,PHENOTHIAZINES,CNS DEPRESSANTS
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUG1 , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUG2 ).",negative,PHENOTHIAZINES,ALCOHOL
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUG1 ,  DRUG2  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,TRANQUILIZERS,SEDATIVE-HYPNOTICS
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUG1 ,  DRUGOTHER  (INCLUDING  DRUG2 ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,TRANQUILIZERS,BARBITURATES
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUG1 ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUG2  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,TRANQUILIZERS,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUG1 ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUG2  (INCLUDING  DRUGOTHER ).",negative,TRANQUILIZERS,CNS DEPRESSANTS
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUG1 ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUG2 ).",negative,TRANQUILIZERS,ALCOHOL
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUG1  (INCLUDING  DRUG2 ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,SEDATIVE-HYPNOTICS,BARBITURATES
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUG1  (INCLUDING  DRUGOTHER ),  DRUG2  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,SEDATIVE-HYPNOTICS,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUG1  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUG2  (INCLUDING  DRUGOTHER ).",negative,SEDATIVE-HYPNOTICS,CNS DEPRESSANTS
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUG1  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUG2 ).",negative,SEDATIVE-HYPNOTICS,ALCOHOL
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUG1 ),  DRUG2  AND OTHER  DRUGOTHER  (INCLUDING  DRUGOTHER ).",negative,BARBITURATES,TRICYCLIC ANTIDEPRESSANTS
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUG1 ),  DRUGOTHER  AND OTHER  DRUG2  (INCLUDING  DRUGOTHER ).",negative,BARBITURATES,CNS DEPRESSANTS
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUG1 ),  DRUGOTHER  AND OTHER  DRUGOTHER  (INCLUDING  DRUG2 ).",negative,BARBITURATES,ALCOHOL
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUG1  AND OTHER  DRUG2  (INCLUDING  DRUGOTHER ).",negative,TRICYCLIC ANTIDEPRESSANTS,CNS DEPRESSANTS
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUG1  AND OTHER  DRUGOTHER  (INCLUDING  DRUG2 ).",negative,TRICYCLIC ANTIDEPRESSANTS,ALCOHOL
"Interaction with Other  DRUGOTHER :  DRUGOTHER  SHOULD BE USED WITH GREAT CAUTION AND IN REDUCED DOSAGE IN PATIENTS WHO ARE CONCURRENTLY RECEIVING OTHER  DRUGOTHER , GENERAL  DRUGOTHER ,  DRUGOTHER , OTHER  DRUGOTHER ,  DRUGOTHER  (INCLUDING  DRUGOTHER ),  DRUGOTHER  AND OTHER  DRUG1  (INCLUDING  DRUG2 ).",negative,CNS DEPRESSANTS,ALCOHOL
[Influence of  DRUG1  and  DRUG2  on MPTP-evoked behavior violations in C57BL/6 mice].,negative,hemantane,doxycycline
"The effects of  DRUG1   DRUG2  [ DRUGOTHER ] (10 mg/kg, p. o.)",negative,anti-parkinsonian drug,hemantane
"The effects of  DRUG1   DRUGOTHER  [ DRUG2 ] (10 mg/kg, p. o.)",negative,anti-parkinsonian drug,(2-adamantyl)hexamethylenimine
"The effects of  DRUGOTHER   DRUG1  [ DRUG2 ] (10 mg/kg, p. o.)",negative,hemantane,(2-adamantyl)hexamethylenimine
"and/or  DRUG1   DRUG2  (100 mg/kg, p. o.), as well as that of neurotoxin  DRUGOTHER  ( DRUGOTHER ) (4 x 20 mg/kg, i. p.)",negative,antibiotic drug,doxycycline
"and/or  DRUG1   DRUGOTHER  (100 mg/kg, p. o.), as well as that of neurotoxin  DRUG2  ( DRUGOTHER ) (4 x 20 mg/kg, i. p.)",negative,antibiotic drug,"1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine"
"and/or  DRUG1   DRUGOTHER  (100 mg/kg, p. o.), as well as that of neurotoxin  DRUGOTHER  ( DRUG2 ) (4 x 20 mg/kg, i. p.)",negative,antibiotic drug,MPTP
"and/or  DRUGOTHER   DRUG1  (100 mg/kg, p. o.), as well as that of neurotoxin  DRUG2  ( DRUGOTHER ) (4 x 20 mg/kg, i. p.)",negative,doxycycline,"1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine"
"and/or  DRUGOTHER   DRUG1  (100 mg/kg, p. o.), as well as that of neurotoxin  DRUGOTHER  ( DRUG2 ) (4 x 20 mg/kg, i. p.)",negative,doxycycline,MPTP
"and/or  DRUGOTHER   DRUGOTHER  (100 mg/kg, p. o.), as well as that of neurotoxin  DRUG1  ( DRUG2 ) (4 x 20 mg/kg, i. p.)",negative,"1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine",MPTP
"Acute administration of  DRUG1  or  DRUG2  failed to influence locomotion in mice, while their combination normalized motor activity.",effect,hemantane,doxycycline
DRUG INTERACTIONS  There are no known drug/drug interactions with oral  DRUG1   Vaccinations with  DRUG2  are not recommended in immunocompromised individuals   DRUGOTHER  together with high-dose intravenous  DRUGOTHER  has caused deaths in children due to haemorrhagic enterocolitis.,negative,ALKERAN,live organism vaccines
DRUG INTERACTIONS  There are no known drug/drug interactions with oral  DRUG1   Vaccinations with  DRUGOTHER  are not recommended in immunocompromised individuals   DRUG2  together with high-dose intravenous  DRUGOTHER  has caused deaths in children due to haemorrhagic enterocolitis.,negative,ALKERAN,Nalidixic acid
DRUG INTERACTIONS  There are no known drug/drug interactions with oral  DRUG1   Vaccinations with  DRUGOTHER  are not recommended in immunocompromised individuals   DRUGOTHER  together with high-dose intravenous  DRUG2  has caused deaths in children due to haemorrhagic enterocolitis.,negative,ALKERAN,melphalan
DRUG INTERACTIONS  There are no known drug/drug interactions with oral  DRUGOTHER   Vaccinations with  DRUG1  are not recommended in immunocompromised individuals   DRUG2  together with high-dose intravenous  DRUGOTHER  has caused deaths in children due to haemorrhagic enterocolitis.,negative,live organism vaccines,Nalidixic acid
DRUG INTERACTIONS  There are no known drug/drug interactions with oral  DRUGOTHER   Vaccinations with  DRUG1  are not recommended in immunocompromised individuals   DRUGOTHER  together with high-dose intravenous  DRUG2  has caused deaths in children due to haemorrhagic enterocolitis.,negative,live organism vaccines,melphalan
DRUG INTERACTIONS  There are no known drug/drug interactions with oral  DRUGOTHER   Vaccinations with  DRUGOTHER  are not recommended in immunocompromised individuals   DRUG1  together with high-dose intravenous  DRUG2  has caused deaths in children due to haemorrhagic enterocolitis.,effect,Nalidixic acid,melphalan
Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous  DRUG1  and who subsequently received  DRUG2  to prevent graft-versus-host disease,effect,melphalan,cyclosporin
"However,  DRUG1 , a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of  DRUG2  during concomitant dosing.",mechanism,ketoconazole,mometasone furoate
"The interaction of  DRUG1 ,  DRUG2 , with other drugs has not been well studied.",negative,Streptase,Streptokinase
"Use of  DRUG1  and  DRUG2  --  DRUGOTHER ,  DRUGOTHER , alone or in combination with  DRUGOTHER  and  DRUGOTHER , may cause bleeding complications.",negative,Anticoagulants,Antiplatelet Agents
"Use of  DRUG1  and  DRUGOTHER  --  DRUG2 ,  DRUGOTHER , alone or in combination with  DRUGOTHER  and  DRUGOTHER , may cause bleeding complications.",negative,Anticoagulants,Streptase
"Use of  DRUG1  and  DRUGOTHER  --  DRUGOTHER ,  DRUG2 , alone or in combination with  DRUGOTHER  and  DRUGOTHER , may cause bleeding complications.",negative,Anticoagulants,Streptokinase
"Use of  DRUG1  and  DRUGOTHER  --  DRUGOTHER ,  DRUGOTHER , alone or in combination with  DRUG2  and  DRUGOTHER , may cause bleeding complications.",negative,Anticoagulants,antiplatelet agents
"Use of  DRUG1  and  DRUGOTHER  --  DRUGOTHER ,  DRUGOTHER , alone or in combination with  DRUGOTHER  and  DRUG2 , may cause bleeding complications.",negative,Anticoagulants,anticoagulants
"Use of  DRUGOTHER  and  DRUG1  --  DRUG2 ,  DRUGOTHER , alone or in combination with  DRUGOTHER  and  DRUGOTHER , may cause bleeding complications.",negative,Antiplatelet Agents,Streptase
"Use of  DRUGOTHER  and  DRUG1  --  DRUGOTHER ,  DRUG2 , alone or in combination with  DRUGOTHER  and  DRUGOTHER , may cause bleeding complications.",negative,Antiplatelet Agents,Streptokinase
"Use of  DRUGOTHER  and  DRUG1  --  DRUGOTHER ,  DRUGOTHER , alone or in combination with  DRUG2  and  DRUGOTHER , may cause bleeding complications.",negative,Antiplatelet Agents,antiplatelet agents
"Use of  DRUGOTHER  and  DRUG1  --  DRUGOTHER ,  DRUGOTHER , alone or in combination with  DRUGOTHER  and  DRUG2 , may cause bleeding complications.",negative,Antiplatelet Agents,anticoagulants
"Use of  DRUGOTHER  and  DRUGOTHER  --  DRUG1 ,  DRUG2 , alone or in combination with  DRUGOTHER  and  DRUGOTHER , may cause bleeding complications.",negative,Streptase,Streptokinase
"Use of  DRUGOTHER  and  DRUGOTHER  --  DRUG1 ,  DRUGOTHER , alone or in combination with  DRUG2  and  DRUGOTHER , may cause bleeding complications.",effect,Streptase,antiplatelet agents
"Use of  DRUGOTHER  and  DRUGOTHER  --  DRUG1 ,  DRUGOTHER , alone or in combination with  DRUGOTHER  and  DRUG2 , may cause bleeding complications.",effect,Streptase,anticoagulants
"Use of  DRUGOTHER  and  DRUGOTHER  --  DRUGOTHER ,  DRUG1 , alone or in combination with  DRUG2  and  DRUGOTHER , may cause bleeding complications.",effect,Streptokinase,antiplatelet agents
"Use of  DRUGOTHER  and  DRUGOTHER  --  DRUGOTHER ,  DRUG1 , alone or in combination with  DRUGOTHER  and  DRUG2 , may cause bleeding complications.",effect,Streptokinase,anticoagulants
"Use of  DRUGOTHER  and  DRUGOTHER  --  DRUGOTHER ,  DRUGOTHER , alone or in combination with  DRUG1  and  DRUG2 , may cause bleeding complications.",negative,antiplatelet agents,anticoagulants
"In the treatment of acute MI,  DRUG1 , when not otherwise contraindicated, should be administered with  DRUG2  ( see below ).",negative,aspirin,Streptokinase
"Anticoagulation and  DRUG1  After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of  DRUG2  has been shown to reduce the incidence of reinfarction and stroke.",negative,Antiplatelets,aspirin
"The addition of  DRUG1  to  DRUG2  causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see",effect,aspirin,Streptokinase
Mutual inhibition of metabolism occurs with concurrent use of  DRUG1  and  DRUG2 ;,mechanism,cyclosporin,methylprednisolone
convulsions have been reported with concurrent use of  DRUG1  and  DRUG2 .,effect,methylprednisolone,cyclosporin
"Drugs that induce hepatic enzymes such as  DRUG1 ,  DRUG2 , and  DRUGOTHER  may increase the clearance of  DRUGOTHER  and may require increased in  DRUGOTHER  dose to achieve the desired response.",negative,phenobarbital,phenytoin
"Drugs that induce hepatic enzymes such as  DRUG1 ,  DRUGOTHER , and  DRUG2  may increase the clearance of  DRUGOTHER  and may require increased in  DRUGOTHER  dose to achieve the desired response.",negative,phenobarbital,rifampin
"Drugs that induce hepatic enzymes such as  DRUG1 ,  DRUGOTHER , and  DRUGOTHER  may increase the clearance of  DRUG2  and may require increased in  DRUGOTHER  dose to achieve the desired response.",mechanism,phenobarbital,methylprednisolone
"Drugs that induce hepatic enzymes such as  DRUG1 ,  DRUGOTHER , and  DRUGOTHER  may increase the clearance of  DRUGOTHER  and may require increased in  DRUG2  dose to achieve the desired response.",advise,phenobarbital,methylprednisolone
"Drugs that induce hepatic enzymes such as  DRUGOTHER ,  DRUG1 , and  DRUG2  may increase the clearance of  DRUGOTHER  and may require increased in  DRUGOTHER  dose to achieve the desired response.",negative,phenytoin,rifampin
"Drugs that induce hepatic enzymes such as  DRUGOTHER ,  DRUG1 , and  DRUGOTHER  may increase the clearance of  DRUG2  and may require increased in  DRUGOTHER  dose to achieve the desired response.",mechanism,phenytoin,methylprednisolone
"Drugs that induce hepatic enzymes such as  DRUGOTHER ,  DRUG1 , and  DRUGOTHER  may increase the clearance of  DRUGOTHER  and may require increased in  DRUG2  dose to achieve the desired response.",advise,phenytoin,methylprednisolone
"Drugs that induce hepatic enzymes such as  DRUGOTHER ,  DRUGOTHER , and  DRUG1  may increase the clearance of  DRUG2  and may require increased in  DRUGOTHER  dose to achieve the desired response.",mechanism,rifampin,methylprednisolone
"Drugs that induce hepatic enzymes such as  DRUGOTHER ,  DRUGOTHER , and  DRUG1  may increase the clearance of  DRUGOTHER  and may require increased in  DRUG2  dose to achieve the desired response.",advise,rifampin,methylprednisolone
"Drugs that induce hepatic enzymes such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER  may increase the clearance of  DRUG1  and may require increased in  DRUG2  dose to achieve the desired response.",negative,methylprednisolone,methylprednisolone
Drugs such as  DRUG1  and  DRUG2  may inhibit the metabolism of  DRUGOTHER  and thus decrease its clearance.,negative,troleandomycin,ketoconazole
Drugs such as  DRUG1  and  DRUGOTHER  may inhibit the metabolism of  DRUG2  and thus decrease its clearance.,mechanism,troleandomycin,methylprednisolone
Drugs such as  DRUGOTHER  and  DRUG1  may inhibit the metabolism of  DRUG2  and thus decrease its clearance.,mechanism,ketoconazole,methylprednisolone
 DRUG1  may increase the clearance of chronic high dose  DRUG2 .,mechanism,Methylprednisolone,aspirin
This could lead to decreased  DRUG1  serum levels or increase the risk of  DRUG2  toxicity when  DRUGOTHER  is withdrawn.,negative,salicylate,salicylate
This could lead to decreased  DRUG1  serum levels or increase the risk of  DRUGOTHER  toxicity when  DRUG2  is withdrawn.,negative,salicylate,methylprednisolone
This could lead to decreased  DRUGOTHER  serum levels or increase the risk of  DRUG1  toxicity when  DRUG2  is withdrawn.,effect,salicylate,methylprednisolone
 DRUG1  should be used cautiously in conjunction with  DRUG2  in patients suffering from hypoprothrombinemia.,advise,Aspirin,corticosteroids
The effect of  DRUG1  on oral  DRUG2  is variable.,negative,methylprednisolone,anticoagulants
There are reports of enhanced as well as diminished effects of  DRUG1  when given concurrently with  DRUG2 .,effect,anticoagulant,corticosteroids
A study published in 2002 found that  DRUG1  causes a statistically significant increase in plasma clearance of  DRUG2 .,mechanism,vigabatrin,carbamazepine
"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering  DRUG1  with  DRUG2  lowered the serum  DRUGOTHER  concentration in patients with treatment-resistant epilepsy.",mechanism,vigabatrin,phenytoin
"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering  DRUG1  with  DRUGOTHER  lowered the serum  DRUG2  concentration in patients with treatment-resistant epilepsy.",negative,vigabatrin,phenytoin
"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering  DRUGOTHER  with  DRUG1  lowered the serum  DRUG2  concentration in patients with treatment-resistant epilepsy.",negative,phenytoin,phenytoin
" DRUG1  inhibits some of the liver's ability to metabolize some other drugs -  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",mechanism,Posicor,terfenadine
" DRUG1  inhibits some of the liver's ability to metabolize some other drugs -  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",mechanism,Posicor,astemizole
" DRUG1  inhibits some of the liver's ability to metabolize some other drugs -  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",mechanism,Posicor,cisapride
" DRUG1  inhibits some of the liver's ability to metabolize some other drugs -  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",mechanism,Posicor,cyclosporine
" DRUG1  inhibits some of the liver's ability to metabolize some other drugs -  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",mechanism,Posicor,tricyclic antidepressants
" DRUGOTHER  inhibits some of the liver's ability to metabolize some other drugs -  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,terfenadine,astemizole
" DRUGOTHER  inhibits some of the liver's ability to metabolize some other drugs -  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,terfenadine,cisapride
" DRUGOTHER  inhibits some of the liver's ability to metabolize some other drugs -  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,terfenadine,cyclosporine
" DRUGOTHER  inhibits some of the liver's ability to metabolize some other drugs -  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,terfenadine,tricyclic antidepressants
" DRUGOTHER  inhibits some of the liver's ability to metabolize some other drugs -  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,astemizole,cisapride
" DRUGOTHER  inhibits some of the liver's ability to metabolize some other drugs -  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,astemizole,cyclosporine
" DRUGOTHER  inhibits some of the liver's ability to metabolize some other drugs -  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,astemizole,tricyclic antidepressants
" DRUGOTHER  inhibits some of the liver's ability to metabolize some other drugs -  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER .",negative,cisapride,cyclosporine
" DRUGOTHER  inhibits some of the liver's ability to metabolize some other drugs -  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 .",negative,cisapride,tricyclic antidepressants
" DRUGOTHER  inhibits some of the liver's ability to metabolize some other drugs -  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 .",negative,cyclosporine,tricyclic antidepressants
Influence of  DRUG1  on  DRUG2  induced antinociception and its pharmacokinetics.,negative,piperine,ibuprofen
"In the present study  DRUG1  (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of  DRUG2  evaluated by both  DRUGOTHER  writhing and formalin test, when it was administered with  DRUGOTHER .",effect,piperine,ibuprofen
"In the present study  DRUG1  (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of  DRUGOTHER  evaluated by both  DRUG2  writhing and formalin test, when it was administered with  DRUGOTHER .",negative,piperine,acetic acid
"In the present study  DRUG1  (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of  DRUGOTHER  evaluated by both  DRUGOTHER  writhing and formalin test, when it was administered with  DRUG2 .",negative,piperine,ibuprofen
"In the present study  DRUGOTHER  (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of  DRUG1  evaluated by both  DRUG2  writhing and formalin test, when it was administered with  DRUGOTHER .",negative,ibuprofen,acetic acid
"In the present study  DRUGOTHER  (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of  DRUG1  evaluated by both  DRUGOTHER  writhing and formalin test, when it was administered with  DRUG2 .",negative,ibuprofen,ibuprofen
"In the present study  DRUGOTHER  (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of  DRUGOTHER  evaluated by both  DRUG1  writhing and formalin test, when it was administered with  DRUG2 .",negative,acetic acid,ibuprofen
 DRUG1  plasma concentration was also increased when it was administered with  DRUG2 .,mechanism,Ibuprofen,piperine
The synergistic antinociception activity of  DRUG1  when administered with  DRUG2  can be attributed to increased plasma concentration of  DRUGOTHER .,mechanism,ibuprofen,piperine
The synergistic antinociception activity of  DRUG1  when administered with  DRUGOTHER  can be attributed to increased plasma concentration of  DRUG2 .,negative,ibuprofen,ibuprofen
The synergistic antinociception activity of  DRUGOTHER  when administered with  DRUG1  can be attributed to increased plasma concentration of  DRUG2 .,negative,piperine,ibuprofen
From this study it can be concluded that  DRUG1  can be used as a bioenhancer along with  DRUG2 .,effect,piperine,ibuprofen
Concurrent use of  DRUG1  and other  DRUG2  may increase the CNS depressant effects of  DRUGOTHER  or these other medications.,negative,alcohol,CNS depression-producing drugs
Concurrent use of  DRUG1  and other  DRUGOTHER  may increase the CNS depressant effects of  DRUG2  or these other medications.,effect,alcohol,methyprylon
Concurrent use of  DRUGOTHER  and other  DRUG1  may increase the CNS depressant effects of  DRUG2  or these other medications.,effect,CNS depression-producing drugs,methyprylon
Protective effect of  DRUG1  and   DRUG2  against the acute toxicity of diepoxybutane to human lymphocytes.,negative,acetyl-l-carnitine,alpha lipoic acid
"(ii)  DRUG1  elicits a significant protective effect on DEB induced toxicity, which was potentiated by   DRUG2 .",effect,acetyl-l-carnitine,alpha-lipoic acid
Hypokalemia may develop during concomitant use of  DRUG1  or  DRUG2 .,negative,steroids,ACTH
 DRUG1  may decrease arterial responsiveness to  DRUG2 .,effect,Thiazides,norepinephrine
 DRUG1  may increase the responsiveness of  DRUG2 .,effect,Thiazide drugs,tubocurarine
" DRUG1  renal clearance is reduced by  DRUG2 , increasing the risk of  DRUGOTHER  toxicity.",mechanism,Lithium,thiazides
" DRUG1  renal clearance is reduced by  DRUGOTHER , increasing the risk of  DRUG2  toxicity.",negative,Lithium,lithium
" DRUGOTHER  renal clearance is reduced by  DRUG1 , increasing the risk of  DRUG2  toxicity.",negative,thiazides,lithium
 DRUG1  may add to or potentiate the action of other  DRUG2 .,effect,Thiazides,antihypertensive drugs
Potentiation occurs with  DRUG1  or  DRUG2 .,negative,ganglionic adrenergic blocking drugs,peripheral adrenergic blocking drugs
Patients studied in clinical trials of  DRUG1  were routinely treated with  DRUG2  and  DRUGOTHER .,negative,TNKase,heparin
Patients studied in clinical trials of  DRUG1  were routinely treated with  DRUGOTHER  and  DRUG2 .,negative,TNKase,aspirin
Patients studied in clinical trials of  DRUGOTHER  were routinely treated with  DRUG1  and  DRUG2 .,negative,heparin,aspirin
" DRUG1  (such as  DRUG2  and  DRUGOTHER ) and drugs that alter platelet function (such as  DRUGOTHER ,  DRUGOTHER , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after  DRUGOTHER  therapy.",negative,Anticoagulants,heparin
" DRUG1  (such as  DRUGOTHER  and  DRUG2 ) and drugs that alter platelet function (such as  DRUGOTHER ,  DRUGOTHER , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after  DRUGOTHER  therapy.",negative,Anticoagulants,vitamin K antagonists
" DRUG1  (such as  DRUGOTHER  and  DRUGOTHER ) and drugs that alter platelet function (such as  DRUG2 ,  DRUGOTHER , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after  DRUGOTHER  therapy.",negative,Anticoagulants,acetylsalicylic acid
" DRUG1  (such as  DRUGOTHER  and  DRUGOTHER ) and drugs that alter platelet function (such as  DRUGOTHER ,  DRUG2 , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after  DRUGOTHER  therapy.",negative,Anticoagulants,dipyridamole
" DRUG1  (such as  DRUGOTHER  and  DRUGOTHER ) and drugs that alter platelet function (such as  DRUGOTHER ,  DRUGOTHER , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after  DRUG2  therapy.",effect,Anticoagulants,TNKase
" DRUGOTHER  (such as  DRUG1  and  DRUG2 ) and drugs that alter platelet function (such as  DRUGOTHER ,  DRUGOTHER , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after  DRUGOTHER  therapy.",negative,heparin,vitamin K antagonists
" DRUGOTHER  (such as  DRUG1  and  DRUGOTHER ) and drugs that alter platelet function (such as  DRUG2 ,  DRUGOTHER , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after  DRUGOTHER  therapy.",negative,heparin,acetylsalicylic acid
" DRUGOTHER  (such as  DRUG1  and  DRUGOTHER ) and drugs that alter platelet function (such as  DRUGOTHER ,  DRUG2 , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after  DRUGOTHER  therapy.",negative,heparin,dipyridamole
" DRUGOTHER  (such as  DRUG1  and  DRUGOTHER ) and drugs that alter platelet function (such as  DRUGOTHER ,  DRUGOTHER , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after  DRUG2  therapy.",effect,heparin,TNKase
" DRUGOTHER  (such as  DRUGOTHER  and  DRUG1 ) and drugs that alter platelet function (such as  DRUG2 ,  DRUGOTHER , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after  DRUGOTHER  therapy.",negative,vitamin K antagonists,acetylsalicylic acid
" DRUGOTHER  (such as  DRUGOTHER  and  DRUG1 ) and drugs that alter platelet function (such as  DRUGOTHER ,  DRUG2 , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after  DRUGOTHER  therapy.",negative,vitamin K antagonists,dipyridamole
" DRUGOTHER  (such as  DRUGOTHER  and  DRUG1 ) and drugs that alter platelet function (such as  DRUGOTHER ,  DRUGOTHER , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after  DRUG2  therapy.",effect,vitamin K antagonists,TNKase
" DRUGOTHER  (such as  DRUGOTHER  and  DRUGOTHER ) and drugs that alter platelet function (such as  DRUG1 ,  DRUG2 , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after  DRUGOTHER  therapy.",negative,acetylsalicylic acid,dipyridamole
" DRUGOTHER  (such as  DRUGOTHER  and  DRUGOTHER ) and drugs that alter platelet function (such as  DRUG1 ,  DRUGOTHER , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after  DRUG2  therapy.",effect,acetylsalicylic acid,TNKase
" DRUGOTHER  (such as  DRUGOTHER  and  DRUGOTHER ) and drugs that alter platelet function (such as  DRUGOTHER ,  DRUG1 , and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after  DRUG2  therapy.",effect,dipyridamole,TNKase
"Dosages of concomitantly administered  DRUG1  should be reduced by approximately half, because  DRUG2  amplifies the therapeutic actions and side-effects of  DRUGOTHER .",effect,opioids,levomepromazine
"Dosages of concomitantly administered  DRUG1  should be reduced by approximately half, because  DRUGOTHER  amplifies the therapeutic actions and side-effects of  DRUG2 .",negative,opioids,opioids
"Dosages of concomitantly administered  DRUGOTHER  should be reduced by approximately half, because  DRUG1  amplifies the therapeutic actions and side-effects of  DRUG2 .",effect,levomepromazine,opioids
Combination with  DRUG1  ( DRUG2 ) is associated with increased risk of seizures.,negative,tramadol,Ultram
Additive sedative effects and confusional states may emerge if  DRUG1  is given with  DRUG2  or  DRUGOTHER .,effect,levomepromazine,benzodiazepines
Additive sedative effects and confusional states may emerge if  DRUG1  is given with  DRUGOTHER  or  DRUG2 .,effect,levomepromazine,barbiturates
Additive sedative effects and confusional states may emerge if  DRUGOTHER  is given with  DRUG1  or  DRUG2 .,negative,benzodiazepines,barbiturates
"Exert particular caution in combining  DRUG1  with other  DRUG2  ( DRUGOTHER  and  DRUGOTHER ): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.",advise,levomepromazine,anticholinergic drugs
"Exert particular caution in combining  DRUG1  with other  DRUGOTHER  ( DRUG2  and  DRUGOTHER ): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.",advise,levomepromazine,tricyclic antidepressants
"Exert particular caution in combining  DRUG1  with other  DRUGOTHER  ( DRUGOTHER  and  DRUG2 ): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.",advise,levomepromazine,antiparkinsonian-agents
"Exert particular caution in combining  DRUGOTHER  with other  DRUG1  ( DRUG2  and  DRUGOTHER ): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.",negative,anticholinergic drugs,tricyclic antidepressants
"Exert particular caution in combining  DRUGOTHER  with other  DRUG1  ( DRUGOTHER  and  DRUG2 ): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.",negative,anticholinergic drugs,antiparkinsonian-agents
"Exert particular caution in combining  DRUGOTHER  with other  DRUGOTHER  ( DRUG1  and  DRUG2 ): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma.",negative,tricyclic antidepressants,antiparkinsonian-agents
 DRUG1  and/or stimulantes of the  DRUG2 / DRUGOTHER  type may counteract the specific actions of  DRUGOTHER .,negative,Caffeine,ephedrine
 DRUG1  and/or stimulantes of the  DRUGOTHER / DRUG2  type may counteract the specific actions of  DRUGOTHER .,negative,Caffeine,amphetamine
 DRUG1  and/or stimulantes of the  DRUGOTHER / DRUGOTHER  type may counteract the specific actions of  DRUG2 .,effect,Caffeine,levomepromazine
 DRUGOTHER  and/or stimulantes of the  DRUG1 / DRUG2  type may counteract the specific actions of  DRUGOTHER .,negative,ephedrine,amphetamine
 DRUGOTHER  and/or stimulantes of the  DRUG1 / DRUGOTHER  type may counteract the specific actions of  DRUG2 .,effect,ephedrine,levomepromazine
 DRUGOTHER  and/or stimulantes of the  DRUGOTHER / DRUG1  type may counteract the specific actions of  DRUG2 .,effect,amphetamine,levomepromazine
The metabolism of  DRUG1  is accelerated by  DRUG2 ;,mechanism,Metopirone,phenytoin
 DRUG1  inhibits the glucuronidation of  DRUG2  and could possibly potentiate  DRUGOTHER  toxicity.,mechanism,Metopirone,acetaminophen
 DRUG1  inhibits the glucuronidation of  DRUGOTHER  and could possibly potentiate  DRUG2  toxicity.,effect,Metopirone,acetaminophen
 DRUGOTHER  inhibits the glucuronidation of  DRUG1  and could possibly potentiate  DRUG2  toxicity.,negative,acetaminophen,acetaminophen
" DRUG1 : In a multiple-dose study in 30 normal weight subjects, coadministration of  DRUG2  and 40 grams of  DRUGOTHER  (e.g., approximately 3 glasses of wine) did not result in alteration of  DRUGOTHER  pharmacokinetics,  DRUGOTHER  pharmacodynamics (fecal fat excretion), or systemic exposure to  DRUGOTHER .",negative,Alcohol,XENICAL
" DRUG1 : In a multiple-dose study in 30 normal weight subjects, coadministration of  DRUGOTHER  and 40 grams of  DRUG2  (e.g., approximately 3 glasses of wine) did not result in alteration of  DRUGOTHER  pharmacokinetics,  DRUGOTHER  pharmacodynamics (fecal fat excretion), or systemic exposure to  DRUGOTHER .",negative,Alcohol,alcohol
" DRUG1 : In a multiple-dose study in 30 normal weight subjects, coadministration of  DRUGOTHER  and 40 grams of  DRUGOTHER  (e.g., approximately 3 glasses of wine) did not result in alteration of  DRUG2  pharmacokinetics,  DRUGOTHER  pharmacodynamics (fecal fat excretion), or systemic exposure to  DRUGOTHER .",negative,Alcohol,alcohol
" DRUG1 : In a multiple-dose study in 30 normal weight subjects, coadministration of  DRUGOTHER  and 40 grams of  DRUGOTHER  (e.g., approximately 3 glasses of wine) did not result in alteration of  DRUGOTHER  pharmacokinetics,  DRUG2  pharmacodynamics (fecal fat excretion), or systemic exposure to  DRUGOTHER .",negative,Alcohol,orlistat
" DRUG1 : In a multiple-dose study in 30 normal weight subjects, coadministration of  DRUGOTHER  and 40 grams of  DRUGOTHER  (e.g., approximately 3 glasses of wine) did not result in alteration of  DRUGOTHER  pharmacokinetics,  DRUGOTHER  pharmacodynamics (fecal fat excretion), or systemic exposure to  DRUG2 .",negative,Alcohol,orlistat
" DRUGOTHER : In a multiple-dose study in 30 normal weight subjects, coadministration of  DRUG1  and 40 grams of  DRUG2  (e.g., approximately 3 glasses of wine) did not result in alteration of  DRUGOTHER  pharmacokinetics,  DRUGOTHER  pharmacodynamics (fecal fat excretion), or systemic exposure to  DRUGOTHER .",negative,XENICAL,alcohol
" DRUGOTHER : In a multiple-dose study in 30 normal weight subjects, coadministration of  DRUG1  and 40 grams of  DRUGOTHER  (e.g., approximately 3 glasses of wine) did not result in alteration of  DRUG2  pharmacokinetics,  DRUGOTHER  pharmacodynamics (fecal fat excretion), or systemic exposure to  DRUGOTHER .",negative,XENICAL,alcohol
" DRUGOTHER : In a multiple-dose study in 30 normal weight subjects, coadministration of  DRUG1  and 40 grams of  DRUGOTHER  (e.g., approximately 3 glasses of wine) did not result in alteration of  DRUGOTHER  pharmacokinetics,  DRUG2  pharmacodynamics (fecal fat excretion), or systemic exposure to  DRUGOTHER .",negative,XENICAL,orlistat
" DRUGOTHER : In a multiple-dose study in 30 normal weight subjects, coadministration of  DRUG1  and 40 grams of  DRUGOTHER  (e.g., approximately 3 glasses of wine) did not result in alteration of  DRUGOTHER  pharmacokinetics,  DRUGOTHER  pharmacodynamics (fecal fat excretion), or systemic exposure to  DRUG2 .",negative,XENICAL,orlistat
" DRUGOTHER : In a multiple-dose study in 30 normal weight subjects, coadministration of  DRUGOTHER  and 40 grams of  DRUG1  (e.g., approximately 3 glasses of wine) did not result in alteration of  DRUG2  pharmacokinetics,  DRUGOTHER  pharmacodynamics (fecal fat excretion), or systemic exposure to  DRUGOTHER .",negative,alcohol,alcohol
" DRUGOTHER : In a multiple-dose study in 30 normal weight subjects, coadministration of  DRUGOTHER  and 40 grams of  DRUG1  (e.g., approximately 3 glasses of wine) did not result in alteration of  DRUGOTHER  pharmacokinetics,  DRUG2  pharmacodynamics (fecal fat excretion), or systemic exposure to  DRUGOTHER .",negative,alcohol,orlistat
" DRUGOTHER : In a multiple-dose study in 30 normal weight subjects, coadministration of  DRUGOTHER  and 40 grams of  DRUG1  (e.g., approximately 3 glasses of wine) did not result in alteration of  DRUGOTHER  pharmacokinetics,  DRUGOTHER  pharmacodynamics (fecal fat excretion), or systemic exposure to  DRUG2 .",negative,alcohol,orlistat
" DRUGOTHER : In a multiple-dose study in 30 normal weight subjects, coadministration of  DRUGOTHER  and 40 grams of  DRUGOTHER  (e.g., approximately 3 glasses of wine) did not result in alteration of  DRUG1  pharmacokinetics,  DRUG2  pharmacodynamics (fecal fat excretion), or systemic exposure to  DRUGOTHER .",negative,alcohol,orlistat
" DRUGOTHER : In a multiple-dose study in 30 normal weight subjects, coadministration of  DRUGOTHER  and 40 grams of  DRUGOTHER  (e.g., approximately 3 glasses of wine) did not result in alteration of  DRUG1  pharmacokinetics,  DRUGOTHER  pharmacodynamics (fecal fat excretion), or systemic exposure to  DRUG2 .",negative,alcohol,orlistat
" DRUGOTHER : In a multiple-dose study in 30 normal weight subjects, coadministration of  DRUGOTHER  and 40 grams of  DRUGOTHER  (e.g., approximately 3 glasses of wine) did not result in alteration of  DRUGOTHER  pharmacokinetics,  DRUG1  pharmacodynamics (fecal fat excretion), or systemic exposure to  DRUG2 .",negative,orlistat,orlistat
 DRUG1 : Preliminary data from a  DRUG2  and  DRUGOTHER  drug interaction study indicate a reduction in  DRUGOTHER  plasma levels when  DRUGOTHER  was coadministered with  DRUGOTHER .,negative,Cyclosporine,XENICAL
 DRUG1 : Preliminary data from a  DRUGOTHER  and  DRUG2  drug interaction study indicate a reduction in  DRUGOTHER  plasma levels when  DRUGOTHER  was coadministered with  DRUGOTHER .,negative,Cyclosporine,cyclosporine
 DRUG1 : Preliminary data from a  DRUGOTHER  and  DRUGOTHER  drug interaction study indicate a reduction in  DRUG2  plasma levels when  DRUGOTHER  was coadministered with  DRUGOTHER .,negative,Cyclosporine,cyclosporine
 DRUG1 : Preliminary data from a  DRUGOTHER  and  DRUGOTHER  drug interaction study indicate a reduction in  DRUGOTHER  plasma levels when  DRUG2  was coadministered with  DRUGOTHER .,negative,Cyclosporine,XENICAL
 DRUG1 : Preliminary data from a  DRUGOTHER  and  DRUGOTHER  drug interaction study indicate a reduction in  DRUGOTHER  plasma levels when  DRUGOTHER  was coadministered with  DRUG2 .,negative,Cyclosporine,cyclosporine
 DRUGOTHER : Preliminary data from a  DRUG1  and  DRUG2  drug interaction study indicate a reduction in  DRUGOTHER  plasma levels when  DRUGOTHER  was coadministered with  DRUGOTHER .,negative,XENICAL,cyclosporine
 DRUGOTHER : Preliminary data from a  DRUG1  and  DRUGOTHER  drug interaction study indicate a reduction in  DRUG2  plasma levels when  DRUGOTHER  was coadministered with  DRUGOTHER .,negative,XENICAL,cyclosporine
 DRUGOTHER : Preliminary data from a  DRUG1  and  DRUGOTHER  drug interaction study indicate a reduction in  DRUGOTHER  plasma levels when  DRUG2  was coadministered with  DRUGOTHER .,negative,XENICAL,XENICAL
 DRUGOTHER : Preliminary data from a  DRUG1  and  DRUGOTHER  drug interaction study indicate a reduction in  DRUGOTHER  plasma levels when  DRUGOTHER  was coadministered with  DRUG2 .,negative,XENICAL,cyclosporine
 DRUGOTHER : Preliminary data from a  DRUGOTHER  and  DRUG1  drug interaction study indicate a reduction in  DRUG2  plasma levels when  DRUGOTHER  was coadministered with  DRUGOTHER .,negative,cyclosporine,cyclosporine
 DRUGOTHER : Preliminary data from a  DRUGOTHER  and  DRUG1  drug interaction study indicate a reduction in  DRUGOTHER  plasma levels when  DRUG2  was coadministered with  DRUGOTHER .,negative,cyclosporine,XENICAL
 DRUGOTHER : Preliminary data from a  DRUGOTHER  and  DRUG1  drug interaction study indicate a reduction in  DRUGOTHER  plasma levels when  DRUGOTHER  was coadministered with  DRUG2 .,negative,cyclosporine,cyclosporine
 DRUGOTHER : Preliminary data from a  DRUGOTHER  and  DRUGOTHER  drug interaction study indicate a reduction in  DRUG1  plasma levels when  DRUG2  was coadministered with  DRUGOTHER .,negative,cyclosporine,XENICAL
 DRUGOTHER : Preliminary data from a  DRUGOTHER  and  DRUGOTHER  drug interaction study indicate a reduction in  DRUG1  plasma levels when  DRUGOTHER  was coadministered with  DRUG2 .,negative,cyclosporine,cyclosporine
 DRUGOTHER : Preliminary data from a  DRUGOTHER  and  DRUGOTHER  drug interaction study indicate a reduction in  DRUGOTHER  plasma levels when  DRUG1  was coadministered with  DRUG2 .,mechanism,XENICAL,cyclosporine
" DRUG1 : In 12 normal-weight subjects receiving  DRUG2  120 mg three times a day for 6 days,  DRUGOTHER  did not alter the pharmacokinetics of a single dose of  DRUGOTHER .",negative,Digoxin,XENICAL
" DRUG1 : In 12 normal-weight subjects receiving  DRUGOTHER  120 mg three times a day for 6 days,  DRUG2  did not alter the pharmacokinetics of a single dose of  DRUGOTHER .",negative,Digoxin,XENICAL
" DRUG1 : In 12 normal-weight subjects receiving  DRUGOTHER  120 mg three times a day for 6 days,  DRUGOTHER  did not alter the pharmacokinetics of a single dose of  DRUG2 .",negative,Digoxin,digoxin
" DRUGOTHER : In 12 normal-weight subjects receiving  DRUG1  120 mg three times a day for 6 days,  DRUG2  did not alter the pharmacokinetics of a single dose of  DRUGOTHER .",negative,XENICAL,XENICAL
" DRUGOTHER : In 12 normal-weight subjects receiving  DRUG1  120 mg three times a day for 6 days,  DRUGOTHER  did not alter the pharmacokinetics of a single dose of  DRUG2 .",negative,XENICAL,digoxin
" DRUGOTHER : In 12 normal-weight subjects receiving  DRUGOTHER  120 mg three times a day for 6 days,  DRUG1  did not alter the pharmacokinetics of a single dose of  DRUG2 .",negative,XENICAL,digoxin
 DRUG1  and Analogues: A pharmacokinetic interaction study showed a 30% reduction in  DRUG2  supplement absorption when concomitantly administered with  DRUGOTHER .,negative,Fat-soluble Vitamin Supplements,beta-carotene
 DRUG1  and Analogues: A pharmacokinetic interaction study showed a 30% reduction in  DRUGOTHER  supplement absorption when concomitantly administered with  DRUG2 .,negative,Fat-soluble Vitamin Supplements,XENICAL
 DRUGOTHER  and Analogues: A pharmacokinetic interaction study showed a 30% reduction in  DRUG1  supplement absorption when concomitantly administered with  DRUG2 .,mechanism,beta-carotene,XENICAL
 DRUG1  inhibited absorption of a  DRUG2  supplement by approximately 60%.,mechanism,XENICAL,vitamin E acetate
"The effect of  DRUG1  on the absorption of supplemental  DRUG2 ,  DRUGOTHER , and nutritionally-derived  DRUGOTHER  is not known at this time.",negative,orlistat,vitamin D
"The effect of  DRUG1  on the absorption of supplemental  DRUGOTHER ,  DRUG2 , and nutritionally-derived  DRUGOTHER  is not known at this time.",negative,orlistat,vitamin A
"The effect of  DRUG1  on the absorption of supplemental  DRUGOTHER ,  DRUGOTHER , and nutritionally-derived  DRUG2  is not known at this time.",negative,orlistat,vitamin K
"The effect of  DRUGOTHER  on the absorption of supplemental  DRUG1 ,  DRUG2 , and nutritionally-derived  DRUGOTHER  is not known at this time.",negative,vitamin D,vitamin A
"The effect of  DRUGOTHER  on the absorption of supplemental  DRUG1 ,  DRUGOTHER , and nutritionally-derived  DRUG2  is not known at this time.",negative,vitamin D,vitamin K
"The effect of  DRUGOTHER  on the absorption of supplemental  DRUGOTHER ,  DRUG1 , and nutritionally-derived  DRUG2  is not known at this time.",negative,vitamin A,vitamin K
" DRUG1 : In 12 normal-weight subjects receiving  DRUG2  80 mg three times a day for 5 days,  DRUGOTHER  did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of  DRUGOTHER .",negative,Glyburide,orlistat
" DRUG1 : In 12 normal-weight subjects receiving  DRUGOTHER  80 mg three times a day for 5 days,  DRUG2  did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of  DRUGOTHER .",negative,Glyburide,orlistat
" DRUG1 : In 12 normal-weight subjects receiving  DRUGOTHER  80 mg three times a day for 5 days,  DRUGOTHER  did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of  DRUG2 .",negative,Glyburide,glyburide
" DRUGOTHER : In 12 normal-weight subjects receiving  DRUG1  80 mg three times a day for 5 days,  DRUG2  did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of  DRUGOTHER .",negative,orlistat,orlistat
" DRUGOTHER : In 12 normal-weight subjects receiving  DRUG1  80 mg three times a day for 5 days,  DRUGOTHER  did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of  DRUG2 .",negative,orlistat,glyburide
" DRUGOTHER : In 12 normal-weight subjects receiving  DRUGOTHER  80 mg three times a day for 5 days,  DRUG1  did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of  DRUG2 .",negative,orlistat,glyburide
" DRUG1  (extended-release tablets): In 17 normal-weight subjects receiving  DRUG2  120 mg three times a day for 6 days,  DRUGOTHER  did not alter the bioavailability of  DRUGOTHER  (extended-release tablets).",negative,Nifedipine,XENICAL
" DRUG1  (extended-release tablets): In 17 normal-weight subjects receiving  DRUGOTHER  120 mg three times a day for 6 days,  DRUG2  did not alter the bioavailability of  DRUGOTHER  (extended-release tablets).",negative,Nifedipine,XENICAL
" DRUG1  (extended-release tablets): In 17 normal-weight subjects receiving  DRUGOTHER  120 mg three times a day for 6 days,  DRUGOTHER  did not alter the bioavailability of  DRUG2  (extended-release tablets).",negative,Nifedipine,nifedipine
" DRUGOTHER  (extended-release tablets): In 17 normal-weight subjects receiving  DRUG1  120 mg three times a day for 6 days,  DRUG2  did not alter the bioavailability of  DRUGOTHER  (extended-release tablets).",negative,XENICAL,XENICAL
" DRUGOTHER  (extended-release tablets): In 17 normal-weight subjects receiving  DRUG1  120 mg three times a day for 6 days,  DRUGOTHER  did not alter the bioavailability of  DRUG2  (extended-release tablets).",negative,XENICAL,nifedipine
" DRUGOTHER  (extended-release tablets): In 17 normal-weight subjects receiving  DRUGOTHER  120 mg three times a day for 6 days,  DRUG1  did not alter the bioavailability of  DRUG2  (extended-release tablets).",negative,XENICAL,nifedipine
"Oral  DRUG1 : In 20 normal-weight female subjects, the treatment of  DRUG2  120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral  DRUGOTHER .",negative,Contraceptives,XENICAL
"Oral  DRUG1 : In 20 normal-weight female subjects, the treatment of  DRUGOTHER  120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral  DRUG2 .",negative,Contraceptives,contraceptives
"Oral  DRUGOTHER : In 20 normal-weight female subjects, the treatment of  DRUG1  120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral  DRUG2 .",negative,XENICAL,contraceptives
" DRUG1 : In 12 normal-weight subjects receiving  DRUG2  120 mg three times a day for 7 days,  DRUGOTHER  did not alter the pharmacokinetics of a single 300-mg dose of  DRUGOTHER .",negative,Phenytoin,XENICAL
" DRUG1 : In 12 normal-weight subjects receiving  DRUGOTHER  120 mg three times a day for 7 days,  DRUG2  did not alter the pharmacokinetics of a single 300-mg dose of  DRUGOTHER .",negative,Phenytoin,XENICAL
" DRUG1 : In 12 normal-weight subjects receiving  DRUGOTHER  120 mg three times a day for 7 days,  DRUGOTHER  did not alter the pharmacokinetics of a single 300-mg dose of  DRUG2 .",negative,Phenytoin,phenytoin
" DRUGOTHER : In 12 normal-weight subjects receiving  DRUG1  120 mg three times a day for 7 days,  DRUG2  did not alter the pharmacokinetics of a single 300-mg dose of  DRUGOTHER .",negative,XENICAL,XENICAL
" DRUGOTHER : In 12 normal-weight subjects receiving  DRUG1  120 mg three times a day for 7 days,  DRUGOTHER  did not alter the pharmacokinetics of a single 300-mg dose of  DRUG2 .",negative,XENICAL,phenytoin
" DRUGOTHER : In 12 normal-weight subjects receiving  DRUGOTHER  120 mg three times a day for 7 days,  DRUG1  did not alter the pharmacokinetics of a single 300-mg dose of  DRUG2 .",negative,XENICAL,phenytoin
" DRUG1 : In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving  DRUG2  120 mg three times a day for 6 days,  DRUGOTHER  did not affect the pharmacokinetics of  DRUGOTHER .",negative,Pravastatin,XENICAL
" DRUG1 : In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving  DRUGOTHER  120 mg three times a day for 6 days,  DRUG2  did not affect the pharmacokinetics of  DRUGOTHER .",negative,Pravastatin,XENICAL
" DRUG1 : In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving  DRUGOTHER  120 mg three times a day for 6 days,  DRUGOTHER  did not affect the pharmacokinetics of  DRUG2 .",negative,Pravastatin,pravastatin
" DRUGOTHER : In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving  DRUG1  120 mg three times a day for 6 days,  DRUG2  did not affect the pharmacokinetics of  DRUGOTHER .",negative,XENICAL,XENICAL
" DRUGOTHER : In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving  DRUG1  120 mg three times a day for 6 days,  DRUGOTHER  did not affect the pharmacokinetics of  DRUG2 .",negative,XENICAL,pravastatin
" DRUGOTHER : In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving  DRUGOTHER  120 mg three times a day for 6 days,  DRUG1  did not affect the pharmacokinetics of  DRUG2 .",negative,XENICAL,pravastatin
" DRUG1 : In 12 normal-weight subjects, administration of  DRUG2  120 mg three times a day for 16 days did not result in any change in either  DRUGOTHER  pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII).",negative,Warfarin,XENICAL
" DRUG1 : In 12 normal-weight subjects, administration of  DRUGOTHER  120 mg three times a day for 16 days did not result in any change in either  DRUG2  pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII).",negative,Warfarin,warfarin
" DRUGOTHER : In 12 normal-weight subjects, administration of  DRUG1  120 mg three times a day for 16 days did not result in any change in either  DRUG2  pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII).",negative,XENICAL,warfarin
"Although undercarboxylated osteocalcin, a marker of vitamin K nutritional status, was unaltered with  DRUG1  administration, vitamin K levels tended to decline in subjects taking  DRUG2 .",negative,XENICAL,XENICAL
"Therefore, as  DRUG1  absorption may be decreased with  DRUG2 , patients on chronic stable doses of  DRUGOTHER  who are prescribed  DRUGOTHER  should be monitored closely for changes in coagulation parameters.",mechanism,vitamin K,XENICAL
"Therefore, as  DRUG1  absorption may be decreased with  DRUGOTHER , patients on chronic stable doses of  DRUG2  who are prescribed  DRUGOTHER  should be monitored closely for changes in coagulation parameters.",negative,vitamin K,warfarin
"Therefore, as  DRUG1  absorption may be decreased with  DRUGOTHER , patients on chronic stable doses of  DRUGOTHER  who are prescribed  DRUG2  should be monitored closely for changes in coagulation parameters.",negative,vitamin K,XENICAL
"Therefore, as  DRUGOTHER  absorption may be decreased with  DRUG1 , patients on chronic stable doses of  DRUG2  who are prescribed  DRUGOTHER  should be monitored closely for changes in coagulation parameters.",negative,XENICAL,warfarin
"Therefore, as  DRUGOTHER  absorption may be decreased with  DRUG1 , patients on chronic stable doses of  DRUGOTHER  who are prescribed  DRUG2  should be monitored closely for changes in coagulation parameters.",negative,XENICAL,XENICAL
"Therefore, as  DRUGOTHER  absorption may be decreased with  DRUGOTHER , patients on chronic stable doses of  DRUG1  who are prescribed  DRUG2  should be monitored closely for changes in coagulation parameters.",advise,warfarin,XENICAL
" DRUG1 : Patients on  DRUG2 , and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of  DRUGOTHER     Tablets therapy.",negative,Diuretics,diuretics
" DRUG1 : Patients on  DRUGOTHER , and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of  DRUG2     Tablets therapy.",negative,Diuretics,ACEON
" DRUGOTHER : Patients on  DRUG1 , and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of  DRUG2     Tablets therapy.",effect,diuretics,ACEON
The possibility of hypotensive effects can be minimized by either discontinuing the  DRUG1  or increasing the salt intake prior to initiation of treatment with  DRUG2 .,effect,diuretic,perindopril
"If  DRUG1  cannot be interrupted, close medical supervision should be provided with the first dose of  DRUG2     Tablets, for at least two hours and until blood pressure has stabilized for another hour.",advise,diuretics,ACEON
The rate and extent of  DRUG1  absorption and elimination are not affected by concomitant  DRUG2 .,negative,perindopril,diuretics
"The bioavailability of  DRUG1  was reduced by  DRUG2 , however, and this was associated with a decrease in plasma ACE inhibition.",negative,perindoprilat,diuretics
 DRUG1  Supplements and  DRUG2 :  DRUGOTHER     Tablets may increase serum potassium because of its potential to decrease aldosterone production.,negative,Potassium,Potassium-Sparing Diuretics
 DRUG1  Supplements and  DRUGOTHER :  DRUG2     Tablets may increase serum potassium because of its potential to decrease aldosterone production.,negative,Potassium,ACEON
 DRUGOTHER  Supplements and  DRUG1 :  DRUG2     Tablets may increase serum potassium because of its potential to decrease aldosterone production.,negative,Potassium-Sparing Diuretics,ACEON
"Use of  DRUG1  ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and others),  DRUGOTHER  supplements or other drugs capable of increasing serum potassium ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and others) can increase the risk of hyperkalemia.",negative,potassium-sparing diuretics,spironolactone
"Use of  DRUG1  ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and others),  DRUGOTHER  supplements or other drugs capable of increasing serum potassium ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and others) can increase the risk of hyperkalemia.",negative,potassium-sparing diuretics,amiloride
"Use of  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUG2  and others),  DRUGOTHER  supplements or other drugs capable of increasing serum potassium ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and others) can increase the risk of hyperkalemia.",negative,potassium-sparing diuretics,triamterene
"Use of  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and others),  DRUG2  supplements or other drugs capable of increasing serum potassium ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and others) can increase the risk of hyperkalemia.",negative,potassium-sparing diuretics,potassium
"Use of  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and others),  DRUGOTHER  supplements or other drugs capable of increasing serum potassium ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and others) can increase the risk of hyperkalemia.",negative,potassium-sparing diuretics,indomethacin
"Use of  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and others),  DRUGOTHER  supplements or other drugs capable of increasing serum potassium ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and others) can increase the risk of hyperkalemia.",negative,potassium-sparing diuretics,heparin
"Use of  DRUG1  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and others),  DRUGOTHER  supplements or other drugs capable of increasing serum potassium ( DRUGOTHER ,  DRUGOTHER ,  DRUG2  and others) can increase the risk of hyperkalemia.",negative,potassium-sparing diuretics,cyclosporine
"Use of  DRUGOTHER  ( DRUG1 ,  DRUG2 ,  DRUGOTHER  and others),  DRUGOTHER  supplements or other drugs capable of increasing serum potassium ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and others) can increase the risk of hyperkalemia.",negative,spironolactone,amiloride
"Use of  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUG2  and others),  DRUGOTHER  supplements or other drugs capable of increasing serum potassium ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and others) can increase the risk of hyperkalemia.",negative,spironolactone,triamterene
"Use of  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and others),  DRUG2  supplements or other drugs capable of increasing serum potassium ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and others) can increase the risk of hyperkalemia.",negative,spironolactone,potassium
"Use of  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and others),  DRUGOTHER  supplements or other drugs capable of increasing serum potassium ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and others) can increase the risk of hyperkalemia.",negative,spironolactone,indomethacin
"Use of  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and others),  DRUGOTHER  supplements or other drugs capable of increasing serum potassium ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and others) can increase the risk of hyperkalemia.",negative,spironolactone,heparin
"Use of  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and others),  DRUGOTHER  supplements or other drugs capable of increasing serum potassium ( DRUGOTHER ,  DRUGOTHER ,  DRUG2  and others) can increase the risk of hyperkalemia.",negative,spironolactone,cyclosporine
"Use of  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUG2  and others),  DRUGOTHER  supplements or other drugs capable of increasing serum potassium ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and others) can increase the risk of hyperkalemia.",negative,amiloride,triamterene
"Use of  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and others),  DRUG2  supplements or other drugs capable of increasing serum potassium ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and others) can increase the risk of hyperkalemia.",negative,amiloride,potassium
"Use of  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and others),  DRUGOTHER  supplements or other drugs capable of increasing serum potassium ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and others) can increase the risk of hyperkalemia.",negative,amiloride,indomethacin
"Use of  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and others),  DRUGOTHER  supplements or other drugs capable of increasing serum potassium ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and others) can increase the risk of hyperkalemia.",negative,amiloride,heparin
"Use of  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and others),  DRUGOTHER  supplements or other drugs capable of increasing serum potassium ( DRUGOTHER ,  DRUGOTHER ,  DRUG2  and others) can increase the risk of hyperkalemia.",negative,amiloride,cyclosporine
"Use of  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1  and others),  DRUG2  supplements or other drugs capable of increasing serum potassium ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and others) can increase the risk of hyperkalemia.",negative,triamterene,potassium
"Use of  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1  and others),  DRUGOTHER  supplements or other drugs capable of increasing serum potassium ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and others) can increase the risk of hyperkalemia.",negative,triamterene,indomethacin
"Use of  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1  and others),  DRUGOTHER  supplements or other drugs capable of increasing serum potassium ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and others) can increase the risk of hyperkalemia.",negative,triamterene,heparin
"Use of  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUG1  and others),  DRUGOTHER  supplements or other drugs capable of increasing serum potassium ( DRUGOTHER ,  DRUGOTHER ,  DRUG2  and others) can increase the risk of hyperkalemia.",negative,triamterene,cyclosporine
"Use of  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and others),  DRUG1  supplements or other drugs capable of increasing serum potassium ( DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and others) can increase the risk of hyperkalemia.",negative,potassium,indomethacin
"Use of  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and others),  DRUG1  supplements or other drugs capable of increasing serum potassium ( DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and others) can increase the risk of hyperkalemia.",negative,potassium,heparin
"Use of  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and others),  DRUG1  supplements or other drugs capable of increasing serum potassium ( DRUGOTHER ,  DRUGOTHER ,  DRUG2  and others) can increase the risk of hyperkalemia.",negative,potassium,cyclosporine
"Use of  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and others),  DRUGOTHER  supplements or other drugs capable of increasing serum potassium ( DRUG1 ,  DRUG2 ,  DRUGOTHER  and others) can increase the risk of hyperkalemia.",negative,indomethacin,heparin
"Use of  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and others),  DRUGOTHER  supplements or other drugs capable of increasing serum potassium ( DRUG1 ,  DRUGOTHER ,  DRUG2  and others) can increase the risk of hyperkalemia.",negative,indomethacin,cyclosporine
"Use of  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and others),  DRUGOTHER  supplements or other drugs capable of increasing serum potassium ( DRUGOTHER ,  DRUG1 ,  DRUG2  and others) can increase the risk of hyperkalemia.",negative,heparin,cyclosporine
 DRUG1 : Increased serum  DRUG2  and symptoms of  DRUGOTHER  toxicity have been reported in patients receiving concomitant  DRUGOTHER  and ACE inhibitor therapy.,negative,Lithium,lithium
 DRUG1 : Increased serum  DRUGOTHER  and symptoms of  DRUG2  toxicity have been reported in patients receiving concomitant  DRUGOTHER  and ACE inhibitor therapy.,negative,Lithium,lithium
 DRUG1 : Increased serum  DRUGOTHER  and symptoms of  DRUGOTHER  toxicity have been reported in patients receiving concomitant  DRUG2  and ACE inhibitor therapy.,negative,Lithium,lithium
 DRUGOTHER : Increased serum  DRUG1  and symptoms of  DRUG2  toxicity have been reported in patients receiving concomitant  DRUGOTHER  and ACE inhibitor therapy.,negative,lithium,lithium
 DRUGOTHER : Increased serum  DRUG1  and symptoms of  DRUGOTHER  toxicity have been reported in patients receiving concomitant  DRUG2  and ACE inhibitor therapy.,negative,lithium,lithium
 DRUGOTHER : Increased serum  DRUGOTHER  and symptoms of  DRUG1  toxicity have been reported in patients receiving concomitant  DRUG2  and ACE inhibitor therapy.,negative,lithium,lithium
Use of a  DRUG1  may further increase the risk of  DRUG2  toxicity.,negative,diuretic,lithium
" DRUG1 : A controlled pharmacokinetic study has shown no effect on plasma  DRUG2  concentrations when coadministered with  DRUGOTHER     Tablets, but an effect of  DRUGOTHER  on the plasma concentration of  DRUGOTHER / DRUGOTHER  has not been excluded.",negative,Digoxin,digoxin
" DRUG1 : A controlled pharmacokinetic study has shown no effect on plasma  DRUGOTHER  concentrations when coadministered with  DRUG2     Tablets, but an effect of  DRUGOTHER  on the plasma concentration of  DRUGOTHER / DRUGOTHER  has not been excluded.",negative,Digoxin,ACEON
" DRUG1 : A controlled pharmacokinetic study has shown no effect on plasma  DRUGOTHER  concentrations when coadministered with  DRUGOTHER     Tablets, but an effect of  DRUG2  on the plasma concentration of  DRUGOTHER / DRUGOTHER  has not been excluded.",negative,Digoxin,digoxin
" DRUG1 : A controlled pharmacokinetic study has shown no effect on plasma  DRUGOTHER  concentrations when coadministered with  DRUGOTHER     Tablets, but an effect of  DRUGOTHER  on the plasma concentration of  DRUG2 / DRUGOTHER  has not been excluded.",negative,Digoxin,perindopril
" DRUG1 : A controlled pharmacokinetic study has shown no effect on plasma  DRUGOTHER  concentrations when coadministered with  DRUGOTHER     Tablets, but an effect of  DRUGOTHER  on the plasma concentration of  DRUGOTHER / DRUG2  has not been excluded.",negative,Digoxin,perindoprilat
" DRUGOTHER : A controlled pharmacokinetic study has shown no effect on plasma  DRUG1  concentrations when coadministered with  DRUG2     Tablets, but an effect of  DRUGOTHER  on the plasma concentration of  DRUGOTHER / DRUGOTHER  has not been excluded.",negative,digoxin,ACEON
" DRUGOTHER : A controlled pharmacokinetic study has shown no effect on plasma  DRUG1  concentrations when coadministered with  DRUGOTHER     Tablets, but an effect of  DRUG2  on the plasma concentration of  DRUGOTHER / DRUGOTHER  has not been excluded.",negative,digoxin,digoxin
" DRUGOTHER : A controlled pharmacokinetic study has shown no effect on plasma  DRUG1  concentrations when coadministered with  DRUGOTHER     Tablets, but an effect of  DRUGOTHER  on the plasma concentration of  DRUG2 / DRUGOTHER  has not been excluded.",negative,digoxin,perindopril
" DRUGOTHER : A controlled pharmacokinetic study has shown no effect on plasma  DRUG1  concentrations when coadministered with  DRUGOTHER     Tablets, but an effect of  DRUGOTHER  on the plasma concentration of  DRUGOTHER / DRUG2  has not been excluded.",negative,digoxin,perindoprilat
" DRUGOTHER : A controlled pharmacokinetic study has shown no effect on plasma  DRUGOTHER  concentrations when coadministered with  DRUG1     Tablets, but an effect of  DRUG2  on the plasma concentration of  DRUGOTHER / DRUGOTHER  has not been excluded.",negative,ACEON,digoxin
" DRUGOTHER : A controlled pharmacokinetic study has shown no effect on plasma  DRUGOTHER  concentrations when coadministered with  DRUG1     Tablets, but an effect of  DRUGOTHER  on the plasma concentration of  DRUG2 / DRUGOTHER  has not been excluded.",negative,ACEON,perindopril
" DRUGOTHER : A controlled pharmacokinetic study has shown no effect on plasma  DRUGOTHER  concentrations when coadministered with  DRUG1     Tablets, but an effect of  DRUGOTHER  on the plasma concentration of  DRUGOTHER / DRUG2  has not been excluded.",negative,ACEON,perindoprilat
" DRUGOTHER : A controlled pharmacokinetic study has shown no effect on plasma  DRUGOTHER  concentrations when coadministered with  DRUGOTHER     Tablets, but an effect of  DRUG1  on the plasma concentration of  DRUG2 / DRUGOTHER  has not been excluded.",mechanism,digoxin,perindopril
" DRUGOTHER : A controlled pharmacokinetic study has shown no effect on plasma  DRUGOTHER  concentrations when coadministered with  DRUGOTHER     Tablets, but an effect of  DRUG1  on the plasma concentration of  DRUGOTHER / DRUG2  has not been excluded.",mechanism,digoxin,perindoprilat
" DRUGOTHER : A controlled pharmacokinetic study has shown no effect on plasma  DRUGOTHER  concentrations when coadministered with  DRUGOTHER     Tablets, but an effect of  DRUGOTHER  on the plasma concentration of  DRUG1 / DRUG2  has not been excluded.",negative,perindopril,perindoprilat
 DRUG1 : Animal data have suggested the possibility of interaction between  DRUG2  and  DRUGOTHER .,negative,Gentamicin,perindopril
 DRUG1 : Animal data have suggested the possibility of interaction between  DRUGOTHER  and  DRUG2 .,negative,Gentamicin,gentamicin
 DRUGOTHER : Animal data have suggested the possibility of interaction between  DRUG1  and  DRUG2 .,int,perindopril,gentamicin
Food Interaction: Oral administration of  DRUG1     Tablets with food does not significantly lower the rate or extent of  DRUG2  absorption relative to the fasted state.,negative,ACEON,perindopril
"However, the extent of biotransformation of  DRUG1  to the active metabolite,  DRUG2 , is reduced approximately 43%, resulting in a reduction in the plasma ACE inhibition curve of approximately 20%, probably clinically insignificant.",negative,perindopril,perindoprilat
" DRUG1  may interact with the following drugs:  DRUG2  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",int,Melatonin,aspirin
" DRUG1  may interact with the following drugs:  DRUGOTHER  and other  DRUG2  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",int,Melatonin,NSAIDs
" DRUG1  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUG2  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,Melatonin,melatonin
" DRUG1  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUG2  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",int,Melatonin,fluvoxamine
" DRUG1  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUG2  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,Melatonin,melatonin
" DRUG1  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUG2  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",int,Melatonin,beta blockers
" DRUG1  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUG2  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,Melatonin,melatonin
" DRUG1  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUG2  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",int,Melatonin,fluoxetine
" DRUG1  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUG2  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",int,Melatonin,progestin
" DRUG1  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUG2  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,Melatonin,melatonin
" DRUG1  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUG2  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,Melatonin,progestin
" DRUG1  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUG2  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",int,Melatonin,benzodiazepenes
" DRUG1  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUG2  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",int,Melatonin,corticosteroids
" DRUG1  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUG2  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,Melatonin,melatonin
" DRUG1  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUG2  may interfere with the efficacy of the  DRUGOTHER ).",negative,Melatonin,corticosteroids
" DRUG1  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUG2 ).",negative,Melatonin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUG1  and other  DRUG2  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,aspirin,NSAIDs
" DRUGOTHER  may interact with the following drugs:  DRUG1  and other  DRUGOTHER  (may lower  DRUG2  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,aspirin,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUG1  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUG2  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,aspirin,fluvoxamine
" DRUGOTHER  may interact with the following drugs:  DRUG1  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUG2  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,aspirin,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUG1  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUG2  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,aspirin,beta blockers
" DRUGOTHER  may interact with the following drugs:  DRUG1  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUG2  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,aspirin,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUG1  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUG2  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,aspirin,fluoxetine
" DRUGOTHER  may interact with the following drugs:  DRUG1  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUG2  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,aspirin,progestin
" DRUGOTHER  may interact with the following drugs:  DRUG1  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUG2  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,aspirin,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUG1  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUG2  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,aspirin,progestin
" DRUGOTHER  may interact with the following drugs:  DRUG1  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUG2  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,aspirin,benzodiazepenes
" DRUGOTHER  may interact with the following drugs:  DRUG1  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUG2  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,aspirin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUG1  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUG2  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,aspirin,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUG1  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUG2  may interfere with the efficacy of the  DRUGOTHER ).",negative,aspirin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUG1  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUG2 ).",negative,aspirin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUG1  (may lower  DRUG2  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,NSAIDs,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUG1  (may lower  DRUGOTHER  levels),  DRUG2  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,NSAIDs,fluvoxamine
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUG1  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUG2  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,NSAIDs,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUG1  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUG2  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,NSAIDs,beta blockers
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUG1  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUG2  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,NSAIDs,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUG1  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUG2  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,NSAIDs,fluoxetine
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUG1  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUG2  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,NSAIDs,progestin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUG1  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUG2  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,NSAIDs,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUG1  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUG2  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,NSAIDs,progestin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUG1  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUG2  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,NSAIDs,benzodiazepenes
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUG1  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUG2  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,NSAIDs,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUG1  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUG2  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,NSAIDs,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUG1  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUG2  may interfere with the efficacy of the  DRUGOTHER ).",negative,NSAIDs,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUG1  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUG2 ).",negative,NSAIDs,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUG1  levels),  DRUG2  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,fluvoxamine
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUG1  levels),  DRUGOTHER  (bioavailability of oral  DRUG2  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUG1  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUG2  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,beta blockers
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUG1  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUG2  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUG1  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUG2  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,fluoxetine
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUG1  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUG2  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,progestin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUG1  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUG2  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUG1  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUG2  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,progestin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUG1  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUG2  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,benzodiazepenes
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUG1  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUG2  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUG1  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUG2  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUG1  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUG2  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUG1  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUG2 ).",negative,melatonin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUG1  (bioavailability of oral  DRUG2  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,fluvoxamine,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUG1  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUG2  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,fluvoxamine,beta blockers
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUG1  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUG2  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,fluvoxamine,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUG1  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUG2  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,fluvoxamine,fluoxetine
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUG1  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUG2  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,fluvoxamine,progestin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUG1  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUG2  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,fluvoxamine,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUG1  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUG2  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,fluvoxamine,progestin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUG1  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUG2  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,fluvoxamine,benzodiazepenes
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUG1  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUG2  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,fluvoxamine,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUG1  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUG2  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,fluvoxamine,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUG1  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUG2  may interfere with the efficacy of the  DRUGOTHER ).",negative,fluvoxamine,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUG1  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUG2 ).",negative,fluvoxamine,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUG1  is increased with coadministration),  DRUG2  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,beta blockers
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUG1  is increased with coadministration),  DRUGOTHER  (may decrease  DRUG2  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUG1  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUG2  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,fluoxetine
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUG1  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUG2  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,progestin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUG1  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUG2  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUG1  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUG2  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,progestin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUG1  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUG2  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,benzodiazepenes
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUG1  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUG2  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUG1  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUG2  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUG1  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUG2  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUG1  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUG2 ).",negative,melatonin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUG1  (may decrease  DRUG2  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,beta blockers,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUG1  (may decrease  DRUGOTHER  levels),  DRUG2  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,beta blockers,fluoxetine
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUG1  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUG2  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,beta blockers,progestin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUG1  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUG2  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,beta blockers,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUG1  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUG2  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,beta blockers,progestin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUG1  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUG2  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,beta blockers,benzodiazepenes
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUG1  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUG2  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,beta blockers,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUG1  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUG2  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,beta blockers,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUG1  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUG2  may interfere with the efficacy of the  DRUGOTHER ).",negative,beta blockers,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUG1  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUG2 ).",negative,beta blockers,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUG1  levels),  DRUG2  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,fluoxetine
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUG1  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUG2  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,progestin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUG1  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUG2  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUG1  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUG2  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,progestin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUG1  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUG2  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,benzodiazepenes
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUG1  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUG2  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUG1  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUG2  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUG1  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUG2  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUG1  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUG2 ).",negative,melatonin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUG1  (reports of psychotic episodes when coadministered),  DRUG2  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,fluoxetine,progestin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUG1  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUG2  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,fluoxetine,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUG1  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUG2  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,fluoxetine,progestin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUG1  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUG2  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,fluoxetine,benzodiazepenes
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUG1  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUG2  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,fluoxetine,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUG1  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUG2  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,fluoxetine,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUG1  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUG2  may interfere with the efficacy of the  DRUGOTHER ).",negative,fluoxetine,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUG1  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUG2 ).",negative,fluoxetine,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUG1  (coadministration of  DRUG2  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,progestin,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUG1  (coadministration of  DRUGOTHER  with  DRUG2  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,progestin,progestin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUG1  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUG2  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,progestin,benzodiazepenes
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUG1  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUG2  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,progestin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUG1  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUG2  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,progestin,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUG1  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUG2  may interfere with the efficacy of the  DRUGOTHER ).",negative,progestin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUG1  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUG2 ).",negative,progestin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUG1  with  DRUG2  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",effect,melatonin,progestin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUG1  with  DRUGOTHER  can inhibit ovarian function in women),  DRUG2  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,benzodiazepenes
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUG1  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUG2  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUG1  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUG2  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUG1  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUG2  may interfere with the efficacy of the  DRUGOTHER ).",negative,melatonin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUG1  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUG2 ).",negative,melatonin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUG1  can inhibit ovarian function in women),  DRUG2  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,progestin,benzodiazepenes
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUG1  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUG2  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,progestin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUG1  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUG2  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,progestin,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUG1  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUG2  may interfere with the efficacy of the  DRUGOTHER ).",negative,progestin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUG1  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUG2 ).",negative,progestin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUG1  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUG2  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,benzodiazepenes,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUG1  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUG2  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,benzodiazepenes,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUG1  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUG2  may interfere with the efficacy of the  DRUGOTHER ).",negative,benzodiazepenes,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUG1  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUG2 ).",negative,benzodiazepenes,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUG1  (coadministration of  DRUG2  and  DRUGOTHER  may interfere with the efficacy of the  DRUGOTHER ).",negative,corticosteroids,melatonin
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUG1  (coadministration of  DRUGOTHER  and  DRUG2  may interfere with the efficacy of the  DRUGOTHER ).",negative,corticosteroids,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUG1  (coadministration of  DRUGOTHER  and  DRUGOTHER  may interfere with the efficacy of the  DRUG2 ).",negative,corticosteroids,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUG1  and  DRUG2  may interfere with the efficacy of the  DRUGOTHER ).",effect,melatonin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUG1  and  DRUGOTHER  may interfere with the efficacy of the  DRUG2 ).",negative,melatonin,corticosteroids
" DRUGOTHER  may interact with the following drugs:  DRUGOTHER  and other  DRUGOTHER  (may lower  DRUGOTHER  levels),  DRUGOTHER  (bioavailability of oral  DRUGOTHER  is increased with coadministration),  DRUGOTHER  (may decrease  DRUGOTHER  levels),  DRUGOTHER  (reports of psychotic episodes when coadministered),  DRUGOTHER  (coadministration of  DRUGOTHER  with  DRUGOTHER  can inhibit ovarian function in women),  DRUGOTHER  and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and  DRUGOTHER  (coadministration of  DRUGOTHER  and  DRUG1  may interfere with the efficacy of the  DRUG2 ).",negative,corticosteroids,corticosteroids
"The incubations were performed in the absence and presence of the non-specific CYP inhibitor,  DRUG1  ( DRUG2 ) and isoform-specific inhibitors.",negative,1-aminobenzotriazole,ABT
" DRUG1  decreased the toxicity of  DRUG2 , increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner.",effect,ABT,precocene I
"Of the isoform-specific CYP inhibitors tested for an effect on the  DRUG1  metabolite profile, only  DRUG2  was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1.",negative,precocene I,tranylcypromine
"With respect to toxicity, the order of CYP inhibitor effectiveness was  DRUG1 > DRUG2 ~ DRUGOTHER > DRUGOTHER .",negative,ABT,diethyldithiocarbamate
"With respect to toxicity, the order of CYP inhibitor effectiveness was  DRUG1 > DRUGOTHER ~ DRUG2 > DRUGOTHER .",negative,ABT,tranylcypromine
"With respect to toxicity, the order of CYP inhibitor effectiveness was  DRUG1 > DRUGOTHER ~ DRUGOTHER > DRUG2 .",negative,ABT,ketoconazole
"With respect to toxicity, the order of CYP inhibitor effectiveness was  DRUGOTHER > DRUG1 ~ DRUG2 > DRUGOTHER .",negative,diethyldithiocarbamate,tranylcypromine
"With respect to toxicity, the order of CYP inhibitor effectiveness was  DRUGOTHER > DRUG1 ~ DRUGOTHER > DRUG2 .",negative,diethyldithiocarbamate,ketoconazole
"With respect to toxicity, the order of CYP inhibitor effectiveness was  DRUGOTHER > DRUGOTHER ~ DRUG1 > DRUG2 .",negative,tranylcypromine,ketoconazole
" DRUG1  and  DRUG2  had no effect, while  DRUGOTHER  appeared to augment  DRUGOTHER  toxicity.",negative,Furafylline,sulfaphenazole
" DRUG1  and  DRUGOTHER  had no effect, while  DRUG2  appeared to augment  DRUGOTHER  toxicity.",negative,Furafylline,quinidine
" DRUG1  and  DRUGOTHER  had no effect, while  DRUGOTHER  appeared to augment  DRUG2  toxicity.",negative,Furafylline,precocene I
" DRUGOTHER  and  DRUG1  had no effect, while  DRUG2  appeared to augment  DRUGOTHER  toxicity.",negative,sulfaphenazole,quinidine
" DRUGOTHER  and  DRUG1  had no effect, while  DRUGOTHER  appeared to augment  DRUG2  toxicity.",negative,sulfaphenazole,precocene I
" DRUGOTHER  and  DRUGOTHER  had no effect, while  DRUG1  appeared to augment  DRUG2  toxicity.",effect,quinidine,precocene I
These results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of  DRUG1  and therefore may not be an appropriate model for  DRUG2  metabolism.,negative,precocene I,precocene I
 DRUG1 : Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving  DRUG2  concomitantly with  DRUGOTHER .,negative,Coumarin-Derivative Anticoagulants,ZOLINZA
 DRUG1 : Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving  DRUGOTHER  concomitantly with  DRUG2 .,negative,Coumarin-Derivative Anticoagulants,coumarin-derivative anticoagulants
 DRUGOTHER : Prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving  DRUG1  concomitantly with  DRUG2 .,effect,ZOLINZA,coumarin-derivative anticoagulants
Physicians should carefully monitor PT and INR in patients concurrently administered  DRUG1  and  DRUG2 .,advise,ZOLINZA,coumarin derivatives
"Other  DRUG1  Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of  DRUG2  and other  DRUGOTHER  (e.g.,  DRUGOTHER ).",negative,HDAC Inhibitors,ZOLINZA
"Other  DRUG1  Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of  DRUGOTHER  and other  DRUG2  (e.g.,  DRUGOTHER ).",negative,HDAC Inhibitors,HDAC inhibitors
"Other  DRUG1  Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of  DRUGOTHER  and other  DRUGOTHER  (e.g.,  DRUG2 ).",negative,HDAC Inhibitors,valproic acid
"Other  DRUGOTHER  Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of  DRUG1  and other  DRUG2  (e.g.,  DRUGOTHER ).",effect,ZOLINZA,HDAC inhibitors
"Other  DRUGOTHER  Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of  DRUG1  and other  DRUGOTHER  (e.g.,  DRUG2 ).",effect,ZOLINZA,valproic acid
"Other  DRUGOTHER  Severe thrombocytopenia and gastrointestinal bleeding have been reported with concomitant use of  DRUGOTHER  and other  DRUG1  (e.g.,  DRUG2 ).",negative,HDAC inhibitors,valproic acid
"The concomitant use of  DRUG1  with other  DRUG2  or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects.",effect,oxybutynin,anticholinergic drugs
"Mean  DRUG1  plasma concentrations were approximately 2 fold higher when  DRUG2  was administered with  DRUGOTHER , a potent CYP3A4 inhibitor.",negative,oxybutynin chloride,DITROPAN XL
"Mean  DRUG1  plasma concentrations were approximately 2 fold higher when  DRUGOTHER  was administered with  DRUG2 , a potent CYP3A4 inhibitor.",negative,oxybutynin chloride,ketoconazole
"Mean  DRUGOTHER  plasma concentrations were approximately 2 fold higher when  DRUG1  was administered with  DRUG2 , a potent CYP3A4 inhibitor.",mechanism,DITROPAN XL,ketoconazole
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  DRUG1  (e.g.,  DRUG2  and  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ), may alter  DRUGOTHER  mean pharmacokinetic parameters (i.e., Cmax and AUC).",negative,antimycotic agents,itraconazole
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  DRUG1  (e.g.,  DRUGOTHER  and  DRUG2 ) or  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ), may alter  DRUGOTHER  mean pharmacokinetic parameters (i.e., Cmax and AUC).",negative,antimycotic agents,miconazole
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  DRUG1  (e.g.,  DRUGOTHER  and  DRUGOTHER ) or  DRUG2  (e.g.,  DRUGOTHER  and  DRUGOTHER ), may alter  DRUGOTHER  mean pharmacokinetic parameters (i.e., Cmax and AUC).",negative,antimycotic agents,macrolide antibiotics
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  DRUG1  (e.g.,  DRUGOTHER  and  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUG2  and  DRUGOTHER ), may alter  DRUGOTHER  mean pharmacokinetic parameters (i.e., Cmax and AUC).",negative,antimycotic agents,erythromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  DRUG1  (e.g.,  DRUGOTHER  and  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUG2 ), may alter  DRUGOTHER  mean pharmacokinetic parameters (i.e., Cmax and AUC).",negative,antimycotic agents,clarithromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  DRUG1  (e.g.,  DRUGOTHER  and  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ), may alter  DRUG2  mean pharmacokinetic parameters (i.e., Cmax and AUC).",mechanism,antimycotic agents,oxybutynin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  DRUGOTHER  (e.g.,  DRUG1  and  DRUG2 ) or  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ), may alter  DRUGOTHER  mean pharmacokinetic parameters (i.e., Cmax and AUC).",negative,itraconazole,miconazole
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  DRUGOTHER  (e.g.,  DRUG1  and  DRUGOTHER ) or  DRUG2  (e.g.,  DRUGOTHER  and  DRUGOTHER ), may alter  DRUGOTHER  mean pharmacokinetic parameters (i.e., Cmax and AUC).",negative,itraconazole,macrolide antibiotics
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  DRUGOTHER  (e.g.,  DRUG1  and  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUG2  and  DRUGOTHER ), may alter  DRUGOTHER  mean pharmacokinetic parameters (i.e., Cmax and AUC).",negative,itraconazole,erythromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  DRUGOTHER  (e.g.,  DRUG1  and  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUG2 ), may alter  DRUGOTHER  mean pharmacokinetic parameters (i.e., Cmax and AUC).",negative,itraconazole,clarithromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  DRUGOTHER  (e.g.,  DRUG1  and  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ), may alter  DRUG2  mean pharmacokinetic parameters (i.e., Cmax and AUC).",mechanism,itraconazole,oxybutynin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUG1 ) or  DRUG2  (e.g.,  DRUGOTHER  and  DRUGOTHER ), may alter  DRUGOTHER  mean pharmacokinetic parameters (i.e., Cmax and AUC).",negative,miconazole,macrolide antibiotics
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUG1 ) or  DRUGOTHER  (e.g.,  DRUG2  and  DRUGOTHER ), may alter  DRUGOTHER  mean pharmacokinetic parameters (i.e., Cmax and AUC).",negative,miconazole,erythromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUG1 ) or  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUG2 ), may alter  DRUGOTHER  mean pharmacokinetic parameters (i.e., Cmax and AUC).",negative,miconazole,clarithromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUG1 ) or  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ), may alter  DRUG2  mean pharmacokinetic parameters (i.e., Cmax and AUC).",mechanism,miconazole,oxybutynin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ) or  DRUG1  (e.g.,  DRUG2  and  DRUGOTHER ), may alter  DRUGOTHER  mean pharmacokinetic parameters (i.e., Cmax and AUC).",negative,macrolide antibiotics,erythromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ) or  DRUG1  (e.g.,  DRUGOTHER  and  DRUG2 ), may alter  DRUGOTHER  mean pharmacokinetic parameters (i.e., Cmax and AUC).",negative,macrolide antibiotics,clarithromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ) or  DRUG1  (e.g.,  DRUGOTHER  and  DRUGOTHER ), may alter  DRUG2  mean pharmacokinetic parameters (i.e., Cmax and AUC).",mechanism,macrolide antibiotics,oxybutynin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUG1  and  DRUG2 ), may alter  DRUGOTHER  mean pharmacokinetic parameters (i.e., Cmax and AUC).",negative,erythromycin,clarithromycin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUG1  and  DRUGOTHER ), may alter  DRUG2  mean pharmacokinetic parameters (i.e., Cmax and AUC).",mechanism,erythromycin,oxybutynin
"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUGOTHER ) or  DRUGOTHER  (e.g.,  DRUGOTHER  and  DRUG1 ), may alter  DRUG2  mean pharmacokinetic parameters (i.e., Cmax and AUC).",mechanism,clarithromycin,oxybutynin
"Concurrent ingestion of  DRUG1  (20 mL of  DRUG2  containing  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) did not significantly affect the exposure of  DRUGOTHER  or  DRUGOTHER .",negative,antacid,antacid
"Concurrent ingestion of  DRUG1  (20 mL of  DRUGOTHER  containing  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) did not significantly affect the exposure of  DRUGOTHER  or  DRUGOTHER .",negative,antacid,aluminum hydroxide
"Concurrent ingestion of  DRUG1  (20 mL of  DRUGOTHER  containing  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) did not significantly affect the exposure of  DRUGOTHER  or  DRUGOTHER .",negative,antacid,magnesium hydroxide
"Concurrent ingestion of  DRUG1  (20 mL of  DRUGOTHER  containing  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) did not significantly affect the exposure of  DRUGOTHER  or  DRUGOTHER .",negative,antacid,simethicone
"Concurrent ingestion of  DRUG1  (20 mL of  DRUGOTHER  containing  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) did not significantly affect the exposure of  DRUG2  or  DRUGOTHER .",negative,antacid,oxybutynin
"Concurrent ingestion of  DRUG1  (20 mL of  DRUGOTHER  containing  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) did not significantly affect the exposure of  DRUGOTHER  or  DRUG2 .",negative,antacid,desethyloxybutynin
"Concurrent ingestion of  DRUGOTHER  (20 mL of  DRUG1  containing  DRUG2 ,  DRUGOTHER , and  DRUGOTHER ) did not significantly affect the exposure of  DRUGOTHER  or  DRUGOTHER .",negative,antacid,aluminum hydroxide
"Concurrent ingestion of  DRUGOTHER  (20 mL of  DRUG1  containing  DRUGOTHER ,  DRUG2 , and  DRUGOTHER ) did not significantly affect the exposure of  DRUGOTHER  or  DRUGOTHER .",negative,antacid,magnesium hydroxide
"Concurrent ingestion of  DRUGOTHER  (20 mL of  DRUG1  containing  DRUGOTHER ,  DRUGOTHER , and  DRUG2 ) did not significantly affect the exposure of  DRUGOTHER  or  DRUGOTHER .",negative,antacid,simethicone
"Concurrent ingestion of  DRUGOTHER  (20 mL of  DRUG1  containing  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) did not significantly affect the exposure of  DRUG2  or  DRUGOTHER .",negative,antacid,oxybutynin
"Concurrent ingestion of  DRUGOTHER  (20 mL of  DRUG1  containing  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) did not significantly affect the exposure of  DRUGOTHER  or  DRUG2 .",negative,antacid,desethyloxybutynin
"Concurrent ingestion of  DRUGOTHER  (20 mL of  DRUGOTHER  containing  DRUG1 ,  DRUG2 , and  DRUGOTHER ) did not significantly affect the exposure of  DRUGOTHER  or  DRUGOTHER .",negative,aluminum hydroxide,magnesium hydroxide
"Concurrent ingestion of  DRUGOTHER  (20 mL of  DRUGOTHER  containing  DRUG1 ,  DRUGOTHER , and  DRUG2 ) did not significantly affect the exposure of  DRUGOTHER  or  DRUGOTHER .",negative,aluminum hydroxide,simethicone
"Concurrent ingestion of  DRUGOTHER  (20 mL of  DRUGOTHER  containing  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ) did not significantly affect the exposure of  DRUG2  or  DRUGOTHER .",negative,aluminum hydroxide,oxybutynin
"Concurrent ingestion of  DRUGOTHER  (20 mL of  DRUGOTHER  containing  DRUG1 ,  DRUGOTHER , and  DRUGOTHER ) did not significantly affect the exposure of  DRUGOTHER  or  DRUG2 .",negative,aluminum hydroxide,desethyloxybutynin
"Concurrent ingestion of  DRUGOTHER  (20 mL of  DRUGOTHER  containing  DRUGOTHER ,  DRUG1 , and  DRUG2 ) did not significantly affect the exposure of  DRUGOTHER  or  DRUGOTHER .",negative,magnesium hydroxide,simethicone
"Concurrent ingestion of  DRUGOTHER  (20 mL of  DRUGOTHER  containing  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ) did not significantly affect the exposure of  DRUG2  or  DRUGOTHER .",negative,magnesium hydroxide,oxybutynin
"Concurrent ingestion of  DRUGOTHER  (20 mL of  DRUGOTHER  containing  DRUGOTHER ,  DRUG1 , and  DRUGOTHER ) did not significantly affect the exposure of  DRUGOTHER  or  DRUG2 .",negative,magnesium hydroxide,desethyloxybutynin
"Concurrent ingestion of  DRUGOTHER  (20 mL of  DRUGOTHER  containing  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ) did not significantly affect the exposure of  DRUG2  or  DRUGOTHER .",negative,simethicone,oxybutynin
"Concurrent ingestion of  DRUGOTHER  (20 mL of  DRUGOTHER  containing  DRUGOTHER ,  DRUGOTHER , and  DRUG1 ) did not significantly affect the exposure of  DRUGOTHER  or  DRUG2 .",negative,simethicone,desethyloxybutynin
"Concurrent ingestion of  DRUGOTHER  (20 mL of  DRUGOTHER  containing  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER ) did not significantly affect the exposure of  DRUG1  or  DRUG2 .",negative,oxybutynin,desethyloxybutynin
" DRUG1  may increase the effects of  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",effect,Sulfamethizole,barbiturates
" DRUG1  may increase the effects of  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",effect,Sulfamethizole,tolbutamide
" DRUG1  may increase the effects of  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",effect,Sulfamethizole,uricosurics
" DRUGOTHER  may increase the effects of  DRUG1 ,  DRUG2 , and  DRUGOTHER .",negative,barbiturates,tolbutamide
" DRUGOTHER  may increase the effects of  DRUG1 ,  DRUGOTHER , and  DRUG2 .",negative,barbiturates,uricosurics
" DRUGOTHER  may increase the effects of  DRUGOTHER ,  DRUG1 , and  DRUG2 .",negative,tolbutamide,uricosurics
"It may also interact with  DRUG1  (increased thrombocytopenia),  DRUG2  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,thiazides,cyclosporine
"It may also interact with  DRUG1  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUG2  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,thiazides,sulfonylurea agents
"It may also interact with  DRUG1  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUG2  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,thiazides,warfarin
"It may also interact with  DRUG1  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUG2  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,thiazides,methotrexate
"It may also interact with  DRUG1  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUG2 ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,thiazides,methotrexate
"It may also interact with  DRUG1  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUG2  (decreased hepatic clearance of  DRUGOTHER ).",negative,thiazides,phenytoin
"It may also interact with  DRUG1  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUG2 ).",negative,thiazides,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUG1  (increased nephrotoxicity),  DRUG2  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,cyclosporine,sulfonylurea agents
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUG1  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUG2  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,cyclosporine,warfarin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUG1  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUG2  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,cyclosporine,methotrexate
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUG1  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUG2 ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,cyclosporine,methotrexate
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUG1  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUG2  (decreased hepatic clearance of  DRUGOTHER ).",negative,cyclosporine,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUG1  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUG2 ).",negative,cyclosporine,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUG1  (increased hypoglycemic response),  DRUG2  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,sulfonylurea agents,warfarin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUG1  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUG2  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,sulfonylurea agents,methotrexate
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUG1  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUG2 ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,sulfonylurea agents,methotrexate
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUG1  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUG2  (decreased hepatic clearance of  DRUGOTHER ).",negative,sulfonylurea agents,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUG1  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUG2 ).",negative,sulfonylurea agents,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUG1  (increased anticoagulant effect),  DRUG2  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,warfarin,methotrexate
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUG1  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUG2 ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,warfarin,methotrexate
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUG1  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUG2  (decreased hepatic clearance of  DRUGOTHER ).",negative,warfarin,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUG1  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUG2 ).",negative,warfarin,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUG1  (decreased renal excretion of  DRUG2 ),  DRUGOTHER  (decreased hepatic clearance of  DRUGOTHER ).",negative,methotrexate,methotrexate
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUG1  (decreased renal excretion of  DRUGOTHER ),  DRUG2  (decreased hepatic clearance of  DRUGOTHER ).",negative,methotrexate,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUG1  (decreased renal excretion of  DRUGOTHER ),  DRUGOTHER  (decreased hepatic clearance of  DRUG2 ).",negative,methotrexate,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUG1 ),  DRUG2  (decreased hepatic clearance of  DRUGOTHER ).",negative,methotrexate,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUG1 ),  DRUGOTHER  (decreased hepatic clearance of  DRUG2 ).",negative,methotrexate,phenytoin
"It may also interact with  DRUGOTHER  (increased thrombocytopenia),  DRUGOTHER  (increased nephrotoxicity),  DRUGOTHER  (increased hypoglycemic response),  DRUGOTHER  (increased anticoagulant effect),  DRUGOTHER  (decreased renal excretion of  DRUGOTHER ),  DRUG1  (decreased hepatic clearance of  DRUG2 ).",negative,phenytoin,phenytoin
"These include  DRUG1 ,  DRUG2 , and oral and inhaled  DRUGOTHER .",negative,sympathomimetic bronchodilators,methylxanthines
"These include  DRUG1 ,  DRUGOTHER , and oral and inhaled  DRUG2 .",negative,sympathomimetic bronchodilators,steroids
"These include  DRUGOTHER ,  DRUG1 , and oral and inhaled  DRUG2 .",negative,methylxanthines,steroids
"However, the co   administration of  DRUG1  with other  DRUG2    containing drugs (e.g.,  DRUGOTHER ) has not been studied and is therefore not recommended.",advise,SPIRIVA,anticholinergic
"However, the co   administration of  DRUG1  with other  DRUGOTHER    containing drugs (e.g.,  DRUG2 ) has not been studied and is therefore not recommended.",advise,SPIRIVA,ipratropium
"However, the co   administration of  DRUGOTHER  with other  DRUG1    containing drugs (e.g.,  DRUG2 ) has not been studied and is therefore not recommended.",negative,anticholinergic,ipratropium
 DRUG1  and  DRUG2  increase the effects of  DRUGOTHER .,negative,MAO inhibitors,beta adrenergic blockers
 DRUG1  and  DRUGOTHER  increase the effects of  DRUG2 .,effect,MAO inhibitors,pseudoephedrine
 DRUGOTHER  and  DRUG1  increase the effects of  DRUG2 .,effect,beta adrenergic blockers,pseudoephedrine
" DRUG1  may reduce the antihypertensive effects of  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  and  DRUGOTHER .",effect,Sympathomimetics,methyldopa
" DRUG1  may reduce the antihypertensive effects of  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER .",effect,Sympathomimetics,mecamylamine
" DRUG1  may reduce the antihypertensive effects of  DRUGOTHER ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER .",effect,Sympathomimetics,reserpine
" DRUG1  may reduce the antihypertensive effects of  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 .",effect,Sympathomimetics,veratrum alkaloids
" DRUGOTHER  may reduce the antihypertensive effects of  DRUG1 ,  DRUG2 ,  DRUGOTHER  and  DRUGOTHER .",negative,methyldopa,mecamylamine
" DRUGOTHER  may reduce the antihypertensive effects of  DRUG1 ,  DRUGOTHER ,  DRUG2  and  DRUGOTHER .",negative,methyldopa,reserpine
" DRUGOTHER  may reduce the antihypertensive effects of  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  and  DRUG2 .",negative,methyldopa,veratrum alkaloids
" DRUGOTHER  may reduce the antihypertensive effects of  DRUGOTHER ,  DRUG1 ,  DRUG2  and  DRUGOTHER .",negative,mecamylamine,reserpine
" DRUGOTHER  may reduce the antihypertensive effects of  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  and  DRUG2 .",negative,mecamylamine,veratrum alkaloids
" DRUGOTHER  may reduce the antihypertensive effects of  DRUGOTHER ,  DRUGOTHER ,  DRUG1  and  DRUG2 .",negative,reserpine,veratrum alkaloids
"When administered concomitantly with  DRUG1    ,  DRUG2  may enhance or precipitate bradycardia, A.V.",effect,ProAmatine,cardiac glycosides
"The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ) may enhance or potentiate the pressor effects of  DRUGOTHER    . Therefore, caution should be used when  DRUGOTHER     is administered concomitantly with agents that cause vasoconstriction.",negative,phenylephrine,pseudoephedrine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER ) may enhance or potentiate the pressor effects of  DRUGOTHER    . Therefore, caution should be used when  DRUGOTHER     is administered concomitantly with agents that cause vasoconstriction.",negative,phenylephrine,ephedrine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER ) may enhance or potentiate the pressor effects of  DRUGOTHER    . Therefore, caution should be used when  DRUGOTHER     is administered concomitantly with agents that cause vasoconstriction.",negative,phenylephrine,phenylpropanolamine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 ) may enhance or potentiate the pressor effects of  DRUGOTHER    . Therefore, caution should be used when  DRUGOTHER     is administered concomitantly with agents that cause vasoconstriction.",negative,phenylephrine,dihydroergotamine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ) may enhance or potentiate the pressor effects of  DRUG2    . Therefore, caution should be used when  DRUGOTHER     is administered concomitantly with agents that cause vasoconstriction.",effect,phenylephrine,ProAmatine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ) may enhance or potentiate the pressor effects of  DRUGOTHER    . Therefore, caution should be used when  DRUG2     is administered concomitantly with agents that cause vasoconstriction.",negative,phenylephrine,ProAmatine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER  or  DRUGOTHER ) may enhance or potentiate the pressor effects of  DRUGOTHER    . Therefore, caution should be used when  DRUGOTHER     is administered concomitantly with agents that cause vasoconstriction.",negative,pseudoephedrine,ephedrine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2  or  DRUGOTHER ) may enhance or potentiate the pressor effects of  DRUGOTHER    . Therefore, caution should be used when  DRUGOTHER     is administered concomitantly with agents that cause vasoconstriction.",negative,pseudoephedrine,phenylpropanolamine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  or  DRUG2 ) may enhance or potentiate the pressor effects of  DRUGOTHER    . Therefore, caution should be used when  DRUGOTHER     is administered concomitantly with agents that cause vasoconstriction.",negative,pseudoephedrine,dihydroergotamine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ) may enhance or potentiate the pressor effects of  DRUG2    . Therefore, caution should be used when  DRUGOTHER     is administered concomitantly with agents that cause vasoconstriction.",effect,pseudoephedrine,ProAmatine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ) may enhance or potentiate the pressor effects of  DRUGOTHER    . Therefore, caution should be used when  DRUG2     is administered concomitantly with agents that cause vasoconstriction.",negative,pseudoephedrine,ProAmatine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2  or  DRUGOTHER ) may enhance or potentiate the pressor effects of  DRUGOTHER    . Therefore, caution should be used when  DRUGOTHER     is administered concomitantly with agents that cause vasoconstriction.",negative,ephedrine,phenylpropanolamine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  or  DRUG2 ) may enhance or potentiate the pressor effects of  DRUGOTHER    . Therefore, caution should be used when  DRUGOTHER     is administered concomitantly with agents that cause vasoconstriction.",negative,ephedrine,dihydroergotamine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  or  DRUGOTHER ) may enhance or potentiate the pressor effects of  DRUG2    . Therefore, caution should be used when  DRUGOTHER     is administered concomitantly with agents that cause vasoconstriction.",effect,ephedrine,ProAmatine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER  or  DRUGOTHER ) may enhance or potentiate the pressor effects of  DRUGOTHER    . Therefore, caution should be used when  DRUG2     is administered concomitantly with agents that cause vasoconstriction.",negative,ephedrine,ProAmatine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  or  DRUG2 ) may enhance or potentiate the pressor effects of  DRUGOTHER    . Therefore, caution should be used when  DRUGOTHER     is administered concomitantly with agents that cause vasoconstriction.",negative,phenylpropanolamine,dihydroergotamine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  or  DRUGOTHER ) may enhance or potentiate the pressor effects of  DRUG2    . Therefore, caution should be used when  DRUGOTHER     is administered concomitantly with agents that cause vasoconstriction.",effect,phenylpropanolamine,ProAmatine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1  or  DRUGOTHER ) may enhance or potentiate the pressor effects of  DRUGOTHER    . Therefore, caution should be used when  DRUG2     is administered concomitantly with agents that cause vasoconstriction.",negative,phenylpropanolamine,ProAmatine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG1 ) may enhance or potentiate the pressor effects of  DRUG2    . Therefore, caution should be used when  DRUGOTHER     is administered concomitantly with agents that cause vasoconstriction.",effect,dihydroergotamine,ProAmatine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUG1 ) may enhance or potentiate the pressor effects of  DRUGOTHER    . Therefore, caution should be used when  DRUG2     is administered concomitantly with agents that cause vasoconstriction.",negative,dihydroergotamine,ProAmatine
"The use of drugs that stimulate alpha-adrenergic receptors (e.g.,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER  or  DRUGOTHER ) may enhance or potentiate the pressor effects of  DRUG1    . Therefore, caution should be used when  DRUG2     is administered concomitantly with agents that cause vasoconstriction.",negative,ProAmatine,ProAmatine
" DRUG1     has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e.,  DRUG2 ), with or without salt supplementation.",negative,ProAmatine,fludrocortisone acetate
" DRUG1 .  DRUG2 , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,ProAmatine,Alpha-adrenergic blocking agents
" DRUG1 .  DRUGOTHER , such as  DRUG2 ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,ProAmatine,prazosin
" DRUG1 .  DRUGOTHER , such as  DRUGOTHER ,  DRUG2 , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,ProAmatine,terazosin
" DRUG1 .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUG2 , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,ProAmatine,doxazosin
" DRUG1 .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUG2 . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,ProAmatine,ProAmatine
" DRUG1 .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUG2  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,ProAmatine,desglymidodrine
" DRUG1 .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,ProAmatine,metformin
" DRUG1 .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,ProAmatine,cimetidine
" DRUG1 .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,ProAmatine,ranitidine
" DRUG1 .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,ProAmatine,procainamide
" DRUG1 .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,ProAmatine,triamterene
" DRUG1 .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,ProAmatine,flecainide
" DRUG1 .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,ProAmatine,quinidine
" DRUGOTHER .  DRUG1 , such as  DRUG2 ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,Alpha-adrenergic blocking agents,prazosin
" DRUGOTHER .  DRUG1 , such as  DRUGOTHER ,  DRUG2 , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,Alpha-adrenergic blocking agents,terazosin
" DRUGOTHER .  DRUG1 , such as  DRUGOTHER ,  DRUGOTHER , and  DRUG2 , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,Alpha-adrenergic blocking agents,doxazosin
" DRUGOTHER .  DRUG1 , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUG2 . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",effect,Alpha-adrenergic blocking agents,ProAmatine
" DRUGOTHER .  DRUG1 , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUG2  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,Alpha-adrenergic blocking agents,desglymidodrine
" DRUGOTHER .  DRUG1 , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,Alpha-adrenergic blocking agents,metformin
" DRUGOTHER .  DRUG1 , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,Alpha-adrenergic blocking agents,cimetidine
" DRUGOTHER .  DRUG1 , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,Alpha-adrenergic blocking agents,ranitidine
" DRUGOTHER .  DRUG1 , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,Alpha-adrenergic blocking agents,procainamide
" DRUGOTHER .  DRUG1 , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,Alpha-adrenergic blocking agents,triamterene
" DRUGOTHER .  DRUG1 , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,Alpha-adrenergic blocking agents,flecainide
" DRUGOTHER .  DRUG1 , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,Alpha-adrenergic blocking agents,quinidine
" DRUGOTHER .  DRUGOTHER , such as  DRUG1 ,  DRUG2 , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,prazosin,terazosin
" DRUGOTHER .  DRUGOTHER , such as  DRUG1 ,  DRUGOTHER , and  DRUG2 , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,prazosin,doxazosin
" DRUGOTHER .  DRUGOTHER , such as  DRUG1 ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUG2 . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",effect,prazosin,ProAmatine
" DRUGOTHER .  DRUGOTHER , such as  DRUG1 ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUG2  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,prazosin,desglymidodrine
" DRUGOTHER .  DRUGOTHER , such as  DRUG1 ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,prazosin,metformin
" DRUGOTHER .  DRUGOTHER , such as  DRUG1 ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,prazosin,cimetidine
" DRUGOTHER .  DRUGOTHER , such as  DRUG1 ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,prazosin,ranitidine
" DRUGOTHER .  DRUGOTHER , such as  DRUG1 ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,prazosin,procainamide
" DRUGOTHER .  DRUGOTHER , such as  DRUG1 ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,prazosin,triamterene
" DRUGOTHER .  DRUGOTHER , such as  DRUG1 ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,prazosin,flecainide
" DRUGOTHER .  DRUGOTHER , such as  DRUG1 ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,prazosin,quinidine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUG1 , and  DRUG2 , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,terazosin,doxazosin
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUG1 , and  DRUGOTHER , can antagonize the effects of  DRUG2 . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",effect,terazosin,ProAmatine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUG1 , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUG2  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,terazosin,desglymidodrine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUG1 , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,terazosin,metformin
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUG1 , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,terazosin,cimetidine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUG1 , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,terazosin,ranitidine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUG1 , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,terazosin,procainamide
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUG1 , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,terazosin,triamterene
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUG1 , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,terazosin,flecainide
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUG1 , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,terazosin,quinidine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUG1 , can antagonize the effects of  DRUG2 . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",effect,doxazosin,ProAmatine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUG1 , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUG2  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,doxazosin,desglymidodrine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUG1 , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,doxazosin,metformin
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUG1 , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,doxazosin,cimetidine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUG1 , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,doxazosin,ranitidine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUG1 , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,doxazosin,procainamide
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUG1 , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,doxazosin,triamterene
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUG1 , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,doxazosin,flecainide
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUG1 , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,doxazosin,quinidine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUG1 . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUG2  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,ProAmatine,desglymidodrine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUG1 . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,ProAmatine,metformin
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUG1 . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,ProAmatine,cimetidine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUG1 . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,ProAmatine,ranitidine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUG1 . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,ProAmatine,procainamide
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUG1 . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,ProAmatine,triamterene
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUG1 . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,ProAmatine,flecainide
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUG1 . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,ProAmatine,quinidine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUG1  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",mechanism,desglymidodrine,metformin
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUG1  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",mechanism,desglymidodrine,cimetidine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUG1  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",mechanism,desglymidodrine,ranitidine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUG1  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",mechanism,desglymidodrine,procainamide
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUG1  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",mechanism,desglymidodrine,triamterene
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUG1  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",mechanism,desglymidodrine,flecainide
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUG1  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",mechanism,desglymidodrine,quinidine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,metformin,cimetidine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,metformin,ranitidine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,metformin,procainamide
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,metformin,triamterene
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,metformin,flecainide
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,metformin,quinidine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,cimetidine,ranitidine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,cimetidine,procainamide
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,cimetidine,triamterene
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,cimetidine,flecainide
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,cimetidine,quinidine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER .",negative,ranitidine,procainamide
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,ranitidine,triamterene
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,ranitidine,flecainide
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,ranitidine,quinidine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 ,  DRUGOTHER , and  DRUGOTHER .",negative,procainamide,triamterene
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUG2 , and  DRUGOTHER .",negative,procainamide,flecainide
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER ,  DRUGOTHER , and  DRUG2 .",negative,procainamide,quinidine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUG2 , and  DRUGOTHER .",negative,triamterene,flecainide
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 ,  DRUGOTHER , and  DRUG2 .",negative,triamterene,quinidine
" DRUGOTHER .  DRUGOTHER , such as  DRUGOTHER ,  DRUGOTHER , and  DRUGOTHER , can antagonize the effects of  DRUGOTHER . Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of  DRUGOTHER  (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ,  DRUG1 , and  DRUG2 .",negative,flecainide,quinidine
 DRUG1  has been studied on a background of  DRUG2  and  DRUGOTHER .,negative,AGGRASTAT,aspirin
 DRUG1  has been studied on a background of  DRUGOTHER  and  DRUG2 .,negative,AGGRASTAT,heparin
 DRUGOTHER  has been studied on a background of  DRUG1  and  DRUG2 .,negative,aspirin,heparin
"The use of  DRUG1 , in combination with  DRUG2  and  DRUGOTHER , has been associated with an increase in bleeding compared to  DRUGOTHER  and  DRUGOTHER  alone (see",effect,AGGRASTAT,heparin
"The use of  DRUG1 , in combination with  DRUGOTHER  and  DRUG2 , has been associated with an increase in bleeding compared to  DRUGOTHER  and  DRUGOTHER  alone (see",effect,AGGRASTAT,aspirin
"The use of  DRUG1 , in combination with  DRUGOTHER  and  DRUGOTHER , has been associated with an increase in bleeding compared to  DRUG2  and  DRUGOTHER  alone (see",negative,AGGRASTAT,heparin
"The use of  DRUG1 , in combination with  DRUGOTHER  and  DRUGOTHER , has been associated with an increase in bleeding compared to  DRUGOTHER  and  DRUG2  alone (see",negative,AGGRASTAT,aspirin
"The use of  DRUGOTHER , in combination with  DRUG1  and  DRUG2 , has been associated with an increase in bleeding compared to  DRUGOTHER  and  DRUGOTHER  alone (see",negative,heparin,aspirin
"The use of  DRUGOTHER , in combination with  DRUG1  and  DRUGOTHER , has been associated with an increase in bleeding compared to  DRUG2  and  DRUGOTHER  alone (see",negative,heparin,heparin
"The use of  DRUGOTHER , in combination with  DRUG1  and  DRUGOTHER , has been associated with an increase in bleeding compared to  DRUGOTHER  and  DRUG2  alone (see",negative,heparin,aspirin
"The use of  DRUGOTHER , in combination with  DRUGOTHER  and  DRUG1 , has been associated with an increase in bleeding compared to  DRUG2  and  DRUGOTHER  alone (see",negative,aspirin,heparin
"The use of  DRUGOTHER , in combination with  DRUGOTHER  and  DRUG1 , has been associated with an increase in bleeding compared to  DRUGOTHER  and  DRUG2  alone (see",negative,aspirin,aspirin
"The use of  DRUGOTHER , in combination with  DRUGOTHER  and  DRUGOTHER , has been associated with an increase in bleeding compared to  DRUG1  and  DRUG2  alone (see",negative,heparin,aspirin
"Interactions for  DRUG1  ( DRUG2 ):   DRUGOTHER , Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ",negative,Vitamin B1,Thiamine
"Interactions for  DRUG1  ( DRUGOTHER ):   DRUG2 , Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ",int,Vitamin B1,Loop Diuretics
"Interactions for  DRUG1  ( DRUGOTHER ):   DRUGOTHER , Oral  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ",int,Vitamin B1,Contraceptives
"Interactions for  DRUG1  ( DRUGOTHER ):   DRUGOTHER , Oral  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ",int,Vitamin B1,Stavudine
"Interactions for  DRUG1  ( DRUGOTHER ):   DRUGOTHER , Oral  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ",int,Vitamin B1,Tricyclic Antidepressants
"Interactions for  DRUGOTHER  ( DRUG1 ):   DRUG2 , Oral  DRUGOTHER ,  DRUGOTHER ,  DRUGOTHER ",int,Thiamine,Loop Diuretics
"Interactions for  DRUGOTHER  ( DRUG1 ):   DRUGOTHER , Oral  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ",int,Thiamine,Contraceptives
"Interactions for  DRUGOTHER  ( DRUG1 ):   DRUGOTHER , Oral  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ",int,Thiamine,Stavudine
"Interactions for  DRUGOTHER  ( DRUG1 ):   DRUGOTHER , Oral  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ",int,Thiamine,Tricyclic Antidepressants
"Interactions for  DRUGOTHER  ( DRUGOTHER ):   DRUG1 , Oral  DRUG2 ,  DRUGOTHER ,  DRUGOTHER ",negative,Loop Diuretics,Contraceptives
"Interactions for  DRUGOTHER  ( DRUGOTHER ):   DRUG1 , Oral  DRUGOTHER ,  DRUG2 ,  DRUGOTHER ",negative,Loop Diuretics,Stavudine
"Interactions for  DRUGOTHER  ( DRUGOTHER ):   DRUG1 , Oral  DRUGOTHER ,  DRUGOTHER ,  DRUG2 ",negative,Loop Diuretics,Tricyclic Antidepressants
"Interactions for  DRUGOTHER  ( DRUGOTHER ):   DRUGOTHER , Oral  DRUG1 ,  DRUG2 ,  DRUGOTHER ",negative,Contraceptives,Stavudine
"Interactions for  DRUGOTHER  ( DRUGOTHER ):   DRUGOTHER , Oral  DRUG1 ,  DRUGOTHER ,  DRUG2 ",negative,Contraceptives,Tricyclic Antidepressants
"Interactions for  DRUGOTHER  ( DRUGOTHER ):   DRUGOTHER , Oral  DRUGOTHER ,  DRUG1 ,  DRUG2 ",negative,Stavudine,Tricyclic Antidepressants
"Other eye drops or medications such as  DRUG1  ( DRUG2 ) and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ) may decrease the effects of  DRUGOTHER  ophthalmic.",negative,acetylcholine chloride,Miochol
"Other eye drops or medications such as  DRUG1  ( DRUGOTHER ) and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ) may decrease the effects of  DRUGOTHER  ophthalmic.",negative,acetylcholine chloride,carbachol
"Other eye drops or medications such as  DRUG1  ( DRUGOTHER ) and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ) may decrease the effects of  DRUGOTHER  ophthalmic.",negative,acetylcholine chloride,Carboptic
"Other eye drops or medications such as  DRUG1  ( DRUGOTHER ) and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ) may decrease the effects of  DRUGOTHER  ophthalmic.",negative,acetylcholine chloride,Isopto Carbachol
"Other eye drops or medications such as  DRUG1  ( DRUGOTHER ) and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ) may decrease the effects of  DRUG2  ophthalmic.",effect,acetylcholine chloride,suprofen
"Other eye drops or medications such as  DRUGOTHER  ( DRUG1 ) and  DRUG2  ( DRUGOTHER ,  DRUGOTHER ) may decrease the effects of  DRUGOTHER  ophthalmic.",negative,Miochol,carbachol
"Other eye drops or medications such as  DRUGOTHER  ( DRUG1 ) and  DRUGOTHER  ( DRUG2 ,  DRUGOTHER ) may decrease the effects of  DRUGOTHER  ophthalmic.",negative,Miochol,Carboptic
"Other eye drops or medications such as  DRUGOTHER  ( DRUG1 ) and  DRUGOTHER  ( DRUGOTHER ,  DRUG2 ) may decrease the effects of  DRUGOTHER  ophthalmic.",negative,Miochol,Isopto Carbachol
"Other eye drops or medications such as  DRUGOTHER  ( DRUG1 ) and  DRUGOTHER  ( DRUGOTHER ,  DRUGOTHER ) may decrease the effects of  DRUG2  ophthalmic.",effect,Miochol,suprofen
"Other eye drops or medications such as  DRUGOTHER  ( DRUGOTHER ) and  DRUG1  ( DRUG2 ,  DRUGOTHER ) may decrease the effects of  DRUGOTHER  ophthalmic.",negative,carbachol,Carboptic
"Other eye drops or medications such as  DRUGOTHER  ( DRUGOTHER ) and  DRUG1  ( DRUGOTHER ,  DRUG2 ) may decrease the effects of  DRUGOTHER  ophthalmic.",negative,carbachol,Isopto Carbachol
"Other eye drops or medications such as  DRUGOTHER  ( DRUGOTHER ) and  DRUG1  ( DRUGOTHER ,  DRUGOTHER ) may decrease the effects of  DRUG2  ophthalmic.",effect,carbachol,suprofen
"Other eye drops or medications such as  DRUGOTHER  ( DRUGOTHER ) and  DRUGOTHER  ( DRUG1 ,  DRUG2 ) may decrease the effects of  DRUGOTHER  ophthalmic.",negative,Carboptic,Isopto Carbachol
"Other eye drops or medications such as  DRUGOTHER  ( DRUGOTHER ) and  DRUGOTHER  ( DRUG1 ,  DRUGOTHER ) may decrease the effects of  DRUG2  ophthalmic.",effect,Carboptic,suprofen
"Other eye drops or medications such as  DRUGOTHER  ( DRUGOTHER ) and  DRUGOTHER  ( DRUGOTHER ,  DRUG1 ) may decrease the effects of  DRUG2  ophthalmic.",effect,Isopto Carbachol,suprofen
Drug Interactions: Women on oral  DRUG1  have shown a significant increase in plasma  DRUG2  levels.,mechanism,contraceptives,vitamin A
"Concomitant administration of substances that are also tubularly secreted (e.g.,  DRUG1 ) could potentially result in delayed clearance of  DRUG2 .",mechanism,probenecid,ALIMTA
"Although  DRUG1  (400 mg qid) can be administered with  DRUG2  in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering  DRUGOTHER  concurrently with  DRUGOTHER  to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).",negative,ibuprofen,ALIMTA
"Although  DRUG1  (400 mg qid) can be administered with  DRUGOTHER  in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering  DRUG2  concurrently with  DRUGOTHER  to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).",negative,ibuprofen,ibuprofen
"Although  DRUG1  (400 mg qid) can be administered with  DRUGOTHER  in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering  DRUGOTHER  concurrently with  DRUG2  to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).",negative,ibuprofen,ALIMTA
"Although  DRUGOTHER  (400 mg qid) can be administered with  DRUG1  in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering  DRUG2  concurrently with  DRUGOTHER  to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).",negative,ALIMTA,ibuprofen
"Although  DRUGOTHER  (400 mg qid) can be administered with  DRUG1  in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering  DRUGOTHER  concurrently with  DRUG2  to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).",negative,ALIMTA,ALIMTA
"Although  DRUGOTHER  (400 mg qid) can be administered with  DRUGOTHER  in patients with normal renal function (creatinine clearance    80 mL/min), caution should be used when administering  DRUG1  concurrently with  DRUG2  to patients with mild to moderate renal insufficiency (creatinine clearance from 45 to 79 mL/min).",advise,ibuprofen,ALIMTA
"Patients with mild to moderate renal insufficiency should avoid taking  DRUG1  with short elimination half-lives for a period of 2 days before, the day of, and 2 days following administration of  DRUG2 .",advise,NSAIDs,ALIMTA
"In the absence of data regarding potential interaction between  DRUG1  and  DRUG2  with longer half-lives, all patients taking these  DRUGOTHER  should interrupt dosing for at least 5 days before, the day of, and 2 days following  DRUGOTHER  administration.",negative,ALIMTA,NSAIDs
"In the absence of data regarding potential interaction between  DRUG1  and  DRUGOTHER  with longer half-lives, all patients taking these  DRUG2  should interrupt dosing for at least 5 days before, the day of, and 2 days following  DRUGOTHER  administration.",negative,ALIMTA,NSAIDs
"In the absence of data regarding potential interaction between  DRUG1  and  DRUGOTHER  with longer half-lives, all patients taking these  DRUGOTHER  should interrupt dosing for at least 5 days before, the day of, and 2 days following  DRUG2  administration.",negative,ALIMTA,ALIMTA
"In the absence of data regarding potential interaction between  DRUGOTHER  and  DRUG1  with longer half-lives, all patients taking these  DRUG2  should interrupt dosing for at least 5 days before, the day of, and 2 days following  DRUGOTHER  administration.",negative,NSAIDs,NSAIDs
"In the absence of data regarding potential interaction between  DRUGOTHER  and  DRUG1  with longer half-lives, all patients taking these  DRUGOTHER  should interrupt dosing for at least 5 days before, the day of, and 2 days following  DRUG2  administration.",negative,NSAIDs,ALIMTA
"In the absence of data regarding potential interaction between  DRUGOTHER  and  DRUGOTHER  with longer half-lives, all patients taking these  DRUG1  should interrupt dosing for at least 5 days before, the day of, and 2 days following  DRUG2  administration.",advise,NSAIDs,ALIMTA
